



# BARCELONA

*28th International Conference on*  
**PHARMACOEPIDEMIOLOGY AND THERAPEUTIC  
RISK MANAGEMENT**

August 23-26, 2012 CCIB Barcelona, Spain

**Jointly Sponsored by:**

- The International Society for Pharmacoepidemiology (ISPE)
- The International Society of Pharmacovigilance (ISoP)
- European Association for Clinical Pharmacology and Therapeutics



[pharmacoepi.org](http://pharmacoepi.org)

*Final Program*

# BOARD OF DIRECTORS & VOLUNTEER LEADERS

## BARCELONA

28th International Conference on  
**PHARMACOEPIDEMIOLOGY AND  
THERAPEUTIC RISK MANAGEMENT**

### ISPE BOARD OF DIRECTORS

#### Officers

Nancy C Santanello, FISPE, *President*  
Stella Blackburn, FISPE, *President-Elect*  
Stephen JW Evans, FISPE, *Immediate Past President*  
Matthew Reynolds, *Vice President Finance*  
Kate Lapane, FISPE, *Vice President Finance - Elect*  
Mark H Epstein, *Executive Secretary*

#### Directors

Elizabeth Andrews, FISPE	Marie Lindquist
Ariel E Arias	Colleen Maxwell
Alison Bourke	Robert F Reynolds, FISPE
Lolkje TW de Jong-van den Berg, FISPE	John D Seeger
Nancy A Dreyer, FISPE	Scott R Smith
Edeltraut Garbe	Eiko Yoshinaga
Richard Hill	Stanley A Edlavitch, <i>Lifetime Emeritus</i>
Kiyoshi Kubota, FISPE	

### 2012 SCIENTIFIC PROGRAM COMMITTEE

Susana Perez-Gutthann, FISPE, *Chair*

#### Core Program Committee

Morten Andersen	Haley Kaplowitz
Frank Andersohn	Kate Lapane, FISPE
Stella Blackburn, FISPE	Joan-Ramon Laporte
Gonzalo Calvo	Dolores Montero
Gillian Caughey	Yola Moride, FISPE
Robert Chen, FISPE	Byung-Joo Park, FISPE
Suellen Curkendall	Jeremy Rassen
Lolkje TW de Jong-van den Berg, FISPE	Robert Reynolds, FISPE
Corinne de Vries, FISPE	Mary Elizabeth Ritchey
Mark Epstein	Elena Rivero, FISPE
Stephen JW Evans, FISPE	Patricia Saddier
Edeltraut Garbe	Nancy C Santanello, FISPE
Tobias Gerhard, FISPE	John D Seeger
Andrew Gilbert	Soko Setoguchi-Iwata, FISPE
Sonia Hernandez-Diaz, FISPE	Montserrat Soriano Gabarro
Richard Hill	Sabine Straus
Andrew Jerdonek	Miriam Sturkenboom, FISPE
Yea-Huei Kao Yang, FISPE	Til Stürmer, FISPE

### CHAIRS/CO-CHAIRS

#### Committees

**Archivist** .....Hugh Tilson, FISPE  
**Bylaws & Policies** .....Michael Lewis, FISPE  
Hugh Tilson, FISPE  
**Development**.....Marianne Ulcickas Yood, FISPE  
Susan Oliveria, FISPE  
**Education** .....Frank Andersohn  
Tobias Gerhard, FISPE  
**Fellowship & Awards**.....Stephen JW Evans, FISPE  
**Finance** .....Matt Reynolds  
**Global Development**.....BJ Park, FISPE  
Kiyoshi Kubota, FISPE  
Yea-Huei Kao Yang, FISPE  
**Management Oversight** .....Stephen JW Evans, FISPE  
**Membership** .....Michael Taylor  
**Nominating** .....Stephen JW Evans, FISPE  
**Public Policy & Ethics** .....Til Stürmer, FISPE  
Jesper Hallas, FISPE  
**Publications**.....Michael Arrighi  
Jennifer Christian  
**Scholarship**.....Frank May, FISPE  
**Scientific Program** .....Susana Perez-Gutthann, FISPE  
**Strategic Planning** .....Stella Blackburn, FISPE

#### Councils

**Academic**.....Almut Winterstein  
Jodi Segal  
**Government/Regulatory** .....Gunilla Sjölin-Forsberg  
Sabine Straus  
**Industry/Service Providers**...Harry Seifert  
Susan Oliveria, FISPE  
**Student**.....Caitlin Knox  
Wilhelmine Meeraus

#### Special Interest Groups

**AsPEN** .....Kiyoshi Kubota, FISPE  
Yea-Huei Kao Yang, FISPE  
**Biologics** .....Veronique Kugener  
Neal Grabowski  
**Comparative Effectiveness  
Research (CER)**.....Tobias Gerhard, FISPE  
**Databases**.....Kevin Haynes  
Andrew Maguire  
**Drug Utilization Research** .....Morten Andersen  
**Medical Device**.....Danica Marinac-Dabic  
Art Sedrakyan  
**Medicines In Pregnancy** .....Sonia Hernandez-Diaz, FISPE  
Elena Rivero, FISPE  
**Molecular Epi/Biomarkers/  
Pharmacogenetics** .....Stephen Kimmel  
Frederick Nyberg  
**Pediatrics**.....Rachel Sobel  
Tamar Lasky

# ABSTRACT REVIEWERS

Adel Abou-Ali  
Losief Abraha  
Ahmad Abuatiyeh  
Obahi Akoria  
Keith Altman  
Carlos Alves  
Frank Andersohn  
Elizabeth Andrews, FISPE  
Daniel Ankrah  
Zuleika Aponte Torres  
Alejandro Arana, FISPE  
Ariel E Arias  
Janet Arrowsmith  
Miia Artama  
Juan Asbun  
Alex Asimwe  
Annlouise Assaf, FISPE  
Abul Kalam Azad  
Andrey Baglikov  
Nicole Baker  
Anjan Banerjee  
Kiran Bapatla  
Dorothee Bartels  
Gillian Bartlett  
Andrew Bate  
Begler Begovic  
Sigrid Behr  
Annette Beiderbeck  
Sarah-Gabrielle Beland  
Svetlana Belitser  
Ria Benko  
Dimitri Bennett  
Anick Berard  
Timothy Beukelman  
Pipasha Biswas  
Michael Blum  
Cheryl Blume  
William Bobo  
Mariette Boerstoel  
Rachael Boggon  
David Bradford

Kimberly Brodovicz  
Jeffrey Brown  
Claudia Cabrera-Moksnes  
Suzanne Cadarette  
Aisling Caffrey  
Bing Cai  
Gloria Caldwell  
Gonzalo Calvo  
Alfonso Carvajal  
Jordi Castellsague  
Gillian Caughey  
Partha Chakraborty  
Kin-Wei Arnold Chan, FISPE  
Julie Chandler  
Chia-Hsuin Chang  
Rachel Charlton  
Chih-Ying Chen  
Lei Chen  
Robert Chen, FISPE  
Yingkai Cheng  
Pankdeep Chhabra  
Jennifer Christian  
Candemir Cigsar  
Alexander Cole  
Preciosa Coloma  
Lyn Colvin  
Meredith Cook  
Deborah Covington  
Cathy Critchlow  
Jeffrey Curtis  
Andrzej Czarnecki, FISPE  
Kourtney Davis  
Sandra de Bie  
Marie L De Bruin  
Hilda de Jong  
Josta de Jong  
Lolkje TW de Jong-van den Berg, FISPE  
Mary De Vera  
Joseph Delaney  
Cynthia DeLuise

Petra Denig  
Julia DiBello  
Rachael DiSantostefano  
Nevena Divac  
David Dore  
Sascha Dublin  
Ruben Duijnhoven  
Stacie Dusetzina  
Tomasz Dyszynski  
Stanley Edlavitch, *Conference Chair Emeritus*  
Vera Ehrenstein  
Alan Ellis  
Sherif Eltonsy  
Cheryl Enger  
Richard Epstein  
Stephen JW Evans, FISPE  
Efe Eworuke  
Gang Fang  
Ge Feng  
Carmen Ferrajolo  
Robert Flynn  
Joan Fortuny  
Annie Fourrier-Reglat  
Andrew Freedman  
Soren Friis  
Jon Fryzek  
Donnie Funch  
Kari Furu  
Genevieve Gabb  
Joshua Gagne  
David Gagnon  
John-Michael Gamble  
Shujun Gao  
Edeltraut Garbe  
Helga Gardarsdottir  
Christiane Gasse  
Ramakrishna Geddam  
Tobias Gerhard, FISPE  
Andrew Gilbert  
Cynthia Girman  
Brian Godman  
Earl Goehring Jr.  
Negar Golchin  
Amanda Golembesky  
Kyna Gooden  
Michael Goodman  
Laura Governale  
Neal Grabowski  
David Graham  
Michael Greenberg  
Sharon Greene  
Carlos Grijalva  
Andrea Gruneir  
Luke Grzeskowiak  
Lia Gutierrez  
Penina Haber  
Tarek Hammad  
Bradley Hammill  
Christian Hampp  
Mohamed Hamzawy  
Reina Haque  
Kunihiko Hayashi  
Kevin Haynes  
Jinghua He  
Klaas Heinemann  
Sean Hennessy, FISPE

Sharon Hensley Alford  
Francisco Hernandez  
Rohini Hernandez  
Sonia Hernandez-Diaz, FISPE  
Ulrik Hesse  
Deanna Hill  
Richard Hill  
Jodie Hillen  
Mikael Hoffmann  
Laura Horne  
Cheng-Yang Hsieh  
John Hsu  
Ruby Huang  
Wan-Ting Huang  
Florence Hunsel  
Daniel Huse  
Krista Huybrechts  
Luisa Ibanez  
Jessica Jalbert  
Ricardo Jimenez-Mendez  
Catherine Johannes  
Ani John  
Michele Jonsson Funk  
Juhaeri Juhaeri  
Yea-Huei Kao Yang, FISPE  
Haley Kaplowitz  
Koji Kawakami  
James Kaye  
Santosh KC  
Judith Kelly  
Alena Khromava  
Helle Kieler  
Helle Wallach Kildemoes  
Clara Kim  
Joseph Kim  
Tomomi Kimura  
Victor Kiri  
Daisuke Koide  
Amit Kondal  
Erna Kristin  
Cara Krulewitch  
Pradeep Kumar  
Makiko Kusama  
Kate Lapane, FISPE  
Tamar Lasky  
Deborah Layton  
Hoa Le  
Sukhyang Lee  
Charles Leonard  
Mitchell Levine, FISPE  
Michael Lewis, FISPE  
Hu Li  
Lin Li  
Caihua Liang  
Huifang Liang  
Nancy Lin  
Marie Lindquist  
Frank Liu  
Wei Liu  
Ruth Lopert  
Sandra Lopez  
Jeanne Loughlin  
Mark Lunt  
Mark Ma  
Christina Mack  
Will Maier

## LOCAL HOST COMMITTEE

Josep Lluís Segú, Chair	Eva Molero
Alejandro Arana, FISPE	Susana Perez-Gutthann, FISPE
Montse Barcelo	Nuria Riera
Gonzalo Calvo	Elena Rivero, FISPE
Carla Franzooni	Montse Soriano
Andrea Margulis	Cristina Varas
Flor Miniello	

## DEVELOPMENT COMMITTEE

Marianne Ulcickas Yood, FISPE, <i>Chair</i>	Andrew Jerdonek
Susan Oliveria, FISPE, <i>Co-chair</i>	Kirk Midkiff
Mark Cziraky, <i>Co-Chair</i>	JJ Nelson
Dimitri Bennet	Cynthia O'Malley
Rhonda L Bohn, FISPE	Syd Phillips
Andrzej Czarnecki, FISPE	Natalie Volkova
Mark H Epstein	Shirley Wang
	Karen Wells
	Jasmanda Wu

# ABSTRACT REVIEWERS

Anke-Hilse Maitland-van der Zee  
 Andrea Margulis  
 Michael Matheny  
 Colleen Maxwell  
 Frank May, FISPE  
 Giampiero Mazzaglia  
 Megan McAuliffe  
 David McClure  
 Wilhelmine Meeraus  
 Chetan Mehndiratta  
 Hemalkumar Mehta  
 Vandana Menon  
 Sharon Meropol  
 Bitu Mesgarpour  
 Dave Miller  
 Donald Miller  
 Daniel Mines  
 Eileen Ming  
 Montserrat Miret  
 Allen Mitchell, FISPE  
 Jingping Mo  
 Maja Mockenhaupt  
 Peter Mol  
 Delores Montero  
 Nicholas Moore, FISPE  
 Elaine Morrato  
 Christine Motzkus-Feagans  
 William Mountford  
 Ully Mulyani  
 Jeffrey Munson  
 Erwan Muros Le Rouzic  
 Azmi Nabulsi  
 Hamid Reza Nakhaipour  
 Pavel Napalkov  
 Jeanenne Nelson  
 Steve Niemcryk  
 Mette Noergaard  
 Niklas Noren  
 Fredrik Nyberg  
 Alexis Ogdie  
 David Olaleye  
 Denise Oleske  
 Susan Oliveria, FISPE

Ibrahim Oreagba  
 Vicki Osborne  
 Robert Overman  
 Byung-Joo Park, FISPE  
 Rae Woong Park  
 Björn Pasternak  
 Sallie-Anne Pearson  
 Michael Peng  
 Susana Perez-Gutthann, FISPE  
 Dyah Perwitasari  
 Ratnakar Pingili  
 Federica Pisa  
 Manel Pladevall-vila  
 Estel Plana Hortonedá  
 Lisa Pont  
 Anton Pottgard  
 Nicole Pratt  
 Mary Prince Panaccio  
 Elena Prokofyeva  
 Danya Qato  
 Jingjing Qian  
 Scott Quinlan  
 Marsha Raebel  
 Thiyagu Rajakannan  
 Darmendra Ramcharran  
 Jeremy Rassen  
 Jennita Reefhuis  
 Joe Reilly  
 Robert F Reynolds, FISPE  
 Mary Elizabeth Ritchey  
 Elena Rivero, FISPE  
 Elizabeth Roughead  
 Annalisa Rubino  
 Susan Sacks, FISPE  
 Patricia Saddier  
 Ahmed Saeed  
 Catherine Saltus  
 Leah Sansbury  
 Nancy C Santanello, FISPE  
 Fabiano Santos  
 Daphne Sawlwin  
 Rene Schade  
 Tania Schink

Sebastian Schneeweiss, FISPE  
 Verena Schneider-Lindner  
 Fred Schneeweiss  
 Marieke Schoonen  
 Katrin Schuessel  
 Martin Schulz  
 Glen Schumock  
 John Seeger  
 Harry Seifert  
 Sarah Sellers  
 Nandini Selvam  
 Soko Setoguchi-Iwata, FISPE  
 Natalia Shcherbakova  
 Xia Sheng  
 Jason Simeone  
 Meredith Smith  
 Daniel Solomon  
 Hong Ji Song  
 Montserrat Soriano Gabarro  
 Patrick Souverein  
 Gayathri Sridhar  
 Paul Stang, FISPE  
 Amy Stark  
 Kathryn Starzyk  
 Gudrun Stefansdottir  
 Michael Steinbuch  
 Douglas Steinke  
 Monika Stender  
 Sabine Straus  
 Marian Strazzeri  
 Til Stürmer, FISPE  
 Parimalakrishnan Sundararajan  
 Vicky Tagalakis  
 Amir Abbas Tahami Monfared  
 Yuexin Tang  
 Kathy Tater  
 Michael Taylor  
 Martina Teichert  
 Bharat Thakrar  
 Veena Thyagarajan  
 Darren Toh  
 Pramote Tragulpiankit  
 Thierry Trenque

Gianluca Trifiro  
 Ilse Truter  
 Katherine Tsai  
 Marianne Ulcickas Yood, FISPE  
 John Urquhart FISPE  
 Judith van den Bosch  
 Jan-Willem van der Velden, FISPE  
 Kristy Van Dinther  
 Kristen Van Dole  
 Zdravko Vassilev  
 Katia Verhamme  
 Patrice Verpillat  
 Vera Vlahovic-Palcevski  
 Rolin Wade  
 Laura Wallace  
 Mari-Ann Wallander, FISPE  
 Douglas Watson  
 Lynn Weekes  
 Li Wei  
 Debora Weiss  
 Winifred Werther  
 Suzanne West, FISPE  
 Bjorn Wettermark  
 Margaret Williamson  
 Amanda Wilson  
 James Wilson  
 Wolfgang Winkelmayer  
 Lesley Wise  
 Robert Wise, FISPE  
 Jasmanda Wu  
 Yu Yan  
 Huiying Yang  
 Mo Yang  
 Shibing Yang  
 Wai Ping Yau  
 Duk Yong Yoon  
 Takunari Yoshinaga  
 Muhammad Younus  
 Zhong Yuan  
 Huifeng Yun  
 Vivienne Zhu  
 Inge Zomerdijk

## IN THIS PROGRAM

### 28th ICPE Agenda

Wednesday, August 22 .....	11
Thursday, August 23 .....	14
Friday, August 24 .....	20
Saturday, August 25 .....	30
Sunday, August 26 .....	40

### 28th ICPE Posters

Poster Guidelines .....	50
Poster Session A .....	51
Poster Session B .....	59
Poster Session C .....	68

### Indexes

Abstract Index .....	78
Advertisers Index .....	89

# FUTURE MEETINGS

## 2012

### 7th Asian Conference on Pharmacoepidemiology

- October 26-28, 2012  
Bangalore, India

## 2013

### ISPE Mid-Year Meeting

- April 11-13, 2013  
Hilton Munich City  
Munich, Germany

### 29th ICPE

- August 25-28, 2013  
Montréal Convention Center  
Montréal, Canada

## 2014

### ISPE Mid-Year Meeting

- April TBD  
Rotterdam, the Netherlands

### 30th ICPE

- October 24-27, 2014  
Taipei International Convention Center  
Taipei, Taiwan



International des Feux Loto-Québec, Montréal International Fireworks Competition | Credit: © Tourisme Montréal, Stéphan Poulin

## 29th International Conference on PHARMACOEPIDEMIOLOGY AND THERAPEUTIC RISK MANAGEMENT



PHARMACOEPI.ORG

Abstract Deadline:  
**FEBRUARY 15, 2013**

The online abstract  
will be operational by  
**MID-DECEMBER 2012**

Meeting information  
will be posted at  
**PHARMACOEPI.ORG**

August 25-28, 2013 | Montréal Convention Center | Montréal, Canada

# MEETING AT-A-GLANCE

## WEDNESDAY, AUGUST 22, 2012

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
	8:00am - 6:00pm <b>Registration Open</b> CCIB Lobby											
	8:00am - 5:00pm <b>Speakers' Ready Room</b> 133							1:30 - 6:00pm <b>Introduction to Pharmacoepidemiology</b> 113				
	8:30am - Noon   <b>Educational Session</b> <b>Pharmacogenetics: From Basics to High Dimensionality</b> 131-132				Noon - 1:30pm <b>Lunch on Your Own</b>		1:30 - 6:00pm   <b>Educational Sessions</b> <b>Pharmacogenetics (Cont.)</b> 131-132					
	8:30am - Noon   <b>Educational Session</b> <b>Medical Device Epidemiology</b> 120-121						1:30 - 6:00pm <b>Medical Device Epidemiology (Cont.)</b> 120-121			6:30pm - ? <b>Student/Young Professionals Meet &amp; Greet</b> Hotel Silken Diagonal		
		9:00am - 5:00pm <b>ISPE Board of Directors Meeting</b> AC Barcelona Forum					2:30 - 6:00pm <b>Student Skills Workshop</b> 129-130					

## THURSDAY, AUGUST 23, 2012

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
	7:30am - 6:00pm <b>Registration Open</b> CCIB Lobby											
	7:00am - 5:00pm <b>Speakers' Ready Room</b> 133											
	8:30am - 12:00pm   <b>Educational Sessions</b>						1:30 - 6:00pm   <b>Educational Sessions</b>					
	Registries/Prospective Cohort Studies 127-128				Noon - 1:30pm <b>Lunch on Your Own</b>		Advanced Topics in Pharmacoepidemiology 114					
	Propensity Scores 131-132				Noon - 1:30pm <b>New Members Luncheon</b> 116		Introduction to Therapeutic Risk Management and Evaluation 113					
	Comparative Effectiveness Research 115						Advanced Drug Utilization Research 127-128					
	Intermediate Pharmacoepidemiology 129-130						Healthcare Databases 131-132					
	Regulatory Pharmacoepi./Health Care Decision-Making 124-125									6:00 - 7:30pm <b>Welcome Reception / Academic Showcase</b> CCIB Entrance Hall		
	Introduction to Drug Utilization Research 113											

## FRIDAY, AUGUST 24, 2012

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	
	7:00am - 6:00pm <b>Registration Open</b> CCIB Lobby												
	7:00am - 5:00pm <b>Speakers' Ready Room</b> 133												
	8:00am - 6:00pm <b>Exhibitors/Posters</b> Exhibit Hall / Rooms 5-6-7-8				10:00-10:30am <b>Break/Posters/Exhibits</b> EH/Rooms 5-6-7-8		12:15 - 1:15pm <b>Round Table Discussions</b> Entrance Hall		3:30 - 5:00pm <b>Plenary Session: ADHD Medication and the Risk of Cardiovascular Events</b> 111/112			7:30 - 8:30pm <b>PDS Editorial Board</b> (By invitation) 124-125	
	8:00am - 6:00pm <b>Exhibitors/Posters</b> Exhibit Hall / Rooms 5-6-7-8				12:45-1:30pm <b>Poster Walks</b> EH/Rooms 5-6-7-8							8:30pm - ? <b>Students/Young Professional Night Out</b> Chiriquito Incercia	
7:00 - 8:00am Poster Session A Set-Up Exhibit Hall Rooms 5-6-7-8	8:15 - 10:00am <b>Opening Session</b> 111-112 Welcome: <i>Susana Perez Gutthann, FISPE</i> Presidential Address: <i>Nancy Santanello, FISPE</i> Keynote: <i>Sir Michael Rawlins</i>				10:30 - Noon <b>Concurrent Sessions</b>		Noon - 1:30pm <b>Lunch/Poster Session A/Exhibits</b> EH / Rooms 5-6-7-8		1:30 - 3:00pm <b>Concurrent Session</b>		5:00 - 6:30pm <b>Symposia &amp; Workshops</b>		
	How Sweet It Isn't 117				ISPE Committee/Council Meetings 132		Breathless in Barcelona 114		Advanced Methods 111/112		6:30 - 7:30pm <b>ISPE Council Meetings</b>		
	Inappropriate Use of Drugs 115				Fellowship & Awards M211		Broken Hearts or Bleeding Bodies 113		Risk of Medication Use in Pregnancy 117		Academic 115		
	Life of the Cancer Patient 113				Finance M215		Diabetic Treatment Outcomes Around the World 111/112		Databases, Therapeutics, and Biomarkers 113		Government/Regulatory 114		
	Methods Tapas 111/112				Public Policy M214		Drug Utilization in Cardiovascular Disease 116		Collaborative Studies in the EU 114		Industry/Service Providers 116		
	Pregnancy: Macedonia 114				Student Council 124-125		Pregnancy: Brains and Pains 115		Regulatory Decision-Making Advances 115				
	Put Your Money Where Your Heart Is 116						Propensity Scores Estan de Moda 117		Medicare Part D Data 116				
									UDIS 132				

# MEETING AT-A-GLANCE

## SATURDAY, AUGUST 25, 2012

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	
7:00am - 6:00pm <b>Registration Open</b> CCIB Lobby						12:45-1:30pm <b>Poster Walks</b> EH/Rooms 5-6-7-8							
7:00am - 5:00pm <b>Speakers' Ready Room</b> 133						Noon - 1:30pm <b>Special Luncheon Workshop:</b> FarmacoEpiEnRed, a Network for Pharmacoepi. in Spain 129-130			3:30-4:00pm <b>Break/Posters/Exhibits</b> EH/Rooms 5-6-7-8	4:00 - 5:30pm <b>Symposia &amp; Workshops</b> Multi-Database Research Networks 111-112			
7:00-8:00am <b>Poster Session B Set-Up</b> Exhibit Hall Rooms 5-6-7-8	8:00am - 6:00pm <b>Exhibitors/Poster Session</b> Exhibit Hall/Rooms 5-6-7-8			10:00-10:30am <b>Break/Posters/Exhibits</b> EH/Rooms 5-6-7-8		10:30am - 12:00pm <b>Concurrent Sessions</b> Drug Utilization Research Methods 111-112 NSAIDs-Measuring Drug Safety 117 Pediatric Tapas 113 Personalized Medicine Tapas 114 Psychotropic Drug Utilization Research 115 Tapas: Junk Drawer (Cajon de Sastre) 116		Noon - 1:30pm <b>Lunch/Poster Session B/Exhibits</b> EH / Rooms 5-6-7-8		1:30 - 2:30pm <b>Plenary Session:</b> Safe and Effective Care for Older Patients with Multi-morbidity 111-112	2:30 - 3:30pm <b>Annual Meeting of ISPE Members &amp; Awards Ceremony</b> 111-112	Electronic Healthcare Databases for Pregnancy Research 117 Pharmacovigilance Legislation 113 Vaccine Safety 114 Drug Safety Monitoring 115 Research in Pharmacoepi 116 Validation 132	
7:30-8:30am <b>EuroDURG General Assembly</b> 124-125	8:30am - 10:00am <b>Concurrent Sessions</b> A "Joint Session" on Aches and Pains 111-112 CV Meds: What Would You Do? 117 Diabetes 113 Do You Trust Your Data? 114 Hormones 115 Treating Pain 116					Noon - 1:30pm <b>ISPE Committee Meetings</b> Bylaws and Policies M213 Education 124-125 Global Development 132 Membership M215 Publications M216						5:30 - 6:30pm <b>SIGs</b> AsPEN 131 Biologics 115 Comparative Effective Research 114 Databases 111-112 Drug Utilization 116 Medical Devices 117 Meds in Pregnancy 113 Molecular Epidemiology 124-125 Pediatrics 132	
						12:15 - 1:15pm <b>Round Table Discussions</b> Entrance Hall							
												7:30pm - 11:30pm <b>Social Event</b> Join us for dinner, entertainment, and dancing to the sounds of <i>Rumba Expresso</i> . CCIB Banquet Hall	

## SUNDAY, AUGUST 26, 2012

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	
7:00am - 4:30pm <b>Registration Open</b> CCIB Lobby													
7:00am - 3:30pm <b>Speakers' Ready Room</b> 133						12:45-1:30pm <b>Poster Walk</b> EH/Rooms 5-6-7-8	1:30pm - 3:00pm <b>Concurrent Sessions</b> ADRS In Europe 111-112 Cancer Pharmacoepi. 117 Identifying Risks in Special Populations 113 Measuring Impact of Risk Minimization 114 Methods: The Real Deal 115 Un Viaje por Vacunas: Vaccine Studies 116			4:30-5:00pm <b>The Final Word:</b> •Poster Awards •Future Meetings <b>Adjournment</b> 111-112			
7:00-8:00am <b>Poster Session C Set-Up</b> Exhibit Hall Rooms 5-6-7-8	8:00am - 1:45pm <b>Exhibitors/Poster Session</b> Exhibit Hall/Rooms 5-6-7-8			10:00-10:30am <b>Break/Posters/Exhibits</b> EH/Rooms 5-6-7-8	10:30am - Noon <b>Symposia &amp; Workshops</b> Comparative Effectiveness Research 111-112 Diabetes 117 Utilisation Research 113 CNODES 114 Pharmacovigilance Legislation 115 Pediatric Pharmacoepi. 116 Electronic Health Records 132		Noon - 1:30pm <b>Lunch/Poster Session C/Exhibits</b> EH / Rooms 5-6-7-8		ISPE Board of Directors Luncheon 124-125		5:15 - 6:15am <b>2013 ICPE Scientific Program Committee</b> 124-125		
										3:00 - 4:30pm <b>Hot Topics Session:</b> Evaluating Cancer Risk with Diabetes Treatment 111-112			

# ICPE EXHIBITORS & SUPPORTERS

as of July 30, 2012

ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2012.

*Thank You*

## ICPE JOINT SPONSORS

- The International Society for Pharmacoepidemiology (ISPE)
- The International Society for Pharmacovigilance (ISoP)
- European Association for Clinical Pharmacology and Therapeutics (EACPT)

## BADGES

All attendees at the ICPE 2012 must wear their name badges to all events.

A badge will be needed for admission to conference related functions such as the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and social evening event at the CCIB. Badges will be included in the registration material. In some cases, tickets for admission will be required (for example-guests).

### Badge Legend

■ Student

■ New Member

■ One-Day Attendee

## EXHIBITORS

- |   |                                |
|---|--------------------------------|
| ■ Bayer HealthCare                          | ■ ParagonRx                    |
| ■ Boehringer Ingelheim, GmbH                | ■ Parexel International        |
| ■ CPRD, Clinical Practice Research Datalink | ■ Pope Woodhead & Associates   |
| ■ Erasmus Medical College                   | ■ PHARMO Institute             |
| ■ European Medicines Agency (EMA)           | ■ Quintiles Outcome            |
| ■ Eu2P                                      | ■ RTI Health Solutions         |
| ■ IMS Health                                | ■ United BioSource Corporation |
| ■ HealthCore, Inc.                          | ■ Uppsala Monitoring Centre    |
| ■ Kantar Health                             | ■ The Degge Group, LTD         |
| ■ LA-SER Research                           | ■ Truven Health Analytics      |
| ■ Maccabi Healthcare Services               | ■ Wiley-Blackwell              |
| ■ MAPI                                      | ■ WHO Collaborating Center DSM |
| ■ Optum                                     | ■ XCENDA                       |

## ACADEMIC SUPPORTERS

- Boston University Schools of Public Health and Medicine - Slone Epidemiology Center
- Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women's Hospital, Harvard Medical School
- Drug Safety Research Unit (DSRU)
- London School of Hygiene & Tropical Medicine
- UNC Gillings School of Global Public Health

## ANNUAL MEETING SPONSORS

### Platinum

- |   |                   |
|---|-------------------|
| ■ CPRD, Clinical Practice Research Datalink | ■ Wiley-Blackwell |
| ■ The Degge Group, LTD                      |                   |

### Gold

- |                              |                                |
|------------------------------|--------------------------------|
| ■ Amgen                      | ■ Merck & Co.                  |
| ■ Bayer Healthcare           | ■ Optum                        |
| ■ Boehringer Ingelheim, GmbH | ■ ParagonRX                    |
| ■ Celgene                    | ■ Pfizer                       |
| ■ Eli Lilly & Company        | ■ Quintiles Outcome            |
| ■ F.Hoffmann-La Roche Ltd    | ■ RTI Health Solutions         |
| ■ IMS Health                 | ■ United BioSource Corporation |
| ■ LA-SER Research            |                                |

### Silver

- |               |                      |
|---------------|----------------------|
| ■ Biogen Idec | ■ PPD, Inc.          |
| ■ Novartis    | ■ Purdue Pharma L.P. |

### Bronze

- |  |                               |
|--|-------------------------------|
| ■ Boston Collaborative Drug Surveillance Program, Boston University School of Medicine | ■ EpiSource                   |
| ■ CSD Medical Research   | ■ Vertex Pharmaceuticals Inc. |
|  | ■ Whiscon                     |

## ORGANIZATIONAL & INSTITUTIONAL MEMBERS

### Pharmaceuticals

- F. Hoffmann-LaRoche Ltd.
- GlaxoSmithKline
- Sanofi-Aventis

### Service Providers

- RTI Health Solutions

### Government/Regulatory Agency

- Department of Health, Pharmaceutical Services, Hong Kong Special Administrative Region, People's Republic of China
- Drug Safety and Effectiveness Network, Canadian Institute of Health Research

### Academic Programs

- Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Harvard School of Public Health
- London School of Hygiene and Tropical Medicine
- McGill Pharmacoepidemiology Research Unit, McGill University
- Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- Regenstrief Institute
- Slone Epidemiology Center, Boston University



***Celgene Corporation is proud to sponsor the 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management***

***Celgene shares ISPE's dedication to enhancing public health through the creation of critical and innovative safety and risk management programs in areas of great medical need***

[www.celgene.com](http://www.celgene.com)

# ISPE SUPPORTERS

## ANNUAL CAMPAIGN as of August 2, 2012

*The Society expresses its sincere appreciation to the following supporters listed below for their contributions in honor of the 28th Annual Meeting (ICPE).*

Keith Altman  
Ulf Bergman, FISPE  
Stella Blackburn,  
FISPE  
David Brown  
Sabrina Cheng  
Ching-Lan Cheng  
Carlos Durán  
Madlen Gazarian  
Miguel Gil Garcia  
Klaas Heinemann

Consuelo Huerta  
Alvarez  
Junichi Kawakami  
Ju-Young Kim  
Judith Kinman  
Jaafer Kurmanji  
Chia-Cheng Lai  
Wei Liu  
Karine Marinier  
Linus Masese

Carl Metzdorff  
Montserrat Miret  
Jeanenne Nelson  
Eunsun Noh  
Belen Oliva Pellicer  
Nwabuogochukwu  
Oreh  
Vaishali Patadia  
Debra Rowett  
Robert Sharrar

Caroline Sirois  
Montserrat Soriano  
Gabarro  
Amir Abbas Tahami  
Monfared  
Robert Vander  
Stichele  
Made Wenten  
Huifeng Yun  
Eu2P

Image: Mirador de Colom Author: J. Trullas Credit: Turisme de Barcelona

# A piece of quality of life



More benefits with fewer side effects.  
Our epidemiological insights help.



*We Innovate Healthcare*

8:00-6:00pm  
**Registration**  
 (CCIB Lobby)

8:00-5:00pm  
**Speakers' Ready Room**  
 (133)

9:00-5:00pm  
**ISPE Board of Directors Meeting**  
 (Hotel AC Barcelona Forum)

(Open to ISPE members; notify ISPE staff if you would like to attend.)

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

8:30-Noon

### Pharmacogenomics: From Basics to High Dimensionality Data Analysis: Concurrent, Introductory and Advanced Topics in the Field of Pharmacogenetic Epidemiology (131-132)

INCLUDES AN AFTERNOON WORKSHOP

#### Course Objectives

- To understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at the level of analysis.
- To better understand the study, design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology.
- To understand how pharmacogenetics relates to the current focus of personalized medicine.
- To have an overview of clinical utility of pharmacogenetics and associated regulatory issues as well as policy-relevant research.

#### Target Audiences

- Members of the Molecular Epidemiology/Biomarkers/Pharmacogenomics (MEBP) SIG
- ISPE members interested in Pharmacogenomics/Pharmacogenetics
- FDA, EMA and other regulators interested in the intersection between pharmacogenetics and epidemiology.
- Clinical pharmacoepidemiologists
- Any scientists interested in learning more about pharmacogenetic epidemiology.

#### Workshop Topics

- Roundtable 1: Methods and Logistics
- Roundtable 2: Advanced methods
- Roundtable 3: Databases
- Roundtable 4: Policy and Regulatory Issues
- Roundtable 5: Clinical Utility and Implementation

#### Course Faculty

- Paul Boutros**, Ontario Center for Cancer Research
- Bruce Carleton**, University of British Columbia
- Andrew Freedman**, EGRP Clinical and Translational Epidemiology Branch (CTEB)
- Rayjean Hung**, Mount Sinai Lenefeld Research Institute
- Amilia M. Issa**, Department of Health Policy and Public Health at the University of the Sciences in Philadelphia
- Stephen Kimmel**, CPeRT, University of Pennsylvania
- Geoffrey Liu**, Molecular Genomics at the University of Toronto
- Anke Hilse Maitland-van der Zee**, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University
- David Pulford**, GlaxoSmithKline
- Leah Sansbury**, Worldwide Epidemiology Division at GlaxoSmithKline

8:30-Noon

### Medical Device Epidemiology (120-121)

INCLUDES AN AFTERNOON SESSION

- Topics will include regulation, safety, effectiveness, and methods. Featuring didactic lectures, cases, Hot Topics and group sessions throughout the day.

#### Course Faculty/Presentations

- Theodore Lystig**, Medtronic, Inc., *Study Design for Postmarket Surveillance*
- Jessica J. Jalbert**, Brigham and Women's Hospital/Harvard Medical School, *Coordinating the Methods Section, Coordinating Small Group Discussions and Presentations, Leading Small Group Discussions*
- Mary Elizabeth Ritchey**, FDA/Center for Devices and Radiological Health, *The Total Product Life Cycle and the Dynamic Regulatory Environment of Medical Devices in U.S.*
- Michael Steinbuch**, Johnson & Johnson *Medical Device & Diagnostics, Innovation and Regulation in Medical Devices in Post-market Settings & Examples of Postmarket Surveillance: Breast Implant*

- Art Sedrakyan**, Cornell Medical College, *Comparative Evidence of Various Hip Implants Used for Conventional Hip Replacement*
- Danica Marinac-Dabic**, FDA/Center for Devices and Radiological Health, *Initiatives, Frameworks, and Developments of Infrastructure and Methodology at the Advent of the Unique Device ID Era*
- Michele Jonsson Funk**, University of North Carolina at Chapel Hill, *Evaluating the Comparative Safety and Effectiveness of Urogynecologic Surgical Mesh*
- Soko Setoguchi**, FISPE, Duke Clinical Research Institute & University of Tokyo, *Real-world Effectiveness of Cardiovascular Devices*

Noon-1:30pm  
Lunch On  
Your Own

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

1:30-6:00pm  
**Introduction to Pharmacogenetics** (cont'd)  
(131-132)

1:30-6:00pm  
**Medical Device Epidemiology** (cont'd)  
(120-121)

1:30-6:00pm  
**Introduction to Pharmacoepidemiology** (113)

\*Included as part of the full meeting registration; registration required.

### Course Faculty/Presentations

**Syed Rizwanuddin Ahmad, FISPE**, US FDA, *Pharmacovigilance/Spontaneous Reporting*  
**Almut Winterstein**, University of Florida, *Cohort Studies*  
**Sonia Hernández-Díaz, FISPE**, Harvard School of Public Health, *Case-Control Studies*  
**Tobias Gerhard, FISPE**, Rutgers University, *Bias and Confounding*

Open to all Students and Young Professionals

2:30-6:00pm  
**Student Skills Workshop**  
(129-130)

**\*\*STUDENTS ONLY\*\***

Organized by  
ISPE Student Council

Included as part of the full meeting registration; registration required.

Attendees will be able to participate in two workshops while networking with other students and recent graduates.

- **How to Get Published.** Featuring presentations packed full of experience and tips about getting published from two distinguished editors and a panel discussion at the end.
- **Careers in Pharmacoepidemiology.** Speakers will provide insight into careers in academia, industry, not-for-profit, and regulatory sectors. There will be ample opportunity for questions following each speaker.

6:30-?

### Students/Young Professionals Meet and Greet (Hotel Silken Diagonal, Avenida Diagonal)

Meet and greet your fellow students and young professionals and enjoy a distinctive view of Barcelona's skyline including the impressive Agbar Tower and Gaudi's Sagrada Familia.



**Working together for a healthier world™**

Committed to improving health and well-being at every stage of life

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent

with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

We are proud to support the **28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management** and welcome the opportunity for the open exchange of scientific ideas and findings to advance the fields of pharmacoepidemiology and risk management.

A small change  
G to C  
with  
a  
huge  
difference

Visit our stand to hear about  
the change from GPRD to CPRD



## Clinical Practice Research Datalink

The English NHS 52 million real world data and interventional research service



Medicines and Healthcare products  
Regulatory Agency



National Institute for  
Health Research

7:30-6:00pm  
**Registration**  
(CCIB Lobby)

7:00-5:00pm  
**Speakers’  
Ready Room** (133)

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

8:30-Noon

### Registries/Prospective Cohort Studies (127-128)

**This workshop will address the following:**

- Registries using prospective observational cohort designs as alternatives to randomized controlled trials (RCTs).
- The scope and purpose of different types of registries and how they are being used today in pharmacoepidemiology and risk management.
- Considerations of registry development in terms of design and data sources; how they are operationalized and applications for research.

#### Educational Objectives

- To describe the evidence hierarchy and differentiate between the important features of various types of “registries” (or “registers”) and review the traditional terms used to describe timing (retrospective and prospective).
- To review the opportunities and developments of “registries” as tools to support pharmacoepidemiology, pharmacovigilance and risk management.
- To critically explore the challenges in the design, establishment and conduct of prospective observational cohort studies, with a focus on minimizing the influence of bias and confounding.

#### Target Audience

- Those interested in designing prospective observational cohort studies, including registries and registers.
- Those interested in conducting prospective studies of comparative effectiveness and safety.
- People wishing to learn how prospective studies, including registries, can be used to support risk management and pharmacovigilance.
- Anyone interested in knowing how prospective studies, including registries, are used to support pharmacovigilance.
- A modest understanding of epidemiologic methods is assumed.

#### Course Faculty/Presentations

**Nancy A. Dreyer, FISPE**, *Quintiles Outcome, Quality*

**Deborah Layton, DSRU**, *Registries and Prospective Cohort Studies - Workshop/Panel Discussion*

**Sonia Hernández Diaz, FISPE**, *Harvard School of Public Health, Pregnancy Registries*

**Saad Shakir, FISPE, DSRU**, *Special Challenges of Registries and Prospective Cohort Studies for Risk Management*

8:30-Noon

### Propensity Scores (131-132)

#### Course Faculty/Presentations

**John D Seeger**, Brigham & Women’s Hospital, *Introduction and Overview of Propensity Scores in Pharmacoepidemiology with Examples*

**Jeremy Rassen**, Brigham & Women’s Hospital, *Implications of Propensity Score – Based Analyses, Including Covariate Selection and Matching*

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

8:30-Noon

### Comparative Effectiveness Research (115)

The course explains the value of comparative effectiveness research (CER) and pragmatic evidence for improving healthcare decisions in the routine care setting by differentiating CER from efficacy or explanatory research. The speakers discuss the trade-offs between different study designs and types of data that were used to conduct CER: a pragmatic randomized controlled trial, a prospective registry, and a retrospective cohort study. Some of the studies combined different types of data to improve efficiency or validity. To illustrate those designs and data, the speakers present case studies from their past and ongoing CER studies. The course covers advanced methods for reducing the biases that can distort estimates of comparative effectiveness.

#### Educational Objectives

- Recognize the value of comparative effectiveness research for improving routine healthcare decisions and how it differs from efficacy or explanatory research.
- Appreciate the trade-offs between different study designs and types of data for conducting comparative effectiveness research.
- Understand methodologic challenges and proposed solutions in non-randomized effectiveness research

#### Target Audience

- The course is designed for those who conduct comparative effectiveness research and assumes knowledge of introductory pharmacoepidemiologic methods.

#### Course Faculty

**Eric S Johnson**, Kaiser Permanente  
**Sebastian Schneeweiss**, FISPE, Brigham & Women's Hospital  
**David J Magid**, Colorado Permanente Medical Group

8:30-Noon

### Intermediate Pharmacoepidemiology -- 2012 Theme: *Dealing with Unmeasured Covariates* (129-130)

Control for the effects of unmeasured covariates is a central problem of observational research. Pharmacoepidemiologists have adopted a wide range of tools to address this issue. Through lectures, examples, and group discussion, we will create a nosology of techniques for dealing with confounding by unmeasured covariates, and achieve a sufficient working knowledge to critically evaluate the uses of each approach. Methods to be covered include: Randomized trials; matching on person and provider; proxy variables for predictors of outcome and exposure; intermediate variables in the effects of covariates for predictors of outcome and exposure; instrumental variables.

#### Course Faculty

**Alexander Walker**, FISPE, WHISCON

8:30-Noon

### Regulatory Pharmacoepidemiology/Health Care Decision-Making (124-125)

#### Educational Objectives

- Understand the intent and structure of regulation to protect the Public Health.
- Appreciate the challenges of decision making with weak data.
- Know about practical approaches typically chosen by regulators.
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making.

- Gain an overview of worldwide challenges for drug regulatory agencies and variations in approach.
- Know about current strategies to strengthen regulation in the face of these challenges.

#### Course Faculty

**Stephen JW Evans**, FISPE, London School of Hygiene and Tropical Medicine  
**Gerald dal Pan**, US FDA  
**June Raine**, MHRA

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

8:30-Noon

### Introduction to Drug Utilization Research (113)

#### Content

- The educational session consists of 6 presentations providing an overview of drug utilization research and presenting essential methods.
- The theoretical framework will be described and the practical application of different methods will be illustrated using selected examples.
- Interpretation of study results taking into account limitations of data sources and methods will be addressed.
- Additional perspectives covered are the importance of drug utilization research for public health and implications for policy decisions.
- Interaction with participants will be encouraged, e.g., by presenting short questions to be considered by the audience, and by giving time for questions and answers during and at the end of presentations.

#### Educational Objectives

- To provide an overview of Drug Utilization Research within the context of Pharmacoepidemiology, Health Services Research and Public Health.
- To describe fundamental principles for classifying and quantifying drug use and to provide an understanding of the methodological challenges.
- To motivate researchers to cooperate on the collection of a minimum dataset of consistent and reliable data in their country or region, in terms of volume, expenditures and quality of drug use, facilitating international cross-national comparisons.
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for evaluating interventions, in particular in drug policy research (time series analysis).

Included as part of the full meeting registration; registration required.

#### Target Audience

- New members of the DUR/HSR SIG.
- Those interested in drug utilization research who need an overview of the area
- Those interested in monitoring medicine use and quality assurance aspects.
- Those working in health care organizations involved in payment and reimbursement of medicines.
- Those working in medicine policy areas.
- Health service planners.

#### Course Faculty/Presentations

- Björn Wettermark**, Centre For Pharmacopi Karolinska Institutet, *Methodical Framework and Skills Needed in Drug Utilization Research*
- Hanne Strøm**, WHO Collaborating Centre for Drug Statistics Methodology, *The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use*
- Morten Andersen**, Centre For Pharmacopi Karolinska Institutet, *Drug Utilization Research and Monitoring in Individual Based Registers - Study Designs and Epidemiological Measures of Drug Use*
- Vera Vlahovic-Palcevski**, Unit for Clinical Pharmacology University of South Australia, *Comparisons of Drug Utilization - Cross - National, Regional and Between Healthcare Units*

Noon -1:30pm

### Lunch On Your Own

Noon-1: 30pm  
**New Member Luncheon (116)**  
 (By Invitation)

1:30-6:00pm

### Advanced Topics in Pharmacoepidemiology (114)

This course is a series of four lectures, covering new and advanced methods of pharmacoepidemiology research.

#### Course Faculty/Presentations

- M Alan Brookhart**, Department of Epidemiology, University of North Carolina, *Early Experiences with Laboratory Data in Pharmacoepidemiologic Databases*
- Miguel Hernan**, Harvard School of Public Health, *Analyzing Observational Studies like Randomized Trials and Visa Versa*

- Mark van der Laan**, University of California Berkeley, *Targeted Maximum Likelihood Estimation in Safety Analysis*
- Tjeerd-Pieter Van Staa**, CPRD, *What Can Pharmacoepidemiology Contribute to Risk-Benefit Assessment?*

1:30-6:00pm

### Introduction to Therapeutic Risk Management and Evaluation – Focus on Implementation in the EU (113)

#### Educational Objectives

- To provide basic overview/framework for biopharmaceutical risk management including:
- Discussion of the implementation of the new EU legislation on Risk Management Plans (RMP).
- An update on US risk evaluation & mitigation strategies (REMS).

- To describe the current requirements for evaluation studies and types of results that have been seen in the past few years.
- To illustrate key concepts of evaluation research with examples of RMP/REMS assessment studies.
- To provide an opportunity for an interactive session in developing and evaluating a Risk Management Plan.

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

### Target Audiences

- Epidemiologists with little prior experience developing RMPs and REMS, and in conducting assessments of such programs.
- Pharmacovigilance and regulatory professionals who are involved with reviewing and negotiating risk RMPs/REMS and their assessments

### Course Faculty/Presentations

**Elizabeth Andrews, FISPE**, RTI Health Solutions, *Course Objectives and Introductions, Overview of Risk Management; and the Role of Evaluation*  
**Stella Blackburn, FISPE**, EMA, *Requirements and Lessons Learned from Evaluating Risk Management Programs in the EU*

**Gerald dal Pan**, US FDA, *Update from the FDA*

**Carla Van Bennekom**, Slone Epidemiology Center, *Examples of RMPs and Evaluations*

**Judith Jones, FISPE**, The Degge Group, *Workshop for Participants to Develop a Risk Management Plan, including an Assessment Approach*

1:30-6:00pm

### Advanced Drug Utilization Research (127-128)

This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel.

The session will involve participants in the:

- Use of drug utilization information from administrative health data to improve medicines use;
- Development of Prescribing Quality Indicators;
- Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention;
- Methods for evaluating the effect of clinical or policy interventions; and,
- Interpretation of the evaluation data and dissemination of results.

### Educational Objectives

- To gain an advanced understanding of planning, implementation and evaluation requirements for an effective quality use of medicines intervention.
- To develop a sophisticated understanding of the importance of project planning processes to the effectiveness of interventions.
- To develop an appreciation of the significance of this work to knowledge transfer at the patient care practice and policy change levels of the health system.

### Target Audience

- Members of the DUR/HSR SIG
- Those interested in quality development and implementation research,

knowledge transfer, evaluation of interventions, health and medicines policy areas, health funds and third party payers;

- Clinical pharmacoepidemiologists; health service planners; clinical guideline developers; and health practitioners.

### Course Faculty/Presentations

**Libby Roughead**, School of Pharmacy and Medical Sciences, University of South Australia, *Methods for Identifying and Managing Problems with Medicines Use in Practice*

**Petra Denig**, University of Groningen, *Developing Valid Prescribing Quality Indicators*

**Colin Dormuth**, PharmacoEpidemiology Working Group, University of British Columbia, *Evaluating Interventions on Drug Utilization: Analysis Methods*

**Jerry Avorn, FISPE**, Harvard Medical School and Brigham & Women's Hospital, *Using Pharmaco-epi to Understand and Improve Medication Use: A U.S. Perspective*

1:30-6:00pm

### Healthcare Databases (131-132)

Using pharmacoepidemiology database resources to address drug safety research.

This highly interactive workshop will:

- Examine the use of database resources in pharmacoepidemiology research;
- Define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource;
- Review the details of data resources within Europe;
- Identify the elements to properly select a study population, and;
- Explore a method to harmonize data from multiple resources.

### Educational Objectives

- Review the Guidelines for Good Database Selection and use in Pharmacoepidemiology Research.

- Gain an understanding of available pharmacoepidemiology resources.
- Develop the skills to select an appropriate resource to conduct pharmacoepidemiology research.
- Learn techniques to identify a study population and validate outcome measures.
- Examine methods for defining exposure.

### Target Audiences

- Members and potential members of the Database SIG.
- Those interested in exploring pharmacoepidemiology resources.

## PRE-CONFERENCE EDUCATIONAL SESSIONS (REGISTRATION REQUIRED)

- Those working in harmonizing data resources.
- Those working in creating analytic datasets.
- Clinical pharmacoepidemiologists.
- Clinical guideline developers.
- Those interested in validating outcomes in secondary databases.
- Health practitioners.

### Course Faculty/Presentations

**Kevin Haynes**, CPeRT, University of Pennsylvania, Co-Chair

**Alison Burke**, CSD EPIC, Co-Chair

**Gillian Hall**, FISPE, Independent Consultant, *Overview of Database Use in Pharmacoepidemiology*

**Matthew Reynolds**, UBC, *Selection of Databases for Pharmacoepidemiology Research*

**Olaf Klungel**, Utrecht University, & **Bing Cai**, Pfizer, *European Data Resources*

**Andrew Maguire**, UBC, & **Vincent Lo Re**, CPeRT, University of Pennsylvania, *Defining Exposure & Validation of Outcomes*

6:00-7:30pm

### Welcome Reception/Academic Showcase (CCIB Entrance Hall)

**Susana Perez-Gutthann**, FISPE, Chair, 2012 Scientific Program Committee

**Josep Lluís Segú**, Chair, 2012 Local Host Committee

**Nancy C Santanello**, FISPE, ISPE President

### Academic Showcase Participants:

- Boston University Schools of Public Health and Medicine - Slone Epidemiology Center
- Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania
- Division of Pharmacoepidemiology and Pharmacoeconomics of the Brigham and Women's Hospital, Harvard Medical School
- Drug Safety Research Unit (DSRU)
- London School of Hygiene & Tropical Medicine
- UNC Gillings School of Global Public Health

## Proven epidemiology expertise to meet your comprehensive drug safety research needs.

Rooted in scientific rigour, the methodologically innovative epidemiology experts of Optum™ can customize their services for work of any scope or specialty, including:

- Risk management—including study design, execution of risk management programmes and safety assessments
- Retrospective and prospective studies
- Regulatory/safety consulting
- Safety signal detection and refinement
- Provider/patient surveys
- Natural history of disease
- Publication and presentation
- Registries

Visit **Booth 16** during the 28th ICPE to learn more about how we can support your drug safety research—or contact Jessica Fachini today at +1 952.917.7085 or [jessica.fachini@optum.com](mailto:jessica.fachini@optum.com).

[www.optuminsight.com/life-sciences](http://www.optuminsight.com/life-sciences)

Optum is a leading health services business whose nearly 35,000 employees worldwide are dedicated to making the health system work better for everyone.



12-28568 © 2012 Optum. All Rights Reserved.



## A shared vision of real-world success

In a future where healthcare efficiency and quality are measured through the lens of 'real-world' insights, external validity demands a focus on the right data sources, best-in-class research and actionable communication.

### IMS is committed to helping you succeed:

- Largest multi-disciplinary team of experts in HEOR, epidemiology and risk management, based in 18 countries worldwide
- Credible scientific voice and deep therapy area knowledge, captured in 200+ publications each year
- Most advanced capabilities in real-world evidence (RWE) management and analysis leveraging relevant IMS proprietary and other key data assets
- Proven expertise in generating and communicating RWE to advance decision maker engagement at all levels
- Market leadership in developing and adapting robust economic models.

Visit the IMS Health team at ICPE in Barcelona. You can find us at stands 6 & 7.

- ✉ [HEORinfo@uk.imshealth.com](mailto:HEORinfo@uk.imshealth.com)
- 📞 Europe + 44 (0)20 3075 4800  
US +1 (703) 837 5150  
Asia Pacific +65 6412 7365  
Latin America + 52 (55) 50 62 52 00
- 🌐 [www.imshealth.com/heor](http://www.imshealth.com/heor)

7:00-6:00pm

**Registration** (CCIB Lobby)

7:00-5:00pm

**Speakers' Ready Room** (133)

7:00-8:00am

**Poster Session A Set-up**

(Exhibit Hall/Rooms 5-6-7-8)

8:00-6:00pm

**Exhibits/Posters**

(Exhibit Hall/Rooms 5-6-7-8)

8:15-10:00am

**OPENING SESSION (111-112)**

■ **Welcome**

**Susana Perez Gutthann, FISPE, Chair, 2012**  
*Scientific Program Committee*

■ **Presidential Address**

**Nancy C Santanello, FISPE, ISPE President**

■ **Keynote Address**

**Sir Michael Rawlins, Chairman, National Institute for Health and Clinical Excellence (NICE),** Perspectives on the Uses of Pharmacoepidemiology in Making Decisions About the Use of Medicines

10:00-10:30am

**Break/Posters/Exhibits**

(Exhibit Hall/ Rooms 5-6-7-8)

10:30 -Noon

**CONCURRENT SESSIONS:  
CONTRIBUTED PAPERS**

**How Sweet It Isn't (117)**

**Moderator: Kay Johannes & Ken Hornbuckle**

10:30am

- **Using Mailed-In Capillary Blood Samples To Detect Diabetes in Community-Dwelling Adults: Evaluation of an Innovative Strategy [1]**  
Elham Rahme, Jean-Louis Chiasson, Caroline Sirois, Youssef Habel, Kaberi Dasgupta. (Canada)

10:45am

- **Prevalence of Known Complications of Diabetes: A Comparison between Large EHR and Claims Databases in the U.S. [2]**  
Aaron WC Kamauu, Stephen Agbor, Emily Dastrup, Scott L DuVall, Bharat Thakrar, Debra Maldonado. (United States)

11:00am

- **Population Attributable Risk of Macrovascular Events Associated with HbA1c, Blood Pressure or Weight in Patients with Type 2 Diabetes Mellitus [3]**  
Edith M Heintjes, Fernie JA Penning-van Beest, Shreekant V Parasuraman, Susan Grandy, Mike Pollack, Ron MC Herings. (Netherlands)

11:15am

- **Population Attributable Risk of Microvascular Events Associated with HbA1c, Blood Pressure or Weight in Patients with Type 2 Diabetes Mellitus [4]**  
Edith M Heintjes, Fernie JA Penning-van Beest, Shreekant V Parasuraman, Susan Grandy, Mike Pollack, Ron MC Herings. (Netherlands)

11:30am

- **Clinical and Economic Benefits of Lowering Severely High Triglycerides on Cardiovascular Events, Pancreatitis, and Diabetes Among Patients with Type 2 Diabetes Mellitus [5]**  
Bhakti Arondekar, Jennifer B Christian, Erin Buysman, Rose Snipes, Terry A Jacobson. (United States)

11:45am

- **Risk Factors for Incident Diabetic Retinopathy in Type II Diabetes in UK Primary Care [6]**  
Elisa Martin-Merino, Joan Fortuny, Elena Rivero, Luis Alberto García-Rodríguez. (Spain)

**Inappropriate Use of Drugs (115)**

**Moderator: Joan-Ramon Laporte & Earl Goehring, Jr.**

10:30am

- **Investigating the Prevalence and Causes of Prescribing Errors in General Practice: The PRACTICE Study [7]**  
Anthony J Avery, Maisoon Ghaleb, Nick Barber, Bryony D Franklin, Sarah Armstrong, Sarah P Slight, Soraya Dhillon, Anette Freyer, Rachel Howard, Brian Serumaga, Olanrewaju Talabi. (United Kingdom)

10:45am

- **General Practitioner (GP) Variability in the Prescribing of Potentially Inappropriate Medication in Older Populations in Ireland [8]**  
Caitriona Cahir, Conor Teljeur, Tom Fahey, Kathleen Bennett. (Ireland)

11:00am

- **Guiding Therapy for Uncomplicated Urinary Tract Infection (UTI) [9]**  
Jessina C McGregor, Miriam R Elman, David T Bearden, David H Smith. (United States)

## 11:15am

- **Trends in Antidepressants and Tamoxifen Co-Prescribing among Women with Breast Cancer, 2004-2010 [10]**  
Stacie B Dusetzina, G Caleb Alexander, Rachel A Freedman, Haiden A Huskamp, Nancy L Keating. (United States)

## 11:30am

- **Prevalence and Correlates of Exceeding the Labeled Maximum Dose of Acetaminophen in the US Adult Population [12]**  
David W Kaufman, Judith P Kelly, Jeffrey M Rohay, Mary K Malone, Rachel B Weinstein, Saul Shiffman. (United States)

## 11:45am

- **Acetaminophen Use Patterns Associated with Excess Dosing [11]**  
Saul Shiffman, Jeffrey M Rohay, Judith P Kelly, Mary K Malone, Rachel B Weinstein, David W Kaufman. (United States)

## Life of the Cancer Patient (113)

**Moderators:** Daniel Mines & Robert F Reynolds, FISPE

## 10:30am

- **Treatment Patterns and Comorbidities in a Population-Based Cohort of Glioblastoma Patients (pts) Diagnosed 1997-2008 [13]**  
Susan A Oliveria, Laura Chu, Deborah Casso, Karen Wells, Wei Dong, Robert Dubrow, Asha Das, David Nerenz, Marianne Ulcickas Yood. (United States)

## 10:45am

- **The Rise of Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer (OPC) in Toronto, Canada: A Case for Vaccinating Males [14]**  
Steven Habbous, Karen P Chu, Anthony La Delfa, Luke Harland, Xin Qiu, Wei Xu, David P Goldstein, John Waldron, Brian O'Sullivan, Shao-Hui Huang, Geoffrey Liu. (Canada)



### Late Phase Research

Late Phase Clinical Trials  
Observational Studies & Registries  
Post Authorisation Safety Studies  
REMs & EU Risk Management Plans  
Direct to Patient Management



### Information Resources

Information, Dissemination  
& Education in Patient-Reported  
Outcomes & Epidemiology



### Strategic Consulting

Health Economics & Outcomes Research  
Patient-Reported Outcomes  
Market Access  
Evidence Synthesis  
Comparative Effectiveness  
Pharmacoeconomics  
Epidemiology  
Regulatory Affairs & Quality Management



### Linguistic Validation

In the field of Patient-Reported  
Outcomes and clinical assessments  
for appropriate cross-cultural use and  
interpretation

# MAPI

The Patient at the Heart of Our Concerns

## Meet us at booth #30

Boston • Berlin • Berwyn • Lexington • Lyon • London • Paris • Philadelphia • Toronto • Utrecht

## 11:00am

- **Risk of Congestive Heart Failure from Trastuzumab (Herceptin) in Elderly Persons with Breast Cancer: A Population-Based Study [740]**  
Huei-Ting Tsai, Claudine Isaacs, Solomon Makgoeng, Andrew N Freedman, Sheila Weiss Smith, Joan L Warren, Arnie L Potosky. (United States)

## 11:15am

- **The Validity of Prescription and Other Health Service Claims and Self-Report in Identifying Cases of Invasive Breast Cancer in Australia [16]**  
Anna Kemp, David B Preen, Kris Rogers, Christobel Saunders, C D'Arcy Holman, Max Bulsara, Fran Boyle, Elizabeth E Roughead. (Australia)

## 11:30am

- **Futile Drug Use at the End of Life? Continuation of Statins after a Cancer Diagnosis [17]**  
Efty Stavrou, Nicholas Buckley, Jake Olivier, Sallie-Anne Pearson. (Australia)

## 11:45am

- **The Associations between Treatment Interruption/Nonadherence to Tamoxifen and Mortality of Breast Cancer Patients: A Population Claim-Based Data Analysis in Taiwan [18]**  
Kun-Pin Hsieh, Li-Chia Chen, Chao-Sung Chang, Yi-Hsin Yang. (Taiwan)

## Methods Tapas (111/112)

Moderators: Tobias Gerhard, FISPE, & Jeremy Rassen

## 10:30am

- **The Impact of Unmeasured Confounders in Cardiovascular Studies Performed in Administrative Databases [19]**  
Odile Sheehy, Mary DeVera, Morgane Kermarrac, Lucie Blais, Elham Rahme, Sylvie Perreault, Jocelyne Moisan, Anick Bérard. (Canada)

## 10:45am

- **Comparison of Five Diagnosis Based Comorbidity Measures in Predicting Health-Related Quality of Life (HRQoL) in Multiple Sclerosis Patients [20]**  
Hemalkumar B Mehta, Sneha D Sura, Michael L Johnson. (United States)

## 11:00am

- **Combining Data in Multi-Country Studies: Mega-Analysis Versus Meta-Analysis [21]**  
Marloes T Bazelier, Joan Bentzen, Peter Vestergaard, Hubert GM Leufkens, Frank de Vries. (Netherlands)

## 11:15am

- **Design Aspects of Pharmacoepidemiological Two-Phase Studies [22]**  
Sigrid Behr, Walter Schill, Iris Pigeot. (Germany)

## 11:30am

- **Use of Claims Data To Predict Dependence in Older Adults [23]**  
Keturah R Faurot, Maurice A Brookhart, Michele L Jonsson Funk, Virginia Pate, Wendy Camelo Castillo, Til Stürmer. (United States)

## 11:45am

- **Automated Identification of Asthma Patients within an Electronical Medical Record Database Using Machine Learning [24]**  
Marjolein Engelkes, Zubair Afzal, Hettie M Janssens, Jan A Kors, Martijn J Schuemie, Katia MC Verhamme, Miriam CJM Sturkenboom. (Netherlands)

## Pregnancy: Macedonia (114)

Moderator: Anick Bérard, FISPE & Stephan Lanes

## 10:30am

- **Clarithromycin Use in Early Pregnancy and the Risk of Miscarriage – A Register Based Nationwide Cohort Study [25]**  
Jon T Andersen, Espen Jimenez-Solem, Morten Petersen, Kasper Broedbaek, Nadia L Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)

## 10:45am

- **Drug Utilization among Pregnant Diabetic Women in US Managed Care [26]**  
Caitlin A Knox, Joseph A Delaney, Almut G Winterstein. (United States)

## 11:00am

- **Pregnancy Outcomes in Women Dispensed Ondansetron in Pregnancy [27]**  
Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)

## 11:15am

- **TNF $\alpha$  Therapies during Pregnancy and Birth Outcomes: A Nordic Population-Based Study [28]**  
Helle Kieler, Miia Artama, Johan Askling, Gabriella Bröms, Mika Gissler, Anders Ekbo, Mette Noergaard, Lars Pedersen, Olof Stephansson, Henrik Toft Sørensen, Fredrik Granath. (Sweden)

## 11:30am

- **Inflammatory Bowel Disease in Pregnancy and Thrombophilic Disorders – Impact of Type of Disease and Treatment [29]**  
Gabriella Bröms, Marie Linder, Fredrik Granath, Maria Elmberg, Olof Stephansson, Helle Kieler. (Sweden)

## 11:45am

- **Microtia: Findings Suggest No Association with Vasoactive Medications [30]**  
Carla M Van Bennekom, Allen A Mitchell, Cynthia A Moore, Martha M Werler. (United States)

## Put Your Money Where Your Heart Is (116)

Moderator: Margaret McDonald & Ulf Bergman, FISPE

### 10:30am

- **The Clinical and Economic Costs Associated with Elevated Triglyceride Levels [31]**

Bhakti Arondekar, Jennifer B Christian, Erin Buysman, Susan L Johnson, Kimberly A Lowe, John D Seeger, Terry A Jacobson. (United States)

### 10:45am

- **Development of a Model Predicting the Medico-Economic Impact of Telemonitoring for Patients with Heart Failure in France [32]**

Samuel Aballéa, Patrice Verpillat, Mohamed-Elmoctar Neine, Yevgeniy Goryakin, Mondher Toumi. (France)

### 11:00am

- **Are Vasodilators of Value in the Care of Patients Hospitalized for Acute Heart Failure? [33]**

Mei Sheng Duh, Francis Vekeman, Adi Eldar-Lissai, Alex Trahey, Siew Haw Ong, Alan H Gradman. (United States)

### 11:15am

- **Comparative Cost-Effectiveness of Interventions To Improve Medication Adherence after Myocardial Infarction [34]**

Kouta Ito, William Shrank, Jerry Avorn, Amanda Patrick, Troyen Brennan, Elliott "Antman, Niteesh Choudhry. (United States)

### 11:30am

- **Impact of Full Coverage for Preventive Medications after Myocardial Infarction on the Time Course of Adherence [35]**

Robert J Glynn, William H Shrank, Jerry Avorn, Raisa Levin, Niteesh K Choudhry. (United States)

### 11:45am

- **Contribution of Lifestyle Factors to Healthy-Adherer Bias in Prevalent Users of Antihypertensive and Lipid-Lowering Drugs [36]**

Mitsuyo Kinjo, Soko Setoguchi. (Japan)

## Value through Innovation



### Even with more than 125 years of experience, we remain intensely curious. For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company, today operating with 145 affiliates. Research is our driving force. And we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. With more than 44,000 employees worldwide and a track record built up in more than 125 years, we are continuously dedicated to improving the outlook for a healthier life.

Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an email to [epidemiology@boehringer-ingelheim.com](mailto:epidemiology@boehringer-ingelheim.com) indicating your interest.

[www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)

PHARMAC  
EPIDEMIOLOGY



**Noon -1:30pm**

**Lunch/Poster Session A/Exhibits**  
(Exhibit Hall/Rooms 5-6-7-8)

**ISPE Committee/Council Meetings**

*Open to all members and new members. Lunch will be available in committee rooms.*

- **Development Committee** (132)
- **Fellowship & Awards Committee** (M211)
- **Finance Committee** (M215)
- **Public Policy Committee** (M214)
- **Student Council** (124-125)

**12:15-1:15pm**

**Round Table Discussions**  
(CCIB Entrance Hall)

*To foster the ability of the more junior ISPE members to network and new ISPE members to meet others attending the ICPE, we are hosting several informal lunchtime discussion roundtables on Friday and Saturday. The facilitators and topics for the tables are listed below. There will be NO formal presentations made at the roundtables. The purposes are discussion, information exchange, and networking. Seating is limited; first-come, first-served.*

- **Jamie Geier, GSK**, Practical Aspects of Implementing Benefit/Risk Frameworks within Companies.
- **Danica Marinac-Dabic**, US FDA, Medical Device Epidemiology and Surveillance: Focus on Registries and Innovative Methods Development.
- **June Raine, EMA**, Post-Marketing Surveillance of New Medicines.

**12:45-1:30pm**

**Poster Walks**  
(Exhibit Hall/Rooms 5-6-7-8)

- **Biologics SIG**
- **Pediatrics SIG**

**1:30-3:00pm**

**CONCURRENT SESSIONS:  
CONTRIBUTED PAPERS**

**Breathless in Barcelona (114)**

**Moderators:** Kourtney Davis & Eric Von Ganse

**1:30pm**

- **Examination of Emergency Inpatient Readmissions within 30 Days from the First Hospitalised COPD Exacerbation in England [37]**  
Andrew M Lawton, Rachael D DiSantostefano, Hana Müllerova. (United Kingdom)

**1:45pm**

- **Safety of Long-Acting beta Agonists (LABA) with or without Inhaled Corticosteroids in Asthma [38]**  
Mohsen Sadatsafavi, Carlo Marra, Larry Lynd, Mark FitzGerald. (Canada)

**2:00pm**

- **Inhaled Corticosteroid (ICS) Use in Chronic Obstructive Pulmonary Disease(COPD) and the Risk of Pneumonia [39]**  
Kristijan H Kahler, Barbara Yawn, Haijun Tian, Frank Li, Jie Zhang, Steve Arcona. (United States)

**2:15pm**

- **Relative Exposure to Inhaled Steroids (Ratio "ICS-to-Total Asthma Therapy"): Concordant Data from Electronic Medical Records (EMRs), Claims Data and Patient-Reported Outcomes (PROs) [40]**  
Laurent Laforest, Licaj Ildir, Gilles Devouasoux, Genevieve Chamba, Laurent Letrilliant, Laure Com Ruelle, Eric H Van Ganse. (France)

**2:30pm**

- **Impact of Omalizumab Initiation on Emergency-Department Visits, Hospitalizations and Corticosteroid Use in Patients with Uncontrolled Asthma Using High-Dose Inhaled Corticosteroids and Long-Acting Beta2-Agonists [41]**  
Marie-Hélène Lafeuille, Jason Dean, Jie Zhang, Mei Sheng Duh, Boris Gorsh, Patrick Lefebvre. (Canada)

**2:45pm**

- **Effectiveness of Omalizumab on Asthma Exacerbations Following Its Introduction in a Large Cohort of Patients with Severe Uncontrolled Asthma [42]**  
Lamiae Grimaldi-Bensouda, Mahmoud Zureik, Michel Aubier, Marc Humbert, Jean Levy, Jacques Benichou, Lucien Abenheim, Mathieu Molimard, (PAX) Group. (France)

**Broken Hearts or Bleeding Bodies (113)**

**Moderators:** Klaas Heinemann & Cristina Varas-Lorenzo

**1:30pm**

- **Pattern of Anticoagulation Control and Risk of Stroke, Bleeding and Mortality [43]**  
Hendrika A van den Ham, Olaf H Klungel, Hubert GM Leufkens, Tjeerd P van Staa. (Netherlands)

**1:45pm**

- **The Use of Single, Dual, or Triple Antithrombotic Therapy and the Risk of Bleeding Events in Patients with Atrial Fibrillation [44]**  
Laurent Azoulay, Sophie Dell'Aniello, Teresa Simon, Christel Renoux, Samy Suissa. (Canada)

## 2:00pm

- **Intrauterine Devices and the Risk of Uterine Perforations: Interim Results from the EURAS-IUD Study [45]**  
Klaas Heinemann, Suzanne Reed, Jürgen Dinger. (Germany)

## 2:15pm

- **Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting [46]**  
Joshua J Gagne, Jennifer M Polinski, Jeremy A Rassen, Michael A Fischer, John D Seeger, Jessica A Myers, Jun Liu, Sebastian Schneeweiss, Niteesh K Choudhry. (United States)

## 2:30pm

- **Risk of Acute Myocardial Infarction (AMI), Stroke, and Death in Parkinson's Disease (PD) Patients Treated with Entacapone (Entac) or Other Adjunctive Therapies (AT) [47]**  
David J Graham, James R Williams, Ya-Hui Hsueh, Katlyn Calia, Mark Levenson, Simone P Pinheiro, Thomas E MaCurdy, Chris Worrall, Jeffrey A Kelman. (United States)

## 2:45pm

- **Heralding of STEMI and NSTEMI: A Prospective CALIBER Study [48]**  
Emily Herrett, Julie George, Harry Hemingway, Liam Smeeth. (United Kingdom)

## Diabetic Treatment Outcomes Around the World (111-112)

Moderators: **Jeanne Loughlin & Alejandro Arana, FISPE**

## 1:30pm

- **Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case-Control Study [49]**  
Fei-Yuan Hsiao, Pei-Hua Hsieh, Wen-Foung Huang, Yi-Wen Tsai, Churn-Shiouh Gau. (Taiwan)

## 1:45pm

- **Long-Term Therapy with Thiazolidinediones May Be Associated with Increased Incidence of Bladder Cancer [50]**  
Ronac Mamtani, Kevin Haynes, Warren B Bilker, David J Vaughn, Brian L Strom, Karen Glanz, James D Lewis. (United States)

## 2:00pm

- **Effect of Metformin Versus Other Antidiabetic Drugs on Colorectal Cancer Stage [51]**  
Susan Spillane, Kathleen Bennett, Linda Sharp, Thomas I Barron. (Ireland)

## 2:15pm

- **Comparative Lung Cancer Mortality with Inhaled Insulin or Comparator: An Observational Follow-Up Study of Patients Previously Enrolled in Exubera Controlled Clinical Trials (FUSE) [52]**  
Nicolle M Gatto, Daniel O Koralek, Michael B Bracken, William T Duggan, Joanna Lem, Sol S Klioze, Neville C Jackson. (United States)

## 2:30pm

- **Risk of First Severe Hypoglycaemic (SH) Coma Event among Patients with Diabetes Who Initiate the Use of Detemir (IDet), Glargine (IGla) and NPH Insulins: A Nationwide Register-Linkage Study in Finland [53]**  
Pasi Korhonen, Fabian Hoti, Panu Erästö, Sari Mäkimattila, Tero Saukonen, Jari Haukka. (Finland)

## 2:45pm

- **Characteristics of Patients Initiating Oral Antidiabetic Therapy in the UK: Evidence of Delayed Treatment? [54]**  
Andrew Maguire, Beth Mitchell. (United Kingdom)

## Drug Utilization in Cardiovascular Disease (116)

Moderators: **Brian Godman & Soko Setoguchi-Iwata, FISPE**

## 1:30pm

- **Time Trends in Antihypertensive Drug Use and Blood Pressures in Swedish Primary Health Care 2001-2008 [55]**  
Magnus Vretblad, Björn Wettermark, Thomas Kahan, Jan Hasselström. (Sweden)

## 1:45pm

- **Predictors of First-Step Antihypertensive Treatment among Older Adults at High Risk for Cardiovascular Outcomes [56]**  
Xiaojuan Li, Wendy Camelo-Castillo, Til Stürmer, Christine L Gray, Virginia Pate, Michele Jonsson Funk. (United States)

## 2:00pm

- **Oral Hypoglycemic Agent Adherence and Hospitalization among Patients with Type 2 Diabetes: A Call for Enhanced Guidelines [57]**  
Vivienne J Zhu, David G Marrero, Wanzhu Tu, Marc B Rosenman, Marc J Overahge. (United States)

## 2:15pm

- **Drug Treatment after Transient ischaemic Attack or Ischaemic Stroke: Are We Doing Enough To Reduce Secondary Risk? [58]**  
Janet K Slugggett, Gillian E Caughey, Michael B Ward, Andrew L Gilbert. (Australia)

## 2:30pm

- **Potentially Inappropriate Drugs in Elderly Hypertensive Patients with Impaired Renal Function [59]**  
Katharina Schmidt-Mende, Björn Wettermark, Morten Andersen, Jan Hasselström. (Sweden)

## 2:45pm

- **Prevalence of Potentially Inappropriate Medication Prescribing among Older US Adults [60]**  
Marcela Jiron, Virginia Pate, Michele Jonsson Funk, Til Stürmer. (Chile)

## Pregnancy, Brains and Pains (115)

**Moderator:** David Miller & Elena Rivero, FISPE

**1:30pm**

- **Treatment of Depression during Pregnancy and Its Effect on Infant NICU Admission [61]**  
De-Kun Li, Jeannette R Ferber. (United States)

**1:45pm**

- **Bipolar Disorder, Mood Stabilizers and Adverse Pregnancy Outcome – A Population Based Cohort Study [62]**  
Robert Bodén, Maria Lundgren, Lena Brandt, Johan Reutfors, Morten Andersen, Helle Kieler. (Sweden)

**2:00pm**

- **Childhood Overweight Following Fetal Exposure to Selective Serotonin Reuptake Inhibitors and Maternal Psychiatric Illness [63]**  
Luke E Grzeskowiak, Andrew L Gilbert, Thorkild IA Sorensen, Jorn Olsen, Henrik T Sorensen, Lars H Pedersen, Janna L Morrison. (Australia)

**2:15pm**

- **Antidepressant Use during Pregnancy and the Risk of Delay in Overall Cognitive Development at 1 Year Old: Results from the OTIS Antidepressants Study [64]**  
Anick Berard, Fatiha Karam, Odile Sheehy, Marie-Claude Huneau, Lucie Blais, Gerald Briggs, Christina Chambers, Adrienne Einarson, William Fraser, Andrea Gaedgik, Diana Jonhson, Kelly Kao, Gideon Koren,

Brigitte Z Martin, Janine E Polifka, Sara H Riordan, Mark Roth, Richard E Tremblay, Sharon Voyer Lavigne, Lori Wolfe, OTIS Collaborative Research Group. (Canada)

**2:30pm**

- **Validating a Gestational Length Algorithm Based on Administrative Health Plan Data [65]**  
Qian Li, Susan E Andrade, William O Cooper, Robert L Davis, Sascha Dublin, Tarek A Hammad, Pamala A Pawloski, Simone P Pinheiro, Marsha A Raebel, Pamela E Scott, David H Smith, Inna Dashevsky, Katherine Haffener, Karin E Johnson, Sengwee D Toh. (United States)

**2:45pm**

- **Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Miscarriage: A Nested Case-Control Study [66]**  
Lars Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Vera Ehrenstein. (Denmark)



## Helping families lead healthier lives.

Families today are busier than ever, with less time for healthy homemade meals. Yet, we know diet affects our weight, energy and overall health. Still, nearly a third of American adults<sup>1</sup> and 17% of children in the U.S.<sup>2</sup> are obese. Unless addressed, this trend will have devastating health effects on current and future generations.

That's why *Lilly for Better Health™* goes beyond medicine with practical health tips and innovative interactive tools to help families achieve a more balanced lifestyle, which includes proper nutrition and physical activity.

Visit [lillyforbetterhealth.com](http://lillyforbetterhealth.com) today. You'll find information and resources to help families get healthy and stay healthy — no matter the pace of life.

[lillyforbetterhealth.com](http://lillyforbetterhealth.com)



1 U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC. Available at <http://www.cnpp.usda.gov/Publications/DietaryGuidelines/2010/PolicyDoc/PolicyDoc.pdf>. Accessed May 10, 2011.

2 Centers for Disease Control and Prevention. NCHS Health E-Stat. Prevalence of Obesity Among Children and Adolescents: United States, Trends 1963-1965 Through 2007-2008. Available at [http://www.cdc.gov/nchs/data/hestat/obesity\\_child\\_07\\_08/obesity\\_child\\_07\\_08.htm](http://www.cdc.gov/nchs/data/hestat/obesity_child_07_08/obesity_child_07_08.htm). Accessed May 10, 2011.

Lilly for Better Health™ is a trademark of Eli Lilly and Company.  
M671948 0511 PRINTED IN USA ©2011, LILLY USA, LLC. ALL RIGHTS RESERVED.

## Propensity Scores Estan de Moda (117)

Moderators: **Til Stürmer, FISPE, & Patrice Verpillat**

### 1:30pm

- **Deriving Propensity Scores for Matching or Stratification in Studies with an Important Subgroup Variable as a Strong Confounder [67]**

Cynthia J Girman, Doug Kou, Mugda Kelkar, Kimberly G Brodovicz, Richard Wyss, Til Stürmer. (United States)

### 1:45pm

- **Optimal Approaches to One-to-Many Propensity Score Matching in Cohort Studies [68]**

Jeremy A Rassen, Abhi A Shelat, Jessica Myers, Robert J Glynn, Kenneth J Rothman, Sebastian Schneeweiss. (United States)

### 2:00pm

- **Comparison of Propensity-Score-Weighted and -Matched Estimates in a Comparative Effectiveness Study: A Demonstration Using STAR\*D Trial Data [69]**

Alan R Ellis, Stacie B Dusetzina, Richard A Hansen, Bradley N Gaynes, Joel F Farley, Til Stürmer. (United States)

### 2:15pm

- **Use of Confounders' Time Patterns To Improve Bias Adjustment with High-Dimensional Propensity Scores [70]**

Jeremy A Rassen, Shirley Wang, John Seeger, Sebastian Schneeweiss. (United States)

### 2:30pm

- **A Comparison of Boosted CART and Logistic Regression for the Estimation of Propensity Scores [71]**

Richard Wyss, Alan R Ellis, Cynthia J Girman, Robert LoCasale, Til Stürmer. (United States)

### 2:45pm

- **Evaluating Propensity Score Balance Measures in Typical Pharmacoepidemiological Settings [72]**

Mohammed S Ali, Rolf HH Groenwold, Wiebe R Pestman, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Anthonius de Boer, Olaf H Klungel. (Netherlands)

### 3:30-5:00pm

## PLENARY SESSION (111/112)

### ADHD Medication and the Risk of Cardiovascular Events

There has been controversy in recent years regarding the question as to whether ADHD medication increases the risk of adverse cardiovascular events. This session will provide an overview of the studies at the core of the controversy and place them in the context of the increasing frequency of ADHD diagnosis and the associated increase in use of stimulants in the young population. Risk benefit considerations will be discussed from an academic, clinical and regulatory perspective.

Co-Chairs: **William Cooper & Sonia Hernández Díaz, FISPE**

- **William Cooper, Vanderbilt University.** Setting the Scene. The frequency of ADHD diagnosis, and associated utilisation of stimulants increasing in North America and Europe. The first presentation will give an overview of the controversy in the context of what is ADHD, issues with diagnosis, and treatment choices. William Cooper's study was published in the NEJM and concluded there was no evidence of an increase in cardiovascular risk associated with stimulant use, although a doubling of risk could not be ruled out.
- **Helga Zoega, University of Iceland.** Utilization patterns of stimulants in the USA and Europe and association with academic progress associated with starting treatment at younger or older age; two studies demonstrating late initiation in treatment is associated with poorer academic performance in math and languages compared with earlier initiation of treatment. Helga Zoega may not be known to all, but comes highly recommended as an excellent speaker by Sonia Hernandez Diaz and Ken Rothman, who were involved with her study.
- **Almut Winterstein, University of Florida.** Results of the second federally funded US cardiac safety study. Sample size very similar to William Cooper's cohort (publication in NEJM), but sampled from Medicaid only. Because of this, high-risk children could be included and have a stratified analysis. Besides the major endpoint of sudden cardiac death/AMI/stroke, we also have a secondary analysis on arrhythmia, which may be of interest. There are also some interesting methodological considerations in looking at very rare events, which are driven largely by high-risk kids.
- **June Raine, MHRA.** Summary of the evidence, reactions to the various stages of the development, and perspective.
- **Panel discussion.**

### 3:00-3:30pm

## Break/Posters/Exhibits

(Exhibit Hall/Rooms 5-6-7-8)

5:00-6:30pm

## CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

### Advanced Methods and Measures for Studying Complex Drug Utilization Patterns with Patient-Level Databases [73] (111/112)

- Petra Denig, Morten Andersen, Helle Wallach Kildemoes, Lisa Pont, Jaco Voorham, Jean Pierre Grégoire. (Netherlands)

### Biases To Consider When Studying the Risk of Medication Use in Pregnancy [74] (117)

- Marian K Bakker, Heli Malm, Hao Wang, Rachel Charlton, Kristin Palmsten, Lolkje TW de Jong-van den Berg. (Netherlands)

*SPONSORED BY THE MEDICINES IN PREGNANCY SIG*

### Databases, Therapeutics, and Biomarkers: The Challenges and Rewards of Incorporating Biological Specimens in Pharmacoeconomic Research [75] (113)

- Leah B Sansbury, Kimberly A Wilson, Joanna F Haas, Bruce Carleton, Tjeerd-Pieter van Staa, Catherine Schaefer. (United States)

*SPONSORED BY THE MOLECULAR EPI/  
BIOMARKERS/PHARMACOGENETICS SIG*

### How To Conduct Collaborative Studies in the EU? Lessons and Results from the Completed Safety of NSAIDs (SOS) Project [76] (114)

- Miriam C Sturkenboom, Annie Fourier-Réglat, Susana Perez-Gutthán, Edeltraut Garbe, Federica Nicotra, Silvana Romio, Eva Molero, Ron Herings, Frantz Thiessard. (Netherlands)

### Improving the Science of Regulatory Decision-Making Advances in 2011/2012 [77] (115)

- Stanley A Edlavitch, Gerald J dal Pan, June M Raine, Bert Leufkens, Jerry Avorn. (United States)

### Medicare Part D Data: Will the US Population-Based Data Be Advancing Pharmacoepidemiology and Public Health? [78] (116)

- Til Stürmer, Michele Jonsson Funk, Kourtney J Davis, David J Graham, Elizabeth Andrews, Jesper Hallas. (United States)

### Unique Device Identification System (UDIS): Implications for Postmarketing Safety and Effectiveness Assessment in the United States and Europe [79] (132)

- Danica Marinac-Dabic, Art Sedrakyan, Michael Steinbuch, Jessica Jalbert, Jay Crowley, Gerold Labek, Mary Beth Ritchey, Soko Setoguchi. (United States)

*SPONSORED BY THE MEDICAL DEVICES SIG*

6:30-7:30pm

## ISPE Council Meetings

Open to all members and new members.

- Academic Council (115)
- Government/Regulatory Council (114)
- Industry/Service Providers Council (116)

7:30-8:30pm

## PDS Editorial Board (124-125)

- By Invitation

8:30pm – ?

## Students/Young Professionals Night Out (Chiringuito Incercia)

- **Do you like the sound of the sea?** Chill-out music? Catching up with old ISPE friends? Making new friends? Come to the Student/Young Professionals dinner in a beach chiringuito and enjoy Barcelona's nightlife. A few metro stops from the CCIB stop.
- **Space is limited.** The dinner is open to students/young professionals who have RSVP'd and received confirmation from the Student Council Chairs.



Image: Vil·la Olímpica Beach  
Author: J. Trullàs  
Credit: Turisme de Barcelona



Bayer HealthCare is a globally operating company with sites on all five continents. Approximately 55,700 people work for the Bayer subgroup in more than 100 countries at all stages of the value-added chain. Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG.

We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products.

We concentrate on five big therapeutic groups in which we make essential contributions to medical progress:

- Cardiovascular and blood diseases
- Oncological diseases
- Ophthalmology
- Women's healthcare
- Imaging techniques

Our Global Epidemiology organization is currently establishing its operations around the world. Opportunities for Epidemiologists with pharmaceutical experience exist at the Associate Director/Senior Epidemiologist and Director level in the US and Europe. To learn more, contact: Montse Soriano-Gabarró at + 49 30 468 194270

For Information about Bayer Healthcare go to  
<http://www.bayerhealthcare.com/scripts/pages/en/index.php>

Bayer is an equal opportunity employer, embracing diversity throughout our global workforce.

7:00-6:00pm  
**Registration**  
 (CCIB Lobby)

7:00-5:00pm  
**Speakers' Ready Room** (133)

7:00-8:00am  
**Poster Session B Set-up**  
 (Exhibit Hall/ Rooms 5-6-7-8)

7:30-8:30am  
**EuroDURG General Assembly**  
 (124-125)

8:00-6:00pm  
**Exhibits/ Posters**  
 (Exhibit Hall/ Rooms 5-6-7-8)

8:30-10:00am

## CONCURRENT SESSIONS: CONTRIBUTED PAPERS

**"A Joint Session" on Aches and Pains**  
 (111-112)

**Moderator:** Doug Watson & Edeltraut Garbe

8:30am

- **Integrating Patient-Reported Outcomes (PRO) and Medical Record Data (MR) in Observational Studies: Results from a Direct-to-Patient Pilot Study in Gout [336]**  
 Elisa Cascade, Paige Marr, Matthew Winslow. (United States)

8:45am

- **Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study [337]**  
 Seoyoung C Kim, Craig Newcomb, David Margolis, Jason Roy, Sean Hennessy. (United States)

9:00am

- **Statins Do Not Influence Giant Cell Arteritis Outcome in the French APOGEE Cohort. A Population-Based Study Using the French Health Insurance System Database [338]**  
 Grégory Pugnet, Laurent Sailler, Robert Bourrel, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)

9:15am

- **Methotrexate Utilization in Rheumatoid Arthritis. Treatment Re-Starts after Gaps of at Least 90 Days [339]**  
 Annette de Thurah, Mette Nørgaard, Rikke Nielsen, Kristian Stengaard-Pedersen. (Denmark)

9:30am

- **Risk of Serious Infection and Malignancy in Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Biologics [340]**  
 Veena Thyagarajan, Heather Norman, Cheryl Enger. (United States)

9:45am

- **Occurrence of Osteonecrosis and Total Joint Replacement among Patients with Osteoarthritis [341]**  
 Kandace L Amend, Daniel Koralek, David D Dore. (United States)

**CV Meds: What Would You Do? (117)**

**Moderators:** K. Arnold Chan, FISPE, & Jennifer Christian

8:30am

- **The Effect of Statin Use on Acute Kidney Injury Risk Following Coronary Artery Bypass Graft Surgery [342]**  
 J Bradley Layton, Abhijit V Kshirsagar, Ross Simpson, Virginia Pate, Michele Jonson-Funk, Til Stürmer, M Alan Brookhart. (United States)

8:45am

- **Statin Use and Risk of Atrial Fibrillation or Flutter: A Population-Based Case-Control Study [343]**  
 Giacomo Veronese, Jonathan Montomoli, Morten Schmidt, Erzsébet H Puhó, Henrik T Sørensen. (Denmark)

9:00am

- **The Assessment of Statin-Associated Severe Muscle Toxicity in Japan - by Using Claims Database with Laboratory Information [344]**  
 Chia-Hsien Chang, Makiko Kusama, Manabu Akazawa, Yea-Huei Kao Yang. (Taiwan)

9:15am

- **Cardiovascular Risk of Olmesartan (Olm) Compared with Other Angiotensin-II Receptor Blockers (ARBs) [345]**  
 David J Graham, Xiao Ding, Shahin Saneinejad, Esther H Zhou, Katlyn Calia, Mark Levenson, Kate Gelperin, Martin Rose, Tarek A Hammad, Thomas E MaCurdy, Chris Worral, Jeffrey A Kelman. (United States)

9:30am

- **Angioedema Events and Use of Drugs That Act on the Renin-Angiotensin-Aldosterone System (RAAS) [346]**  
 Darren Toh, Marsha E Reichman, Monika Houstoun, Marry Ross Southworth, Xiao Ding, Adrian F Hernandez, Mark Levenson, Lingling Li, Azadeh Shoaibi, Gwen Zornberg, Sean Hennessy. (United States)

9:45am

- **Risk of Acute Renal Failure Likely Due to Concurrent Use of ACE-Inhibitors, Angiotensin Receptors Blockers, Diuretics and Anti-Inflammatory Drugs [347]**  
 Francesco Lapi, Laurent Azoulay, Hui Yin, Samy Suissa. (Canada)

## Diabetes:

### A Little Bit of This and That (113)

Moderators: Michael Steinbuch & Dorothee Bartels

#### 8:30am

- **International Comparison of the Utilisation of Anti-Diabetic Medicines [348]**  
Agnes I Vitry, Zhi Hui Eeow, Gillian E Caughey. (Australia)

#### 8:45am

- **The Impact of a National Program on Judicious Use of Antidiabetic Medicines [349]**  
Yeqin Zuo, Jeff Elliott, Louise Lor, Mark Bartlett, Jonathan Dartnell, Lynn Weekes. (Australia)

#### 9:00am

- **Validation of Diabetic Retinopathy and Maculopathy Diagnoses Recorded in a UK Primary Care Database [350]**  
Elisa Martin-Merino, Joan Fortuny, Elena Rivero, Luis Alberto García-Rodríguez. (Spain)

#### 9:15am

- **Aspirin and the Risk of All-Cause Mortality in New Users of Oral Antidiabetes Drugs [351]**  
Caroline Sirois, Jocelyne Moisan, Elham Rahme, Jean-Pierre Grégoire. (Canada)

#### 9:30am

- **Statin Initiation in Elderly Patients Using Antidiabetes Drugs [352]**  
Marie-Laure Laroche, Marie-Claude Breton, Eric Demers, Jean-Pierre Gregoire, Jocelyne Moisan. (France)

#### 9:45am

- **Antipsychotics and the Risk of Type 2 Diabetes in Children and Youth [353]**  
William V Bobo, William O Cooper, Charles M Stein, Mark Olsson, David Graham, James Daugherty, Catherine D Fuchs, Wayne A Ray. (United States)

### Do You Trust Your Data? (114)

Moderators: Stephen JW Evans, FISPE, & Susan Oliveira, FISPE

#### 8:30am

- **Validity of Diagnostic Codes and Liver-Related Laboratory Abnormalities To Identify Acute Liver Failure among Kaiser Permanente Patients with Diagnoses of Drug-Induced Hepatitis [354]**  
Vincent Lo Re, Kevin Haynes, Kimberly B Fortier, Dena M Carbonari, James D Lewis, Brian L Strom, Kimberly A Forde, David S Goldberg, K R Reddy, Jason A Roy, Amy R Marks, Jolanda De Beor, Douglas A Corley. (United States)

#### 8:45am

- **Validity of Administrative Data To Identify Off-Label Use of Second Generation Antipsychotics [355]**  
Daniel M Hartung, Luke Middleton, Bentson H McFarland, Marian S McDonagh, Dean G Haxby, K J McConnell. (United States)

#### 9:00am

- **Validation of ICD9 Coding as Reported in Administrative Data – Results from a Review of Patient Medical Records [356]**  
Robert G Sharrar, Glen Magee, Jane Koch, Scott Chavers. (United States)

#### 9:15am

- **Performance and Validity of Record Linkage without Unique Personal Identifiers [357]**  
Chih-Ying Chen, Jessica J Jalbert, Lauren Williams, Andrew Rothman, Lynne W Stevenson, Garrick C Stewart, John D Seeger, Soko Setoguchi. (United States)

#### 9:30am

- **Validation of Congenital Malformation Diagnostic Codes Recorded in Québec Administrative Databases [358]**  
Lucie Blais, Anick Bérard, Fatima-Zohra Kettani, Amélie Forget. (Canada)

#### 9:45am

- **Estimating Disease Progression in Metastatic Cancer Patients Using Dispensing Data: A Validation Study [359]**  
Vikram Joshi, Barbara-Ann Adelstein, Preeyaporn Srasuebku, Timothy Dobbins, Elements of Cancer Care (EoCC) Investigators, Sallie-Anne Pearson. (Australia)

### Hormones: Can't Live with Them, Can't Live without Them (115)

Moderators: Annlouise Assaf, FISPE, & David Dore

#### 8:30am

- **Long-Term Active Surveillance Study for Oral Contraceptives (LASS): Final Results on Cardiovascular Safety [360]**  
Klaas Heinemann, Anita Assmann, Sabine Moehner. (Germany)

#### 8:45am

- **VTE Risk in Users of Combined Oral Contraceptives: Impact of a 24-Day Regimen Containing Drospirenone [361]**  
Suzanne Reed, Kristina Bardenheuer, Juergen Dinger. (Germany)

#### 8:45am

- **Patterns Of Antihypertensive Medication Use in Medicaid - Eligible Pregnant Women [362]**  
Brian T Bateman, Sonia Hernandez-Diaz, Krista Huybrechts, Kristen Palmsten, Michael A Fischer. (United States)

#### 9:15am

- **Drospirenone Versus Other Progestin-Based Combined Oral Contraceptives and the Risk of Incident Ulcerative Colitis: A Comparative Safety Study [363]**  
Wei Liu, Steven T Bird, Mahyar Etminan, Joseph AC Delaney, Caitlin Knox. (United States)

#### 9:30am

- **Postmenopausal Estrogen Therapy Increases the Risk of Gallstone Disease – A Population-Based Case-Control Study [364]**  
Maja S Hellfritsch, Trine Frøslev, Rune Erichsen, Henrik T Sørensen. (Denmark)

#### 9:45am

- **The Safety of Oral Hormone Replacement Therapy: Final Results from the EURAS-HRT Study [365]**  
Klaas Heinemann, Anita Assmann, Jürgen Dinger. (Germany)

## Treating Pain (116)

**Moderators:** Nicholas Moore, FISPE, & Laura Wallace

### 8:30am

- **Trends in Opioid Prescribing between 2000 and 2009 in Germany. A Regional Claims Data Analysis [366]**  
Peter Ihle, Rainer Sabatowski, Ingrid Schubert. (Germany)

### 8:45am

- **Dramatic Increases in the Use of Strong Opioids in the Elderly [367]**  
C Ineke Neutel, Svetlana Skurtveit, Christan Berg. (Canada)

### 9:00am

- **Risk of Unintentional Overdose Following Outpatient Opioid Treatment for Pain [368]**  
Elizabeth V Lawler, Jennifer Fonda, David R Gagnon, John Hermos, Catherine Barber, Matthew Miller. (United States)

### 9:15am

- **Can the EU-ADR Database Network Detect Timely Drug Safety Signals? [369]**  
Gianluca Trifirò, Vaishali Patadia, Martijn Schuemie, Preciosa Coloma, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Federica Nicotra, Lars Pedersen, Joahn van der Lei, Miriam Sturkenboom. (Italy)

### 9:30am


- **Drug Intoxication in Patients Registered for Liver Transplantation for Acute Liver Failure: Results from the 7- Country SALT Study [370]**  
Ezgi S Gulmez, Séverine Lignot, Dominique Larrey, Georges P Pageaux, Jacques Bernuau, Franco Bissoli, Yves Horsmans, Jean L Montastruc, Bruno Stricker, Douglas Thorburn, Fatima Hamoud, Sophie Micon, Régis Lassalle, Jérémy Jové, Patrick Blin, Nicholas Moore. (France)

### 9:45am

- **Effect of Regulatory Measures on Nimesulide Utilization in the Lisbon Region [371]**  
Daniel Pinto, Pedro A Caetano, Bruno Heleno, António Faria-Vaz, Isabel Santos. (Portugal)

### 10:00-10:30am

**Break/Posters/Exhibits**  
(Exhibit Hall/  
Rooms 5-6-7-8)



RTI HEALTH SOLUTIONS®




RISKS AND BENEFITS:

**Define. Measure. Evaluate. Communicate.**

**SPECIAL GIFT!**

Receive a bottle of olive oil at our booth



We provide full-service solutions for your international epidemiological, safety, and risk management needs.

Visit our exhibit booth to learn how we can help you *define, measure, evaluate and communicate* the risks and benefits of your products.

[www.rtihs.org](http://www.rtihs.org)

LEADING RESEARCH...  
MEASURES THAT COUNT

Research Triangle Park • Ann Arbor • Barcelona • Lund • Manchester • Sheffield • Waltham

10:30-12:00pm

## CONCURRENT SESSIONS: CONTRIBUTED PAPERS

### Drug Utilization Research Methods (111-112)

**Moderator:** Suellen Curkendall & John D Seeger

**10:30am**

- **Are Low-Cost Generic Prescriptions Faithfully Captured in US Pharmacy Claims Databases? [372]**

Julie C Lauffenburger, M Alan Brookhart. (United States)

*Student Award Recipient – Third Best Abstract Submitted by a Student*

**10:45am**

- **Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi-Automatic Methods Using Anti-TNF Therapy as Model [373]**

Thomas Cars, Björn Wettermark, Gunnar Ekeving, Bo Vikström, Rickard Malmström, Lars L Gustafsson, Ulf Bergman, Martin Neovius, Bo Ringertz. (Sweden)

**11:00am**

- **Impact of Exposure Misclassification Due to Incomplete Drug Data in Observational Studies of Safety and Effectiveness [374]**

John-Michael Gamble, Jeffrey A Johnson, Finlay A McAlister, Sumit R Majumdar, Scot H Simpson, Dean T Eurich. (Canada)

**11:15am**

- **Drug Exposure Misclassification Because of Prior-Authorization Policies: A Cautionary Tale for Researchers Using Databases Limited to Formulary-Approved Prescriptions [375]**

John-Michael Gamble, Jeffrey A Johnson, Sumit R Majumdar, Finlay A McAlister, Scot H Simpson, Dean T Eurich. (Canada)

**11:30am**

- **Trajectory Models: A New Approach to Classifying and Predicting Long-Term Medication Adherence [376]**

Jessica A Myers, William H Shrank, Juliana Pakes, Niteesh K Choudhry. (United States)

**11:45am**

- **Non-Adherence to Chronic Drug Regimens When Costs Increase: Expected Drug Use and Non-Linear Cost-Sharing Effects [377]**

John Hsu, Maggie Price, Vicki Fung. (United States)

### NSAIDs - Measuring Drug Safety (117)

**Moderators:** Jordi Castellsagué & Doug Watson

**10:30am**

- **Comparing Measures of Regularity of NSAID Dispensings Based on Register Data [378]**

Tobias Svensson, Fredrik Granath, Morten Andersen. (Sweden)

**10:45am**

- **Impact of Case Validation on Incidence Rates of Upper Gastrointestinal Complications [379]**

Federica Pisa, Jordi Castellsague, Valentina Rosolen, Nuria Riera-Guardia, Manuela Giangreco, Daniela Drigo, Susana Perez-Gutthann, Fabio Barbone. (Italy)

**11:00am**

- **Risk of Acute Liver Failure Leading to Transplantation after NSAID or Paracetamol Exposure: Final Results of the 7 European-Country Study of Acute Liver Transplant (SALT) [380]**

Ezgi S Gulmez, Séverine P Lignot, Dominique Larrey, Corinne deVries, Susanna Perez-Gutthann, Jean L Montastruc, Miriam Sturkenboom, Jacques Bénichou, Giampaolo Velo, Achille Caputi, Francesco Salvo, Sophie Micon, Fatima Hamoud, Régis Lassalle, Jérémy Jové, Georges P Pageaux, Yves Horsmans, Jacques Bernuau, Franco Bissoli, Bruno Stricker, Douglas Thorburn, Angelo Gatta, Estela Monteiro, Irene Vafiadis, Aiden McCormick, Herold Metselaar, Emine Sen, Alison Nightingale, Patrick Blin, Nicholas Moore. (France)

**11:15am**

- **Risk of Ischemic Stroke Associated with the Use of Individual Non-Steroidal Anti-Inflammatory Drugs [382]**

Bianca Kollhorst, Tania Schink, Andrea Arfe, Ron Herings, Silvia Romio, Rene Schade, Martijn Schuemie, Hubb Stratman, Frantz Thiessard, Vera V Valkhoff, Christine Varas Lorenzo, Marco Villa, Miriam Sturkenboom, Edeltraut Garbe. (Germany)

**11:30am**

- **Nonsteroidal Anti-Inflammatory Drug Use and Brain Tumor Risk: A Nested Case-Control Study in General Practice Research Database. [383]**

Michael A O'Rouke, Finian J Bannon, Liam J Murray, Carmel M Hughes, Marie M Cantwell, Anna T Graves, Chris R Cardwell. (United Kingdom)

**11:45am**

- **Proton Pump Inhibitors and Traditional Nonsteroid Anti-Inflammatory Drugs and the Risk of Acute Interstitial Nephritis and Acute Kidney Injury [381]**

Charles E Leonard, Cristin P Freeman, Craig W Newcomb, Peter P Reese, Maximilian Herlim, Warren B Bilker, Sean Hennessy, Brian L Strom. (United States)

## Pediatric Tapas (113)

Moderators: Jennita Reefhuis & Helle Kieler

### 10:30am

- **Medication Use and Hospital Admission Rates among Preterm Born Children Compared to Full Term Born Infants [384]**  
Leanne MA Houweling, Irene D Bezemer, Fernie JA Penning-van Beest, Willemijn Meijer, Richard A van Lingen, Ron MC Herings. (Netherlands)

### 10:45am

- **Initial Findings from the Anti-Psychotics, Keep It Documented for Safety (A+KIDS) Medication Registry for North Carolina Medicaid Youth [385]**  
Robert B Christian, Joel F Farley, Jerry Mckee, David Wei, Troy Trygstad, Trista Pfeiffenberg, Steve Wegner, Brian B Sheitman. (United States)

### 11:00am

- **Influence of Relative Age on Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children [386]**  
Richard L Morrow, E Jane Garland, James M Wright, Malcolm Maclure, Suzanne Taylor, Colin R Dormuth. (Canada)

### 11:15am

- **Pediatric Acute Liver Injury: Signal Detection Using Multiple Healthcare Databases from EU-ADR Network [387]**  
Carmen Ferrajolo, Gianluca Trifiró, Peciosa M Coloma, Katia MC Verhamme, Matijn J Schuemie, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Carlo Giaquinto, Lorenza Scotti, Paul Avillach, Lars Pedersen, Johan van der Lei, Miriam CJM Sturkenboom. (Netherlands)

### 11:30am

- **Determinants of Atomoxetine and Central Nervous System Stimulant Treatment Initiation [388]**  
Stephan Linden, Almut G Winterstein. (United States)

### 11:45am


- **Prevalence and Determinants of ADHD Medication of Children and Adolescents in Germany – Results of the KiGGS Study [389]**  
Hildtraud C Knopf, Heike Hölling, Robert Schlack. (Germany)



Identify, collect, analyze and communicate real-world data with UBC's evidence generation and analysis solutions.

The data tell a compelling story. The profile and burden of a disease. How it's treated. Where it's treated and by whom. The impact of a treatment. How it's valued. And how it's reimbursed. In short, the data can inform your strategy and optimize products positioning, uptake and health policy. Data matters.

UBC understands how to generate and analyze the right evidence to improve your product's performance. **Visit our booth to learn more and meet our staff.**



*Because evidence matters...*

US +1 866 458 1096  
EU +44 (0) 20 8834 0100  
info@unitedbiosource.com  
**unitedbiosource.com**

## Personalized Medicine Tapas (114)

Moderators: Geoffrey Liu & Anokhi Kapasi

10:30am

- **The SLCO1B1 c.521T>C Polymorphism and the Risk of Adverse Reactions during Simvastatin and Atorvastatin Therapy [390]**  
Catherine E de Keyser, Matthijs L Becker, Anke-Hilse Maitland-van der Zee, André G Uitterlinden, Albert Hofman, Loes E Visser, Bruno H Stricker. (Netherlands)

10:45am

- **CYP2C9 Variants and Risk of Gastrointestinal Bleeding Associated with NSAID Use: A Case-Control Study [391]**  
Ana Estany-Gestal, Carmelo Aguirre, Borja Ruiz, Xavier Vi, Alfonso Carvajal, Inés Salado, Luca Rodella, Ugo Moretti, Luisa Ibáñez, Adolfo Figueiras. (Spain)  
*Student Award Recipient – Second Best Abstract Submitted by a Student*

11:00am

- **Lack of Association between SLCO1B1 Polymorphisms and Clinical Myalgia Following Rosuvastatin Therapy [392]**  
Jacqueline S Danik, Daniel I Chasman, Jean G MacFadyen, Fredrik Nyberg, Bryan J Barratt, Paul M Ridker. (United States)

11:15am

- **Vascular Endothelial Growth Factor (VEGF) Pathway Polymorphisms and Esophageal Cancer Outcome [393]**  
Lawson Eng, Abul Kalam Azad, Xin Qiu, Dangxiao Cheng, Alvina Tse, Olusola Faluyi, Daniel J Renouf, Sharon Marsh, Sevtaf Savvas, Jennifer J Knox, Gail E Darling, Rebecca KS Wong, Wei Xu, Geoffrey Liu. (Canada)

11:30am

- **Extraction of Hepatitis C Genotype from Clinical Notes for Patients Missing a Veterans Affairs Lab-Confirmed Genotype [394]**  
Scott L DuVall, Tyler B Forbush, Richard E Nelson, Joanne LaFleur. (United States)

11:45am

- **The Effect of Omeprazole and Esomeprazole on the Maintenance Dose of Phenprocoumon [395]**  
Talitha I Verhoef, Miranda JL Zuurhout, Rianne MF van Schie, William K Redekop, Felix JM van der Meer, Saskia le Cessie, Tom Schalekamp, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)

## Psychotropic Drug Utilization Research (115)

Moderators: Helga Gardarsdottir & Julie Zito, FISPE

10:30am

- **New Psychiatric Diagnoses and Medication Use after Intensive Care: A Danish Nationwide Cohort Study [396]**  
Christian F Christiansen, Hannah Wunsch, Martin B Johansen, Morten Olsen, Henrik T Sørensen. (Denmark)

10:45am

- **Access, Benefit Design, and Antipsychotic Drugs in the Medicare Part D Program [397]**  
Vicki Fung, Mary Price, John Hsu. (United States)

11:00am

- **Antidepressants and Risk of Discontinuation of Diabetes Medicines [398]**  
Gillian E Caughey, Adrian K Preiss, Agnes I Vitry, Andrew L Gilbert, Elizabeth E Roughead. (Australia)

11:15am

- **Persistence and Dose Escalation in the Use of Anti-Dementia Medication [399]**  
Kathleen Bennett, David Williams, Linda Brewer. (Ireland)

11:30am

- **Characteristics and Trends of Low-Dose Second Generation Antipsychotic Use in Two State Medicaid Programs [400]**  
Daniel M Hartung, Judy Zerzan, Nancy E Morden, Traci Yamashiti, Suhong Tong, Anne M Libby. (United States)

11:45am

- **Trends in Prevalence of ADHD Drug Treatment in the Netherlands from 2000 until 2010 [401]**  
L Mehlkopf, LMA Houweling, ER Heerdink, FJA Penning-van Beest. (Netherlands)



*28th International Conference on*  
**PHARMACOEPIDEMIOLOGY AND THERAPEUTIC  
RISK MANAGEMENT**

August 22-26, 2012 | CCIB | Barcelona, Spain

## Tapas: Junk Drawer (Cajon de Sastre) (116)

Moderator: Jessica Jalbert

### 10:30am

- **Orlistat and the Risk of Acute liver Injury: A Self-Controlled Case-Series Study in United Kingdom General Practice Research Database [402]**

Julia Langham, Liam Smeeth, Ruth Brauer, Krishnan Bhaskaran, Ian Douglas. (United Kingdom)

### 10:45am

- **Comparative Effectiveness of Linezolid and Vancomycin among a National Cohort of Veterans Affairs (VA) Patients with Methicillin-Resistant Staphylococcus Aureus (MRSA) Pneumonia [403]**

Aisling R Caffrey, Laura A Puzniak, Daniela E Myers, Kerry L LaPlante. (United States)

### 11:00am

- **Risk of Venous Thromboembolism among Taiwan Osteoporosis Population: Alendronate vs. Raloxifene Users [404]**

Tzu-Chieh Lin, Cheng-Han Lee, Yea-Huei Kao Yang, Chyun-Yu Yang. (Taiwan)

### 11:15am

- **Quantifying Staphylococcus aureus Disease Burden with Clinical Microbiology Culture Data: Attributable Time Trends in a Regional Healthcare System [405]**

Aisling R Caffrey, Kalpana Gupta, Brian J Quilliam, Peter D Friedmann, Kerry L LaPlante. (United States)

### 11:30am

- **The Prevalence of X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Denmark from 1995-2010 [406]**

Stine Skovbo, Mary Nguyen-Nielsen, Lars Pedersen, Henrik T Sørensen, Jon Fryzek. (Denmark)

### 11:45am

- **Risk of Incident Cardiovascular Disease Events in Patients with Psoriasis: A Retrospective Cohort Study Using the General Practice Research Database [407]**

Paola Primatesta, Estel Plana, Zuleika Aponte Torres. (Switzerland)

## Noon -1:30pm

### Lunch/Poster Session B/Exhibits

(Exhibit Hall/Rooms 5-6-7-8)

## ISPE Committee/Council Meetings

–Open to all members and new members.

–Lunch will be available in committee rooms.

- **Bylaws and Policies Committee (M213)**
- **Education Committee (124-125)**
- **Global Development Committee (132)**
- **Membership Committee (M215)**
- **Publications Committee (M216)**

## Noon -1:30pm

### Special Luncheon Workshop (129-130)

- **FarmacoEpiEnRed, a Network for Pharmacoepidemiology in Spain [408]**

**Moderators:** Susana Perez-Gutthann, FISPE Ana Afonso, Daniel Prieto-Alhambra, Antonio Escudero Garcia, Ana Estany Gestal, Elisa Martín-Merino, Nuria Riera-Guardia, Sandra López-León, Susana Perez-Gutthann, Sonia Hernández-Díaz. (Spain)

## 12:15-1:15pm

### Round Table Discussions

(CCIB Entrance Hall)

- To foster the ability of the more junior ISPE members to network and new ISPE members to meet others attending the ICPE, we are hosting several informal lunchtime discussion roundtables on Friday and Saturday. The facilitators and topics for the tables are listed below. There will be NO formal presentations made at the roundtables. The purposes are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

**Stephen JW Evans, FISPE, *Appropriate Study Designs on Pharmacoepidemiology***

**Ken Rothman, FISPE, *Back to the Future: Immortal Time and Related Problems in Retrospective Cohort Studies***

**Sebastian Schneeweiss, FISPE, *Methodological Challenges in Pharmacoepidemiology***

12:45-1:30pm

## Poster Walks

(Exhibit Hall/Rooms 5-6-7-8)

- CER (Comparative Effectiveness Research) SIG
- Databases SIG
- Medical Devices SIG
- Molecular Epidemiology SIG

1:30-2:30pm

## PLENARY SESSION

**Pharmacoepidemiology: The Essential Discipline in the Provision of Safe and Effective Care for Older Patients with Multimorbidity**[409] (111-112)

- Andrew Gilbert, Elizabeth Roughead, Jerry Avorn, Morten Andersen, Gillian Caughey. (Australia)

2:30-3:30pm

—Open to all participants.

## Annual Meeting of ISPE MEMBERS & AWARDS CEREMONY (111-112)

### Annual Meeting of ISPE Members

- Nancy C Santanello, FISPE, ISPE President
- Matthew Reynolds, Vice President Finance



### Awards Ceremony

#### ICPE 2012

- Presented by Nancy C Santanello, FISPE

Josep Lluís Segú, Chair, 2012 Local Host Committee  
Susana Perez-Gutthann, FISPE, Chair, 2012 Scientific Program Committee

#### Student Awards

- Presented by Susan Perez-Gutthann, FISPE

—**The Andrew McAfee Award:** (*Best Abstract submitted by a student/researcher from a developing country*): **Carlos Durán**

—**Third Best Abstract:** **Julie Lauffenburger**

—**Second Best Abstract:** **Ana Estany-Gestal**

—**The Stanley A. Edlavitch Award and Oral Presentation**  
(*Best Abstract submitted by a student/post-doc*)

**Muhammad Zubair Afza**, *Automatic Generation of a Case-Detection algorithm for Hepatobiliary Disease Using Machine Learning on Free-Text Electronic Health Records* [410]

Zubair Afzal, Martijn J Schuemie, Emine Sen, Geert W 't Jong, Miriam C Sturkenboom, Jan A Kors. (Netherlands)

- *Certificates of Appreciation*  
**Shelia Weiss Smith, FISPE**  
**Judith K Jones, FISPE**

#### Induction of ISPE Fellows (FISPE)

- Nancy C Santanello, FISPE, ISPE President

—*Inductees*

**AnnLouise Assaf, FISPE**

**Lolkje TW de Jong-van den Berg, FISPE**

**Tobias Gerhard, FISPE**

**Jesper Hallas, FISPE**

**Yea-Huei Kao Yang, FISPE**

**Julie A Zito, FISPE**

#### The Ronald D. Mann Best Article Award

**Brian Strom, FISPE**, Editor-in-Chief

**Sean Hennessy, FISPE**, Regional Editor for the Americas

**BJ Park, FISPE**, Regional Editor for Asia, Africa, Oceania

#### Installation of New ISPE President

- **Stella Blackburn, FISPE**



Image: Casa Milà "La Pedrera"  
Author: L. Bertran  
Credit: Turisme de Barcelona

3:30-4:00pm

Break/Posters/Exhibits (Exhibit Hall/Rooms 5-6-7-8)

4:00-5:30pm

## CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

**Cross-National or Multi-Database Research Networks: A New Initiative in Asia-Pacific Region and Ongoing Initiatives in Europe and US [411] (111-112)**

- Byung-Joo Park, Monique Elseviers, Ulf Bergman, Yea-Huei Kao Yang, Kiyoshi Kubota, Wai Ping Yau, Bjorn Wettermark, Paul Stang, Nicole Pratt, Natasha Chen, Morten Andersen, Soko Setoguchi. (United States)

**Electronic Healthcare Databases for Pregnancy Research: Panacea or Trojan Horse? [412] (117)**

- Krista F Huybrechts, Kristin Palmsten, Andrea V Margulis, William O Cooper, Christina Chambers, Sonia Hernández-Díaz. (United States)

**Evaluating the Effectiveness of Risk Minimisation Measures in the Context of the New Pharmacovigilance Legislation in the EU [413] (113)**

- Annalisa Rubino, Sabine Straus, Laurent Auclert, Laurie J Zografos, Elizabeth B Andrews. (United Kingdom)

**Global Collaborations in Vaccine Safety, Present and Future [414] (114)**

- Robert T Chen, Jan Bonhoeffer, Patrick Zuber, Miriam Sturkenboom, Claudia Velozzi, Hector Izurieta, Michael Greenberg, Steven Black, Thomas Verstraeten. (Switzerland)

**Integrating Methods for Semi-Automated Drug Safety Monitoring of Newly Marketed Medications Using Databases: Illustrations with a Prototype [415] (115)**

- Sebastian Schneeweiss, Joshua Gagne, Jeremy Rassen, Robert Glynn, Shirley Wang, Mandy Patrick, Jessica Myers, Stephen Evans. (United States)

**Transparent, Reproducible and Reusable Research in Pharmacoepidemiology (116)**

- Helga Gardarsdottir, Brian C Sauer, Huifang Liang, Patrick Ryan, Olaf Klungel, Robert Reynolds. (Netherlands)

*SPONSORED BY THE DATABASES SIG*

**Validate in One Data Source and Apply Results to Another – What Could Possibly Go Wrong? Assumptions behind Addressing Outcome Misclassification in Distributed Data Models [417] (132)**

- Nicholas J Everage, David D Dore, John D Seeger. (United States)

5:30-6:30pm

**Special Interest Group (SIG) Meetings**

Open to all members and new members.

- AsPEN SIG (131)
- Biologics SIG (115)
- Comparative Effectiveness Research (CER) SIG (114)
- Database SIG (111-112)
- Drug Utilization/Health Services Research SIG (116)
- Medical Devices SIG (117)
- Medications in Pregnancy SIG (113)
- Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG (124-125)
- Pediatrics SIG (132)

7:30-11:30pm

**Social Event (CCIB Banquet Hall)**

*Bring your dancing shoes!*

- Admission is by badge or ticket
- Admission includes 2 drink tickets



***Come and celebrate with us!*** Join us for dinner, entertainment, and dance the evening away! Including performances by Rumba Espresso – a live band, which features excerpts from Catalan gypsy music infused with Latin rhythms such as the Gipsy Kings, Peret, Pescaïlla and Los Manolos. The evening will end with a DJ playing international music from the 80's to the present to see who can showcase the best dance moves!

For those seeking a more relaxing atmosphere to chat with ISPE friends, the terrace facing the Mediterranean Sea is the perfect spot.



Safe?

Effective?

Better?

**THE RIGHT APPROACH  
FOR THE RIGHT QUESTION**

Copyright © 2012 Quintiles

**Quintiles acquires Outcome to offer full spectrum of interventional and observational research**

Regulators, payers, prescribers and patients demand to know about your product in the real world. That's why Quintiles, a leader in interventional IIIb/IV studies, recently acquired Outcome Sciences, the unparalleled experts in observational research. Together, we offer the expertise and experience in real-world and late phase research that you need to determine the right approach for the right question. Whatever your research objectives — from monitoring safety and evaluating benefit-risk, to demonstrating effectiveness and gaining market access, to proving efficacy in new indications — our experts provide you with the most comprehensive approach to evidence development.

More at [www.quintiles.com/outcome](http://www.quintiles.com/outcome). Visit us at the 28th ICPE—**Booth 8**.



**7:00-4:30pm**  
**Registration**  
 (CCIB Lobby)

**7:30-3:30pm**  
**Speakers' Ready Room (133)**

**7:00-8:00am**  
**Poster Session C Set-up**  
 (Exhibit Hall Rooms 5-6-7-8)

**8:00-1:45pm**  
**Exhibits/Posters**  
 (Exhibit Hall Rooms 5-6-7-8)

**8:30-10:00am**

## CONCURRENT SESSIONS: CONTRIBUTED PAPERS

### AEDs in Pregnancy and Beyond (111-112)

**Moderators:** Deborah Covington & Amanda Golembesky

**8:30am**

• **Topiramate Use in Pregnancy and Risk of Oral Clefts [689]**

Daniel Mines, Patricia Tennis, Suellen Curkendall, De-Kun Li, Craig Peterson, Elizabeth B Andrews, Brian Calingaert, Hong Y Chen, Daina B Esposito, Nicholas Everage, Crystal N Holick, Nicole M Meyer, Ella T Nkhoma, Sherry Quinn, Kenneth J Rothman, K Arnold Chan. (United States)

**8:45am**

• **Discontinuation of Antiepileptic Drugs in Pregnancy; A UK Population Based Study in The Health Improvement Network (THIN) [690]**

Shuk-Li Man, Irene Petersen, Mary Thompson, Irwin Nazareth. (United Kingdom)

**9:00am**

• **Lamotrigine Use in Pregnancy and Risk of Orofacial Cleft Risk, an Update [691]**

Hao Wang, Ester Garne, Maria A Loane, Helen Dolk, Joan K Morris, Lolkje TW de Jong-van den Berg. (Netherlands)

**9:15am**

• **Methods for Linking Mothers and Infants within Health Plans for Studies of Medication Safety in Pregnancy [692]**

Sascha Dublin, Karin Johnson, Sarah Beaton, T C Cheetham, Pamela E Scott, Sengwee D Toh, William O Cooper, Robert L Davis, De-Kun Li, Pamala Pawloski, Marsha Raebel, David H Smith, Tarek A Hammad, Susan E Andrade. (United States)

**9:30am**

• **Utilization of Antiepileptic Drugs in Florida Medicaid Women with Epilepsy of Child-bearing Age [693]**

Xuerong Wen, Kimford J Meador, Almut G Winterstein, Abraham G Hartzema. (United States)

**09:45am**

• **Prenatal Diagnosis of Birth Defects and Potential Selection Bias in Studies of Birth Defects Measured after Birth: How Severe Is the Problem? [694]**

Lars Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Vera Ehrenstein. (Denmark)

### Disease-Based Strategies for Active Surveillance (117)

**Moderator:** Andrez Czarnecki, FISPE & Joan-Ramon Laporte

**8:30am**

• **Incidence and Time-to-Onset of Hematologic Events among Genotype 1 Chronic Hepatitis C Patients Being Treated with Pegylated Interferon and Ribavirin [695]**

Michele Manos, Jeanne Darbinian, Baris Deniz, Montserrat Vera-Llonch, Valentina Scvachko. (United States)

**8:45am**

• **ARITMO Project. Torsade de Pointes Associated to Antimicrobials, Antipsychotics and Antihistamines: An Analysis of the French Spontaneous Reporting Database [696]**

Francesco Salvo, Moretti Ugo, Annie Fourrier-Réglat, Pascal Auriche, Estelle Meuriot, Nicholas Moore, Miriam C Sturkenboom, Emanuel Raschi, Antoine Pariente. (France)

**9:00am**

• **An Open Database for Surveillance of QT Prolongation of Marketed Drugs: ECG-VIEW [697]**

Man Young Park, Dukyong Yoon, Nam-Kyong Choi, Joongyub Lee, Rae Woong Park. (Republic of Korea)

**9:15am**

• **Are Developing Countries Prepared To Monitor Long-Term Toxicities of Antiretrovirals? Findings on Active Surveillance Activities in Sub-Saharan Africa [698]**

Jude I Nwokike, Hye Lynn Choi. (United States)

**9:30am**

• **Value of Information in Prospective Drug Safety Monitoring Using Claims Databases [699]**

Amanda R Patrick, Jessica Myers, Milton C Weinstein, Robert J Glynn, Sebastian Schneeweiss. (United States)

**9:45am**

• **Prevalence of PDDI Prescriptions in Two Italian Regions [700]**

Elena Tragni, Manuela Casula, Pieri Vasco, Giampiero Favato, Alberico Marcobelli, Maria G Trotta, Alberico L Catapano. (Italy)

## Drug Utilization Research: Adherence and Persistence (113)

**Moderators:** Robert Vander Stichele & Earl Goehring, Jr.

### 8:30am

- **The Effect of Copayment on Antiretroviral Medication Adherence for Newly Treated HIV-Positive Adults with Commercial Insurance [701]**

Jonathan Todd, William Miller, Virginia Pate, M Alan Brookhart. (United States)

### 8:45am

- **Patient-Reported Reasons for Discontinuation of Commonly Used Treatments for Moderate to Severe Psoriasis [702]**

Howa Yeung, Abby S Van Voorhees, Kristina Callis Duffin, Bruce A Brod, Stephen M Schleicher, Bruce F Bebo, Daniel B Shin, Joy Wan, Andrea B Troxel, Joel M Gelfand. (United States)

### 9:00am

- **Difference in Persistence Rates between Responders and Non-Responders to Mailed Questionnaires [703]**

Harm CJ Geers, Eibert R Heerdink, Marcel L Bouvy. (Netherlands)

### 9:15am

- **Real-Life Treatment Persistence with Golimumab (GLM), Etanercept (ETA), and Aimumab (ADA) in Patients with Rheumatoid Arthritis in Canada [704]**

Amir Abbas Tahami Monfared, Hayssam Khalil. (Canada)

### 9:30am

- **Determinants, Pattern, and Outcomes of Non-Adherence to HAART in a Portuguese Cohort of HIV-1 Infected Subjects [705]**

Milene Fernandes, Rui Simões, Luís Caldeira, Andreia Leite, José A Freitas, Paulo J Nicola, Ana P Martins, Maria AJ Vasco. (Portugal)

### 9:45am

- **Twelve-Year Trend in Treatment Seeking for Buprenorphine, Heroin and Amphetamine Abuse in Finland [706]**

Hanna Uosukainen, Jussi Kauhanen, Sari Voutilainen, Jaana Föhr, Mika Paasolainen, Jari Tiihonen, Kirsti Laitinen, Ifeoma N Onyeka, J Simon Bell. (Finland)



## population health intelligence

### Advanced Pharmacoepidemiology Research

Learn about LA-SER's expertise through our ICPE 2012 scientific presence, including:

- ▶ Six poster presentations ▶ Three oral presentations
- ▶ Participation in workshop "European initiatives to study adverse events of treatments for Diabetic Mellitus"

Visit us at booth 12 to hear more about our specialist capabilities.

[www.la-ser.com](http://www.la-ser.com)

London ■ Paris ■ New York ■ Montreal ■ Krakow ■ Oviedo ■ Madrid ■ Verona ■ Lörrach



## Keeping Your Eyes Open (114)

**Moderator:** Abraham Hartzema, FISPE

### 8:30am

- **Propensity Scores in Sequential Monitoring of New Drugs: Evaluation of Dynamic Matching [707]**

Joshua J Gagne, Shirley Wang, Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

### 8:45am

- **Value of Disease Risk Scores in Comparative Effectiveness Research with Emerging Therapies [708]**

Robert J Glynn, Joshua J Gagne, Sebastian Schneeweiss. (United States)

### 9:00am

- **The Power of Electronic Healthcare Databases for Active Drug Safety Surveillance in Children and Adolescents: An EU-ADR Study [709]**

Sandra de Bie, Preciosa Coloma, Carmen Ferrajolo, Gianluca Trifirò, Katia Verhamme, Martijn Schuemie, Sabine Straus, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Bruno Stricker, Johan van der Lei, Miriam Sturkenboom. (Netherlands)

### 9:15am

- **An Application of Univariate Self-Case Control Series Method Using THIN Database in the OMOP CDM for Active Drug Safety Surveillance [710]**

Xiaofeng Zhou, Bing Cai, Sundaresan Murugesan, Qing Liu, Andrew Bate, Robert Reynolds. (United States)

### 9:30am


- **Trends in Medication and Survival Following an Acute Myocardial Infarction in Primary Care in the UK – Re-Analysis of THIN Database with OMOP Common Data Model [711]**

Bing Cai, Xiaofeng Zhou, Sundaresan Murugesan, Qing Liu, Harshvinder Bhullar, Andrew Bate. (United States)

### 9:45am

- **PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) Work Package 6: Project Synthesis [712]**

Lamiae Grimaldi-Bensouda, Laurent Auclert. (France)



**OUR WORK IS SOMEONE'S HOPE.  
JOIN US.**

Merck, established in 1891, is a global research-driven pharmaceutical company dedicated to putting patients first. This philosophy was first articulated by George Merck and still guides us today. Join us and experience our culture first-hand – one of strong ethics & integrity, diversified experiences and a resounding passion for improving human health. As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.

**MRL Epidemiology** – Improving research to assess patient outcomes. Our mission is the scientific study of disease, endpoints and patient outcomes to evaluate benefits and the risks of our products. At Merck, we pride ourselves on meeting patient expectations – leveraging the most complete data and a strong cohesive effort to make the products that make life better.

**We provide epidemiologic and outcomes research for all Merck drugs and vaccines. Using existing information, database analyses and conducting epidemiology studies across the globe, we characterize disease natural history for new therapeutic areas, assist in clinical trial design based on the epidemiology of the disease, develop and validate patient reported outcomes, link biomarkers to outcomes and help understand the safety of our products pre- and post-launch. Our team is an active member of clinical development and outcomes research teams.** MRL Epidemiology includes the Pharmacoepidemiology and Database Research Unit (PEDRU) which concentrates Merck's efforts to lead in the application and development of pharmacoepidemiologic methods, and to further the appropriate use of large automated databases to address drug safety and risk/benefit issues across the full spectrum of Merck's portfolio. MRL Epidemiology also includes European Research Units and an Asia Pacific Unit based in China.

Join us and participate in our investigative design and interpretation that enables us to bring life-enhancing products to market.

Visit [www.merck.com/careers](http://www.merck.com/careers) to find out how.



## Safety of Psychotropic Medications in Adult Populations (115)

**Moderator:** Tobias Gerhard, FISPE & Ulf Bergman, FISPE

**8:30am**

- **Was the Use of Antipsychotic Drugs with Arrhythmogenic Potential Changed in the Last Years? A Population-Based, Database Study in 5 European Countries [713]**

Alessandro Oteri, Giampiero Mazzaglia, Francesco Innocenti, Ron Herings, Irene Bezemer, Edeltraut Garbe, Jacob Holstiege, Tania Schink, Elisabetta Poluzzi, Aurora Puccini, Sinna Pilgaard Ulrichsen, Lars Pedersen, Miriam C Sturkenboom, Gianluca Trifirò. (Netherlands)

**8:45am**

- **The Risk of Antipsychotic-Induced Parkinsonism and Its Management [714]**

Krista F Huybrechts, Katsiaryna Bykov, Raisa Levin, Jerry Avorn. (United States)

**9:00am**

- **Anti-Dementia Drugs in Patients with Alzheimer's Disease and the Risk of Developing Seizures or Epilepsy: A Population-Based Nested Case-Control Analysis [715]**

Patrick Imfeld, Michael Bodmer, Susan S Jick, Christoph R Meier. (Switzerland)

**9:15am**

- **Comparative Cardiovascular Safety of Dementia Medications: A Cross-National Study [716]**

Emil L Fosbol, Eric D Peterson, Ellen Holm, Gunnar H Gislason, Yinghong Zhang, Lesley Curtis, Lars Kober, Isao Iwata, Christian Torp-Pedersen, Soko Setoguchi. (United States)

**9:30am**

- **Cardiovascular Outcomes in Patients Using Clopidogrel with Selective Serotonin Reuptake Inhibitors [717]**

Patrick A Haueis, Joshua J Gagne, Stefan Russmann, Sebastian Schneeweiss. (United States)

**9:45am**

- **Use of cetuximab in a real-life setting in France with respect to KRAS status: results of EREBUS cohort study[718]**

Annie Fourier-Reglat, Denis Smith, Magali Rouyer, Eric Francois, Emmanuel Mitry, Alain Monnereau, Antonio Sa-Cunha, Emmanuelle Bignon, Alise Le Monies, Jeremy Jove, Pernelle Noize, Nicholas Moore. (France)

## Tapas: Classification Challenges (116)

**Moderators:** Corinne de Vries, FISPE, & Dorothee Bartels

**8:30am**

- **Reporting of Studies Conducted Using Observational Routinely-Collected Data [RECORD] Initiative [719]**

Sinead M Langan, Irene Petersen, Eric I Benchimol, Liam Smeeth, David Moher, Fiona Stanley, Henrik T Sorensen, Astrid Guttmann, Kate Walters, Sara Thomas, Ian Douglas, Laura Horsfall, Erik Von Elm. (United Kingdom)

**8:45am**

- **Development and Validation of a Classification Algorithm for Prophylactic Versus On-Demand Factor VIII Therapy in Patients with Hemophilia A [720]**

Francis Vekeman, Jennifer Pocoski, Wendy Cheng, Alex Trahey, Sujata Sarda, Satish Valluri, Ronald Preblich, Mei Sheng Duh. (United States)

**9:00am**

- **Is Off-Label Use a Risk Factor for Adverse Drug Events? [721]**

Tewodros Eguale, David L Buckeridge, Nancy E Winslade, Andrea Benedetti, James A Hanley, Robyn Tamblyn. (Canada)

**9:15am**

- **The Role of Surveillance Bias in the Incidence of the Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders [722]**

Amanda B Wilson, Marianne N Prout, Tuhina Neogi, Susan Jick. (United States)

**9:30am**

- **Validation of Congenital Cardiac Malformations in the General Practice Research Database [723]**

Fatmatta Kuyateh, Andrea V Margulis, Yulan Ding, Adel Abou-Ali, Marian Callahan, Tarek A Hammad. (United States)

**9:45am**

- **Development of a New System for Registration of Patient Registries [724]**

Richard Gliklich, Dan Levy, Michelle Leavy, Daniel M Champion, Jannette Karl, Elise Berliner. (United States)

**10:00-10:30am**

**Break/Posters/Exhibits (Exhibit Hall Room 5-6-7-8)**

*28th International Conference on*  
**PHARMACOEPIDEMIOLOGY AND  
 THERAPEUTIC RISK MANAGEMENT**

**BARCELONA**

10:30-Noon

## CONCURRENT SESSIONS: SYMPOSIA AND WORKSHOPS

### Electronic and Personal Health Records: Utility and Challenges for Comparative Effectiveness Research (CER) [725] (111-112)

- Jessica J Jalbert, Martijn J Schuemie, Miriam CJM Sturkenboom, Eric S Johnson, Suzanne L West, Soko Setoguchi. (United States)

*SPONSORED BY THE CER SIG*

### European Initiatives To Study Adverse Events of Treatments for Diabetes Mellitus [726] (117)

- Marie L De Bruin, Miriam CJM Sturkenboom, Lamiae M Grimaldi, Rafael Simó. (Netherlands)

### Globalisation of Utilisation Research: Current Challenges and Triumphs [727] (113)

- Lisa G Pont, Andrew L Gilbert, Ilse Truter, Veronika J Wirtz, Yea-Huei Kao Yang, Frank May, Morten Anderson. (Australia)

*SPONSORED BY THE DRUG UTILIZATION/HEALTH SERVICES RESEARCH SIG*

### Introduction to the Canadian Network for Observational Drug Effect Studies (CNODES) [728] (114)

- Samy Suissa, David Henry, Colin Dormuth, Robert Platt, Pierre Ernst, Lorraine Lipscombe, Sebastian Schneeweiss. (Canada)

### New Pharmacovigilance Legislation: A Call to Arms to the Pharmacoepidemiology Community [729] (115)

- Stella CF Blackburn, Peter R Arlett, Stephen J Evans, Susana Perez-Gutthann. (United Kingdom)

### Small Patients, Big Challenges – Current Topics in Pediatric Pharmacoepidemiology [730] (116)

Katia M Verhamme, Sandra de Bie, Timothy Beukelman, Susan A Oliveria, Tamar Lasky, Rachel Sobel. (United States)

*SPONSORED BY THE PEDIATRICS SIG*

### The Real Potential of Routine Electronic Health Records for Clinical Trials: Putting Them to the Test [731] (132)

- Tjeerd P van Staa, Liam Smeeth, John Parkinson, Kourtney Davis, Hubert GM Leufkens. (United Kingdom)

Noon-1: 30pm

### Lunch/Poster Session C/Exhibits

(Exhibit Hall Room 5-6-7-8)

### ISPE Board of Directors Luncheon (124-125)

(Meeting open to all members; check with staff if you wish to attend)

12:45-1:30pm

### Poster Walk (Exhibit Hall Room 5-6-7-8)

- Medicines in Pregnancy SIG

1:30-3:00pm

## CONCURRENT SESSIONS: CONTRIBUTED PAPERS

### ADRS in Europe (with one exception) [111-112]

**Moderators:** Michael Taylor & Gonzalo Calvo

1:30pm

#### • Rare Serious Adverse Events: Comparison of Patient- and Physician-Reported Outcomes [732]

Juergen Dinger, Marita Kieble, Kristina Bardenheuer. (Germany)

1:45pm

#### • Prevalence and Preventability of Self-Reported Adverse Drug Events – A Cross-Sectional Population-Based Survey in Sweden [733]

Katja M Hakkarainen, Karolina Andersson Sundell, Max Petzold, Staffan Hägg. (Sweden)

2:00pm

#### • Medications in Pregnancy Abstracts Presented at ICPE 2001-2009: Trends in Subsequent Publication [734]

Deborah L Covington, 1 Paige Churchill, Lindsay B Crampton. (United States)

2:15pm

#### • Using Electronic Healthcare Records for Drug Safety Signal Detection: A Comparative Evaluation of Statistical Methods [735]

Martijn J Schuemie, Preciosa M Coloma, Huub Straatman, Ron M Herings, Gianluca Trifirò, Justin N Matthews, David Prieto-Merino, Mariam Molokhia, Lars Pedersen, Rosa Gini, Francesco Innocenti, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Johan van der Lei, Miriam C Sturkenboom. (Netherlands)

2:30pm

#### • Drug Safety Signals Detected Using Electronic Health Records and Spontaneous Reporting Systems Data: The Experience of EU-ADR Project [736]

Vaishali Patadia, Martijn Schuemie, Preciosa Coloma, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Carla Fornari, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom, Gianluca Trifirò. (United States)

2:45pm

#### • Poor Traceability of Biologicals in Adverse Event Reporting Systems [737]

Niels S Vermeer, Sabine MJM Straus, Aukje K Mantel-Teeuwisse, Toine CG Egberts, Hubert GM Leufkens, Marie L De Bruin. (Netherlands)

## Cancer Pharmacoepidemiology (117)

Moderators: David Brown & James Kaye

### 1:30pm

- **A Matched Cohort Study Examining Digoxin Exposure and Prostate Cancer Mortality [738]**

Evelyn M Flahavan, Kathleen Bennett, Linda Sharp, Thomas I Barron. (Ireland)

### 1:45pm

- **Tamoxifen Therapy and Risk of Dementia in Breast Cancer Patients: A Danish Nationwide Cohort Study [739]**

Anne G Ording, Deidre P Cronin-Fenton, Henrik T Sorensen, Anders B Jensen, Timothy L Lash. (Denmark)

### 2:00pm

- **Insulin Glargine and Risk of Cancer: A Cohort Study in the French National Healthcare Insurance Database [15]**

Patrick Blin, Régis Lassalle, Caroline Dureau, Basmah Ambrosino, Marie-Agnès Bernard, Abdelilah Abouelfath, Henri Gin, Claire Le Jeunne, Antoine Pariente, Cécile Droz-Perroteau, Nicholas Moore. (France)

### 2:15pm

- **Use of Orlistat and Risk of Colorectal Cancer [741]**

Jin-Liern Hong, Robert Sandler, Christoph Meier, Susan Jick, Til Stürmer. (United States)

### 2:30pm

- **Bisphosphonates and Esophageal Cancer in the GPRD [742]**

Alec Walker, Julie Chandler, Robert Lubwama, Nancy Santanello. (United States)

### 2:45pm

- **Androgen Deprivation Therapy and the Risk of Colorectal Cancer in Prostate Cancer Patients [743]**

Jonathan Assayag, Hui Yin, Samy Suissa, Laurent Azoulay. (Canada)



ParagonRx would like to offer our sincerest congratulations to our co-founder

**Gary Slatko, M.D.**

upon his appointment to the FDA as

***Office Director of Medication Error Prevention and Risk Management***



[www.paragonrx.com](http://www.paragonrx.com)

## Identifying Risks in Special Populations (113)

**Moderator:** Joanna Haas, FISPE & Brian Sauer

### 1:30pm

- **Optimisation of a Signal Detection Method on Spontaneous Reports of Adverse Events Post Immunisation [744]**

Lionel Van Holle, Ziad Zeinoun, Vincent Bauchau. (Belgium)

### 1:45pm

- **A Novel Bayesian Hierarchical Model Using Two-Dimensional Groupings of Drugs and Adverse Events for Detection of Adverse Drug Reactions in Large Databases [745]**

Mark N Brook, David Prieto Marino, Stephen JW Evans. (United Kingdom)

### 2:00pm

- **Temporal Pattern Discovery on Electronic Health Records – A Source of Reference in Signal Detection Work [746]**

Kristina Star, Johanna Strandell, Sarah Fridén, Lovisa Sällstedt, Jeanette Johansson, Ralph I Edwards. (Sweden)

### 2:15pm

- **Uncovering Hidden Patterns in Pharmacovigilance through Robust Subgroup Surveillance [747]**

Johan Hopstadius, G Niklas Norén. (Sweden)

### 2:30pm

- **A Systematic Analysis of Drug Name Confusion in the FDA AERS Database Using Disproportionality Analysis [748]**

Robbert P van Manen. (Netherlands)

### 2:45pm

- **Utilisation of Fentanyl Buccal Tablets in Primary Care in England: Focus on ‘Off Label’ Use in Support of Risk Management [749]**

Vicki Osborne, Deborah Layton, Carole Fogg, Marie Linquist, Saad AW Shakir. (United Kingdom)

## Measuring Impact of Risk Minimization (114)

**Moderator:** Ken Hornbuckle & Marie Linquist

### 1:30pm

- **Efficacy of a Structured Prescription Form To Minimize Medication Errors in an Ecuadorian Rural Hospital [750]**

Carlos E Durán, Patricia Ortiz, Daniel Intriago, Francisco Nina, Carmen E Cabezas. (Ecuador)  
*The Andrew McAfee Award – Best Abstract Submitted by a Student from a Developing Country*

### 1:45pm

- **Development of a New Type of Risk Minimization Tool To Reduce Medication Errors [751]**

Meredith Y Smith, Tony Tran. (United States)

### 2:00pm

- **Assessing Physician Compliance To Recommended Liver Function Test (LFT) Monitoring Guidance in Patients with Metastatic Breast Cancer (MBC) Using Lapatinib [752]**

Sarah H Landis, Clara Chen, Julie A Byrne, Rahul Dhanda, Jeanenne J Nelson. (United States)

### 2:15pm

- **Evaluation of Warnings in Labeling: Association of Label Changes and REMS on Physician Discontinuation of Exenatide BID Following Pancreatitis Diagnosis [753]**

Hui Zhang, Ann Bui, Suzanne Grimshaw, Lee Meller, Sean Zhao. (United States)

### 2:30pm

- **Rational Use of Diagnostic Imaging for Acute Low Back Pain in Australia [754]**

Santosh Khanal, Yeqin Zuo, Eimir Hurley, Aine Heaney, Karen Kaye. (Australia)

### 2:45pm

- **Determinants of Impact of Drug Safety Warnings. A Retrospective Analysis of Direct Healthcare Professional Communications [755]**

Sigrid Piening, Katrin C Reber, Jaap E Wieringa, Sabine M Straus, Pieter A de Graeff, Flora M Haaijer-Ruskamp, Peter G Mol. (Netherlands)

## Methods: The Real Deal (115)

**Moderators:** M Alan Brookhart & Rene Schade

### 2:45pm

- **Primary Non-Compliance and Its Determinants: Implications for Misclassification of Drug Exposure [761]**

Robyn Tamblyn, Tewodros Eguale, Samuel Torontour. (Canada)

### 1:45pm

- **A Comparison of Methods for Estimating Exposure-Time Trends in Case-Case-Time-Control Designs [757]**

Shirley V Wang, Josh J Gagne, Robert Glynn, Sebastian Schneeweiss. (United States)

### 2:00pm

- **Utility of the Nested Case Control Design for Risk Assessment in the Presence of an Important Risk Modifier in Pharmacoepidemiological Studies: Evidence from Simulated Data [758]**

Victor A Kiri, Maurille Tepie-Feudjo, Andrew Rodham, Cathy Critchlow, Gilbert MacKenzie. (United Kingdom)

### 2:15pm

- **Calendar Time as an Instrumental Variable in Nonexperimental Comparative Effectiveness Research of Dynamic Therapies [759]**

Christina D Mack, M Alan Brookhart, Robert Glynn, Til Stürmer. (United States)

### 2:30pm

- **Cox’s Proportional Hazards Regression Using Instrumental Variables [760]**

Todd Mackenzie, Nancy Morden, Tor Tosteson, Therese Stukel. (United States)

### 1:30pm

- **Statistical Methods for Comparing the Effectiveness of Treatment Regimens in Long-Term Observational Comparative Effectiveness Research (CER) Studies with Time-Varying Treatments [756]**

Larry F Leon, Yong Mun, Bann-Mo Day, X. Sylvia Hu. (United States)



Safety and Epidemiology Research  
Health Outcomes Research  
Late Phase Research  
Comparative Effectiveness Research  
Medical Chart and Survey Research

Visit Us  
at Booth  
#16 & #17

## Real-World Insight Into Real-World Health Care

At HealthCore, our team of highly experienced researchers, including epidemiologists, biostatisticians, physicians, pharmacists, and health economists, study the “real-world” safety and effectiveness of drugs, medical devices, and care management interventions that support medical decision-making.

- Disease burden, natural history of disease and drug utilization research
- Epidemiologic studies of medical product treatment and health outcomes
- Safety surveillance of newly marketed medical products
- Surveys of physician compliance and practice patterns and patient reported outcomes
- Risk minimization (REMS)
- Systematic literature reviews and meta-analyses

# HealthCore®

real-world insight

800 Delaware Ave. • Fifth Floor • Wilmington, DE 19801  
With offices in Andover, MA, Alexandria, VA and Atlanta, GA

info@healthcore.com • www.healthcore.com • For more information, contact Michael Chance at 610.918.8313

## Un Viaje por Vacunas: Vaccine Studies (116)

Moderator: Harold Heijbel & Patricia Saddier

1:30pm

### • Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccine: Multinational Self Controlled Case Series Study in Europe [762]

Daniel Weibel, Silvana Romio, Jeanne P Dieleman, Corinne S de Vries, Cormac Sammon, Nick Andrews, Anders P Hviid, Henrik Svanström, Ditte Mølgaard-Nielsen, Maryse Lapeyre-Mestre, Agnès Sommet, Christel Saussier, Harald Heijbel, Lisen Arnheim-Dahlström, Jonas Hallgren, Par Sparen, Mees Mosseveld, Martijn Schuemie, Nicoline van der Maas, Bart C Jacobs, Tuija Leino, Terhi Kilpi, Jann Storsaeter, Henning K Olberg, Kari Johansen, Piotr Kramarz, Jan Bonhoeffer, Miriam CJM Sturkenboom. (Netherlands)

1:45pm

### • Self-Controlled Analyses of the Risk of Guillain-Barré Syndrome Associated with Influenza A(H1N1) 2009 Monovalent Vaccines [763]

Claudia Vellozzi, Jerome Tokars, Frank DeStefano. (United States)

2:00pm

### • Estimating Influenza Vaccine Effectiveness Using a Natural Experiment [764]

Leah J McGrath, Abhijit Kshirsagar, Stephen R Cole, Lily Wang, David J Weber, Til Stürmer, M Alan Brookhart. (United States)

2:15pm

### • The Risk of Immune Thrombocytopenic Purpura Associated with Vaccines in Adults: A Multicenter Case-Control Study [765]

L Grimaldi-Bensouda, M Michel, J F Viillard, D Adoue, N Magy-Bertrand, M Khellaf, M Hacin, O Fain, A S Morin, P Quittet, B Pan-Pettesch, B Bonnotte, N Chalumeau-Costedoat, M Ruel, P Leighton, E Aubrun, A Alperovitch, L Abenheim, B Godeau, PGRx-ITP Study Group. (France)

2:30pm

### • Risk of Febrile Convulsions after MMRV Vaccination in Comparison to MMR or MMR+V Vaccination [766]

Tania Schink, Jacob Holstiege, Garbe Edeltraut. (Germany)

2:45pm

### • Surveillance of Pertussis in The Netherlands: Monitoring the Impact of Recent Changes in the Vaccination Program [767]

NAT. van der Maas, SC de Greeff, FR Mooi, HE de Melker. (Netherlands)

3:00-4:30pm

## HOT TOPICS SESSION (111-112)

### Evaluating Cancer Risk with Diabetes Treatment: Methodological Challenges

Moderators: Til Stürmer, FISPE, & Nancy C Santanello, FISPE

#### Background

- Multiple study design issues apply to pharmacoepidemiology studies of the incidence of long term outcomes such as cancers. We use pharmacoepidemiology studies in diabetes as a common theme to illustrate such issues.

#### Objectives

- To review the practical and logistical challenges associated with pharmacoepidemiology studies of cancer, particularly in diabetes treatment.

#### Description

- We will address issues related to time scales and comparators, selective adherence, detection bias, and induction periods. We will also address treatment dynamics leading to lack of long-term exposures, lack of long-term follow-up in many databases, and lack of potentially important confounders (e.g., medical history and family history of cancers). Many of these issues can be addressed adequately with a new user design and comparator drug classes, which allows us to focus on treatment initiation decision processes, to attenuate confounding and selection bias, to address induction periods, and discontinuation, switching and augmenting of medications separate from confounding or channeling bias at baseline.

#### Speaker/Presentations

- Cynthia Girman, *Motivation*
- Robert Glynn, *Time Scales and Comparators*
- M Alan Brookhart, *Selective Adherence*
- James Lewis, FISPE, *Detection Bias*
- Alec Walker, FISPE, *Induction Periods*
- Nancy C Santanello, FISPE, *Wrap-up & panel discussion*

#### Panel Discussants

- Cynthia Girman
- Robert Glynn
- M Alan Brookhart
- Til Stürmer, FISPE
- James Lewis, FISPE
- Alec Walker, FISPE
- June Raine

4:30-5:00pm

## THE FINAL WORD (111-112)

#### Poster Awards

- Mary Beth Ritchey, Poster Walk Chair

#### Future Meetings

2013 Mid-Year Meeting - Munich

ICPE 2013- Montreal

- Yola Moride, FISPE, Chair, Scientific Program Committee

5:00pm

### Adjournment of ICPE 2012

5:15-6:15pm

### 2013 ICPE Scientific Program Committee Meeting (124-125)

***In our 25th year of Consulting and Research in Drug Safety  
and Pharmacoepidemiology***



**THE DEGGE GROUP, LTD.**

- ❖ Pharmacoepidemiology: Natural History of Disease, Retrospective, and Prospective Cohort Studies
- ❖ Risk Evaluation & Mitigation Strategies
- ❖ Surveys: Stakeholder / Benchmarking
- ❖ Systematic Literature Reviews
- ❖ Registries: Drug, Device, Disease, and Pregnancy
- ❖ US & International Regulatory Advice
- ❖ Pharmacogenetics
- ❖ Advisory Board & Adjudication Panel Management

**Our Poster Presentations**

Session A, August 24: "Observational Cohort Study of Pneumonia in Enfuvirtide-Exposed and Unexposed Patients"

Session B, August 25: "Assessing Healthcare Data Linkage Capabilities Using an Online Database Resource"

**Visit us @Booth#4**  
**#research needs**  
**#win kindle fire**  
**#b.r.i.d.g.e. demo**

- 180+ standardized database profiles
- 75 defined data fields
- Profiles from 25 countries
- Continuously updated profiles
  - Longitudinal EMR and claims
  - Drug or disease specific cohorts
  - Registries
  - National surveys
  - National surveillance systems
  - Spontaneous reporting systems



## OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

**NOTE:** Neither ISPE nor the CCIB will be responsible for any poster that is left up overnight or is lost or damaged.

## POSTER SESSION

Posters will be displayed in Rooms 5-6-7-8 of the CCIB (Barcelona Convention Center), August 24-26. Each day will have a separate poster session. All posters for a specific day's session must be removed that day.

- **Friday, August 24** ..... Poster Session A
- **Saturday, August 25** ..... Poster Session B
- **Sunday, August 26** ..... Poster Session C

### 1. Set Up:

- 7:00am-8:00am; all posters must be in place by 8:00am. The poster sessions will be held in rooms 5-6-7-8 of the CCIB.

### 2. Hours:

- Posters will be displayed from 8:00am-6:00pm on Friday and Saturday and 8:00am-1:45pm on Sunday.

### 3. Discussion Time:

- **General:** Presenters should be at their posters between 12:45-1:15pm.

- **Poster Walks:** organized by the ISPE Special Interest Groups (SIGs). Daily from 12:45-1:30pm. Presenters should be at their posters at that time.

#### Friday

- Biologics SIG
- Pediatrics SIG

#### Saturday

- Molecular Epidemiology-Biomarkers-Pharmacogenetics SIG
- CER (Comparative Effectiveness Research) SIG
- Medical Devices SIG
- Databases SIG

#### Sunday

- Medicines in Pregnancy SIG

The poster walks offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

A group of judges will select the best poster of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced during The Final Word session at 4:30pm, Sunday, August 26

### 4. Take Down:

- All posters must be taken down by 6:30pm on Friday and Saturday, and by 5:00pm on Sunday.

## NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program, which will be available at the ISPE Registration Desk (Registry Main Desk). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The **abstract number**, for use in locating abstracts in the Final Program and the special issue of Pharmacoepidemiology and Drug Safety, is in brackets [ ] after the title of the abstract.

## POSTER SPECIFICATIONS

1. Posters must be designed to fit a freestanding poster board **3 feet WIDE x 7 feet HIGH**; we suggest the poster itself should be 3 feet wide x 5 feet high (90 cm wide x 150 cm high) [PORTRAIT]. Posters may be attached to the boards using DOUBLE-SIDED VELCRO tape.
2. **Disclosure Statement**  
A disclosure statement must accompany each poster. The statement should be a positive disclosure of financial and other interests of each author/presenter that may pose a conflict of interest or the appearance of a conflict of interest. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.
3. **Call4Posters**  
Pick-up posters ordered through Call4Posters® at the ICPE Registration Desk.

8:00am – 6:00pm

## Biologics

- 1 **The Effect of Air Pollution on Anemia and Response to Treatment with Erythropoiesis Stimulating Agents in Dialysis Patients [80]**  
Maurice A Brookhart, Wolfgang C Winkel-mayer, Jamie Hart, Francine Laden. (United States)
- 2 **How Much Are Biosimilars Used in Southern Italy? A Retrospective Analysis of Epoetin Utilization in the Local Health Unit of Messina in the Years 2010–2011 [81]**  
Gianluca Trifirò, Carmelina Sgroi, Salvatore Coppolino, Rosarita Ferrara, Vincenzo Arcoraci, Pasquale Cananzi, Vincenzo Savica, Martijn Schuemie, Achille P Caputi. (Italy)
- 3 **Utilization Pattern of Golimumab (Simponi®) in Patients with Inflammatory Arthritis in Real-Life Clinical Practice in Canada [82]**  
Amir Abbas Tahami Monfared. (Canada)
- 4 **Drug-Related Progressive Multifocal Leuko-encephalopathy (PML): Data Mining of FDA AERS (Adverse Event Reporting System) [86]**  
Chiara Sacripanti, Carlo Piccini, Elisabetta Poluzzi, Fabrizio De Ponti. (Italy)
- 5 **Methods To Link a National Arthritis Cohort with Medicare Administrative Claims Data [91]**  
Jeffrey R Curtis, Lang Chen, Timothy Beukel-man, Aseem Bharat, Fenglong Xie, Kenneth G Saag, Elizabeth Delzell. (United States)

## Drug Utilization / Health Services Research

- 6 **Measuring Prescription Adherence by Medication Possession Ratio in Zagreb, Croatia [93]**  
Josip Culig, Vesna Bacic-Vrca, Jelena Boskovic, Marcel Leppée. (Croatia)
- 7 **Therapeutic Inertia Research on Adult DM Patients in Taiwan [94]**  
Huang Li-Ying, Shau Wen-Yi, Su Syi, Yeh Hseng-Long, Lai Mei-Shu. (Taiwan)
- 8 **Mining Medication Information from Clinical Discharge Summaries [95]**  
Sujin Kim, Christopher Burton. (United States)
- 9 **A Review of the Use of Hospital-Based Databases in Observational Inpatient Studies of Drugs [96]**  
Michael D Larsen, Thomas Cars, Jesper Hallas. (Denmark)
- 10 **Early Access Programs: Resources for Pharmacoepidemiology Studies Prior to Product Approval [97]**  
William C Maier, Carl De Moor, Ron Christensen. (United Kingdom)
- 11 **The Humana Database – A Data Source for Pharmacoepidemiologic Research [98]**  
Shannon L Michels, Claudia Uribe. (United States)

- 12 **Utility of NCHS Public-Use Prescription Drug Files [99]**  
Chris P Schneiderman, David J Nimke, Rebecca A Jenrow, Dianlin Guo, Steve J Niemcryk. (United States)
- 13 **Development of Intervention Tools Demanded by the International Monetary Fund and the European Union To Improve Prescribing Quality of Acid Suppressive, Anti-platelet and Anti-Inflammatory Drugs [101]**  
Daniel Pinto, Pedro A Caetano, Bruno Heleno, David Rodrigues, Emilia C Monteiro, Isabel Santos. (Portugal)
- 14 **Contraceptives Use and Knowledge among Medical and Pharmacy Students [102]**  
André Coelho, Teresa Guimarães, João A Pedro. (Portugal)
- 15 **Clinical Pharmacy in General Practice in Central Denmark Region [103]**  
Pia Ehlers, Kirstine M Gommesen, Anne-Grete Ramlov, Birgit S Toft. (Denmark)
- 16 **Development and Validation of a Questionnaire To Assess Spanish-Speaking Patients' Knowledge about Their Oral Anticoagulant Treatment [104]**  
Consuelo Izazola-Conde, Abraham Majluf-Cruz, Juan Mandoki, Juan Molina-Guarneros. (Mexico)
- 17 **Health Care Screening and Preventive Practices in the United States Workforce [105]**  
Margaret McDonald, Margaret Moffatt, Jingying Zhou, Jack Mardekian. (United States)
- 18 **Adherence to Hospital Drug Formularies Varied in Denmark – A Comparison at the National Level [106]**  
Hanne T Plet, Lene J Kjeldsen, Jesper Hallas. (Denmark)
- 19 **Nurse-Led Interventions To Enhance Medication Adherence: Systematic Review and Meta-Analysis [107]**  
Yoleen P Van Camp, Bart Van Rompaey, Monique M Elseviers. (Belgium)
- 20 **Adherence to Preventive Statin Therapy According to Socioeconomic Position [108]**  
Helle Wallach Kildemoes, Finn Diderichsen, Morten Andersen, Theis Lange. (Denmark)
- 21 **Healthcare Resource Utilization (HRU) Associated with Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and Subsequent Post-Hospitalization Recurrence and Death: A Danish Cohort Study [109]**  
Christian F Christiansen, Martin B Johansen, Sigrun A Johannesdottir, Morten Olsen, Xiao Xu, Timothy L Lash, Joseph Parker, Nestor Molfino, Jon P Fryzek. (Denmark)
- 22 **A Proposed Checklist To Interpret Cross-National Comparison Studies of Drug Utilization [110]**  
Elena Ballarin, Pili Ferrer, Mònica Sabaté, Hans Petri, Marietta Rottenkolber, Joan Fortuny, Joerg Hasford, Luisa Ibáñez. (Spain)

- 23 **Inpatient Drug Consumption in Europe (PROTECT Project) [111]**  
Pili Ferrer, Elena Ballarin, Mònica Sabaté, Hans Petri, Marietta Rottenkolber, Joan Fortuny, Joerg Hasford, Luisa Ibáñez. (Spain)
- 24 **Are Health Authorities and Health Insurance Companies Taking Full Advantage of the Availability of Generic Risperidone; Implications for the Future? [112]**  
Brian Godman, Kathleen Bennett, Marion Bennie, Thomas Burkhardt, Manuela Schmitzer, Andrew Martin, Peter Skjold, Bjorn Wettermark, Corrine Zara, Lars L Gustafsson. (Sweden)
- 25 **Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries? [113]**  
Brian Godman, Marion Bennie, Stephen Campbell, Kristina Garuoliene, Marija Kalaba, Vanda Markovic-Pekovic, Vera Vlahovic-Palcevski, Bjorn Wettermark, Corrine Zara, Lars L Gustafsson. (Sweden)
- 26 **Opportunities To Enhance Prescribing Efficiency for Patients with Diabetes in Abu Dhabi without Compromising Care [114]**  
Mohammed Abuelkhair, Brian Godman, Sahar Fahmy, Shajahan Abdu, Lars Gustafsson. (Sweden)
- 27 **Influence of Recent Initiatives in the Republic of Srpska To Improve Prescribing Efficiency; Influence and Future Direction [115]**  
Vanda Markovic-Pekovic, Brian Godman, Ranko Škrbic, Vera Vlahovic-Palcevski, Lars L Gustafsson. (Sweden)
- 28 **Comparing and Contrasting Reforms To Improve Prescribing Efficiency for Different Drug Classes in Croatia [116]**  
Brian Godman, Luka Voncina, Vera Vlahovic-Palcevski, Slavica Sovic, Maja Relja. (Sweden)
- 29 **Are Targeted Initiatives Needed To Enhance Prescribing Efficiency: Scotland as a Case History [117]**  
Marion Bennie, Brian B Godman, Iain Bishop, Stephen Campbell. (Sweden)
- 31 **Evaluating One Year Production of the Collaborative Centre of the Brazilian Unified Health System (SUS): A Partnership between Academy and Government for Improving Pharmaceutical Assistance [119]**  
Augusto Afonso Guerra, Francisco Assis Acurcio, Livia Lovato Pires de Lemos, Renata Cristina Macedo, Daniel Resende Faleiros, Dalila Pessoa, Rosangela Gomes, Nélio Gomes Ribeiro Junior, Adriana Rodrigues da Mata, Renata Cristina Macedo Resende, Daniel Faleiros, Micheline Rosa Silveira. (Brazil)
- 32 **Gender and Drug Utilization – A Systematic Analysis of Gender Differences in Incidence of Drug Therapy in Sweden [120]**  
Desirée Loikas, Björn Wettermark, Mia von Euler, Karin Schenck-Gustafsson. (Sweden)
- 33 **Drug Utilisation Study in a Public Hospital Southwest Nigeria – A Retrospective and Prospective Study [121]**  
Ibrahim Oreagba, Ismail Adeosun. (Nigeria)

- 34 Time and Motion Studies Alongside Clinical Trials: Scientific and Operational Considerations [122]**  
Erwin De Cock, Krista A Payne, Jess Sohal. (Canada)
- 35 Analysis of the Relationship between the Antibiotic Consumption and the Bacterial Resistance in a Private Hospital of Mexico City [123]**  
Odalis Rodríguez, Aline Espinosa, Rosa Elena Hi, Marcos Aguilar, J Bojalil. (Mexico)
- 36 Use of Brand Names of Discontinued Brand Drug Products by Prescribers When Generic Equivalents Exist [124]**  
Chi-Ming Tu, Kellie Taylor, Grace Chai. (United States)
- 37 Risk of Herb-Drug Interactions Associated with the Consumption of Psychoactive Substances among Health Technologies Students [125]**  
Liliana A Caetano, Sofia Grilo, Pedro Reis, André Coelho. (Portugal)
- 38 Attitudes, Perceptions and Knowledge of General Practitioners towards Adverse Drug Reaction Reporting in Malaysia: Preliminary Results [127]**  
Isa Naina Mohamed, Boekhtiar Borhanuddin, Ahmad Nazrun Shuid, Nur Farhana Mohd. Rozi. (Malaysia)
- 39 Retrospective Multinational Chart Review Studies of Adverse and Serious Adverse Events in Europe: Opportunities and Challenges [128]**  
Krista A Payne, Dara Stein, Erwin De Cock. (Canada)
- 40 Risk Factors for Acute Decompensation of Chronic Kidney Disease in Hospitalised Patients in Nephrology Department [129]**  
Lobna Ben Mahmoud, Antoine Pariente, Ahmed Hakim, Hanene Ghozzi, Zouheir Sahnoun, Khawla Kammoun, Khaled Zeghal. (Tunisia)
- 41 Effectiveness of Actions To Improve the Adherence of Pharmacological Treatment, in Diabetic and Hypertensive Patients: Experience of Mexico [130]**  
Dolores Mino, Hortensia Reyes. (Mexico)
- 42 Psychosocial Factors Associated with the Prescription of Generic Drugs by Dentist in Morocco [131]**  
Samir Ahid, Ghizlane Berdai, Amale Bouziane, Bassima Chami, Redouane Abouqal, Yahia Cherrah. (Morocco)
- 43 Management of Neurogenic Detrusor Overactivity in Patients with Spinal Cord Injury in Taiwan [133]**  
Edward Chia-Cheng Lai, Yea-Huei Kao Yang, Hann-Chorng Kuo, Kwong Ng, Emily Cheng. (Taiwan)
- 44 Factors Associated with Prescription and Nonprescription Drug among Children Living in Poor Areas [134]**  
Djanilson B Santos, Mauricio L Barreto, Luiz AF Filho, Helena LL Coelho. (Brazil)
- 45 Differences in Gastroprotective Medication Use between Australia and Nova Scotia, Canada [135]**  
Susan E Tett, Ingrid Sketris, Charmaine Cooke, Sander Veldhuyzen van Zanten, Nadia Barozzi. (Australia)
- 46 Racial and Ethnic Differences in the Use of Prescription and Nonprescription among Children Living in Poor Areas [136]**  
Djanilson B Santos, Mauricio L Barreto, Cinthia S Lisboa, Helena LL Coelho. (Brazil)
- 47 Patterns of Use of Antimuscarinic Drugs for Overactive Bladder: A Study of the Norwegian Prescription Database [137]**  
Siri Ann Mauseth, Olav Spigset, Svetlana Skurtveit. (Norway)
- DUR in the Elderly**
- 48 Vascular Protection with ACE Inhibitors or Angiotensin II Receptor Antagonists Following Type 2 Diabetes Treatment Initiation in Elderly [138]**  
Line Guénette, Marie-Claude Breton, Jean-Pierre Grégoire, Jocelyne Moisan. (Canada)
- 49 Treatment with Rivastigmine or Galantamine and Risk of Hospitalization for an Adverse Cardiac Event: A Database Study from the Netherlands [139]**  
Mieke G Berkens, Edeltraut Kröger, Pierre-Hugues Carmichael, Souverein C Patrick, Rob van Marum, Toine CG Egberts. (Canada)
- 50 Cardiovascular Disease Prevention among US Nursing Home Residents with Diabetes [140]**  
Eunsun Noh, Brian J Quilliam. (United States)
- 51 Patterns of Drug Use by Initiators of Dabigatran and Warfarin: Uptake and Persistence [141]**  
Marsha E Reichman, David J Graham, Michael Wernecke, Mary Ross Southworth, Chelsea Lam, Chris M Worrall, Mark Levenson, Thomas E MaCurdy, Monika Houstoun, Gwen Zornberg, Rongmei Zhang, Jeffrey A Kelman. (United States)
- 52 Characteristics of Elderly Patients Prescribed Sitagliptin and Other Oral Antihyperglycemic Agents in a Large U.S. Medicare Claims Database [142]**  
Tzuyung D Kou, Kimberly G Brodovicz, Samuel S Engel, Charles M Alexander, Cynthia J Girman. (United States)
- 53 Use of Vitamin K Antagonists in Friuli Venezia Giulia, Italy, 2001 to 2010: A Population-Based Study [143]**  
Federica Pisa, Valentina Rosolen, Manuela Giangreco, Francesca Zorzi, Jacopo Cancelli, Fabio Barbone, Amato De Monte. (Italy)
- 54 Variation in the Days Supply Field for Osteoporosis Medications in Ontario [144]**  
Andrea M Burden, Anjie Huang, Mina Tadrous, Suzanne M Cadarette. (Canada)
- 55 COX-2 and Non-Selective NSAID Use in Those at Increased Risk of NSAID-Related Adverse Events [145]**  
Jenni Ilomaki, Svetla Gadzhanova, Elizabeth E Roughead. (Australia)
- 56 Osteoporosis: Preliminary Results of a Treatment Adherence during a Systematic Follow-Up of Fragility Fractures [146]**  
Sylvie Perreault, Julio Fernandes, Josée Delisle, Cyrielle Beaubois, Pierre Beaumont, Sylvain Gagnon, Alain Jodoin, Yves Laflamme, Stéphane Leduc, Jean-Marc MacThiong, Michel Malo, Gilles Maurais, Stefan Parent, Pierre Ranger, Yves Troyanov. (Canada)
- 57 Incident Use, Discontinuation and Switching of Antidepressant Drugs in the Rotterdam Study [147]**  
Nikkie Aarts, Raymond Noordam, Bruno H Stricker, Loes E Visser. (Netherlands)
- 58 Benzodiazepine Exposure and Real-Life Utilization among Elderly: A French Longitudinal Cohort Study [148]**  
Cedric Collin, Christel Saussier, Marie-Anne Courne, Evelyne Falip, Maryse Lapeyre-Mestre, Nathalie Richard. (France)
- 59 Antidementia Drugs Utilisation Patterns in Europe: Predictive Factors of Switch and Discontinuation of Cholinesterase Inhibitors in the ICTUS Cohort Study [149]**  
Virginie Gardette, Sandrine Andrieu, Christelle Cantet, Bruno Vellas, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)
- 60 Trends in Initiation of Antiparkinsonian Drug Treatment among Patients with Parkinson's Disease in the UK between 1997 and 2010. Are Treatment Recommendations Followed? A Population-Based Analysis [150]**  
René Schade, Miriam CJM Sturkenboom. (Netherlands)
- 61 Psychotropic Drug Use before and after First Diagnosis of Alzheimer's Disease: An Analysis of German Claims Data [151]**  
Veronika Egen-Lappe, Peter Ihle, Ingrid Schubert. (Germany)
- 62 Dementia Mortality Rates and Cholinesterase Inhibitors Consumption in Castilla y Leon (Spain). An Ecologic Study [152]**  
Carlos Treceño, Luis Martín Arias, Pilar García Ortega, Antonio Escudero, Verónica Velasco, María Sáinz, Inés Salado, Alfonso Carvajal. (Spain)
- 63 Antipsychotic Drug Prescribing to Patients on Anti-Dementia Drugs in a South African Patient Population [153]**  
Ilse Truter. (South Africa)

- 64 Potentially Inappropriate Medication Use among Patients with Alzheimer Disease in REAL.FR: Be Aware of Atropinic and Benzodiazepine Drugs! [154]**  
François Montastruc, Virginie Gardette, Christelle Cantet, Antoine Piau, Maryse Lapeyre-Mestre, Bruno Vellas, Sandrine Andrieu, Jean-Louis Montastruc. (France)
- 65 Influence of Patient, Physician, and Hospital Characteristics on Oxaliplatin Receipt among Older Stage II and III Colorectal Cancer Patients in the US [155]**  
Jennifer L Lund, Tili Stürmer, Hanna K Sanoff, Alan Brookhart, Robert S Sandler, Joan L Warren. (United States)
- 66 Bevacizumab for Neovascular Age-Related Macular Degeneration [156]**  
Aline Silva, Luiz Furlan, Flávia Elias. (Brazil)
- 67 Prevalence and Associated Factors of Food Supplement Use in Community Dwelling Population over Age of 50 in Ireland [157]**  
Jure Peklar, Kathryn Savva, Mitja Kos, Martin Henman. (Ireland)
- 68 Medication Review in Polypharmacy Patients [158]**  
Kirsten Schaefer, Mikala Holt Havndrup, Hans Okkels Birk, Hans Harrestrup Andersen. (Denmark)
- 69 Risk Factors for Co-Medication of Contraindicated Drugs in Hospitalized Elderly Patient [159]**  
Eun Kyoung Ahn, Rae Woong Park. (Republic of Korea)
- 70 Oxycodone Use in Australian Veterans at Risk of Respiratory Depression [160]**  
Svetla Gadzhanova, Simon Bell, Elizabeth Roughead. (Australia)
- 71 Identification of COPD Patients in Epidemiological Studies Using Administrative Databases [161]**  
Holger Gothe, Kim Saverno, Raffaella Matteucci Gothe, Nimet Durdu, Andrea Stefan, Gottfried Endel, Joseph E Biskupiak, Diana Brixner, Uwe Siebert. (Austria)
- 72 Prior Pneumococcal Vaccination and Hospitalization for Community-Acquired Pneumonia in Elderly Veterans [162]**  
Chenghui Li, Teresa Hudson, Guoqing Chen. (United States)
- 73 Inappropriate Prescribing in Elderly Patients in a Brazilian Nursing Home [163]**  
Mariana MG Nascimento, Mariana L Pereira, Francisco A Acurcio, Carlos AC Dias Jr, Andréia Q Ribeiro. (Brazil)
- 74 Nationwide Variation in Nursing Home Antipsychotic Use, Staffing and Quality of Care [164]**  
Becky A Briesacher, Jennifer Tjia, Terry Field, Kathy M Mazor, Jennifer L Donovan, Abir O Kanaan, Leslie R Harrold, Celeste A Lemay, Jerry H Gurwitz. (United States)
- 75 Overview of Drug Use among the Elderly in Japan Using IMS Prescription Database [165]**  
Kaori Nomura, Manabu Akazawa. (Japan)
- 76 Polypharmacy in the Elderly: A Deeper Analysis of Drug Utilization in Sweden and Germany [166]**  
Jelina Nordin, Björn Wettermark, Gisbert W Selke, Irene Langner. (Sweden)
- 77 Feasibility of a Novel Data Source for Drug Utilisation Research in Aged Care [167]**  
Lisa G Pont, Marc Postma, Gerard Stevens, Michael Dolton, Andrew McLaclan. (Australia)
- 78 Drug Use Pattern and Drug Related Problems in Elderly People with Dementia in Sweden [168]**  
Linda Ring Eriksson, Henrik Lövborg, Eva Malmberg, Thomas Bradley. (Sweden)
- 79 Medication Reviews of Patients Using Drugs Most Frequently Involved in Drug Related Hospital Admissions [169]**  
Martina Teichert, Susan Noyon, Anouk Wereldsma, Ton Schalk, Jacqueline Janssen, Michel Wensing, Peter de Smet. (Netherlands)
- 80 The Effects of Abrupt Antipsychotic Discontinuation in Cognitively Impaired Hospitalised Elderly: A Pilot Study [170]**  
Majda Azermai, Sebastiaan Engelborghs, Robert Vander Stichele, Monique Elseviers, Stefan Van der Mussele, Hans Debruyne, Luc Van Bortel, Mirko Petrovic. (Belgium)
- 81 The Prevalence of Potentially Inappropriate Prescribing in Older Patients Presenting to an Emergency Department Following a Fall [171]**  
Geraldine McMahon, Liam Mahoney, Caitriona Cahir, Kathleen Bennett. (Ireland)
- 82 Drug Use among Elderly People in China – A Pooled Study [173]**  
Peishan Wang, Zhenlin Jia. (China)
- 83 Bisphosphonate (BP) Route of Administration and Selected Health Outcomes of Interest (HOIs) among Women with Postmenopausal Osteoporosis (PMO) [175]**  
Florence T Wang, Fei Xue, Jessica Perhandidis, Eva Ng, Cathy Critchlow, David D Dore. (United States)
- 84 Antipsychotic Drug Use and the Risk of Venous Thromboembolism in Elderly Patients with Dementia [177]**  
Niklas Schmedt, Edeltraut Garbe. (Germany)
- 85 How Representative Is the Medicare Part D Population? [178]**  
Virginia Pate, Michele Jonsson Funk. (United States)
- 86 Altering Eligibility Criteria To Identify Disease Cohorts in Insurance Claims Databases: An Example of Postmenopausal Osteoporosis (PMO) [179]**  
Fei Xue, Michael Lane, Cynthia O'Malley, Akhila Balasubramanian, Angelika Manthrip-ragada, Cathy Critchlow. (United States)
- 87 Use of Medicines in a Rural Setting: Frequency of Subjects at Risk of Medicine Misuse [180]**  
Sophie Girard, Karine Pérès, Pernelle Noize, Antoine Pariente, Jean-François Dartigues, Philippe Cestac, Fabienne Bazin, Annie Fourier-Réglat. (France)
- 88 Significant Differences between Methods To Estimate Renal Function May Have Major Implications in Drug Dosing and Adverse Reactions in the Elderly: Concordant Results in a Cross-Comparison between Croatia and Sweden [181]**  
Suzana Mimica Matanovic, Vera Vlahovic-Palcevski, Ulf Bergman, Ingegerd Odar-Cederlöf, Anders Hellden. (Croatia)
- 89 Adverse Drug Reactions in Patients with Alzheimer's Disease or Another Dementia in France: A National Cross-Sectional Study [182]**  
Marie-Laure Laroche, Marie-Christine Perault-Pochat, Isabelle Ingrand, Louis Merle, Carmen Kreft-Jais, Anne Castot, French Pharmacovigilance Centres Network AFCRPV. (France)
- 90 Drop-Out Rates in Patients with and without Screening Period in the SCOT Trial [183]**  
Li Wei, Thomas M MacDonald, on behalf of the SCOT study group collaborators. (United Kingdom)
- 91 Variations in Recruitment Rate in a Multicentre Streamlined Safety Trial [184]**  
Li Wei, Thomas M MacDonald, Robert W Flynn, Adam Wilson, Isla S Mackenzie. (United Kingdom)

## Patient with Infections and Their Treatments

- 92 Observational Cohort Study of Pneumonia in Enfuvirtide-Exposed and Unexposed Patients [185]**  
Earl L Goehring, Jr, Sharmila A Kamani, Miklos Salgo, John C Pezzullo, Susan T Sacks, Judith K Jones. (United States)
- 93 Impact of Managed Problem Solving (MAPS) Antiretroviral Adherence Intervention on Depressive Symptoms [186]**  
Robert Gross, Scarlett L Bellamy, Jennifer Chapman, Xiaoyan Han, Jacqueline O'Duor, Steven C Palmer, Peter S Houts, Brian L Strom, James C Coyne. (United States)
- 94 Efficacy and Safety of Tenofovir for the Treatment of Chronic Hepatitis B: A Systematic Review [187]**  
Gustavo LA de Oliveira, Alessandra M Almeida, Cristina MR Brandão, Mariana M Barbosa, Eli IG Andrade, Mariângela L Cherchiglia, Francisco A Acurcio. (Brazil)
- 95 Incidence of Adverse Reactions in HIV and TB Co-Infection: A Prospective Study [188]**  
Parthasarathi Gurumurthy, Subhashini Gonchi, Atiqulla Shariff, Rajendraprasad Shivaswamy, Sudheer Areeparamdil, SN Mothi, T Swami. (India)

## Studies in the Elderly

- 83 Bisphosphonate (BP) Route of Administration and Selected Health Outcomes of Interest (HOIs) among Women with Postmenopausal Osteoporosis (PMO) [175]**  
Florence T Wang, Fei Xue, Jessica Perhandidis, Eva Ng, Cathy Critchlow, David D Dore. (United States)
- 84 Antipsychotic Drug Use and the Risk of Venous Thromboembolism in Elderly Patients with Dementia [177]**  
Niklas Schmedt, Edeltraut Garbe. (Germany)
- 85 How Representative Is the Medicare Part D Population? [178]**  
Virginia Pate, Michele Jonsson Funk. (United States)
- 86 Altering Eligibility Criteria To Identify Disease Cohorts in Insurance Claims Databases: An Example of Postmenopausal Osteoporosis (PMO) [179]**  
Fei Xue, Michael Lane, Cynthia O'Malley, Akhila Balasubramanian, Angelika Manthrip-ragada, Cathy Critchlow. (United States)

- 96 Hearing Impairment Associated with Oral Terbinafine Use [189]**  
Joep Scholl, Kees van Grootheest, Eugene van Puijenbroek. (Netherlands)
- 97 Safety Profile of Antiinfectives Used in a 13 Years Period, Report of a National Pharmacovigilance Centre [190]**  
Gloria Shalviri, Naghme Javidnikou, Kheirollah Gholami. (Islamic Republic of Iran)
- 98 Characterization of a Cohort of Incident Hepatitis C Patients in the US (2005-2010): Comorbidities, Use of Medications and Diagnostic Tests [192]**  
Salil D Sheth, Montserrat Vera-Llonch, Joseph Lynch, Winifred Werther, Raymond Rubin. (United States)
- 99 Long-Term Effectiveness of Ribavirin Plus Pegylated Interferon Combination Therapy for Hepatitis C Patients in Taiwan: A Population-Based Study [193]**  
Yu-Tseng Chu, Pei-Jer Chen, Chun-Jen Liu, Raymond NC Kuo, Yi-Chun Yeh, Mei-Shu Lai. (Taiwan)
- 100 Oseltamivir Treatment and Adverse Outcomes and Influenza-Related Complications in Children and Adults [194]**  
Donnie Funch, Betsey Gardstein, K Arnold Chan, Elizabeth Maloney, Andrew D Mosholder. (United States)
- 101 Risk of Acute Liver Injury in a Cohort of Oral Antimicrobial Users [195]**  
James A Kaye, Jordi Castellsague, Christine L Bui, Brian Calingaert, Lisa J McQuay, Nuria Riera, Catherine W Saltus, Scott Quinlan, Crystal N Holick, Peter M Wahl, Kiliana Suzart, Kenneth J Rothman, Mari-Ann Wallander, Susana Perez-Gutthann. (United States)
- 102 Sepsis Antibacterials as Marker for Sepsis Incidence in a Clinical Database? [197]**  
Ümniye Balaban, Verena Schneider-Lindner, Holger A Lindner, Daniela Olenik, Thomas Friedrich, Armin Kalenka, Christel Weiß, Manfred Thiel. (Germany)
- 103 Use of Antimalarial Chemoprophylaxis and the Risk of Developing Eye Disorders [198]**  
Cornelia Schneider, Miriam Adamkova, Susan S Jick, Patricia Schlagenhauf, Katie Miller, Hans-Georg Rhein, Christoph R Meier. (Switzerland)
- 104 Epidemiology of Herpes Zoster and Its Complication: A Population Based Study in Israel [199]**  
Dalia Weitzman, Oren Shavit, Raanan Cohen, Gabriel Chodick, Varda Shalev. (Israel)
- 105 Risk of Venous Thromboembolism (VTE) in Patients with Chronic Hepatitis C (CHC) [200]**  
Shirin Ahmed, Vinay Mehta, Neika Vendetti, Kerry Ann Phang, Ying Su, Hopiy Kim, T Christopher Mast, Nancy Santanello. (United States)
- 106 Comparison of the Renal Safety of Tenofovir and Stavudine in Patients on Antiretroviral Therapy at a Kenyan Referral Hospital [201]**  
Linus A Masese, Faith A Okalebo, Lawrence EM Mwangangi, Kepha O Bosire, Moses Mwangi. (Kenya)
- 107 Antimicrobial Utilization for Culture-Confirmed Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in a Large, Regional Cohort [202]**  
Aisling R Caffrey, Kalpana Gupta, Brian J Quilliam, Peter D Friedmann, Kerry L LaPlante. (United States)
- 108 Antiretroviral Prescription and Adherence in a Portuguese Cohort of HIV-1 Infected Subjects: An overall Analysis of Changes over the Years 2005 – 2008 [203]**  
Milene Fernandes, Rui Simões, Luís Caldeira, Andreia Leite, José A Freitas, Paulo J Nicola, Ana P Martins, Maria AJ Vasco. (Portugal)
- 109 Implications for Failure To Adjust Dose in Obese Patients: Higher Risk of Treatment Failure [204]**  
Gillian Bartlett, Cristina Longo, Brenda MacGibbon, Nancy Mayo, Stella Daskalopoulou, Ellen Rosenberg. (Canada)
- 110 Antibacterial Use: Age and Gender Specific Prescribing [205]**  
Zsuzsanna Biczok, Maria Matuz, Ria Benko, Peter Doro, Andrea Bor, Edit Hajdu, Gyongyver Soos. (Hungary)
- 111 Antibiotic Consumption in 8 European Countries: Analyses from Data Provided by IMS Health [206]**  
Mònica Sabatés, Pili Ferrer, Elena Ballarín, Marietta Rottenkolber, Hans Petri, Joan Fortuny, Joerg Hasford, Luisa Ibáñez. (Spain)
- 112 Ongoing Programmes To Reduce the High Rate of Antibiotic Consumption in Serbia; Current Situation and Future Direction [207]**  
M Bajcetic, M Kalaba, B Godman, T Sipetic, S Coenen, A Versporten, H Goossens. (Sweden)
- 113 Patterns in Influenza Antiviral Medication Use before and during the 2009 H1N1 Pandemic, Vaccine Safety Datalink Project, United States, 2000-2010 [208]**  
Sharon K Greene, David K Shay, Ruihua Yin, Natalie L McCarthy, Roger Baxter, Michael L Jackson, Steven J Jacobsen, James D Nordin, Stephanie A Irving, Allison L Naleway, Jason M Glanz, Tracy A Lieu. (United States)
- 114 The Effect of Reimbursement System Versus Global Financial System on Prescribing and Cost of Antibiotics [209]**  
Erna Kristin, Lili Komariah Darmawiredja, Iwan Dwiprahasto. (Indonesia)
- 115 Treatment of Acute Cystitis in Hungary: Quality of Antibiotic Prescribing [210]**  
Ria Benko, Maria Matuz, Zoltan Juhasz, Zsuzsanna Biczok, Reka Viola, Peter Doro, Edit Hajdu, Gyongyver Soos. (Hungary)
- 116 Prescribed Dosages and Dosage Forms of Antibacterial Treatment [211]**  
Maria Matuz, Ria Benko, Zsuzsanna Biczok, Peter Doro, Reka Viola, Edit Hajdu, Gyongyver Soos. (Hungary)
- 117 Antibiotic Use across Five European Countries: A Drug Utilization Study from the ARITMO Project [212]**  
Giampiero Mazzaglia, Francesco Innocenti, Alessandro Oteri, Ron MC Herings, Irene D Bezemer, Jacob Holstiege, Elisabetta Poluzzi, Aurora Puccini, Sinna Pilgaard Ulrichsen, Lars Pedersen, Tania Schink, Edeltraut Garbe, Mariam Molokhia, Miriam C Sturkenboom, Gianluca Trifirò. (Italy)
- 118 Antimycotic Use across Europe: A Drug Utilization Study from the ARITMO Project [213]**  
Elisabetta Poluzzi, Aurora Puccini, Giampiero Mazzaglia, Francesco Innocenti, Alessandro Oteri, Ron Herings, Irene Bezemer, Jacob Jakob Holstiege, Sinna Pilgaard Ulrichsen, Lars Pedersen, Edeltraut Garbe, Tania Schink, Fabrizio De Ponti, Miriam C Sturkenboom, Gianluca Trifirò. (Italy)
- 119 Oseltamivir Utilization during the 2009 H1N1 Influenza Pandemic, Taiwan [214]**  
Chia-Ping Su, Chia-Hsueh Chang, Wen-Yi Shau, Hsu-Wen Chou, Shu-Ting Chen, Mei-Shu Lai. (Taiwan)
- 120 Pharmacoepidemiological Overview of Antimicrobial Prescribing Using a Large Claims Database in South Africa [215]**  
Ilse Truter. (South Africa)
- 121 Anti-Fungal Products Dispensed by a Group of Community Pharmacies in South Africa [216]**  
Ilse Truter, Michael Graz. (South Africa)
- 122 A Systematic Review of the Use of Antimicrobial Therapy for Symptom Management in Patients Receiving Palliative Care [217]**  
Joseph H Rosenberg, Jessina C McGregor, Jennifer S Albrecht, Erik K Fromme, Angela C Comer, Jon P Furuno. (United States)
- 123 Multidisciplinary Interventions To Improve Antibiotic Use [218]**  
Fátima Roque, Sara Soares, Luiza Breitenfeld, Adolfo Figueiras, Maria T Herdeiro. (Portugal)
- 124 Factors Related to Antibiotic Resistances – How Could Community Pharmacists Improve It? [219]**  
Fátima Roque, Sara Soares, Luiza Breitenfeld, Adolfo Figueiras, Maria T Herdeiro. (Portugal)
- 125 Healthcare Utilization in Phase 3 Telaprevir Clinical Trials for the Treatment of Genotype 1 Chronic Hepatitis C Patients [220]**  
Winifred Werther, Jyoti Aggarwal, Thomas F Goss, Montserrat Vera-Llonch. (United States)
- 126 Antimalarial Drug Utilization and Parasite Density among Patients in a Nigerian Teaching Hospital [221]**  
Aduragbenro D Adedapo. (Nigeria)

- 127 Determinants of Antibiotics Prescription among Doctors in a Nigerian Teaching Hospital [222]**  
Olayinka O Ogunleye, Adesola F Yinka-Ogunleye. (Nigeria)
- 128 Prevalence and Susceptibility Patterns of Urine Isolates of *Escherichia coli* to Various Fluoroquinolones in South-South Nigeria [223]**  
Nwabuogochukwu C Oreh, Anthony A Attamma. (Nigeria)
- 129 Outpatient Antibiotic Prescription in the South of Portugal [224]**  
Isabel MPS Ramalhinho, Afonso M Cavaco, José J Cabrita. (Portugal)
- 130 The Effect of Depression Risk in HIV Patients on Anti-Retroviral Therapy (ART) Choice and the Risk of Subsequent Depression Diagnosis after Exposure [225]**  
Bruce JO Wong, Woodie M Zachry, III, Kao-Tai Tsai, Jennifer M Griffith, Stephanie E Kirbach, Katherine L Gooch. (United States)

## Hematology

- 131 From Indication to Time in Therapeutic Range. Effectiveness of Oral Anticoagulation Guidelines in Patients with Atrial Fibrillation [226]**  
Luis Pereira de Sousa, Ivana Burba, Cettina Ruberto, Luca Lattuada, Fabio Barbone, Antonio Di Chiara. (Italy)
- 132 Use of Oral Antiplatelet Agents in Friuli Venezia Giulia, Italy, 2001 to 2010: A Population-Based Study [227]**  
Valentina Rosolen, Federica Pisa, Daniela Drigo, Francesca Zorzi, Andrea Morsanutto, Amato De Monte, Fabio Barbone. (Italy)
- 133 Anticoagulant Use in Patients with Cancer Associated Venous Thromboembolism: A Retrospective Cohort Study [228]**  
Elham Rahme, Guillaume Feugère, Caroline Sirois, Elodie Ramos. (Canada)
- 134 The Association between Use of Serotonergic Antidepressants and Perioperative Bleeding during Hip Replacement – A Retrospective Follow-Up Study [229]**  
Michael Dall, Annie Primdahl, Frank Damborg, Jesper Hallas. (Denmark)
- 135 Identification of Hemophilia Patients in Medicaid Claims Data [230]**  
Katsiaryna Bykov, Rhonda L Bohn, Bruce M Ewenstein, Jerry Avorn, John D Seeger. (United States)
- 136 Changes in Platelet Counts over Time in HIV and Hepatitis C Virus (HCV) Co-Infected Patients [231]**  
Danijela Stojanovic, Jonathan Schelfhout, Amy Houtchens, Heidi M Crane, Elizabeth Brown, Nina Kim, Mari M Kitahata, Teresa L Kauf, Joseph AC Delaney. (United States)

- 137 Higher Daily Vitamin K Intake Is Associated with Greater Anticoagulation Stability during Initiation Phase of Warfarin Therapy [232]**  
Ron C Li, Brian F Finkelman, Jinbo Chen, Luanne Bershaw, Colleen Brensinger, Sarah K Booth, Stephen E Kimmel. (United States)
- 138 Non-Traumatic Joint Disorders and Analgesic Narcotic Use in Hemophilia A Patients [233]**  
Anne Dilley, Nydjie Payas, Jin Wang, Wildon Farwell, Sally McAlister. (United States)
- 139 Long-Term Course of the Severe Haemophilia A or B Patients in Sweden: Results from a Cohort Register Study [234]**  
Susanna Lövdahl, Erik Berntorp, Karin M Henriksson, Jan Astermark. (Sweden)
- 140 Evaluation of Second Malignancies in Patients Receiving Bortezomib (Btz) [235]**  
Jane Porter, Megan McAuliffe, Kelly Hardiman, Dixie-Lee Esseltine, Carol Satler, Rachel Neuwirth, Maria Ponsillo. (United States)
- 141 A Comparison of the Effectiveness of Statins in Reducing Total Cholesterol and Low-Density Lipoprotein Cholesterol [236]**  
Anna But, Janne Suvisaari, Jaana Suvisaari, Leo Niskanen, Jari Haukka. (Finland)

- 142 Cancer Risk in Long-Term Users of Vitamin K Antagonists: A Nested Case-Control Study [237]**  
Anton Pottegård, Søren Friis, Jesper Hallas. (Denmark)
- 143 Renal Function Impairment by Overanticoagulation? [238]**  
Jan C van Blijderveen, Katia M Verhamme, Miriam C Sturkenboom, Silvana A Romio, Sabine M Straus, Bruno C Stricker. (Netherlands)
- 144 Safety of Off-Label Erythropoiesis Stimulating Agents (ESAs) in Critically Ill Patients: A Systematic Review and Meta-Analysis [239]**  
Bita Mesgarpour, Benedikt Heindinger, Michael Schwameis, Calvin Kienbacher, Markus Müller, Harald Herkner. (Austria)
- 145 A Review of Postmarketing Adverse Event Reports from AERS for Dabigatran (Pradaxa) [240]**  
Keith Altman, Susan Pieper. (United States)

## Methods

- 147 The Role of Spontaneous Events Databases for Benefit-Risk Analysis [242]**  
Nawab Qizilbash, Ignacio Méndez, Rainel Sánchez de la Rosa. (United Kingdom)
- 148 Case-Crossover Studies in the Presence of Exposure Time Trends and Immeasurable Time [243]**  
Shirley V Wang, Malcolm Maclure, Sebastian Schneeweiss. (United States)
- 149 Use of Multiple Sources and Capture-Recapture Method To Estimate the Frequency of Hospitalizations Related to Drug Abuse [244]**  
Emilie Jouanjus, Laure Pourcel, Sylvie Saivin, Laurent Molinier, Maryse Lapeyre-Mestre. (France)

- 150 Health Screening Participation and Risk of All-Cause Mortality [245]**  
Tsugumichi Sato, Nobuhiro Ooba, Kiyoshi Kubota. (Japan)
- 151 Up in Smoke! Capturing Smoking History from Clinical Notes [246]**  
Tyler B Forbush, Scott L DuVall. (United States)
- 152 Development of a Web-Based Interactive Tool To Display Cohort Characteristics from a Variety of Patient Populations and Data Sources [247]**  
Aaron WC Kamauu, Emily Dastrup, Scott L DuVall. (United States)
- 153 Analysis of Unbalanced Contingency Tables of Web-Based Potential Adverse Event Reports [248]**  
Michael J Goodman, Olivia R Sheng, Mark Valentine, Frederick S Albright, Beilai Cai. (United States)
- 154 Prevalence of Comorbidity of Chronic Diseases: A South African Pharmacy Benefit Management Company (PBM) Database Analysis [249]**  
Lourens Rothmann, Martie S Lubbe, Jan J Gerber, Anne-Marie Bekker. (South Africa)
- 155 Using Natural Language Processing of Electronic Health Records To Identify Patients with ANCA-Associated Vasculitides in the Veterans Affairs [250]**  
Scott L DuVall, Aaron WC Kamauu, Pavel Napalkov, Andrew T Anglemeyer, Ronald A Cantrell, Curry L Koenig. (United States)
- 156 Impact of Pharmacy Benefit Eligibility on Morbidity in a US Medical Claims Database [251]**  
James R Williams, Cathy Lally, Anne Dilley. (United States)
- 157 Self-Controlled Design in Pharmacoepidemiology: Systematic Review of Methodology and Application [252]**  
Sun-Young Jung, Ju-Young Shin, Nam-Kyong Choi, Joongyub Lee, Jong-Mi Seong, Ye-Jee Kim, Byung-Joo Park. (Republic of Korea)
- 158 Using Marginal Structural Logistic Modeling for Risk Ratio Estimation in Longitudinal Pharmacoepidemiological Studies [253]**  
Igor Karp. (Canada)
- 159 Implications of Immortal Time When Outcomes Are Non-Fatal [254]**  
Caihua Liang, John D Seeger, David D Dore. (United States)
- 160 Methods To Improve Study Representativeness in Prospective Observational Research [255]**  
William K Mountford. (United States)
- 161 A Framework for Simulation Studies Based on Complex Healthcare Utilization Data for Methods Evaluation [256]**  
Jessica A Myers, Sebastian Schneeweiss, Jennifer A Polinski, Jeremy A Rassen. (United States)

**162 A Hybrid Empirical/Simulation Approach to Testing the Performance of the High-Dimensional Propensity Score [257]**  
Jeremy A Rassen, Jessica Myers, Jennifer M Polinski, Sebastian Schneeweiss. (United States)

**163 Propensity Score Development in a Rare Disease Registry [258]**  
Amanda B Wilson, Alexander Cole. (United States)

**164 Bootstrap-Based Aggregation Method for Distributed Time-to-Event Analyses of Medication Effects [259]**  
Marie-Eve Beauchamp, Michal Abrahamowicz, Rolina van Gaalen, Robyn Tamblyn. (Canada)

**165 Choices in Analytically Defining Dichotomous Covariates [260]**  
Steven M Brunelli, Joshua J Gagne, Krista F Huybrechts, Amanda R Patrick, Shirley Wang, John D Seeger. (United States)

**166 Variance Estimate of Instrumental Variable Two-Stage Logistic Regression Causal Odds Ratio Estimator [261]**  
Bing Cai, Thomas R Ten Have, Dylan S Small. (United States)

**167 Sample Size and Serious Adverse Events in Late Phase Comparative Studies [262]**  
Terry A Cox. (United States)

**168 An Efficient and Inexpensive System for the Distribution and Tracking of Investigational Medicinal Products in Streamlined Safety Trials [263]**  
Robert W Flynn, Patrick G McDonnell, Isla S Mackenzie, Li Wei, Thomas M MacDonald. (United Kingdom)

**169 A Pilot Study To Investigate the Supply of Investigational Medicinal Product to Patients Via Mail in a Streamlined Safety Study [264]**  
Robert W Flynn, Wendy Saywood, Isla S Mackenzie, Li Wei, Thomas M MacDonald. (United Kingdom)

**170 Obtaining Risk Ratios from Regression Models: A Cautionary Tale [265]**  
David R Gagnon, Hongsheng Wu, Kelly Cho, Elizabeth V Lawler. (United States)

**171 An Example in Which Omitting an Instrumental Variable from a Propensity Score Leads to a Biased Estimate of the Effect of an Exposure [266]**  
Mark Lunt, Richie Wyss, Robert Glynn, Charles Poole, Kenneth Rothman, Til Stürmer. (United Kingdom)

Abstract Withdrawn by Author [267]

**172 Characterization of Missing Data in Clinical Registry Studies: Study Design and Methods [268]**  
Aaron B Mendelsohn, Pattria W Mattox, Zhao-hui Shu, Nancy A Dreyer, Priscilla Velentgas. (United States)

Abstract Withdrawn by Author [269]

**173 Comparison of Interaction and Subgroup Effects in Observational Studies and Randomized Clinical Trials: Three Empirical Examples [270]**  
Amand F Schmidt, Maroeska M Rovers, Olaf H Klungel, Arno W Hoes, Mirjam J Knol, Mirjam Nielen, Antonius de Boer, Rolf HH Groenwold. (Netherlands)

Abstract Withdrawn by Author [271]

**174 Media Campaign for Recruitment to a Streamlined Safety Trial in Scotland [272]**  
Li Wei, Adrian Hapca, Isla S Mackenzie, Thomas M MacDonald. (United Kingdom)

**175 The Role of PS Estimation and Implementation in the Presence of Heterogeneous Effects of Covariates on Treatment [273]**  
Richard Wyss, Mark Lunt, Til Stürmer. (United States)

**176 Estimated vs. True PSs for Controlling Baseline Covariates in RCTs [274]**  
Richard Wyss, Alan Brookhart, Charles Poole, Robert J Glynn, Til Stürmer. (United States)

## Pediatrics

**177 Descriptive Cohort Study of Antibiotic Prescription to the Swedish Children Born in 2006 [275]**  
Jenny Hellman, Katarina Baatz, Mikael Hoffmann. (Sweden)

**178 Antibiotic Prescriptions in Outpatient Children: A Multiregional Comparison [276]**  
Daniele Piovani, Antonio Clavenna, Maurizio Bonati. (Italy)

**179 Antiviral Prescription Rates in Paediatric Populations of 5 European Countries: A Drug Utilization Study from the ARITMO Project [279]**  
Jakob Holstiege, Tania Schink, Giampiero Mazzaglia, Gianluca Trifirò, Francesco Innocenti, Alessandro Oteri, Ron Herings, Irene Bezemer, Elisabetta Poluzzi, Aurora Puccini, Sinna Pilgaard Ulrichsen, Lars Pedersen, Miriam C Sturkenboom, Edeltraut Garbe. (Germany)

**180 Paediatric Oseltamivir Prescriptions in Primary Care in United Kingdom, Italy and Netherlands during the 2009 A/H1N1 Pandemic [281]**  
Sandra de Bie, Katia Verhamme, Gino Picelli, Sabine Straus, Carlo Giaquinto, Bruno Stricker, Mike Sharland, Miriam Sturkenboom. (Netherlands)

**181 Trends in Antihypertensive Medication Use among Children and Adolescents: 2001-2008 [282]**  
Mona Cai, M Alan Brookhart. (United States)

**182 Topical Use of Corticosteroids among Children and Adolescents with Atopic Dermatitis in Germany [283]**  
Yong Du, Hildtraud Knopf. (Germany)

**183 Monitoring of DMARDs Safety in Children with JIA in Crimea [286]**  
Oleksandr V Matvieiev, Natalya V Matvieieva. (Ukraine)

**184 A Cross-Sectional Study on Patient Treated with Anti Epileptic Drugs [287]**  
Vijayakumar Arumugam, Geetha Kandasamy, AnandaThangaduri Subramaniam, Kota Greeshma, Anju Mohan, Rajasekaran Aiyalu. (India)

**185 A Population-Based Study of Stimulant Drug Treatment for ADHD and Academic Progress in Children [289]**  
Helga Zoega, Kenneth J Rothman, Krista F Huybrechts, Orn Olafsson, Gisli Baldursson, Anna B Almarsdottir, Solveig Jonsdottir, Matthias Halldorsson, Sonia Hernández-Díaz, Unnur Valdimarsdottir. (United States)

**186 Trends in Antidepressant Prescribing in Children in the United Kingdom, a Study in The Health Improvement Network (THIN) [290]**  
Linda PMM Wijlaars, Irwin Nazareth, Irene Petersen. (United Kingdom)

**187 Trends in Paediatric ADHD Drug Prescription in the UK and Cardiovascular Event Rates [291]**  
Raphaëlle Beau Lejdstrom, Stephen JW Evans, Ian Douglas, Liam Smeeth. (United Kingdom)

Abstract Withdrawn by Author [292]

**188 Psychotropic Treatment among Youth in Foster Care in the U.S. [293]**  
Stephen Crystal, Lauren Vanderwerker, Cecilia Huang, Tobias Gerhard, Sheree Neese Todd, Scott Bilder. (United States)

**189 Psychotropic Drug Utilization in Children with Concomitant ADHD and Anxiety [294]**  
Xinyue Liu, Paul Kubilis, Dandan Xu, Almut G Winterstein. (United States)

**190 Prevalence and Determinants of Psychotropic Drug Use in Institutionalized Children and Adolescents with Mild Intellectual Disability and Behavioural Problems [295]**  
Arlette Scheifes, Daniël de Jong, Joost Jan Stolker, Henk Li Nijman, Antoine CG Egberts, Eibert R Heerdink. (Netherlands)

**191 Continuity and Adherence with Stimulant Therapy in Children and Adolescents in Germany: A Claims Data Analysis [296]**  
Veronika Egen-Lappe, Gerd Lehmkuhl, Ingrid Schubert. (Germany)

**192 Attention Deficit/Hyperactivity Disorder: Prescribing Patterns of Methylphenidate and Atomoxetine [297]**  
Ilse Truter. (South Africa)

**193 Iatrogenic Aluminum and Neurocognitive Performances of Moroccan Children [299]**  
Fatima-Zahra Azzaoui, Hinde Hami, Ahmed Ahami. (Morocco)

- 194 Methadone and Perinatal Outcomes – A Prospective Cohort Study [300]**  
 Brian J Cleary, Maeve Eogan, Michael P O'Connell, Tom Fahy, Paul J Gallagher, Tom Clarke, Martin J White, Christine McDermott, Ann O'Sullivan, Deirdre Carmody, Justin Gleeson, Deirdre J Murphy. (Ireland)
- 195 Psychomotor Effects of In Utero Exposure to Psychotropic Medications: A Comparative Study in EFEMERIS Database [301]**  
 Isabelle Lacroix, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 196 Infant and Childhood Neurodevelopmental Outcomes Following Prenatal Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) [302]**  
 Heli Malm, Miia Artama, Alan S Brown, Mika Gissler, David Gyllenberg, Susanna Hinkka-Yli-Salomäki, Ian McKeague, Andre Sourander. (Finland)
- 197 Parent's Use of Hypnotics Predicts Alimemazine Use in Infants and Toddlers [304]**  
 Ingvild Holdø, Marte Handal, Svetlana Skurtveit, Jørgen G Bramness. (Norway)
- 198 Pediatric Use of Single-Entity Extended Release Oxycodone [305]**  
 Susan Oliveria, Laura E Wallace, Syd Phillips, Karen E Wells, Sharon Hensley Alford, Yuequin Zhao, Gaurav Deshpande, Marianne Ulcickas Yood. (United States)
- 199 Use of Single-Entity Oxycodone and Oxycodone Combination Products in Pediatric Patients [306]**  
 Laura E Wallace, Susan Oliveria, Syd Phillips, Karen E Wells, Sharon Hensley Alford, Marianne Ulcickas Yood. (United States)
- 200 Analysis of Cardiovascular Events or Diabetes Mellitus during Androgen Deprivation Therapy in Korean Prostate Cancer Patients [308]**  
 JiHoi Kim, YoungJoo Kim, ByungKoo Lee. (Republic of Korea)
- 201 Relative Age, Academic Performance and Stimulant Prescribing for ADHD: A Nationwide Cohort Study [310]**  
 Helga Zoëga, Unnur Valdimarsdóttir, Sonia Hernández-Díaz. (United States)
- 202 Off-Label Use of Octreotide in Infants [311]**  
 Ann W McMahon, Suzanne Treadway, Pamela Weinel, Judith U Cope, Marilyn N Flack, Suzanne Rich, Dianne Murphy. (United States)
- 203 Soy Diet Influences the Expression of Estrogen Receptors alpha in Rat Ovary [312]**  
 Paraskevi Papaioannidou, Ioannis Kyriakidis, Theodora Papamitsou, Ioannis Makaronidis, Fotios Tsanakalis, Maria Dermentzopoulou. (Greece)
- 204 The Influence of Soy Diet on Rat Testis during Early Development [313]**  
 Ioannis Papaioannidis, Theodora Papamitsou, Ioannis Makaronidis, Ioannis Kyriakidis, Fotios Tsanakalis, Maria Dermentzopoulou, Antonia Sioga, Paraskevi Papaioannidou. (Greece)
- 205 The Treatment of Teething Symptoms: Observational Study of Pediatricians in Real-World General Practice [314]**  
 Sohéla El Kebir, Anne-Laure Fayard, Remi Gauchoux, Jean Stagnara, Marie-France Bordet. (France)
- 206 Spirometry Testing in a Population of Italian Asthmatic Children [315]**  
 Marina Bianchi, Antonio Clavenna, Marco Sequi, Angela Bortolotti, Ida Fortino, Luca Merlino, Maurizio Bonati. (Italy)
- 207 Effectiveness of Palivizumab in Respiratory Syncytial Virus Prophylaxis in Children with Cystic Fibrosis [316]**  
 Almut G Winterstein, Efe Eworuke, Dandan Xu, Pamela Schuler. (United States)
- 208 National Trends in Ambulatory Care Visits for Acute Otitis Media in Children under Five Years of Age in the US [317]**  
 Xiaofeng Zhou, Cynthia de Luise, Michael Gaffney, Catharine W Burt, Kimberly J Center, Daniel A Scott. (United States)
- 209 Analysis of ADHD (Attention-Deficit/Hyperactivity Disorder) among Flu-Vaccinated Pediatric Population in the United States Medical Claims Database [318]**  
 Katherine Tsai. (United States)
- 210 Pediatric Cancer Registries in North America and Europe [319]**  
 Sonia S Maruti, Karen Bartley, Raphael Rousseau, Jamie Robinson, Michael Taylor. (United States)
- 211 Burden of Mental Disorders in Childhood Estimate Using Administrative Health Data [320]**  
 Antonio Clavenna, Massimo Cartabia, Antonella Costantino, Angela Bortolotti, Ida Fortino, Luca Merlino, Maurizio Bonati. (Italy)
- 212 Results of Testing the Linkage of the Vaccination Registration Praeventis with the IPCI Medical Record Database in the Netherlands [321]**  
 Jeanet Kemmeren, Johan van der Lei, Petra Oomen, Hester de Melker, Miriam Sturkenboom. (Netherlands)
- 213 Impact of Maternal Attachment on Infant Development at 1-Year of Age: Results from the OTIS Antidepressants in Pregnancy Study [323]**  
 Fatiha Karam, Anick Berard, Odile Sheehy, Marie-Claude Huneau, Gerald Briggs, Christina Chambers, Adrienne Einarson, Diana Jonhson, Kelly Kao, Gideon Koren, Brigitte Z Martin, Janine E Polifka, Sara H Riordan, Mark Roth, Sharon Voyer Lavigne, Lori Wolfe, OTIS Collaborative Research Group. (Canada)
- 214 Pediatric Epidemiological Study for Chronic Hepatitis B (CHB) [324]**  
 Zuleika Aponte Torres, Hongfei Zhang, Jacek Mizerski, Deirdre Kelly, Maureen M Jonas, Malgorzata Pawlowska, Paloma Jara, Teresa Wozniakowska, Alexandrina Constantinescu, Florence Lacaille, María José Mellado, Vasilii Uchaikin, Giorgina Mieli-Vergani, Aldo Trylesinski. (Spain)
- 215 Male/Female Incidence Ratio of ADHD Drug Treatment in the Netherlands from 2000 until 2010 [325]**  
 L Mehlkopf, LMA Houweling, ER Heerdink, FJA Penning-van Beest. (Netherlands)
- 216 Increase in Psychotropic Drug Use between 2006 and 2010 among Adolescents in Norway: A Nationwide Prescription Database Study [326]**  
 Anne KM Steffenak, Bodil Wilde-Larssen, Gun Nordstrøm, Svetlana Skurtveit, Ingeborg Hartz. (Norway)
- 217 Differences in the Prescribing Behavior of Oral Contraceptives in Adolescents and Adults [327]**  
 Kristina Bardenheuer, Sarah Kern, Janke Leddin. (Germany)
- 218 Phenotypic Spectrum of Hematological and Visceral Disease in Type 3 Gaucher Disease and Response to Imiglucerase Therapy: Preliminary Analysis from the ICGG Gaucher Registry [328]**  
 J Alexander Cole, Pramod Mistry, Edwin H Kolodny, Anna Tytki-Szymanska, Nadia Belmatoug, Juan F Cabello, Ashok Vellodi, Gregory Grabowski. (United States)
- 219 Marketing, Prescribing and Dispensing of Methylphenidate in Belo Horizonte, Minas Gerais, Brazil [329]**  
 Edson Perini, Daniela Garcia Rezende Garcia Junqueira, Lorena Gomes Cunha Lana, Tatiana Chama Borges Cruz. (Brazil)
- 220 Review of All Products Authorized by the European Medicines Agency from 1995 to 2011 in Regard to Pediatric Investigation Plan Applications [330]**  
 Julie Mouchet, Marine Albrieux, Will Maier. (France)

## Dermatology

- 221 A'TEAM: Atopy' Therapeutic Education Assessment Measure: A Tool for Evaluating Therapeutic Education in Atopic Dermatitis [331]**  
 Charles Taieb. (France)
- 222 The Use of GP Questionnaires To Assess Psoriasis Severity in The Health Improvement Network (THIN) Database [333]**  
 Paula L Thompson, Stéphanie Chretien, Françoise Bugnard, William C Maier, Tetsuro Ito, Mike Spencer, Gwilym Thompson. (United Kingdom)

**223 A Review of Stevens Johnson (SJS), Toxic Epidermal Necrolysis (TEN), and Erythema-Multiforme (E-M) Reports from the FDA AERS Database from 1968-2009 [334]**  
Keith L Altman. (United States)

**224 Screening Method for Association of a Drug to Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis Using a Claims Database [335]**  
Joongyub Lee, Nam-Kyong Choi, Bo Ram Yang, Young-Jin Ko, Ji Young Kim, Byung-Joo Park. (Republic of Korea)

## Poster Walk - Biologics SIG

**225 Malignancy and Infection Rates in Psoriasis Patients with or without Treatment and in a General Population in the US: 2005 – 2009 [83]**  
Mellissa Yong, Jennifer Schenfeld, Mary Anthony, David Pariser, Alexa B Kimball. (United States)

**226 Utilization of Tumor Necrosis Factor alpha Inhibitors (TNFi) in Patients with Ankylosing Spondylitis [84]**  
Jinghua He, Douglas J Watson, Paul M Peloso. (United States)

**227 A Comparison of Post-Authorization Adverse Events of Biopharmaceuticals and Small Molecules within the Same Anatomical Therapeutic Chemical Class [85]**  
Hans C Ebbens, Esraa Al-Temimi, Ellen H Moors, Aukje K Mantel-Teeuwisse, Huub Schellekens, Hubert G Leufkens. (Netherlands)

**228 Case Definition for Progressive Multifocal Leukoencephalopathy Following Treatment with Monoclonal Antibodies [87]**  
Dirk Mentzer, Jürgen Prestel, Ortwin Adams, Ralf Gold, Hans-Peter Hartung, Hartmut Hengel, Bernd C Kieseier, Wolf-Dieter Ludwig, Brigitte Keller-Stanislawski. (Germany)

**229 Incidence of Infections, Cardiovascular, and Hepatic Events among Initiators of TNF- $\alpha$  Inhibitor Therapy Compared to Methotrexate Users [88]**  
Elsie L Grace, Dale Q Marmaduke, Stephen P Motsko. (United States)

**230 Characteristic Differences among Crohn's Disease Patients Who Initiated IFXliximab vs. Non-Biologic Therapy — ENCORE Registry [89]**

Zhiping Huang, Melissa Whipple, Xingshu Zhu, Egli Martin, Walter Reinisch, Paul Rutgeerts, Jean Frederic Colombel, Geert D'Haens, Anders Ekbohm, Denesh Chitkara, Doug Watson. (United States)

**231 Incidence of Selected Opportunistic Infections among Children with Juvenile Idiopathic Arthritis [90]**

Timothy Beukelman, Fenglong Xie, John W Baddley, Lang Chen, Elizabeth Delzell, Carlos G Grijalva, Nivedita M Patkar, Kenneth G Saag, Kevin L Winthrop, Jeffrey R Curtis. (United States)

**232 Rates of Systemic Adverse Events Following Intravitreal Injection of Anti-VEGF Medications for the Treatment of Age-Related Macular Degeneration (AMD) [92]**

Winifred Werther, Emily Gower, Sandra Casard, Laura Chu, Rohit Varma, Ronald Klein. (United States)

## Poster Walk -Pediatrics SIG

**233 Antibiotic Use in Children and the Use of Medicines by Parents [277]**

Josta de Jong, Jens HJ Bos, Tjalling W de Vries, Lolkje TW de Jong-van den Berg. (Netherlands)

**234 Antibiotic Prescription Rates in Paediatric Populations of 5 European Countries: A Drug Utilization Study from the ARITMO Project [278]**

Jakob Holstiege, Tania Schink, Giampiero Mazzaglia, Gianluca Trifirò, Francesco Innocenti, Alessandro Oteri, Ron Herings, Irene Bezemer, Elisabetta Poluzzi, Aurora Puccini, Sinna Pilgaard Ulrichsen, Lars Pedersen, Miriam C Sturkenboom, Edeltraut Garbe. (Germany)

**235 Utilization of Antidiabetic Drugs among U.S. Children and Adolescents, 2002-2011 [284]**  
Christian Hampp, Vicky Borders-Hemphill, David G Moeny, Diane K Wysowski. (United States)

**236 Aminoglycoside Eardrops and Risk of Sensorineural Hearing Loss in Children with Non-Intact Tympanic Membranes [285]**  
Wei Liu, Patrick J Antonelli, Dandan Xu, Almut Winterstein. (United States)

**237 Second Generation Antipsychotics and Risk of Type 2 Diabetes in Publicly Insured Children and Adolescents [288]**  
Tobias Gerhard, William V Bobo, Mark Olsson, Stephen Crystal. (United States)

**238 The Association between ADHD Treatment in Childhood and Substance Use and Abuse in Adults – A Long-Term Follow-Up [303]**

Els van den Ban, Kristiaan van der Heijden, Linda Verhaar, Patrick C Souverein, Herman van Engeland, Toine AC Egberts, Eibert R Heerdink, Hannah Swaab. (Netherlands)

**239 Pediatric Insomnia and Utilization of Prescription Sedative-Hypnotics: A Descriptive Study [307]**

Laura E Wallace, Aditi Kadakia. (United States)

**240 Adverse Events to Antiretroviral Therapy for HIV-Infected Children in Lagos, Nigeria: A Retrospective Study [309]**

Kazeem A Oshikoya, Saheed Lawal, Ibrahim A Oreagba, Olufunsho Awodele, Sunday O Olayemi, Edna O Iroha, Veronica C Ezeaka, Edamisan O Temiye, Adebola O Akinsulie, Oluwaranti Opanuga, Titilope Adeyemo, Olufunmilayo A Lesi, Sulaimon A Akanmua. (Nigeria)

**241 Agreement between Parental-Reported Usage and Dispensed Asthma Drugs in Children. A Comparison between the BAMSE-Cohort and the Swedish Prescribed Drug Register [322]**

Elin Dahlén, Catarina Almqvist-Malmros, Anna Bergström, Björn Wettermark, Inger Kull. (Sweden)

**242 Patterns of Topical Calcineurin Inhibitor Drug Use. Impact of Regulatory Actions in Off-Label Use [332]**

Belen Oliva, Miguel Gil, Dolores Montero, Consuelo Huerta, Ana Afonso, Miguel Angel Macia, Veronica Bryant, Arturo Alvarez. (Spain)

**END SESSION A**



Image: Port Vell, Rambla de mar  
Author: Espai D'imatge  
Credit: Turisme de Barcelona

8:00am – 6:00pm

## Molecular Epidemiology

- 1 **Is Primary Care Ready for Pharmacogenomics? A Feasibility Study of Warfarin Pharmacogenomic Testing in a Family Medicine Clinic [418]**  
Gillian Bartlett, Martin Dawes, Quynh Nguyen, Michael S Phillips. (Canada)
- 2 **Genetic Variation in GATA-4 Might Affect the Coumarin Maintenance Dose [420]**  
Rianne van Schie, Judith Wessels, Lukas van Hoorn, Talitha Verhoef, Tom Schalekamp, Saskia le Cessie, Felix van der Meer, Frits Rosendaal, Loes Visser, Martina Teichert, Albert Hofman, Peter Buhre, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)
- 3 **Effect of Genetic Variation in the ABCB1 Gene on Switching, Discontinuation, and Dosage of Antidepressant Therapy: Results from the Rotterdam Study [421]**  
Raymond Noordam, Nikkie Aarts, Bruno H Stricker, Loes E Visser. (Netherlands)
- 4 **Analyses of the Effect of Tobacco Smoking on Physiological Measures [422]**  
Anna E Kettermann, Jiping Chen, Ling Yang. (United States)
- 5 **Factors Influencing the Adoption of Personalized Genomic Diagnostics in Breast Cancer: A Survey of Oncologists [424]**  
Amalia M Issa, Dhaval Patil. (United States)
- 6 **Relationship between Inflammatory Cytokines and Serum Uric Acid Levels with Adverse Cardiovascular Outcomes in Patients with Stable Coronary Heart Disease during Long-Term Follow-Up [426]**  
Dietrich Rothenbacher, Andrea Kleiner, Wolfgang Koenig, Paola Primatesta, Lutz P Breitling, Hermann Brenner. (Germany)
- 7 **Pharmacogenetic epidemiology [427]**  
Sandra Lopez Leon. (Spain)
- 8 **Cancer Patients' Preferences for Pharmacogenetic Testing (PGx) [429]**  
Sinead Cuffe, Henrique Hon, Xin Qiu, Kimberly Tobros, Bradley De Souza, Graham McFarlane, Chung-Kwun Amy Wong, Sohaib Masroor, Abdul Kalam Azad, Ekta Hasani, Natalie Rozanec, Natasha Leigh, Shabbir Alibhai, Wei Xu, Amalia M Issa, Geoffrey Liu. (Canada)

## Risk Management & Communication

- 9 **Improved Drug Packaging Design Can Improve Patient Safety [432]**  
Laura W Bakke, Sigurd Hortemo, Tor Endestad, Steinar Madsen. (Norway)
- 10 **Behavioural Assessment Offers Improved Evaluation of Risk Minimisation Tools (RMT) [433]**  
Anjan K Banerjee, Simon Ingate, Jon Mann, Steve Hutson, Rebecca Zhang. (United Kingdom)

- 11 **Safety Issues Seem To Occur More Often in Highly Innovative Drugs [434]**  
Peter G Mol, Arna H Arnardottir, Sabine M Straus, Domenico Motola, Flora M Haaijer-Ruskamp, Pieter A de Graeff. (Netherlands)
- 12 **Medication Errors Related to Patches for Systemic Pain Relief in a Swedish Incident Reporting System [435]**  
Eva Tärning, Ingela Jacobsson, Thomas Bradley, Anna K Jönsson, Henrik Lövborg. (Sweden)
- 13 **Effectiveness of Varenicline Medication Guide for Conveying Safety Information to Patients: A REMS Assessment Survey [436]**  
Cheryl Enger, Muhammad Younus, Kenneth R Petronis, Jingping Mo, Robert Gately, John D Seeger. (United States)
- 14 **Nurses' Attitudes and Adverse Drug Reaction Reporting [437]**  
Joana I Marques, Teresa M Herdeiro, Jorge J Polónia. (Portugal)
- 15 **Compliance Survey for Thalidomide Safety Use (part5); after Revision of TERMS [438]**  
Yuko Shirakuni, Chizuko Hattori, Nobuyasu Yamaguchi, Teruyoshi Kubo, Norihito Kawashita, Tatsuya Takagi, Masao Nasu. (Japan)
- 16 **Evaluation of Bayesian Methodology for Use in Manufacturing Related Automated Signal Detection with Batch(lot) Specific Adverse Event Reports [439]**  
Nicole Kellier, Ilya Lipkovich, Ken Hornbuckle. (United States)
- 17 **New Medical Products Governance in France: What Is the Impact on Post Approval Studies Requested by the French Health Authorities [440]**  
Remi Gauchoux, Delphine Bayle, Sohela El Kebir. (France)
- 18 **Are General Sales List (GSL) Medication Labels and Patient Information Leaflets Adequate? [441]**  
Wai-Ping Yau, Si Han Goh, Mui Ling Tan. (Singapore)
- 19 **Assessing Current Public awareness of Anti-Counterfeiting Measures in Health Products [442]**  
Xinhui Qiu, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
- 20 **Healthcare Professionals' Attitudes towards Adverse Drug Reaction Reporting in Nepal: A Factor Analytic Study [443]**  
KC Santosh, Pramote Tragulpiankit, Sarun Gorsanan, I Ralph Edwards. (Nepal)
- 21 **In-Site Measuring of the Role of Educational Package To Increase GPs' Awareness of ADR Reporting System [444]**  
Hristina Lebanova, Emilia Naseva, Evgeni Grigorov, Veselina Stoyneva, Ilko Getov. (Bulgaria)
- 22 **Sources of Information Supporting Drug Withdrawal from the Market Due to Safety Reasons [445]**  
Nuno Craveiro, Carlos Alves, Carlos Fontes-Ribeiro, Francisco Batel-Marques. (Portugal)
- 23 **Non-Response in a Pharmacy and Patient Based Intensive Monitoring System [446]**  
Linda Harmark, Harmen Huls, Han De Gier, Kees van Grootheest. (Netherlands)
- 24 **Patients' Motives for Participating in Active Post Marketing Surveillance [447]**  
Linda Harmark, Miguel Lie-Kwie, Lisette Berm, Han De Gier, Kees van Grootheest. (Netherlands)
- 25 **Public Awareness of Adverse Drug Reactions and Pharmacovigilance System in Korea [448]**  
Jin Lee, Eunhee Lee, Jaewoo Jung, Minhye Kim, Hyeryun Kang, Sangheon Cho. (Republic of Korea)
- 26 **A Nine-Year Review of Adverse Events Related to Chinese Herbal Medicine Rhizoma Atractylodis Contaminated with Tropane Alkaloids (2002-2011) in Hong Kong [449]**  
Kin-chung Chow, Xiao-ling HU, Ka-yiu Yuen, Chi-hang Lam, Ching-kan Leung, Man-kin Lam. (China)
- 27 **Patient Reported Outcomes (PRO) Are Key to Post Launch Safety and Risk Management [450]**  
Anjan K Banerjee, Simon Ingate, Steven Mayall, Sally Okun, David Clifford, Paul Wicks, James Heywood. (United Kingdom)
- 28 **Double Standard for Risk Minimization Program for Thalidomide in Japan [451]**  
Yukari Kamijima, Tsugumichi Sato, Kiyoshi Kubota. (Japan)
- 29 **Examining the Readability of Two Package Inserts for Self-Medication in South Korea [452]**  
Iyn-Hyang Lee, Hyung Won Lee, Nam Kyung Je, Sukhyang Lee. (Republic of Korea)
- 30 **Minimizing Patient Medication Errors: The Role of Anxiety in Self-Injection Failures [453]**  
Meredith Y Smith, Heather Coffin. (United States)
- 31 **Indicators of Drug-Seeking Aberrant Behaviours during Post-Marketing Use of Fentanyl Buccal Tablets: Risk Scores in Support of Risk Management [454]**  
Vicki Osborne, Deborah Layton, Carole Fogg, Saad AW Shakir. (United Kingdom)
- 32 **Completing Epidemiology Questionnaires Incorporated into Cancer Clinical Trials: A Patient Preference Analysis [455]**  
Henrique Hon, Ehab Fadhel, Jalal Ebrahim, Lawson Eng, Anthony La Delfa, Luke Harland, Kimberly Tobros, Dolly Han, Christine E Simmons, Zahra Kassam, Wei Xu, Geoffrey Liu, Sinead Cuffe. (Canada)
- 33 **REMS – Lesson Learned from Effectiveness Assessments [456]**  
Ken Hornbuckle, Amanda McDaniel, Debbie Gash, Meghan Jones, Brande Ellis, Nayan Acharya. (United States)
- 34 **Lessons Learned with Risk Minimization Activities in the US and EU [457]**  
Ken Hornbuckle, Amanda McDaniel, Debbie Gash, Meghan Jones, Brande Ellis, Nayan Acharya. (United States)

**35 Specialist Cohort Event Monitoring Studies at the Drug Safety Research Unit – A New Paradigm [458]**  
Vanessa Marshall, Saad A Shakir. (United Kingdom)

**36 Use of Recommendations in Implementing Pharmacoepidemiology Studies for Vaccines [459]**  
Leslie Montigon, GLC Ferreira. (France)

**37 Development of the Post-Marketing Requirements (PMR) Database [460]**  
Julie Mouchet, Marine Albrieux, Will Maier. (France)

**38 Patient's Educational Material as a Tool To Minimise Risks of Centrally Authorised Products in Europe [461]**  
Madalena Arriegas, Antonio Addis, Ana Hidalgo-Simon, Annalisa Rubino. (United Kingdom)

**39 Effectiveness of Risk Minimisation Measures: A Review of Centrally Authorised Products in the EU [462]**  
Irina Caplanusi, Annalisa Rubino, Ana Hidalgo-Simon, Peter Arlett. (United Kingdom)

**40 Validation of the Draft FDA Blueprint for Prescriber Continuing Education Program for ER/LA Opioids: An Evidence-Based Approach [463]**  
Gary Slatko, Marc DeLuca. (United States)

**41 Communicating Quantitative Benefit and Risk Summaries in Promotional Labeling or Print Advertising: A Literature Review [464]**  
Suzanne L West, Linda Squiers, Lauren McCormack, Brian G Southwell, Emily S Brouwer, Vanessa Boudewyns, Helen Sullivan, Amie O'Donoghue. (United States)

**42 Measurable Recommendations of Additional Risk Minimisation Measures of Medicinal Products in the EU [466]**  
Inge M Zomerdiijk, Gianluca Trifirò, Fakhredin A Sayed-Tabatabaei, Sabine MJM Straus, Miriam CJM Sturkenboom. (Netherlands)

## Pharmacovigilance

**43 Difference in Rates of Abuse Following Reformulation of Extended Release (ER) Oxycodone Using Data from the Radars® System Poison Center Program [467]**  
S G Severtson, B B Bartelson, J Davis, A Muñoz, M F Schneider, P M Coplan, H D Chilcoat, J L Green, R C Dart. (United States)

**44 Use of Recently Developed Substances as Doping in University Athletes and Risk of Adverse Reactions [469]**  
Oleksandr V Matvieiev, Natalya V Matvieieva, Ekaterina Yu Yeremenko. (Ukraine)

**45 A Six-Year Review of Adverse Events Related to Yunaconitine and Crassicauline A (2006-2011) in Hong Kong [470]**  
Oi-lai Tsoi, Ka-yiu Yuen, Jackie Leung, Ronald Lam. (China)

**46 Severity of Adverse Drug Reactions Reported from Hospitals and Ambulatory Care Settings in Central Portugal: An Update [471]**  
Francisco Batel-Marques, Carlos Alves, Diogo Mendes, Carlos Fontes-Ribeiro. (Portugal)

**47 Ten Years of Activity of the Regional Pharmacovigilance Unit of Central Portugal and Its Contribution for Drug Safety Knowledge [472]**  
Diogo Mendes, Carlos Alves, Carlos Fontes-Ribeiro, Francisco Batel-Marques. (Portugal)

**48 Factors Causing or Contributing to Adverse Drug Reactions in Hospitalized Patients [473]**  
Camelia D Bucsa, Andreea M Farcas, Marius T Bojita. (Romania)

**49 Medication Error: A Critical Analysis of the Recent Literature [474]**  
Michela S De Meo, Marilena Romero. (Italy)

**50 Development and Content Validation of a Patient-Reported Adverse Drug Event Questionnaire [475]**  
S T de Vries, F M Haaijer-Ruskamp, D de Zeeuw, P Denig. (Netherlands)

**51 Exposure to New Medicines Prior to Market Authorisation: Too Few Patients and Insufficient Follow-Up [476]**  
Ruben G Duijnhoven, Sabine MJM Straus, June Raine, Anthonius de Boer, Arno W Hoes, Marie L De Bruin. (Netherlands)

**52 MIHARI – Medical Information for Risk Assessment Initiative Year 3 [477]**  
Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)

**53 Development of an Educational Pharmacovigilance Program in Francophone East European Countries [478]**  
Andreea Farcas, Camelia Bucsa, Cristina Mogosan. (Romania)

**54 Bayesian Hierarchical Models for ADR Detection Using Different Criteria To Group the Adverse Reactions [479]**  
Ruth Farmer, David Prieto-Merino, Stephen J Evans. (United Kingdom)

**55 Adverse Drug Reactions (ADRs) in Patients Treated for Colorectal Cancer: From the Oncologists to the Patients [480]**  
Delphine Deligné, Pernelle Noize, Françoise Haramburu, Angela Grelaud-Boussinot, Magali Rouyer, Denis Smith, Annie Fourier-Réglat. (France)

**56 Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions [481]**  
Masayuki Hashiguchi, Shungo Imai, Keiko Uehara, Mayumi Mochizuki. (Japan)

**57 Safety of Non-Prescription Medications: Knowledge and Attitude of Community Pharmacy Customers in Saudi Arabia [482]**  
Hisham Aljadhey, Ghada Assiri, Mansour Adam. (Saudi Arabia)

**58 Is Spontaneous Reporting Always the Most Important Information Supporting Drug Withdrawals for Pharmacovigilance Reasons in France? [483]**  
Pascale Olivier, Marie-Noelle Paludetto, Jean-Louis Montastruc. (France)

**59 Drug Induced-anaphylaxis: A Decade Review of Reporting to the Portuguese Pharmacovigilance Authority [484]**  
Inês Ribeiro-Vaz, Joana Marques, Pascal Demoly, Jorge Polónia, Eva Gomes. (Portugal)

**60 Adverse Drug Reactions Resulting from Self-Medication – Evidence from Germany [485]**  
Marietta Rottenkolber, Sven Schmiedl, Dominik Rottenkolber, Katrin Farker, Bernd Drewelow, Karen Salje, Marion Hippus, Petra A Thürmann, Joerg Hasford. (Germany)

**61 Survey in a Sample of Italian Hospitals on Patient Safety [488]**  
Michela S De Meo, Laura Fabrizio, Maria G Cattaneo, Susanna Ciampalini, Marilena Romero, the Working Group. (Italy)

## Pharmacovigilance Methods

**62 FDA AERS and WHO Vigibase Yielded Different Results in Disproportionality Analysis for Propylthiouracil [489]**  
Huifang Liang, Carlos Vallarino, Gregory Fusco. (United States)

**63 Grouping Related Medical Terms May Not Expedite Detection of Disproportional Reporting Patterns in Pharmacovigilance [490]**  
Richard Hill, Johan Hopstadius, Magnus Lerch, G Niklas Norén. (Sweden)

**64 Performance of Observational Screening by System Organ Class [491]**  
Gregory E Powell, Jeffery L Painter. (United States)

**65 Practical Implications of a 0-Day Versus 30-Day Persistence Window on Datamining Observational Data [492]**  
Gregory Powell, Kristen Van Dole, Stephanie Reisinger. (United States)

**66 Speed of Detection of Adverse Events in Spontaneous Adverse Event Databases Compared with Epidemiological Studies: Two Related Cases [493]**  
Nawab Qizilbash, Ignacio Méndez, Rainer Sánchez de la Rosa. (United Kingdom)

**67 Challenges in Calculating Rate Ratios of Treatment-Associated Adverse Events after Changes in Therapy in Observational Studies [494]**  
Lawrence Rasouliyan, Dave P Miller. (Spain)

**68 Signal Detection on Spontaneous Reports: A Comparison of the Performance of a Method Based on Disproportionality and a Method Based on the Time from Immunisation to Onset of Adverse Events [495]**  
Lionel Van Holle, Vincent Bauchau. (Belgium)

**69 Characterisation of Databases (DBs) Used for Signal Detection (SD): Results of a Survey of IMI PROTECT Work Package (WP) 3 Participants [496]**  
 Antoni FZ Wisniewski, Kristina Juhlin, Mona Laursen, Miguel M Macia, Katrin Manlik, Vlasta K Pinkston, Suzie Seabroke, Jim Slatery. (United Kingdom)

**CER Methods**

**70 A Network Meta-Analysis of Antibiotics for Treatment of Hospitalized Patients with Suspected or Proven Methicillin-Resistant Staphylococcus aureus (MRSA) Infection [497]**  
 Michèle Bally, Nandini Dendukuri, Alison Sinclair, Stéphane P Ahern, Michel Poisson, James Brophy. (Canada)

**71 Comparative Effectiveness of First Step Antihypertensives and Risk of Cardiovascular Outcomes in Older Adults [500]**  
 Wendy Camelo Castillo, Til Stürmer, Mugdha Gokhale, Virginia Pate, Michele Jonsson Funk. (United States)

**72 Evidence Based Drug Therapy and Medium-Long-Term Outcomes in Very Old Patients after Acute Myocardial Infarction [501]**  
 Silvia Cascini, Ursula Kirchmayer, Lisa Bauleo, Mirko Di Martino, Nera Agabiti, Danilo Fusco, Marina Davoli. (Italy)

**73 Adherence to Antihypertensive Agents after a Recent Ischemic Stroke and Risk of Cardiovascular Outcomes [503]**  
 Sylvie Perreault, Amy YX Yu, Robert Côté, Alice Dragomir, Brian White-Guay, Stéphanie Dumas. (Canada)

**74 Comparative Evaluation of Short-Term Risk of Cardiovascular Events with Antidiabetic Step-Up Therapies among Older Adults [504]**  
 Mugdha Gokhale, Michele Jonsson Funk, Richard Wyss, Virginia Pate, Til Stürmer. (United States)

**75 Comparative Effectiveness of Dipeptidyl Peptidase-4 Inhibitor for the Risk of Cardiovascular and Cerebrovascular Disease in Patients with Type 2 Diabetes [505]**  
 Jong-Mi Seong, Nam-Kyong Choi, Ju-Young Shin, Ye-Jee Kim, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

**76 GLP-1 Agonists (Exenatide and Liraglutide) and the Risk of Cancer: A Meta-Analysis of Published Randomized Controlled Clinical Trials [506]**  
 Carlos Alves, Ana Filipa Macedo, Francisco Batel-Marques. (Portugal)

**77 Acute Pancreatitis Associated with GLP-1 Agonists (Exenatide and Liraglutide) Exposure: A Meta-Analysis of Published Evidence [507]**  
 Carlos Alves, Ana Filipa Macedo, Francisco Batel-Marques. (Portugal)

**78 Active Monitoring of the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel in Routine Care [508]**  
 Joshua J Gagne, Jeremy A Rassen, Niteesh K Choudhry, Rhonda L Bohn, Amanda R Patrick, Gayathri Sridhar, Jun Liu, Sebastian Schneeweiss. (United States)

**79 Comparative Safety and Effectiveness of Generic Versus Branded Alendronate in Medicare Population [511]**  
 Huifeng Yun, Kenneth G Saag, Jeffrey R Curtis, Lingli Guo, Meredith Kilgore, Paul Muntner, Elizabeth Delzell. (United States)

**80 Comparative Safety of Conventional and Atypical Antipsychotics and the Risk of Ischemic Stroke among the Elderly [512]**  
 Ju-Young Shin, Nam-Kyong Choi, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

**81 Changes after Reformulation of Extended-Release Oxycodone in Calls to US Poison Centers for Oxycodone and Heroin [513]**  
 Paul M Coplan, Hrishikesh Kale, Lauren Sandstrom, Howard D Chilcoat. (United States)

**82 The Impact of Long-Acting Injectable Versus Oral Antipsychotics on Hospitalization Rates in Patients with Schizophrenia: A Systematic Review and Meta-Analysis [515]**  
 Marie-Hélène Lafeuille, Jason Dean, Valérie Carter, Mei Sheng Duh, John Fastenau, Riad Dirani, Patrick Lefebvre. (Canada)

**83 Switching the Pharmaceutical Dosage Form of Extended-Release Valproate Is Associated with Therapeutic Modification of Antiepileptic Therapy [516]**  
 Katrin Schuessel, Stephanie von Klot, Martin Schulz. (Germany)

**84 Pharmacotherapy Is More Effective in Childhood Than in Juvenile Absence Epilepsy in Long-Term Follow-Up [517]**  
 Rimma G Gamirova, Rosa M Shaimardanova, Lilia E Ziganshina. (Russian Federation)

**85 Tacrolimus Versus Cyclosporine in Maintenance Immunosuppressive Regimens in Renal Transplantation in Brazil (2000/2004), a Cost-Effectiveness Matched Analysis [519]**  
 Augusto Afonso Guerra Junior, Francisco Assis Acurcio, Grazielle Dias Silva, Cibele Comini Cesar, Mariangela Leal Cherchiglia, Odilon Vanni Queiroz. (Brazil)

**86 Immunosuppressive Therapy Impact in Kidney Transplant [521]**  
 Patricia Pereira, Carla Teixeira de Barros, Ana Luísa Papoila, Isabel Ramalhinho. (Portugal)

**87 Impact of Oropharyngeal Exercises on Patients with Moderate Obstructive Sleep Apnea [522]**  
 Abhay Dharamsi, Geetha Kandasamy, Vijayakumar Arumugam, Rajasekaran Aiyalu. (India)

**88 Management of Patients with Colon Cancer in France: Description of the Cohort FDRK (Feuille De Route Cancer du Côlon (K)) [523]**  
 L Grimaldi-Bensouda, T André, O Bouché, C Mariette, R Benamouzig, M Ychou, E Mitry, C Tournigand, A Fabre, J Rudant, L Abenhaim, FDRK Study Group. (France)

**89 Challenges of IPTW Estimation with Combined Exposures: An Example Using Hemodialysis Data [526]**  
 Alan R Ellis, Abhijit V Kshirsagar, Wolfgang C Winkelmayr, M Alan Alan Brookhart. (United States)

**90 Heterogeneity in Published Evidence for Stroke Prevention in Patients with Atrial Fibrillation: A Systematic Review [527]**  
 Teresa A Simon, David Jakouloff, Stephen A Mitchell, Syed A Raza, Ian Lockhart, Pieter Drost. (France)

**91 Disease Risk Scores (DRS) as a Confounder Summary Method: Systematic Review and Recommendations [528]**  
 Mina Tadrous, Joshua J Gagne, Til Stürmer, Suzanne M Cadarette. (Canada)

**92 Health Status to Policy Advocacy and New Drug Licenses [529]**  
 Yaowares Oppamayun, Wimon Suwannakawong, Somchai Preechataveekid. (Thailand)

**93 Safety Evaluation of Generic and Brand-Name Products of Ampicillin Sodium/Sulbactam Sodium for Injection [530]**  
 Chizuru Yabumoto, Mamiko Tsugane, Takako Nozawa, Kaori Nomura, Sozu Takashi, Etsuko Uejima. (Japan)

**Comparative Effectiveness Research (CER)**

**Abstract Withdrawn by Author [531]**

**94 Performance of Overall Versus Subgroup Propensity Scores When an Important Subgroup Variable Is a Strong Confounder [532]**  
 Mugdha Gokhale, Michele Jonsson Funk, Richard Wyss, Virginia Pate, Til Stürmer. (United States)

**95 Beware of Policy-Induced Selection Bias in Drug Effect Studies: Example in the Comparative Effectiveness of Oral Bisphosphonates [533]**  
 Suzanne M Cadarette, Linda Levesque, Muhammad Mamdani, Sylvie Perreault, David N Juurlink, J Michael Paterson, Greg Carney, Nadia Gunraj, Milica Nikitovic, Gillian A Hawker, Colin R Dormuth. (Canada)

**96 Methodological Considerations in Estimating Drug Adherence for a Long-Acting Injectable Medication [534]**  
 Elizabeth J Campagna, Erik Muser, John W Newcomer, Joseph Parks, Elaine H Morrato. (United States)

- 97 Geospatial Variations in Drug Utilization and the Potential for Confounding by Geography [535]**  
Elisabeth D Root, Deborah Thomas, Elizabeth J Campagna, John W Newcomer, Joseph Parks, Elaine H Morrato. (United States)
- 98 Evaluating Effects of Changing Treatments in Longitudinal Studies [536]**  
Xiaolei Zhou, Beth Sherrill, Yun Wu, Lee Bennett, Jianmin Wang. (United States)
- 99 Time-Dependent Propensity Score and Collider-Stratification Bias: Inhaled beta2-Agonist and Risk of Coronary Heart Disease [537]**  
Mohammed S Ali, Rolf HH Groenwold, Wiebe R Pestman, Svetlana V Belitser, Arno W Hoes, Anthonius de Boer, Olaf H Klungel. (Netherlands)
- 100 Change in Exposure in Studies of Chronic Conditions: Insights from a Mixed Effects Multinomial Logit Model [538]**  
Maurille Feudjo Tepie, Andrew Roddam, Cathy Critchlow, Andrew Taylor, Samara Ferguson, Shelley Fordred, Jonathan Bayly. (United Kingdom)
- 101 Graphical Representation of Confounding Potential for Measured Covariates [539]**  
Drew G Levy, David C Norris, Ventrakam Kuturu, Debra Maldonato, Charles Barr. (United States)
- 102 Performance of Instrumental Variable Methods in Case-Control and Cohort Studies: A Simulation Study [540]**  
M Jamal Uddin, Rolf HH Groenwold, Anthonius de Boer, Svetlana V Belitser, Kit CB Roes, Olaf H Klungel. (Netherlands)

**Cardiovascular**

- 103 Cardiovascular Risk Factors Associated with Essential Hypertension [541]**  
Ghizlane Berrada El Azizi, Samir Ahid, Saadia Abir, Fedoua Ellouali, Amine Elmajhad, Mouna Charif d'Ouazzane, Sahar Mouram, Abdelali Boukili, Mohammed Cherti, Yahia Cherrah. (Morocco)
- 104 Antihypertensive Drug Compliance and Its Related Factors in a Korean Population [542]**  
Hee-Young Shin, Min-Ho Shin, Jung-Ae Rhee. (Republic of Korea)
- 105 Risk of Acute Myocardial Infarction (AMI), Stroke, or Death in GPRD Patients Treated with Olmesartan (Olm) or Other Angiotensin Receptor Blockers (ARBs) [543]**  
Esther H Zhou, Kate Gelperin, David J Graham, Mark Levenson, Martin Rose, Ya-Hui Hsueh, Tarek A Hammad. (United States)
- 106 The Effect of Statins on the Risk of First Non-Fatal Myocardial Infarction: A Population-Based Observational Study Using the PGRx Information System [544]**  
L Grimaldi-Bensouda, M Rossignol, N Danchin, J Dallongeville, E Bruckert, J Banayan, Y Cottin, A Khachatryan, J Benichou, L Abenheim, PGRx MI Group. (France)

- 107 Use of Low Dose Aspirin Increased Cardiovascular Risk in Incident Diabetic Patients [545]**  
Ye-Jee Kim, Mi-Sook Kim, Nam-Kyong Choi, Jong-Mi Seong, Ju-Young Shin, Ji Eun Park, Byung-Joo Park. (Republic of Korea)
- 108 Long-Term Compliance to Acetylsalicylic Acid in Patients after Acute Coronary Syndrome [546]**  
Andrey N Baglikov, Vladimir V Rafalskiy. Russian Federation)
- 109 Diuretics and the Risk of Developing Gout [547]**  
Saskia G Bruderer, Susan S Jick, Christoph R Meier. (Switzerland)
- 110 Secondary Prevention Drugs Following Acute Myocardial Infarction after Hospital Discharge, 6 and 24 Months Thereafter: Results from the EOLE Cohort [548]**  
Cécile Droz-Perroteau, Caroline Dureau, Daniel Thomas, Nicolas Danchin, Jacques Tricoire, Jacques Bénichou, François Paillard, Serge Hercberg, Philip Robinson, Hélène Maïzi, Marie-Agnès Bernard, Patrick Blin, Nicholas Moore. (France)
- 111 Use of Allopurinol and Risk of Myocardial Infarction: A Case-Control Study [549]**  
Lamia Grimaldi-Bensouda, Annick Alperovitch, Elodie Aubrun, Pascal Richette, Pascal Hilliquin, Nicolas Danchin, Philippe-Gabriel Steg, Bruno Fautrel, Michel Rossignol, Lucien Abenheim, PGRx MI Group. (France)
- 112 Spironolactone and the Risk of Breast Cancer: A Cohort Study [550]**  
Isla S Mackenzie, Thomas M MacDonald, Alastair M Thompson, Steven Morant, Li Wei. (United Kingdom)
- 113 Use of Fibrates and Risk of Cancer: Results from a Nested-Case-Control Study [551]**  
Francesco Salvo, Fabienne Bazin, Basmah Ambrosino, Regis Lassalle, Philip Robinson, Nicholas Moore, Bernard Begaud, Antoine Pariente. (France)
- 114 Cardiovascular Diseases and Drugs and the Risk of Developing Rosacea [552]**  
Julia Spoendlin, Johannes J Voegel, Susan S Jick, Christoph R Meier. (Switzerland)
- 115 Confounding Adjustment in a Distributed Data System without Sharing of Individual-Level Data [553]**  
Darren Toh, Marsha E Reichman, Monika Houston, Xiao Ding, Bruce Fireman, Eric Gravel, Adrian F Hernandez, Lingling Li, Erick Moyneur, Azadeh Shoabi, Mary Ross Southworth, Gwen Zornberg, Sean Hennessy. (United States)
- 116 Adverse Reactions to Medicines Used in Cardiovascular Conditions in a Cardiac Care Unit [554]**  
Parthasarathi Gurumurthy, Rajesh Kenche, Atiqulla Shariff, Arun Srinivas. (India)

- 117 Non Steroidal Anti-Inflammatory Drugs (NSAIDs) and Increased Risk of Hypertension Treatment Intensification: A Population-Based Cohort Study [555]**  
Jean-Pascal Fournier, Agnès Sommet, Robert Bourrel, Stéphane Oustric, Maryse Lapeyre-Mestre, Jean-Louis Montastruc. (France)
- 118 Calcium Channel Blocker (CCB) Treatments and Cancer Risk. Linking Danish National Health Care Databases [556]**  
Ulrik Hesse, Pernille F Rønne, Lamiae Grimaldi. (Denmark)
- 119 Severe Liver Injury (SLI) among Dronedarone, Amiodarone or Sotalol Initiators [557]**  
Gwen L Zornberg, John R Senior, David J Graham, Clara Kim, Michael Wernecke, Leonard B Seeff, Judy A Racoosin, Mark I Avigan, Marsha E Reichman, Thomas E MaCurdy, Chelsea Lam, Mary Ross Southworth, Monika Houston, Mark Levenson, Azadeh Shoabi, Eileen Wu, Chris Worrall, Jeffrey A Kelman. (United States)
- 120 Near Real-Time Safety Surveillance of Dabigatran among VA Users [558]**  
Diane Dong, Francesca Cunningham, Lisa Longo, Rong Jiang, Peter Glassman, Chester B Good. (United States)
- 121 Impact of Comorbidities on Risk of Cardiovascular Hospitalization among Patients with and without Atrial Fibrillation [559]**  
Mary Panaccio, Gordon Cummins, Raymond Miao, Pamela Davis, Charles Wentworth, Stephan Lanes, Matthew Reynolds, Shannon L Michels, Andrew Koren. (United States)
- 122 Statin Use and Cataract Surgery – A Nationwide Retrospective Cohort Study [560]**  
Chao-Lun Lai, Wen-Yi Shau, Chia-Hsuin Chang, Ming-Fong Chen, Mei-Shu Lai. (Taiwan)
- 123 Influence of Time Dependent Covariates on Estimation of Risk of Acute Myocardial Infarction Comparing Sulfonylurea with Metformin in Type 2 Diabetes [561]**  
Zhiwen Liu, Kimberly G Brodovicz, Doug Kou, Gregory T Golm, Douglas J Watson, Cynthia J Girman. (United States)
- 124 Patterns of Comorbidities and Procedures among Patients with Metastatic Melanoma within SEER/Medicare (USA) [562]**  
Daniel O Koralek, Michael T Taylor. (United States)
- 125 Arterial Thromboembolic Events among Older Renal Cell Cancer Patients [563]**  
Sumitra Shantakumar, Alexandra Connelly-Frost, Haojie Li, Monica G Kobayashi. (United States)
- 126 Risk of Gastrointestinal Conditions among Patients with Atrial Fibrillation [564]**  
François Laliberté, Yuliya Moore, Katherine Dea, Joyce C LaMori, Samir H Mody, JaCinda L Jones, Michele D Arledge, CV Damaraju, Mei Sheng Duh, Jeff R Schein, Patrick Lefebvre. (Canada)

**127 Patients with Obstructive Pulmonary Disease Have an Increased Risk of ECG Documented Out-of-Hospital Cardiac Arrest [565]**  
Miriam J Warnier, Marieke Blom, Abdenasser Bardai, Patrick C Souverein, Arno W Hoes, Frans Rutten, Anthonius de Boer, Marie L De Bruin, Hanno L Tan. (Netherlands)

**128 Awareness of Severe Hypertriglyceridemia in U.S. Adults: NHANES 2001-2008 [566]**  
Jennifer B Christian, Nancy E Bourgeois, Kimberly A Lowe. (United States)

**129 Challenges in Evaluating External Validity of Predictive Models for Survival in Patients with Pulmonary Arterial Hypertension [567]**  
Erwan Muros Le Rouzic, Jean-Christophe Lemarié, Raymond L Benza, Marc Humbert, Michael D McGoon, Daniel Rosenberg, Olivier Sitbon, Dave P Miller. (Switzerland)

**130 The Epidemiological Case-Control Results from the Drug-Induced Arrhythmia Risk Evaluation (DARE) Study [568]**  
Vanessa Marshall, Edward Tong, Elijah Behr, Saad A Shakir. (United Kingdom)

**131 Detection of QT Prolongation Signals Using an Electronic Health Record Database [569]**  
Dukyong Yoon, Man Young Park, Eun Kyoung Ahn, Nam-Kyong Choi, Joongyub Lee, Rae Woong Park. (Republic of Korea)

**132 ARITMO Project. QT Prolongation Associated to Antimicrobials, Antipsychotics and Antihistamines: An Analysis of the French Spontaneous Reporting Database [570]**  
Francesco Salvo, Ugo Moretti, Annie Fourrier-Réglat, Pascal Auriche, Stefania Antoniazzi, Nicholas Moore, Miriam C Sturkenboom, Raschi Emanuel, Antoine Pariente. (France)

**133 Giant Cell Arteritis and Cardiovascular Events in the French APOGEE Cohort. A Population-Based Study Using the French Health Insurance System Database [571]**  
Grégory Pugno, Laurent Sailler, Robert Bourrel, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)

**134 What Is the Burden of Hospitalizations for Heart Failure in France in 2010? [572]**  
Bruno Bouvet, Mathieu Rocchi, Pascal De Groote, Michel Galinier, Jean-Noël Trochu, Patrice Verpillat. (France)

**135 Combining Electronic Health Records and Patient-Reported Information in the UK: Preliminary Results from WASPS (Wales SAIL + PRO Study) [573]**  
Elisa Cascade, David Ford, Mark Nixon, Caroline Brooks, Martin Heaven. (United States)

**136 Cardiovascular Risk Factors among Women in the United States by Race/Ethnicity [574]**  
Margaret McDonald, Françoise Pickart, Jingying Zhou, Jack Mardekian. (United States)

**137 Persistence with Statins and Reduction of Low Density Lipoprotein Cholesterol: Analysis of Real-Life Data from Community Settings [575]**  
Varda Shalev, Inbal Goldstein, Avi Porath, Gabriel Chodick. (Israel)

**138 Comparative Safety of Statins in Japanese Patients: A Short-Term Prospective Case-Cohort Study (Japan Statin Study, JSS) [576]**  
Shigeru Kageyama, Masaki Kitamura, Akira Kokan, Kiyoshi Kubota, Hideaki Kurata, Kenichi Matsui, Nobuhiro Ooba, Takao Orii, Tsugumichi Sato, Yoshihiro Shimodozono, Emiko Shina, Yukari Yaju, Takuhiro Yamaguchi, Hiroshi Yoshida. (Japan)

### Diabetes & Other Endocrine

**139 Glyburide Is Associated with an Increased Risk of Acute Coronary Events Compared to Gliclazide in Patients with a History of Ischemic Heart Disease [577]**  
Ahmed S Abdelmoneim, Dean T Eurich, John-Michael Gamble, Jeffery A Johnson, John Seubert, Weiyu Qiu, Scot H Simpson. (Canada)

**140 The Use of Pioglitazone and the Risk of Bladder Cancer in Patients with Type 2 Diabetes [578]**  
Laurent Azoulay, Hui Yin, Kristian B Filion, Jonathan Assayag, Agnieszka Majdan, Michael Pollak, Samy Suissa, Samy Suissa. (Canada)

**141 The Burden of Type 2 Diabetes on Work Productivity: A Systematic Review [579]**  
Marie-Claude Breton, Line Guénette, Mohamed Amine Amiche, Jeanne-Françoise Kayibanda, Jean-Pierre Grégoire, Jocelyne Moisan. (Canada)

**142 Incidence of Diabetic Maculopathy among Patients with Diabetic Retinopathy [580]**  
Elisa Martin-Merino, Joan Fortuny, Elena Rivero, Luis Alberto García-Rodríguez. (Spain)

**143 Risk Factors for Incident Diabetic Macular Edema in Type II Diabetes in UK Primary Care [581]**  
Elisa Martin-Merino, Joan Fortuny, Elena Rivero, Luis Alberto García-Rodríguez. (Spain)

**144 Type 2 Diabetes Mellitus and Cancer Risk: A Population-Based Study [582]**  
Jinghua He, Tzuyung D Kou, Kimberly G Brodovicz, Samuel S Engel, Amy Sun, Cynthia J Girman. (United States)

**145 Estimating Chronic Kidney Disease in a UK Population with Type II Diabetes Mellitus [583]**  
Claudia S Cabrera, Alex Asiimwe, Alison Lee. (Sweden)

**146 Algorithm To Estimate Duration of Known Type 2 Diabetes in Electronic Healthcare Databases [584]**  
Kimberly G Brodovicz, T Doug Kou, Rishi Desai, Se Li, Samuel S Engel, Charles M Alexander, Cynthia J Girman. (United States)

**147 Using Functional Principal Component Analysis (FPCA) for Sparse Longitudinal Data (SLD): Example of HbA1c in Patients with Diabetes Mellitus [585]**  
Therese M Sheppard, William G Dixon. (United Kingdom)

**148 Combining Phase III and Phase IV Data: The Example of Rosiglitazone [586]**  
Gudrun Stefanssondottir, Charlotte Rietbergen, Diederick E Grobbee, Hubert GM Leufkens, Marie L De Bruin. (Netherlands)

**149 Diabetes Mellitus, Antidiabetic Drugs and the Risk of Developing Rosacea [587]**  
Julia Spoendlin, Johannes J Voegel, Susan S Jick, Christoph R Meier. (Switzerland)

**150 Evaluation of Methods To Estimate Days' Supply of Oral Antidiabetic Drugs in the Health Improvement Network [588]**  
Kevin Haynes, Kimberly B Fortier, Craig Newcomb, Jason A Roy, Eileen E Ming, Laura Horne, Jennifer Wood-Ives, Brian L Strom, Vincent Lo Re III. (United States)

**151 Disinvestment Debate in a Brazilian State: Insulin Versus It's Analogue Glargine for Diabetes Control [589]**  
Ana Luisa C Souza, Francisco A Acurcio, Augusto A Guerra Junior, Renata Cristina R Macedo, Leonardo M Diniz. (Brazil)

**152 Socio-Demographic Characteristics and ADR Severity in Antidiabetic-Treated Patients: Profiles and Correlations [590]**  
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)

**153 Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs? [591]**  
Marloes T Bazelier, Frank de Vries, Peter Vestergaard, Hubert GM Leufkens, Marie L De Bruin. (Netherlands)

**154 Metformin Does Not Alter the Risk of Lung Cancer: A Case-Control Analysis [592]**  
Michael Bodmer, Claudia Becker, Christian Meier, Susan S Jick, Christoph R Meier. (Switzerland)

**155 Histamine-2 Receptor Antagonists and the Risk of Lung Cancer in Diabetic Patients – A Nationwide Study [593]**  
Chia-Hsueh Chang, Jou-Wei Lin, Li-Chiu Wu, Lee-Ming Chuang, Mei-Shu Lai. (Taiwan)

**156 Regional Differences in Baseline Characteristics of Type 2 Diabetes Mellitus Patients from the Effectiveness of Diabetes Control with Vildagliptin and Vildagliptin/mEformin' (EDGE) Study [594]**  
Raymond G Schlienger, Giovanni Bader, Nicole Hagner, Chantal Mathieu, on behalf of the EDGE Steering Committee. (Switzerland)

**157 Drug Induced Hypoglycemia in Hospitalized Patients: Prevalence, Incidence Rate and Risk Factors [595]**  
Parthasarathi Gurumurthy, Rahul Patel, Anand Harugeri, Narahari G Moda, Ramesh Madhan. (India)

### CV, DM & Endocrine DUR

**158 Treatment Patterns and Persistence in Hypertensive Diabetes Patients Treated with Fixed or Unfixed Combinations of Angiotensin Receptor Blockers (ARB), Amlopidine (AML) and Hydrochlorothiazide (HCT) [596]**  
Birgit Ehlken, Karel Kostev, Anna Sandberg, André MS Oberdiek. (Germany)

- 159 Pharmacological Treatment of Heart Failure in Primary Healthcare in Stockholm – High Adherence to Guidelines but Still Room for Improvement [597]**  
Ramin Zarrinkoub, Desirée Loikas, Birgitta Lilja, Jamilette Miranda-Tellez, Björn Wettermark. (Sweden)
- 160 In-Hospital Cardiovascular Drugs Use in Acute Myocardial Infarction Patients and In-Hospital Mortality from 2004 to 2008 in Taiwan [598]**  
Ching-Lan Cheng, Cheng-Han Lee, Yi-Heng Li, Yea-Huei Kao Yang. (Taiwan)
- 161 Utilization of Lipid Lowering Drugs in Hungary between 2005 and 2010: Cost and Benefit [599]**  
Peter Doro, Andrea Bor, Ria Benko, Zsuzsanna Biczok, Maria Matuz, Reka Viola, Gyongyver Soos. (Hungary)
- 162 Performance Measures of Diabetes Management Do Not Always Predict Better Glycemic Control: The Need for Case-Mix Adjustment [601]**  
Grigory Sidorenkov, Jaco Voorham, Flora Haaijer-Ruskamp, Dick de Zeeuw, Petra Denig. (Netherlands)
- 163 Utilization of Antidiabetic Drugs among U.S. Adults, 2002-2011 [602]**  
Christian Hampp, Vicky Borders-Hemphill, David G Moeny, Diane K Wysocki. (United States)
- 164 Autonomous Region Variations in Use and Cost of Antidiabetic Drugs over Time [603]**  
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)
- 165 Benefit & Risk Preferences of Patients for New Drugs To Treat Type II Diabetes Mellitus [604]**  
Arna Arnardottir, Flora Haaijer-Ruskamp, Sabine Straus, Pieter de Graeff, Paul Krabbe, Peter Mol. (Netherlands)
- 166 Agreement in Balancing Benefit and Risk of New Drugs between Patients and Regulators [605]**  
Arna H Arnardottir, Ilknur Dolu, Paul Krabbe, Sabine M Straus, Pieter A de Graeff, Flora M Haaijer-Ruskamp, Peter G Mol. (Netherlands)
- 167 Comorbidity and Adherence to Oral Antihyperglycemic Agents in Ireland [606]**  
Miriam P O'Shea, Mary Teeling, Kathleen Bennett. (Ireland)
- 168 Evaluation of the Effect of the Regulatory Action Using Electronic Medical Records Data [607]**  
Eiko Tada, Kaori Yamada, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 169 Utilisation and Characteristics of New Users of Oral Antidiabetes Drugs (OAD) in the UK: 2006 2010 [608]**  
Andrew Maguire, Beth Mitchell. (United Kingdom)
- 170 Quantifying Usage of Exenatide BID in Patients with Renal Impairment (2008-2010) [609]**  
Kwame Appenteng, Dale Marmaduke, John Roberts, H Zhang, Stephen Motsko. (United States)
- 171 Prevalence of Comorbid Chronic Conditions in Metabolic Syndrome Patients Using Medicine Claims Data [610]**  
Johanita R Burger, Martie S Lubbe, Jan HP Serfontein. (South Africa)
- 172 Discontinuation of Anticoagulant Care during Admission in a Psychiatric Hospital [611]**  
Heshu Abdullah-Koolmees, Tjetske Gerbranda, Vera HM Deneer, Mathieu M Tjoeng, Alex JM De Ridder, Helga Gardarsdottir, Eibert R Heerdink. (Netherlands)
- 173 Predictors of Non-Adherence to Statins: Population-Based Restrospective Cohort Study [612]**  
Maria del Mar Garcia, Marc Comas, Anna Ponjoan, Ruth Martí, Rafel Ramos. (Spain)
- 174 The Evaluation of Appropriateness of Therapy after Percutaneous Coronary Intervention in the Lazio Region (Italy) [613]**  
Luigi Pinnarelli, Flavia Mayer, Giovanna Cappai, Lisa Bauleo, Ursula Kirchmayer, Nera Agabiti, Valeria Belleudi, Danilo Fusco, Marina Davoli. (Italy)
- 175 The Utilisation of Ivabradine in General Practice in England; Focus on Compliance with Licence [616]**  
Claire Doe, Carole Fogg, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 176 Utilisation and Tolerability of Aliskiren; Final Results of a Prescription Event Monitoring Study [617]**  
Claire Doe, Carole Fogg, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 177 The Prescribing of Fibrates in General Practice in the UK and the Impact of Regulatory Advice [618]**  
Katherine L Donegan. (United Kingdom)
- 178 Racial and Gender Disparities in Lipid-Lowering Medication Use: Results from the Multi-Ethnic Study of Atherosclerosis (MESA) [619]**  
Robyn McClelland, Neal Jorgensen, Wendy Post, Szklo Moyses, Kronmal Richard. (United States)
- 179 Interrupted Time Series Analysis on the Impact of Dronedarone Authorisation on Italian and Swedish Antiarrhythmic Prescriptions [620]**  
Carlo Piccinni, Emanuel Raschi, Elisabetta Poluzzi, Aurora Puccini, Thomas Cars, Björn Wettermark, Igor Diemberger, Giuseppe Boriani, Fabrizio De Ponti. (Italy)
- 180 Treatment Quality Indicators Predict Improved Cardiovascular and Renal Risk Factor Control in Diabetes Patients: A Prospective Cohort Study Using the GIANTT Database [621]**  
Grigory Sidorenkov, Jaco Voorham, Dick de Zeeuw, Flora M Haaijer-Ruskamp, Petra Denig. (Netherlands)
- 181 Trends in the Consumption of Antihypertensive Therapy in Portugal, 2004-2011 [622]**  
Carla Torre, Jose Guerreiro, Suzete Costa. (Portugal)
- 182 Treatment Duration of Dual Antiplatelet Therapy and Re-Hospitalization for Acute Coronary Syndrome after Percutaneous Coronary Intervention [623]**  
Shih-Chin Chen, Fei-Yuan Hsiao, Chii-Ming Lee, Churn-Shiouh Gau. (Taiwan)
- 183 Dronedarone Associated Pulmonary Toxicity and Prior Amiodarone Exposure: A Pharmacovigilance Analysis [624]**  
Eileen Wu, Vicky Borders-Hemphill, Min Chen, Hina Mehta, Susan Lu. (United States)
- 184 Prescription Pattern Monitoring in South Korea during 2009-2010 Using WHO-ATC/DDD Tool [625]**  
Jihye Ha, Chan Young Park, Ji Eun Kang, Han Sung Na, Hee Jung Shin, Hae Deum Kim, Doo Won Seo, Young Hoon Kim, Myeon Woo Chung. (Republic of Korea)
- 185 Profile and Costs of Dyslipidemic Patients Served by the Unified Health System, Brazil [628]**  
Juliana Duarte, Francisco Acurcio, Augusto Guerra Júnior, Mariângela Cherchiglia, Eli lola Andrade. (Brazil)
- 186 Pro-Arrhythmic Risk of Oral Antihistamines (H1): Combining Adverse Event Reporting Data with Drug Utilization Data across Europe [629]**  
Elisabetta Poluzzi, Emanuel Raschi, Brian Godman, Ariola Koci, Christian Berg, Iain Bishop, Jurij Furst, Marija Kalaba, Ott Laius, Ugo Moretti, Catherine Sermet, Bjorn Wettermark, Miriam Sturkenboom, Fabrizio De Ponti. (Sweden)
- 187 Attitude of Prescribing Proton Pump Inhibitors in Patients Using Clopidogrel for Secondary Prevention of Cardiovascular Events Utilizing Survey Study [630]**  
Suvimol Niyomnaitam, Stephen E Kimmel, Warren B Bilker, John H Holmes. (United States)
- 188 Have Increases in Co-Payments for Medicines Further Burdened Australians in Remote and Disadvantaged Areas? [631]**  
Anna Kemp, John Glover, David B Preen, Max Bulsara, James Semmens, Elizabeth E Roughton. (Australia)
- 189 Variable Approaches to Enhancing the Prescribing of Losartan Once Generics Available; Influence and Future Direction [632]**  
Brian Godman, Kathleen Bennett, Marion Bennie, Thomas Burkhardt, Jean-Paul Fagot, Ulrik Hesse, Andrew Martin, Peter Skjold, Bjorn Wettermark, Corrine Zara, Lars L Gustafsson. (Sweden)
- 190 Influence of Lifting Prescribing Restrictions for Losartan in Austria; Implications for Other Classes [633]**  
Brian Godman, Manuela Schmitzer, Thomas Burkhardt, Anna Buscics, Lars L Gustafsson. (Sweden)

**191 Chronic Heart Failure in the Elderly: Clinical Characteristics and Resource Utilization Following Initial Hospitalization [634]**  
Caroline Korves, Adi Eldar-Lissai, Robert Wei, Hari Sharma, Kristina Chen, Siew Hwa Ong, Mei Sheng Duh. (United States)

**192 Are Patients with Central and Branch Retinal Vein Occlusion at Increased Risk of Cardiovascular Disease? [635]**  
Emil Löfroth, Sara Bruce Wirta, Karl-Johan Myrén. (Sweden)

**193 Is There Any Difference in the Experience and Beliefs of Current and Former Statin Users? [636]**  
Gudrun Thengilsdottir, Janine M Traulsen, Anna B Almarsdottir. (Iceland)

**194 Service Provider Utilization Patterns in Patients with Type 2 Diabetes with Medicaid or Employer-Based Health Insurance Coverage [637]**  
Mona H Cai, Tzuyung D Kou, Kimberly G Brodovicz, Kimberly A Wilson, Charles M Alexander, Samuel S Engel, Cynthia J Girman. (United States)

**195 Evaluation of a Computerised Decision Support System for Use by Non Medical Prescribers in Type 11 Diabetes [638]**  
Jessica Thompson, Stephen R Chapman. (United Kingdom)

**196 Patient Characteristics at Type 2 Diabetes Diagnosis for Patients with Medicaid and Those with Employer Based Health Insurance [639]**  
Kimberly A Wilson, Tzuyung D Kou, Kimberly G Brodovicz, Mona Cai, Charles M Alexander, Samuel S Engel, Cynthia J Girman. (United States)

**197 Necessary Metrics for Evaluation of Coordination of Care of Individuals with Diabetes Mellitus [640]**  
Jodi B Segal, Eva H Dugoff. (United States)

**198 High-Risk Prescribing of Aliskiren in Practice: Findings from the GIANTT Diabetes Cohort [641]**  
Jaco Voorham, Hiddo J Lambers Heerspink, Peter GM Mol, Dick de Zeeuw, Petra Denig. (Netherlands)

**199 Changes in Antihypertensive Prescribing Patterns during 1990-2009 [642]**  
Humberto Fariñas, Macarena C Cáceres, Moyano Paloma, LLerena Adrián. (Spain)

**200 Trends in Utilization of Medications with Adverse Metabolic Effects in a Managed Care Population between 1999-2008 [643]**  
Steven T Bird, Monica Munoz, Almut Winterstein, Rhonda Cooper-Dehoff, Joseph AC Delaney. (United States)

**201 Weight Loss Drug Consumption by the Brazilian Population Based on the POF 2002-2003 [644]**  
Anamaria V Zaccolo, Sotero S Mengue. (Brazil)

**256 Dabigatran Drug Utilization Data and Adverse Event Reporting during the First Year of U.S. Marketing [1042]**  
Melinda McLawhorn, Kusum Mistry, Grace Chai, Susan Lu, Allen Brinker, Judy Staffa, Min Chen. (United States)

## Methods in Databases

**202 Feasibility and Value of Creating Longitudinal Patient Records from Transcribed Clinical Notes [647]**  
Scott L DuVall, Gerasimos Petratos, Aaron WC Kamauu. (United States)

**203 Using Database Enrollment To Exclude Subjects from Retrospective Studies [649]**  
Stephan F Lanes. (United States)

**204 Use of Bayesian Method To Predict Missing Lifestyle Information in the General Practice Research Database (GPRD) [650]**  
Jamie T Laudati, Tzuyung D Kou, Kimberly G Brodovicz, Cynthia J Girman, Hanzhe Zheng. (United States)

**205 A Clinical Classification Dictionary for Read Codes in the General Practice Research Database [651]**  
Hoa V Le, Chi T Truong, David Webb, Lakshmi Mynepalli, Elizabeth Hodgson, Dimitri Bennett, John Logie, Carlyne Averell. (United States)

**206 Development and Evaluation of Claims-Based Algorithms To Identify Advanced Chronic Kidney Disease [652]**  
Hoa V Le, Chi T Truong, Charlotte F Carroll, Jennifer B Christian, David A Webb, Samantha A Laurent, Amit Shukla, John W Logie, Carlyne Averell. (United States)

**207 Developing Quality Scores for Electronic Health Records for Clinical Research [654]**  
A Rosemary Tate, Natalia Beloff, Timothy Williams, Shivani Puri, Tjeerd van Staa. (United Kingdom)

**208 A Comparison of Drug Exposure Characteristics across a Range of Drugs and Databases [655]**  
Stephanie J Reisinger, Gregory Powell. (United States)

**209 Examination of the Completeness of Hospitalization Data from the MedMining Electronic Medical Record (EMR) Database [656]**  
Matthew W Reynolds, Richard S Swain, Kathy Fraeman, Niki Palmetto, Nataliya Volkova. (United States)

**210 The CODEX Method: A Systematic Approach for Harmonization of Event Measurement and Data Extraction for Multi-Database Studies. An Application in the SOS Project [658]**  
René Schade, Juliane Neubronner, Tania Schink, Vera E Valkhoff, Silvana Romio, Andrea Arfè, Jordi Castellsagué, Giovanni Corrao, Ron Herings, Silvia Lucchi, Gino Picelli, Huub Straatman, Frantz Thiessard, Cristina Varas Lorenzo, Marco Villa, Edeltraut Garbe, Miriam CJM Sturkenboom. (Netherlands)

**211 Use of Common Data Model To Enable Meaningful Comparison of Disease Burden among Disparate Databases [659]**  
Gary Schneider, Gregory Powell, Stephanie Reisinger. (United States)

**212 Potential Bias When Excluding Concepts from Terminologies with Different Granularity: An illustration in the SOS Project [660]**  
Frantz Thiessard, Sébastien Cossin, Fleur Mouglin, Andrea Arfè, Edeltraut Garbe, Ron Herings, Silvia Lucchi, Federica Nicotra, Gino Picelli, Silvana Romio, René Schade, Tania Schink, Huub Straatman, Vera E Valkhoff, Mendel Haag, Marco Villa, Cristina Varas Lorenzo, Miriam Sturkenboom, Annie Fourrier-Réglat. (France)

**213 Using Advanced Healthcare Data Analytics To Identify and Characterize Central Venous Catheterization Episodes Via Electronic Health Records in the Veterans Affairs [661]**  
Scott L DuVall, Aaron WC Kamauu, Brian C Sauer. (United States)

**214 Example of Introduction of Database in Pharmacovigilance Department Practice [662]**  
Oleksandr V Matvieiev, Natalya V Matvieieva. (Ukraine)

**215 Utility of Pharmacovigilance Reports for LQT/TdP Case Ascertainment [663]**  
Julie Arnott, Mariam Molokhia. (United Kingdom)

**216 Assessment of a Severity Classification Approach to Detecting Signals of Severe Drug Induced Liver Injury (DILI) [665]**  
Yingkai Cheng, Arie Regev, Karin Benoit, Indiana Strombom. (United States)

## Devices

**217 Fragile Skin? From Sensation to Evaluation [668]**  
Marek Haftek, Catherine Oliveres-Ghouthy, Charles Taieb. (France)

**218 Drug Screening Tests Improve Treatment Retention in a Cohort of Outpatients Starting Opioid Substitution Therapy [669]**  
Julie Dupouy, Lise Dassieu, Robert Bourrel, Jean Christophe Poutrain, Serge Bismuth, Stéphane Oustric, Maryse Lapeyre-Mestre. (France)

**219 Descriptive Epidemiology of Medical Device Use among Patients with Breast, Lung or Prostate Cancer in the National Inpatient Sample [676]**  
Carrie M Kuehn, Heather N Watson, Kevin L Ong, Muhima A Mohamed, Jorge A Ochoa, Jon P Fryzek. (United States)

**Pharmacoeconomics & Outcomes Research**

- 220 Pharmacoeconomics & Outcomes Research Cost-Utility Analysis of Antihypertensive Medications in Nigeria: A Decision Analysis [679]**  
Obinna I Ekwunife, Charles E Okafor, Charles C Ezenduka. (Nigeria)
- 221 Pharmacoeconomic Analysis of the Basic Care of Hypertension and Other Associated Cardiovascular Risk Factors [680]**  
Ghizlane Berrada El Azizi, Samir Ahid, Saadia Abir, Fedoua Ellouali, Amine El Majhad, Mouna Charif d'Ouazzane, Sahar Mouram, Abdelali Boukili, Mohammed Cherti, Yahia Cherrah. (Morocco)
- 222 The Cost of Hospitalization of Hip Osteoarthritis Patients in France in 2010 [681]**  
Charles Taieb. (France)
- 223 The Medication Adherence Report Scale (MARS-5) in a Swedish Sample with Bipolar Disorder – A Pilot Study [682]**  
Ann-Charlotte Mårdby, Annika Bäck, Rob Horne, Mikael Landén, Karolina Andersson Sundell. (Sweden)
- 224 The Impact of Abuse Deterrent Formulations on Outcomes Associated with Prescription Opioid Abuse [683]**  
Carl L Roland, David A Brown. (United States)
- 225 Factors Associated with Quality of Life in Patients with Chronic Hepatitis B in Brazil [684]**  
Alessandra M Almeida, Isabel C Gomes, Anderson L Silva, Gustavo LA Oliveira, Cristina MR Brandão, Mariângela L Cherchiglia, Eli Iôla G Andrade, Francisco A Acurcio. (Brazil)
- 226 The Impact of Therapy Intensification to Blood Pressure Outcome on the Ambulatory Hypertensive Patients: An Observational Study in Indonesian Hospital [685]**  
Rita Suhadi, Iwan Dwiprahasto, Jarir Atthobari, Bambang Irawan. (Indonesia)
- 227 Osteoarthritis in France the Cost of Ambulatory Care in 2010 [686]**  
Charles Taieb. (France)
- 228 Lund Integrated Medicines Management (LIMM)-Model Improves the Health Care Process and Patient Outcomes [688]**  
Tommy Eriksson. (Sweden)

**Poster Walk - Molecular Epidemiology-Biomarkers-Pharmacogenetics SIG**

- 229 Genetic Variants Are Not Associated with Increased Time to Maintenance Dose in Patients Initiating Warfarin Therapy [419]**  
Brian S Finkelman, Ron C Li, Jinbo Chen, Luanne Bershaw, Colleen M Brensinger, Stephen E Kimmel. (United States)

- 230 Genetic Polymorphisms and the Risk of New-Onset Diabetes after Transplantation: A Systematic Review and Meta-Analysis [423]**  
Eileen Choong, Anantharaman Vathsala, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
- 231 Challenges in Screening Rare Diseases: The ZOOM Experience [425]**  
Audrey Muller, David J Balding, Hans H Klünemann, David Linden, Daniel Ory, Marc C Patterson, Mercè Pineda, Josef Priller, Frédéric Sedel, Harbajan Chadha-Boreham, James E Wraith, Peter Bauer. (Switzerland)
- 232 Increasing the Value of Retrospective and Prospective Real-World Registries with Pharmacogenomic Testing and an Integrated Personalized Medicine Approach: Opportunities & Challenges [428]**  
Krista A Payne, Felix W Frueh, Jess Sohal. (Canada)
- 233 Manganese Superoxide Dismutase Polymorphism and Breast Cancer Recurrence: A Danish Population-Based Case-Control Study of Breast Cancer Patients Treated with Cyclophosphamide Epirubicin and 5-fluorouracil [431]**  
Anne G Ording, Deidre P Cronin-Fenton, Mariann Christensen, Timothy L Lash, Thomas Ahern, Lars Pedersen, Jens Peter Garne, Herman Autrup, Henrik T Sorensen, Steven Hamilton-Dutoit. (Denmark)

**Poster Walk - CER (Comparative Effectiveness Research) SIG**

- 234 Comparative Effectiveness of First Line Therapy for HIV Infection: Proven Clinical Benefit over 10 Years [499]**  
Emily S Brouwer, Prema Menezes, Sam Stinnette, Brant Stalzer, Linda Bell, Oksana Zakharova, Evelyn B Quinlivan, Amy Heine, Sonia Napravnik, Joseph J Eron. (United States)
- 235 Comparative Effectiveness of Losartan vs Candesartan in Patients with Heart Failure [502]**  
Henrik Svanström, Björn Pasternak, Anders Hviid. (Denmark)
- 236 The Effect of the Timing of Oral Hormonal Emergency Contraceptives on Pregnancy Rate [509]**  
Vivian WY Leung, Judith A Soon, Larry D Lynd, Carlo A Marra, Marc Levine. (Canada)
- 237 Comparative Efficacy of Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer: A Meta-Analysis [510]**  
Huei-Ting Tsai, David Penson, Kepher H Makambi, John H Lynch, Arnold L Potosky. (United States)
- 238 Impact of Long-Acting Injectable Versus Oral Antipsychotics on Rehospitalization Rates and Emergency Room Visits among Relapsed Schizophrenia Patients [514]**  
Marie-Hélène Lafeuille, François Laliberté-Auger, Patrick Lefebvre, Christian Frois, John Fastenau, Mei Sheng Duh. (United States)

- 239 Does Long-Acting Injectable Risperidone Make a Difference to the Real-Life Treatment of Schizophrenia? Results of the French Cohort for the General Study of Schizophrenia (CGS) [518]**  
Lamia Grimaldi-Bensouda, Federic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, Beatrice Beauflis, Guillaume Vaiva, Helene Verdoux, Yola Moride, Alban Fabre, Florence Thibaut, Lucien Abenheim, The CGS Study Group. (France)
- 240 Dose-Response Relationship between Post-Progression Bevacizumab Exposure and Survival among Metastatic Colorectal Cancer Patients [520]**  
E Dawn Flick, Charles E Barr, Susan M Fish, Larry F Leon, Yong Mun, Darshan Dalal. (United States)
- 241 Comparative Safety of Inhaled Medications in Patients with Chronic Obstructive Pulmonary Disease: Systematic Review and Mixed Treatment Comparison Meta-Analysis of Randomized Controlled Trials [525]**  
Yaa-Hui Dong, Hsien-Ho Lin, Wen-Yi Shau, Yun-Chun Wu, Chia-Hsuei Chang, Mei-Shu Lai. (Taiwan)

**Poster Walk - Databases SIG**

- 242 Performance of Group Sequential Methods for Active Post-Licensure Medical Product Safety Surveillance Using Observational Health Care Databases [645]**  
Jennifer C Nelson, Shanshan Zhao, Andrea J Cook, Lisa A Jackson. (United States)
- 243 Applying High Dimensional Propensity Score Method to the THIN Database with OMOP Common Data Model [646]**  
Bing Cai, Xiaofeng Zhou, Sundaresan Murugesan, Qing Liu, Andrew Bate, Robert Reynolds. (United States)
- 244 Assessing Healthcare Data Linkage Capabilities Using an Online Database Resource [648]**  
Anokhi J Kapasi, Sharmila A Kamani, Earl L Goehring, Jr, Bao-Anh Nguyen-Khoa, Varinder P Singh, Judith K Jones. (United States)
- 245 A Novel Process for the Identification, Development and Assessment of Database Coding Algorithms for 7 Rheumatologic Conditions [653]**  
Vinay Mehta, Matthew W Reynolds, Robert J LoCasale, Natalie Jones, Bruce E Landon, Martin J Bergman, Tanyaba Rehman, Edward A Bortnichak. (United States)
- 246 Back in Barcelona, the Landscape of Database Research over the Last Decade [657]**  
Nuria Riera-Guardia, Catherine W Saltus, Christine L Bui, David Harris, James A Kaye, Patricia Tennis, Jordi Castellsague, Susana Perez-Gutthann. (Spain)

**247 An Electronic Causality Assessment Tool for Drug-Induced Liver Injury [664]**

T Craig Cheetham, Julie Papay, Janet Shin, Fang Niu, Rich Murry, Greg Powell, Steph Reisinger, Patrick Ryan, Christine M Hunt. (United States)

**248 Prevalence and Characterization of Potential PPI-Clopidogrel Interaction in a Prescription Database in 2006-2009 [666]**

Cristiana M Desogus, Manuela Casula, Salvatore Riegler, Simona Cammarota, Anna Citarella, Enrica Menditto, Ettore Novellino, Alberico L Catapano, Elena Tragni. (Italy)

**249 The EU-ADR Alliance: A Federated Collaborative Framework for Drug Safety Studies [667]**

Eva Molero, Carlos Díaz, Ferran Sanz, Jose Luis Oliveira, Gianluca Trifirò, Annie Fourrier-Réglat, Mariam Molokhia, Lars Pedersen, Scott Boyer, Lorenza Scotti, Rosa Gini, Ron Herings, Carlo Giaquinto, María Isabel Loza, Giampiero Mazzaglia, Johan van der Lei, Miriam Sturkenboom. (Spain)

**Poster Walk - Medical Devices SIG**

**250 Baseline Burden of Heart Failure Limits Benefit of ICD for Elderly Recipients [671]**

Chih-Ying Chen, Lynne W Stevenson, John D Seeger, Lauren Williams, Jessica J Jalbert, Andrew Rothman, Garrick C Stewart, Soko Setoguchi. (United States)

**251 Effect of Physician and Hospital Experience on Outcomes Following Carotid Artery Stenting (CAS) [672]**

Jessica J Jalbert, Marie D Gerhard-Herman, Louis L Nguyen, Andrew T Rothman, Lauren A Williams, Chih-Ying (Natasha) Chen, John D Seeger, Soko Setoguchi. (United States)

**252 Probabilistic vs Deterministic Linkage of Large Device Registries to Medicare Data [675]**

Soko Setoguchi, Jessica A Myers, Jessica J Jalbert, Chih-Ying Chen. (United States)

**253 Estimates of Invasive Home-Use Medical Device Adverse Events Resulting in Hospitalization [677]**

Veronica V Sansing, George Aggrey, Brockton Hefflin. (United States)

**254 Coding of Ophthalmic Medical Device Adverse Event Reports: A Comparison of FDA Patient Problem Codes and MedDRA [678]**

Fred Schneiweiss, Dorian Villeags, Wendy Ye, Osas Ayela-Uwangué, Samuel Yonren. (United States)

**END SESSION B**

Image: Park Güell  
 Author: J. Trullàs  
 Credit: Turisme de Barcelona



8:00am – 1:45pm

## Vaccines

- 1 **Effectiveness of the Influenza A(H1N1)pdm09 Vaccine in Adults Recommended for Annual Influenza Vaccination: A Case-Control Study [768]**  
Giedre Gefenaite, Margot Tacken, Jens Bos, Irina Stirbu-Wagner, Joke C Korevaar, Ronald P Stolk, Bert Wolters, Marc Bijl, Maarten J Postma, Jan Wilschut, Kristin L Nichol, Eelko Hak. (Netherlands)
- 2 **The Risk of Juvenile Arthritis Following Quadrivalent HPV Vaccination: The Ontario Grade 8 HPV Vaccine Cohort Study [772]**  
Leah M Smith, Paul Brassard, Heather J Whitaker, Paddy Farrington, Jeff C Kwong, Linda E Lévesque. (Canada)
- 3 **Temporal Scan Statistics for Vaccine and Drug Safety Studies [773]**  
Martin Kulldorff. (United States)
- 4 **Disproportionality Analysis of Vaccine Reports – A Comparison of VAERS and VigiBase [774]**  
David B Martin, Johan Hopstadius, Johanna Strandell, Robert Ball, Jerry Labadie. (United States)
- 5 **Patterns and Predictors of Rotavirus Vaccine Use among Commercially-Insured U.S. Infants [775]**  
Catherine A Panozzo, M Alan Brookhart. (United States)
- 6 **Effects of a Multi-Faceted Program To Increase Influenza Vaccine Coverage among Health Care Workers: A Hospital-Based Cluster Randomized Controlled Trial [776]**  
Josien Riphagen-Dalhuisen, Hans Burgerhof, Gerard Frijstein, Nannet van der Geest-Blankert, Marita Danhof-Pont, Herbert de Jager, Nita Bos, Ed Smeets, Marjan de Vries, Pieter Gallee, Eelko Hak. (Netherlands)
- 7 **Safety of the 2010-2011 Influenza Vaccinations in the Department of Veteran Affairs [777]**  
Kwan Hur, Francesca Cunningham, Rongping Zhang, Bharat Thakkar, Michele Eskridge. (United States)
- 8 **International Collaborative Case Series Safety Monitoring for Pandemic 2009 H1N1 Vaccines: Estimation of the Risk of Guillain-Barre Syndrome [778]**  
Caitlin N Dodd, Hector Izurieta, Patrick Zuber, Silvana Romio, Miriam Sturkenboom, Wei Hua, Jan Bonhoeffer, Daniel Weibel, Claudia Vellozzi, Genevieve Deceuninck, Thirugnanam Umaphathi, Jim Buttery, Kristine Macartney, Vesta Richardson, Nigel Crawford, Steven Black, The Global GBS-H1N1 Working Group. (United States)
- 9 **Agreement between Patients' Self-Report and Medical Records for Vaccination: The PGRx Database [779]**  
Lamia Grimaldi-Bensouda, Elodie Aubrun, Pamela Leighton, Annick Alépérovitch, Jacques Benichou, Michel Rossignol, Lucien Abenhaim, PGRx Study Group. (France)

- 10 **The Risk of Systemic Lupus Erythematosus Associated with Vaccines: A Case-Control Study in France and Canada [780]**  
Lamia Grimaldi-Bensouda, Michel Rossignol, Elodie Aubrun, Pamela Leighton, Olivier Fain, Michel Ruel, Laurent Machet, Jean-François Viillard, Veronique Le Guern, Isabelle Kone-Paut, Nathalie Costedoat-Chalumeau, Lucien Abenhaim, PGRx-Lupus Study Group. (France)
- 11 **Guillain-Barré Syndrome and Pandemic Influenza A(H1N1) 2009 Vaccines: Meta-Analysis of Observational Risk Estimate Studies from 2010 and 2011 [781]**  
Daniel Weibel, Caitlin Dodd, Silvana Romio, Jan Bonhoeffer, Steve Black, Miriam CJM Sturkenboom. (Netherlands)
- 12 **Evaluating the Safety of 2009 H1N1 Influenza Vaccine Using a Claims-Based Health System [782]**  
Natalie L McCarthy, Julianne Gee, Nancy Lin, Veena Thyagarajan, Yi Pan, Sue Su, Bruce Turnbull, K Arnold Chan, Eric Weintraub. (United States)
- 13 **Active Monitoring of Adverse Events during an MF59®-Adjuvanted H5N1 Influenza Vaccination Campaign in Taiwan [783]**  
Wan-Ting Huang, Wen-I Hsiao, Chi-Hsi Chang, Mei-Cheng Peng, Jen-Hsiang Chuang. (Taiwan)
- 14 **Report on BCG Vaccine-Associated Suppurative Lymphadenitis [785]**  
Raccoon Chung, Joanna So, Clive Chan, Forest Lam, Linda Woo, KM Kam, Heston Kwong. (China)
- 15 **Tolerability of a Combined dTP-IPV-Hib- and a 7- or 10-Valent Pneumococcal Vaccination in Infancy – Work in Progress [786]**  
Jeanet Kemmeren, Ingrid Drijfhout, Marina Conyn-van Spaendonck, Hester de Melker. (Netherlands)
- 16 **Risk of Febrile Seizures in Children Following Trivalent Inactivated Influenza Vaccine in the Vaccine Safety Datalink Project, 2010-11 [787]**  
Alison C Tse, Hung Fu Tseng, Sharon K Greene, Claudia Vellozzi, Eric Weintraub, Natalie McCarthy, Jerome Tokars, Frank DeStefano, Karen Broder, Lisa Jackson, Jennifer Nelson, Martin Kulldorff, Melisa Rett, Tracy Lieu, Lingling Li, James D Nordin, Jason Glanz, Simon Hambidge, Matthew F Daley, Edward A Belongia, Stephanie Irving, Nicola Klein, Roger Baxter, Allison Naleway, S Michael Marcy, Steven J Jacobsen, Grace M Lee. (United States)

## Pregnancy

- 17 **Prevalence of Urinary Tract Infections and Pharmacotherapy Use in Pregnancy – National Birth Defects Prevention Study (NBDPS), 1997–2007 [788]**  
Simerpal K Gill, Cheryl Broussard, Krista Crider, Robert J Berry, Tonia Carter, Charlotte Hobbs, Jennita Reefhuis. (United States)

- 18 **Sulfamethizole in Pregnancy and the Risk of Neonatal Jaundice or Kernicterus – A Nationwide Register Based Cohort Study [789]**  
Pia Klarskov, Jon T Andersen, Espen Jimenez-Solem, Henrik E Poulsen. (Denmark)  
Antimalarial Drugs and the Risk for the
- 19 **Pregnant Women and Fetuses: Review of the Literature [790]**  
Flory Tsobo Muanda, Anick Berard. (Canada)
- 20 **Risks and Benefits of the Use of Metronidazole during Pregnancy: A Review of the Evidence [791]**  
Fabiano Santos, Ema Ferreira, Anick Bérard. (Canada)
- 21 **Safety of Macrolide Antibiotics Use during Pregnancy [792]**  
Anat Bahat Dinur, Ilan Matok, Rafael Gorodischer, Gideon Koren, Arnon Wiznitzer, Amalia Levy. (Israel)
- 22 **Prevalence of Exposure to Mebendazol and Pyrimin during Pregnancy – A Nationwide Cohort Study [793]**  
Arendse L Torp-Pedersen, Espen Jimenez-Solem, Jon T Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)
- 23 **Pregnancy Prevention Programme of Isotretinoin and the Adherence by Dutch Community Pharmacists [795]**  
Ineke Crijns, Rudi Bloemberg, Sabine Straus, Lolkje de Jong-van den Berg. (Netherlands)
- 24 **Progesterone in Pregnancy: A Comparative Study in EFEMERIS Database [796]**  
Isabelle Lacroix, Caroline Hurault-Delarue, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 25 **Exposure to Enoxaparin during the First Trimester of Pregnancy and the Risk of Major Malformations [797]**  
Meital Shlomo, Ilan Matok, Rafael Gorodischer, Gideon Koren, Arnon Wiznitzer, Amalia Levy. (Israel)
- 26 **Increasing First Trimester Use of Opioid Analgesics [798]**  
Richard A Epstein, Wayne A Ray, William V Bobo, Peter R Martin, James A Morrow, Patrick G Arbogast, William O Cooper. (United States)
- 27 **Major Malformations Following Exposure to Nonsteroidal Antiinflammatory Drugs during the First Trimester [799]**  
Sharon Daniel, Ilan Matok, Rafael Gorodischer, Gideon Koren, Elia Uziel, Arnon Wiznitzer, Amalia Levy. (Israel)
- 28 **The Use of Antiepileptic Drug during Pregnancy in Finland 1996–2008 [801]**  
Miia Artama, Mika Gissler, Heli Malm, Annukka Ritvanen. (Finland)

- 29 Antiepileptic Drug Use among Pregnant Women in the U.S., 2001-2007: A MEPREP Study [802]**  
William V Bobo, Robert L Davis, Sengwee D Toh, De-Kun Li, Susan E Andrade, T Craig Cheetham, Pamala Pawloski, Sascha Dublin, Simone Pinheiro, Tarek Hammad, Pamela E Scott, Richard A Epstein, Patrick G Arbogast, James A Morrow, Judith A Dudley, Jean M Lawrence, Lyndsay A Avalos, William O Cooper. (United States)
- 30 SSRI Use during Pregnancy and the Risk of Stillbirth and Neonatal Mortality [805]**  
Espen Jimenez-Solem, Jon Trærup Andersen, Morten Petersen, Kasper Broedbaek, Christian Torp-Pedersen, Henrik Enghusen Poulsen. (Denmark)
- 31 Use of Prescription Databases in Studies of SSRI Exposure in Pregnancy. Impact of Misclassification on Measured Risk Associations [807]**  
Svetlana Skurtveit, Randi Selmer, Aage Tverdal, Wenche Nystad, Kari Furu, Marte Handal. (Norway)
- 32 Prevalence and Trends in the Use of Anti-psychotics during Pregnancy in the U.S., 2001-2007 [808]**  
Darren Toh, Qian Li, Craig Cheetham, William O Cooper, Robert L Davis, Sascha Dublin, Tarek A Hammad, De-Kun Li, Pamala A Pawloski, Simone P Pinheiro, Marsha A Raebel, Pamela E Scott, David H Smith, William V Bobo, Jean M Lawrence, Inna Dashevsky, Katherine Haffenreffer, Lyndsay A Avalos, Susan E Andrade. (United States)
- 33 Does Maternal Lamotrigine Use Increase the Risk for Club Foot? [809]**  
Hao Wang, Ester Garne, Maria A Loane, Helen Dolk, Joan K Morris, Lolkje TW de Jong-van den Berg. (Netherlands)
- 34 Pregnancy Outcomes in Women Exposed to Adalimumab for the Treatment of Rheumatoid Arthritis [812]**  
Christina D Chambers, Diana L Johnson, Ronghui Xu, Yunjun Luo, Kenneth L Jones. (United States)
- 35 Caffeine Intake during Pregnancy and the Risk of Preterm Birth [813]**  
Rihab Gamaoun, Odile Sheehy, Anick Berard. (Canada)
- 36 Predictors of Caffeine Intake during Pregnancy [814]**  
Rihab Gamaoun, Odile Sheehy, Anick Bérard. (Canada)
- 37 Prenatal Care and Antiretroviral Therapy Use during Pregnancy among HIV- Infected Women on Medicaid [815]**  
Kelesitse Phiri, Paige L Williams, Katherine B Dugan, William O Cooper, George R Seage, Sonia Hernández-Díaz. (United States)
- 38 Trends in Dispensations of High Dose Folic Acid and Birth Prevalence of Major Congenital Malformations [816]**  
Anick Berard, Audrey-Ann Richard-Tremblay, Odile Sheehy. (Canada)
- 39 Antihistamines Use in Early Pregnancy and Risk of Birth Defects [817]**  
Qian Li, Allen A Mitchell, Sonia Hernández-Díaz. (United States)
- 40 Exposure to NSAIDs during Pregnancy and Risk of Development of Birth Defects: A 4 Months Study in a Large Indian Hospital [818]**  
Chetan Mehndiratta, Pipasha Biswas. (India)
- 41 Prescription of Drugs during Pregnancy in Japan [820]**  
Taku Obara, Manabu Akazawa, Takayoshi Ohkubo, Mami Ishikuro, Hirohito Metoki, Aiko Shono, Hidekazu Nishigori, Nariyasu Mano, Nobuo Yaegashi, Shinichi Kuriyama. (Japan)
- 42 Infant Outcomes among Pregnant Women Who Used Oseltamivir for Treatment of Influenza during the H1N1 Epidemic [821]**  
Haiyan Xie, Abdool Yasseen III, Ri-hua Xie, Ann Sprague, Deshayne Fell, Ning Liu, Graeme Smith, Mark Walker, Shi Wu Wen. (Canada)
- 43 Online Purchasing of Isotretinoin: E-Pharmacies Provision of Safety Information [822]**  
Briege M Lagan, Helen Dolk, Marlene Sinclair, Bronagh White. (United Kingdom)
- 44 Asthma Management in Pregnancy [823]**  
Rachel Charlton, Annie Hutchison, Kourtney Davis, Corinne de Vries. (United Kingdom)
- 45 Is the Use of Asthma Medication in Pregnancy in Accordance with Guidelines? [824]**  
Priscilla A Zetstra - van der Woude, J S Vroegop, Jens H Bos, Lolkje TW de Jong-van den Berg. (Netherlands)
- 46 Outcomes of Infants Born to Pregnant Women Who Received Influenza A (H1N1) 2009 Live Attenuated Monovalent Vaccine: Enhanced Surveillance Using the Vaccine Adverse Event Reporting System (VAERS) [826]**  
Pedro L Moro, Oidda I Museru, Karen Broder, Yenlik Zheteyeva, Naomi Tepper, Natalia Revzina, Isaac McCullum, Paige Lewis, Jorge Arana, Faith Barash, Dmitry Kissin, Claudia Vellozzi. (United States)
- 47 Outcomes of Drug Use during Pregnancy: A Novel Database in the Netherlands To Study Drugs Risk on the yet Unborn [828]**  
Leanne MA Houweling, Chantal WPM Hukkelhoven, Anne Marieke Schiere, Rients van Wijngaarden, Ron MC Hering. (Netherlands)
- 48 Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens [829]**  
Sonia Chaabane, Anick Bérard. (Canada)
- 49 Time Trends and Risk Factors for Medication Use during Pregnancy [830]**  
Amir Rosenblatt, Ilan Matok, Michael Friger, Gideon Koren, Eitan Lunenfeld, Amalia Levy. (Israel)
- 50 Analysis Using of Drugs during Pregnancy in the Clinical Centre University of Sarajevo (CCUS) for Year 2011 [831]**  
Begler Begovic, Amra Cabaravdic, Vildana Causevic. (Bosnia and Herzegovina)
- 51 Maternal Medication and Herbal Use and Risk of Hypospadias: Data from the National Birth Defects Prevention Study, 1997-2007 [832]**  
Jennifer N Lind, Cheryl S Broussard, Jennita Reefhuis, Suzan L Carmichael, Margaret A Honein, Richard S Olney, Martha M Werler, Sarah C Tinker. (United States)
- 52 Predicting Enrollment and Study Duration in Pregnancy Exposure Registries [834]**  
Deborah L Covington, Kenne Mountford, Paige Churchill. (United States)
- 53 Trends in Medication Use in Pregnancy over a Ten Year Period [835]**  
Deborah L Covington, Kenne Mountford, Laura McKain. (United States)
- 54 Pregnancy Prevention Programs (PPPs) in the EU [836]**  
Ineke Crijns, Inge Zomerdijk, Lolkje de Jong-van den Berg, Sabine Straus. (Netherlands)
- 55 Prescription Drug Use among Pregnant Women in Opioid Maintenance Treatment [837]**  
Ingunn Olea Lund, Anders Engeland, Furu Kari, Ravndal Edle, Svetlana Skurtveit, Handal Marte. (Norway)
- 56 Major Malformations in Babies Whose Mothers Had Pre-Existing Diabetes during Pregnancy [838]**  
Anita McGrogan, Julia Snowball, Corinne S de Vries. (United Kingdom)
- 57 Methodology on Study Using Administrative Data of Selective Serotonin Reuptake Inhibitors during Pregnancy and the Risk of Infants [839]**  
Aiko Shono, Taku Obara, Shinichi Kuriyama, Manabu Akazawa. (Japan)
- 58 Drugs Associated with Teratogenic Mechanisms: Prescription Rates among Pregnant Women and a Systematic Review of Effects [840]**  
Marleen van Gelder, Jens Bos, Nel Roeleveld, Lolkje de Jong-van den Berg. (Netherlands)
- 59 Prenatal Use of Medicines and Substances: Prevalence and Assessment of Mothers' Safety Knowledge [841]**  
Mariam I Wahab, Yogini H Jani, Alastair G Sutcliffe, Ian C Wong. (United Kingdom)

- 60 Patterns of Medication Use during Pregnancy and Prevalence of Birth Defects in a Large Administrative Claims Database [842]**  
Ella T Nkhoma, Yueqin Zhao, Daina B Esposito, Daniel Mines, Crystal N Holick. (United States)
- 61 Drug Use and Spontaneous Abortion: A Case/Control Study [843]**  
Delphine Abadie, Caroline Hurault-Delarue, Christine Damase-Michel, Jean Louis Montastruc, Isabelle Lacroix, The French Pharmacovigilance Centers participating to TERAPPEL. (France)
- 62 National Birth Defects Prevention Study – Medication Results Published in 2004-2011 [844]**  
April L Dawson, Audrey Flak, Jennita Reefhuis. (United States)
- 63 Prescription Drugs in Pregnancy. A UK Primary Care Study [845]**  
Lucia Cea-Soriano, Luis Alberto García-Rodríguez, Sonia Hernández-Díaz. (Spain)
- 64 Fetal Safety of an Adjuvanted Influenza A(H1N1)pdm09 Vaccine [846]**  
Ditte Mølgaard-Nielsen, Björn Pasternak, Henrik Svanström, Tyra G Krause, Hanne-Dorthe Emborg, Mads Melbye, Anders Hviid. (Denmark)

### Validity in Databases

- 65 Validation of an Algorithm Ascertainig Cases of Osteonecrosis of the Jaw in the Swedish National Patient Register [847]**  
Johan Bergdahl, Fredrik Granath, Fredrik Jarnbring, Madeleine Svensson, Vera Ehrenstein, Helle Kieler, Henrik Toft Sørensen, Ylva Trolle Lagerros. (Sweden)
- 66 Positive Predictive Value for Upper Gastrointestinal Bleeding in Four Health Care Databases Using Different Coding Systems in the EU-ADR Project [848]**  
Vera E Valkhoff, Preciosa M Coloma, Francesco Lapi, Rosa Gini, Malene Schou Nielsson, Mees Mosseveld, Mariam Molokhia, Martijn Schuemie, Miriam CJM Sturkenboom, Gianluca Trifirò. (Netherlands)
- 67 Validation of Cataract Diagnosis in the UK General Practice Research Database [849]**  
Elizabeth M Kang, Adel Abou-Ali, Simone P Pinheiro, Tarek A Hammad. (United States)
- 68 Validation of Glaucoma Diagnosis in the UK General Practice Research Database [850]**  
Adel Abou-Ali, Elizabeth M Kang, Simone P Pinheiro, Tarek A Hammad. (United States)
- 69 Safety Montiroing – Linking Databases & Creating Metrics [852]**  
Partha Chakraborty. (India)

- 70 Accuracy of Coding-Based Algorithms in Identification of Acute Myocardial Infarction from Multi-Country Electronic Healthcare Records (EHR) Databases [853]**  
Preciosa M Coloma, Vera E Valkhoff, Giampiero Mazzaglia, Malene Schou Nielsson, Lars Pedersen, Mariam Molokhia, Bartholomeus Mosseveld, Pablo Morabito, Martijn J Schuemie, Miriam CJM Sturkenboom, Gianluca Trifirò. (Netherlands)
- 71 Using an Automated Computer-Based Algorithm To Increase the Efficiency of Selecting the Best Match from National Death Index Linkage Results [854]**  
Kirk D Mickiff, Brian Calingaert, Patricia Tennis, David Harris, Elizabeth B Andrews. (United States)
- 72 Identification of Patients with Diabetes Mellitus Type 2 in insurance Claims Data – Are Problems Caused by Ambiguous ICD-10 Codes? [855]**  
Sigrid Behr, Bianca Kollhorst, Franz-Werner Dippel, Edeltraut Garbe. (Germany)
- 73 Deterministic Linkage between Cystic Fibrosis Patient Registry Data to Medicaid Analytical Extract Data [856]**  
Efe Eworuke, Almut G Winterstein. (United States)
- 74 Positive Predictive Value of Diagnosis Codes for ‘Anemia Caused by Bleeding’ in the Danish Registry of Patients [857]**  
Trine Frøselev, Jihen Zalfani, Inès B Ghezala, Morten Olsen, Johan FB Arendt, Rune Erichsen. (Denmark)
- 75 Validity of Myocardial Infarction and Stroke Diagnosis Codes in a Managed Care Organization Database [858]**  
Patricia Saddier, John Hansen, Michael Emery, Bruce Fireman, Trung Tran, Roger Baxter. (United States)
- 76 An Audit of the Diagnostic Coding of Pancreatitis of 331 Patients in Tayside, Scotland [859]**  
Zahra Ghorbanifard, Afsoun Sayad Daryabakhsh, Li Wei, Michael J Murphy, Thomas M MacDonald. (United Kingdom)
- 77 Validation of Claims Record on Acute Ischemic Stroke in the National Health Insurance Research Database Using Taiwan Stroke Registry as Reference [860]**  
Cheng-Yang Hsieh, Edward Chia-Cheng Lai, Ching-Lan Cheng, Chih-Hung Chen, Ming-Liang Lai, Yea-Hui Yang Kao. (Taiwan)
- 78 An Algorithm Using Free-Text To Identify Sudden Cardiac Death in the General Practice Research Database [861]**  
Meghan Jones, Elizabeth Brunner, Elena Moscarelli, Chetan Shatapathy, Justo Sierra-Johnson, Tjeerd P van Staa, Stephen Motsko. (United States)

- 79 Comparison of Various Strategies for Source Data Verification on Quality of Results in Observational Studies: A Simulation [862]**  
Edmond S Malka, Margaret S Richards, Erica JM Velthuis, Torsten Sernau, Missy Orr. (United States)
- 80 The Current State of Validation of Administrative Healthcare Databases in Italy. A Systematic Review [863]**  
Alessandro Montedori, Paolo Eusebi, Massimiliano Orso, Francesco Cozzolino, Rita De Florio, Maria Laura Luchetta, Iosief Abraha. (Italy)
- 81 Efficient Source Data Verification in Non-Interventional Studies: Literature Review of Current Methods [864]**  
Erica JM Velthuis, Margaret S Richards, Edmond S Malka. (Netherlands)

### Musculoskeletal DUR

- 82 The Use of Gastrointestinal Protection for NSAID and Low-ASA Users. A Longitudinal Quality Study of Continuation across Hospitalisation [865]**  
Michael D Larsen, Jesper Hallas. (Denmark)
- 83 Inappropriate Use of Gastroprotective Agent for Non-Steroidal Anti-Inflammatory Drug Therapy: A Hospital Cross Sectional Study [866]**  
Jarir At Thobari. (Indonesia)
- 84 Does Medication Adherence Itself Confer Fracture Protection? An Investigation of the Healthy Adherer Effect in Observational Data [867]**  
Jeffrey R Curtis, Huifeng Yun, Jeff Lange, Robert Matthews, Kenneth G Saag, Elizabeth Delzell. (United States)
- 85 Patterns of Intravenous Vitamin D Use among Hemodialysis Patients in the United States [868]**  
Anne C Beaubrun, Abhijit V Kshirsagar, Betsy Sleath, Lily Wang, M Alan Brookhart. (United States)
- 86 Adherence to Anti-Osteoporosis Therapy in an Italian Local Health Unit [869]**  
Manuela Casula, Alessandro Filippi, Fioralba Decè, Luisa Defendi, Luciana Gandolfi, Laura Perego, Rossana Piccinelli, Alberico L Capano, Elena Tragni. (Italy)
- 87 Prescribing of Strong Opioid Analgesics by UK Primary Care Physicians from 2000 to 2010 [870]**  
Che Suraya Zin, Li-Chia Chen, Roger D Knaggs. (United Kingdom)
- 88 Profile of Use of Anti-Tumor Necrosis Factor (anti-TNF) Agents in Rheumatoid Arthritis Patients in a Brazilian Healthcare Database, 2008-2010 [871]**  
Felipe Ferré, Cristiano S Moura, Adriana M Kakehasi, Augusto A Guerra-Júnior, Grazielle D Dias, Alessandra M Almeida, Marina A Machado, Walter L Santos, Odilon V Queiroz, Eli lola G Andrade, Mariângela A Cherchiglia, Francisco A Acurcio. (Brazil)

- 89 Missing Data in Questionnaire Based Studies—Methodological Challenges and Success of a Regression-Based Imputation Model [872]**  
Anna Gilchrist, Edward Tong, Debbie Layton, Carole Fogg, Saad Shakir. (United Kingdom)
- 90 Does the Dosing Regimen Affect Refill Adherence for Bisphosphonates? [873]**  
Anna K Jönsson, Eva Lesén, Anders Carlsten, Karolina Andersson Sundell, Ann-Charlotte Mårdby. (Sweden)
- 91 Methodological Considerations for Examining OTC NSAID Exposure and Its Effects on Health Outcomes Using EMR Database [874]**  
Niki Palmetto, Nataliya Volkova, Richard S Swain, Kathy Fraeman, Matthew W Reynolds. (United States)
- 92 Correlates of Acetaminophen-Containing Product Knowledge [875]**  
Judith P Kelly, David W Kaufman, Jeffrey M Rohay, Mary K Malone, Rachel B Weinstein, Saul Shiffman. (United States)
- 93 Acetaminophen Use Patterns Associated with Label Deviations [876]**  
Jeffrey M Rohay, Saul Shiffman, Judith P Kelly, Mary K Malone, Rachel B Weinstein, David W Kaufman. (United States)
- 94 Consumption of Anti-Osteoporosis Medications in Spain [877]**  
M Esther Salgueiro, Gloria Manso, Xavier Castells, Francisco J Jimeno, Lucía Ordoñez, Verónica Gonzalez, Alfonso Rodríguez, Dolores Capellà. (Spain)
- 99 Laboratory Monitoring of Patients Treated with Antihypertensive Therapy and Newly Exposed to Non Steroidal Anti-Inflammatory Drugs [882]**  
Jean-Pascal Fournier, Maryse Lapeyre-Mestre, Agnès Sommet, Julie Dupouy, Jean-Christophe Poutrain, Jean-Louis Montastruc. (France)
- 100 Risk of Upper Gastrointestinal Complications Associated with Use of Individual Non-Steroidal Anti-Inflammatory Drugs in the SOS Project [883]**  
Silvia Lucchi, Vera Valkhoff, Bianca Kollhorst, Tania Schink, Edeltraut Garbe, Andrea Arfè, Jordi Castellsague, Ron Herings, Federica Nicotra, Silvana Romio, Francesco Salvo, René Schade, Martijn Schuemie, Huub Straatman, Frantz Thiessard, Miriam Sturkenboom, Marco Villa. (Italy)
- 101 Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and the Risk of Advanced Prostate Cancer [884]**  
Salaheddin M Mahmud, Eduardo L Franco, Robert W Platt, David Skarsgard, Patricia Beck, Jon Tonita, Armen G Aprikian. (Canada)
- 102 Risk Models for Predicting Stroke and Upper Gastrointestinal Complications in NSAID Users: The SOS Project [885]**  
Silvana A Romio, Yvonne Vergouwe, Vera Valkhoff, Martijn Schuemie, Rene Schade, Cristina Varas Lorenzo, Edeltraut Garbe, Silvia Lucchi, Ron Herings, Andrea Arfè, Tania Schink, Jule Neubronner, Frantz Thiessard, Huub Straatman, Marco Villa, Federica Nicotra, Miriam Sturkenboom, Ewout Steyerberg. (Netherlands)
- 103 Immediate and Delayed Impact of Oral Glucocorticoid Therapy on Risk of Serious Infection in Older Patients with Rheumatoid Arthritis: A Nested Case-Control Analysis [886]**  
William G Dixon, Michal Abrahamowicz, Marie-Eve Beauchamp, David W Ray, Sasha Bernatsky, Samy Suissa, Marie-Pierre Sylvestre. (United Kingdom)
- 106 Choice of the Denominator for Case-Population Studies: Event Rates for Registration for Liver Transplantation in Acute Liver Failure Associated with NSAIDs or Paracetamol in France in the SALT Study [889]**  
Ezgi S Gulmez, Dominique Larrey, Georges P Pageaux, Séverine Lignot, Régis Lassalle, Jérémy Jové, Francesco Salvo, Fatima Hamoud, Sophie Micon, Patrick Blin, Nicholas Moore. (France)
- 107 Use of Bisphosphonates and Risk of Atypical Femur Fracture: A Systematic Review and Meta-Analysis [890]**  
Seoyoung C Kim, Lydia Gedmintas, Daniel H Solomon. (United States)
- 108 Potentially Harmful Prescription of NSAIDs in a Primary Care Population with Musculoskeletal Complaints [891]**  
Aafke R Koffeman, Geert W 't Jong, Vera E Valkhoff, Margreet F Warlé-van Herwaarden, Pim AJ Luijsterburg, Miriam CJM Sturkenboom, Sita MA Bierma-Zeinstra, Patrick JE Bindels. (Netherlands)
- 109 Use of Bisphosphonates and the Risk of Osteonecrosis: A Systematic Review and Meta-Analysis of Observational Studies [892]**  
Chien-Chang Lee, Yun-Ning Chen, Hung-Wen Chen, Si-Huei Lee. (Taiwan)
- 110 Association of Serum Potassium and Arrhythmia in Patients Prescribed NSAIDs [894]**  
Michael D Murray, Xiaochun Li, Susan Ofner, Evgenia Teal, Hisham Aljadhey. (United States)
- 111 Etoricoxib in the UK: Continuing vs. New Users after the COX-2 Urgent Safety Restriction (USR) [895]**  
Douglas J Watson, Vinay Mehta. (United States)
- 112 Etoricoxib Prescribing by GPs in the UK after the COX-2 Urgent Safety Restriction (USR) [896]**  
Douglas J Watson, Vinay Mehta. (United States)
- 113 Incidence of Cardiovascular (CV) Events with Etoricoxib in the UK after the COX-2 Urgent Safety Restriction (USR) [897]**  
Douglas J Watson, Vinay Mehta. (United States)
- 114 Exploratory Analysis To Improve Identification of Early Users of Prolia® in a Claims Database [898]**  
Florence T Wang, Fei Xue, Jessica Perhanidis, Eva Ng, Cathy Critchlow, David D Dore. (United States)
- 115 The SOS Project: Incidences of Reported Cardiovascular Events in RCTs [899]**  
Francesco Salvo, Annie Fourrier-Réglat, Fabienne Bazin, Federica Nicotra, Nuria Riera, Mendel Haag, Nicholas Moore, Miriam C Sturkenboom, Antoine Pariente. (France)
- 116 Incidence Rates (IR) of Events Related to Over-Suppression of Bone Turnover among Women with Postmenopausal Osteoporosis (PMO) [900]**  
Fei Xue, Chuck Wentworth, William Finkle, Cathy Critchlow. (United States)
- 117 Exploring the Use of an Adverse Event Detection Tool on Real Data: Temporal Relationship between Two Events and the Exposure to Oral Biphosphonates [901]**  
Odile Sauzet, Antonio Escudero, Alfonso Carvajal, Mariam Molokhia, Victoria R Cornelius. (United Kingdom)
- 118 A Survey of Patient Awareness and Use of Medicine Containing Acetaminophen [902]**  
Denise M Boudreau, Heidi Wirtz, Michael Von Korff, Sheryl L Catz, Jackie St. John, Paul E Stang. (United States)

**Musculoskeletal**

- 95 Is It Important To Focus on the Treatment of Osteoporosis in Both Genders? [878]**  
Andrea Bor, Peter Doro, Maria Matuz, Zsuzsanna Biczok, Ria Benko, Reka Víola, Gyongyver Soos. (Hungary)
- 96 Non-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Progression and Survival: A Systematic Review [879]**  
Una C Mc Menamin, Liam J Murray, Claire Higgins, Carmel M Hughes, Chris CR Cardwell, Marie M Cantwell. (United Kingdom)
- 97 Exposure to Non Steroidal Anti-Inflammatory Drugs and Risk of Cervical Intraepithelial Neoplasia Grade III [880]**  
Janine A Glover, Jessica C Wilson, Liam J Murray, Lesley A Anderson, Christopher R Cardwell, Marie M Cantwell, Carmel M Hughes. (United Kingdom)
- 98 Use of Non-Steroidal Anti-Inflammatory Drugs and Heart Failure Risk in the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project [881]**  
Andrea Arfè, Bianca Kollhorst, Tania Schink, Edeltraut Garbe, Ron Herings, Huub Straatman, René Schade, Marco Villa, Silvia Lucchi, Federica Nicotra, Vera Valkhoff, Silvana Romio, Frantz Thiessard, Martijn Schuemie, Cristina Varas Lorenzo, Antoine Pariente, Miriam Sturkenboom, Antonella Zambon. (Italy)

Withdrawn by Author [903]

Withdrawn by Author [904]

- 121 Pain Management: Observation and Side Effects [905]**  
Charles Taieb. (France)
- 122 Trends in the Frequency of Gastrointestinal Perforation in a Cohort of Patients with Rheumatoid Arthritis [906]**  
Jeffrey R Curtis, Angel Lanas, Ani John, David A Johnson, Kathy L Schulman. (United States)
- 123 Cohort Entry Criteria and Co-Morbidities in a Claims-Based Male Osteoporotic Population [907]**  
Wendy J Carman, Angelika Manthripragada, Cynthia O'Malley, David Dore. (United States)
- 124 Digital Ulcers Outcome Registry (DUO) in Patients with Systemic Sclerosis (SSc): Methodology To Characterize Patients in Terms of Recurrence of Digital Ulcers (DU) [908]**  
Daniel M Rosenberg, Barbara S Schwierin, Michelle Palmer, Christopher P Denton, Loïc Guillevin, Thomas Krieg, Marco Matucci-Cerinic, on behalf of the DUO Registry investigators. (Switzerland)
- 125 Risk Factors Associated with Allopurinol Related Stevens-Johnson Syndrome – A Case Control Study in Taiwan [909]**  
Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin, Angela WF On, Chao-Kai Hsu, Meng-Yu Weng. (Taiwan)
- 126 Impact of Gastroesophageal Reflux Disease (GERD) Definition on Incidence Rate of Endoscopies among Osteoporotic Patients [910]**  
Robert N Lubwama, Julie Chandler, Tzuyung D Kou. (United States)

## DUR Nervous System

- 127 Prescribing and Administration of Parkinson's Disease Medications [911]**  
Yasmin Al-Din, Naomi Ford, Fiona Needleman, Yvonne Semple, Donald Grosset, Graeme Macphee. (United Kingdom)
- 128 Benzodiazepine Use and Risk of Dementia: A Prospective Population-Based Cohort Study [912]**  
Sophie Billioti de Gage, Bernard Bégaud, Fabienne Bazin, Héléne Verdoux, Jean-François Dartigues, Karine Pérès, Tobias Kurth, Antoine Pariente. (France)
- 129 Length of Hospital Stay of Patients with Schizophrenia: Relation to Antipsychotic Monotherapy vs. Polypharmacy [913]**  
Adrián Llerena, Humberto Fariñas, Macarena C Cáceres, Alfredo de la Rubia, Eva M Peñas-Lledó. (Spain)

- 130 Timing of Concomitant Drug Use in Pharmacoepidemiological Studies [914]**  
Victoria Abbing-Karahagopian, Helga Gardarsdottir, Patrick C Souverein, Olaf H Klungel, Bert GM Leufkens, Toine CG Egberts, Marieke L De Bruin. (Netherlands)
- 131 Pharmacological Treatment and Demographic Characteristics of Adult Patients with Attention Deficit Hyperactivity Disorder, Sweden [915]**  
Shahram Bahmanyar, Helle Kieler. (Sweden)
- 132 Treatment of ADHD with Psychostimulants in Patients on Opioid Maintenance Therapy (OMT) in Norway – A Nationwide Study [916]**  
Kari Furu, Øystein Karlstad, Svetlana Skurtveit, Randi Selmer. (Norway)
- 133 Inpatient Treatment of Schizophrenia during 2001-2010: Average Length of Stay, Use of Diagnostic Tests and Drug Treatment [917]**  
Adrián Llerena, Macarena C Cáceres, Humberto Fariñas, Eva M Peñas-Lledó, Alfredo de la Rubia. (Spain)
- 134 Effects of Recent Earthquake on the Prescribing Pattern of Antidepressant and Antipsychotic Drugs in the Southern Italian Province of L'Aquila [918]**  
Gianluca Trifirò, Giovanna Sini, Claudio Linguiti, Michele Tari, Carmen Ferrajolo, Paolo Stratta, Fabio Allegrini, Alessandro Rossi. (Italy)
- 135 Prevalence and Patterns of Antidepressant Use among Women of Reproductive Age in Northern Ireland (NI) [919]**  
Anthony Wemakor, Helen Dolk, Karen Casson, Lolkje Jong-van den Berg. (United Kingdom)
- 136 Trends in Use of Benzodiazepines, Opioids, Tramadol, and Z-Drugs from 1998 to 2008 in a Managed Care Population [920]**  
Monica A Munoz, Danijela Stojanovic, Mahyar Etminan, Almut G Winterstein, Joseph AC Delaney. (United States)
- 137 Analyses of Switching and Combination Use of Antidepressants in Young Swedish Adults [921]**  
Karolina Andersson Sundell, Max G Petzold, Susanna M Wallerstedt. (Sweden)
- 138 Utilization Patterns of Strattera in Germany, Netherlands, Sweden and UK [922]**  
Kwame Appenteng, Angelo Camporeale, Michel Denarie, Jennifer Millard, Stephen Motsko. (United States)
- 139 Assessing the Effect of a Guideline Change on Prevalence of Benzodiazepine Use by Including the Birth Cohort Dimension [923]**  
Maarten J Bijlsma, Eelko Hak, Jens H Bos, Lolkje T de Jong-van den Berg, Fanny Jansen. (Netherlands)
- 140 Hypnotic Drugs Use and Quality of Life: Longitudinal Analysis from the VISAT Cohort [924]**  
Céline Caillet, Olivia Boeuf-Cazou, Laure Pourcel, Maryse Lapeyre-Mestre, Anne Roussin. (France)

- 141 National Trends in Antipsychotic Medication Use for Non-Psychotic Depression [925]**  
Tobias Gerhard, Ayse Akincigil, Neil Foglio, Stephen Crystal, Mark Olfson. (United States)
- 142 Mapping the Pro-Arrhythmic Risk of Antipsychotics: Combining Adverse Drug Reactions with Drug Utilization Data across Europe [926]**  
Emanuel Raschi, Elisabetta Poluzzi, Brian Godman, Ariola Koci, Christian Berg, Iain Bishop, Marija Kalaba, Ott Laius, Ugo Moretti, Manuela Schmitzer, Catherine Sermet, Bjorn Wettermark, Miriam Sturkenboom, Fabrizio De Ponti. (Sweden)
- 143 Medication Use and Comorbid Diseases in a Multiple Sclerosis (MS) Population: Electronic Health Record-Based Data [927]**  
Jove Graham, JB Jones, Amy Bieniek, Anne Dilley, Made Wenten, RaeAnn Maxwell, Terrie Livingston. (United States)
- 144 Long-Term Effects of Regulatory Warnings and Increased Media Coverage on Paroxetine and Other SSRIs Use [928]**  
Juan F Hernandez, Aukje K Mantel-Teeuwisse, Ghislaine van Thiel, Svetlana Belitser, Jan Warmerdam, Vincent de Valk, Jan Raaijmakers, Toine Pieters. (Netherlands)
- 145 Trend in Opioids Analgesic Consumption in Europe from 2002 to 2009: Impact of National Regulations [929]**  
Maryse Lapeyre-Mestre, Aurore Palmaro. (France)
- 146 Prescribing Pattern of Psychotropic Substances in a Nigerian Neuro-Psychiatric Hospital [930]**  
Mohammed S Lawal, Ibrahim I Oreagba, Sunday O Olayemi, Olufunsho A Awodele, Ismail A Ishola. (Nigeria)
- 147 Utilization of Prescription Sedative Hypnotics in Patients with and without Insomnia Diagnosis [931]**  
Laura E Wallace, Aditi Kadakia. (United States)
- 148 Clinical and Cost Effectiveness Analysis of Post-Operative Analgesia [932]**  
Linsey Watt, Cristina Coelho, Yvonne Semple, Anne Boyter, Julia Robertson, Neil Storey, James Maybin. (United Kingdom)
- 149 Impact on Physician Prescribing Practices of a Computerized Reminder for Biological Surveillance in Antipsychotic Therapy [933]**  
Jean-Frederic Westphal, Cathy Nonnenmacher. (France)
- 150 Prevalence and Patterns of Antiepileptic Drug-Containing Drug Combinations at Risk of Clinically Relevant Drug Interactions in a Teaching Psychiatric Hospital [934]**  
Jean-Frederic Westphal, Cathy Nonnenmacher. (France)
- 151 Prescribing Trends of Dosulepin in General Practice: Reducing the Potential for Fatal Overdose [935]**  
Jenny Wong, Suzie Seabroke. (United Kingdom)

**152 Serum Levels of Regulatory Peptides in Patients Treated with Antipsychotics [936]**  
Vijayakumar Arumugam, Raj Kapoor Balasubramanian, Rajasekaran Ayialu, Joel Varghese. (India)

**153 Risk of Suicide Attempts among Different Antidepressants in Cancer Patients [937]**  
Ju Young Kim, Sun Young Jung, Jung Hoon Ahn. (Republic of Korea)

**154 Evolution of Epileptic Seizures during Five Years in Patients Treated with Sodium Valproate [938]**  
Samir Ahid, Driss Benchafia, Halima Belaidi, Hamid Ouahabi, Yahia Cherrah. (Morocco)

**155 Influence of Body Mass Index on the Choice of Therapy for Depression and Follow-Up Care [939]**  
Denise M Boudreau, David Arterburn, Andy Bogart, Sebastien Haneuse, Mary K Theis, Emily Westbrook, Greg Simon. (United States)

**156 Prevalence of Medication Use for Somatic Disease in Hospitalized Psychiatric Patients [940]**  
Heshu Abdullah-Koolmees, Helga Gardarsdottir, Lennart S Stoker, Judith Vuyk, Toine CG Egberts, Eibert R Heerdink. (Netherlands)

**157 Comparative Evaluation of Two Drug Interaction Screening Programs in 84625 Psychiatric Inpatients [941]**  
Olesya I Zorina, Patrick Haueis, Waldemar Greil, Renate Grohmann, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)

**158 Does Lifting an Administrative Restriction on Antidepressant Drug Prescribing Influence Treatment Patterns? [942]**  
Gudrun Thengilsdottir, Helga Gardarsdottir, Anna B Almarsdottir, Chris B McClure, Eibert R Heerdink. (Iceland)

**159 Multiple Sclerosis Treatment Patterns: A US Insurance Claims Database Study [943]**  
Made Wenten, Cathy Lally, Scott Friedman, Anne Dilley. (United States)

**160 Antipsychotic Medication Adherence in Patients with Schizophrenia or Schizoaffective Disorder [944]**  
Johan Reutfors, Lena Brandt, Olof Stephansson, Helle Kieler, Morten Andersen, Robert Bodén. (Sweden)

## Nervous System

**161 Triptans and Serious Cardiovascular Events: Possible Safety Signals from the FDA Adverse Event Reporting System Database [945]**  
Giuseppe Roberto, Carlo Piccinni, Chiara Biagi, Ariola Koci, Domenico Motola, Alberto Vaccheri, Nicola Montanaro, Elisabetta Poluzzi. (Italy)

**162 The Use of Antidepressants and the Risk of Interstitial Lung Disease (ILD) in Patients with Respiratory Disease: A Nested Case-Control Study [946]**  
Francesco Lapi, Abbas Kezouh, Natalie Saad, Samy Suissa, Pierre Ernst. (Canada)

**163 A Comparison between the Standard Self Controlled Case Series Design and a Modification To Account for Events That Censor the Observation Period [947]**  
Ruth Brauer, Liam Smeeth, Karim Anaya-Izquierdo, C Paddy Farrington, Heather Whitaker, Ian Douglas. (United Kingdom)

**164 Patterns and Determinants of Anti-Inflammatory Drug Use among Users of Antidepressants between 1997 and 2006 in Denmark [948]**  
Ole Köhler, Ole Mors, Christiane Gasse, Liselotte Petersen. (Denmark)

**165 Use of Antipsychotics and Risk of Cerebrovascular Events in Schizophrenic Patients: A Nested Case-Control Study [949]**  
Pei-Hua Hsieh, Fei-Yuan Hsiao, Susan Shur-Fen Gau, Churn-Shiouh Gau. (Taiwan)

**166 Adverse Events of Cholinesterase Inhibitors: Ten Years of WHO's Vigibase Reports [950]**  
Edeltraut Kröger, Marie-Laure Laroche, Mieke Berkers, Marie Moulis, Pierre-Hugues Carmichael, Patrick Souverein, Rob van Marum, Toine Egberts. (France)

**167 Risk Factors for Carbamazepine Induced Serious Skin Reactions [951]**  
Ilma Bertulyte, Sofie Schwan, Jessica Schubert, Pär Hallberg. (Sweden)

**168 Assessment of Malignancy Risk in Patients with Multiple Sclerosis Treated with Intramuscular Interferon beta-1a: A Retrospective Evaluation Using a Health Insurance Claims Database and Postmarketing Surveillance Data [952]**  
Gary Bloomgren, Bjorn Sperling, Kimberly Cushing, Made Wenten. (United States)

**169 The Risk of Glaucoma Attack in Patients Received Anticonvulsants [953]**  
Ying-Hua Chen, Wen-Yi Shau, Chia-Hsui Chang, Shih-Jen Chen, Mei-Shu Lai. (Taiwan)

**170 Measuring Psychotropic Drug Exposures in Register-Based Studies – Validity of a Dosage Assumption of 1 Unit Per Day in Older Finns [954]**  
Maria Rikala, Sirpa Hartikainen, Leena K Saastamoinen, Maarit J Korhonen. (Finland)

**171 A Cohort Analysis of the Association between Parkinson's Disease and Cancer Using the UK General Practice Research Database [955]**  
Kevin Wing, Ian Douglas, Krishnan Bhaskaran, Liam Smeeth. (United Kingdom)

**172 Weight Gain Associated with Antipsychotics in a Naturalistic Setting. Icaro Study [956]**  
Verónica Velasco, Natalia Jimeno, Antonio Escudero, Paz Redondo, Inés Salado, María Sáinz, Mercedes Durán, Luis Martín Arias, Roberto Prieto, Delio Guerra, Rocío Gómez, José María Martínez, Vicente Molina, Alfonso Carvajal. (Spain)

**173 Preadmission Antidepressant Use and Mortality Following Atrial Fibrillation: A Population-Based Cohort Study [957]**  
Morten Olsen, Christian Christiansen, Frank Mehnert, Henrik T Sørensen. (Denmark)

**174 Risk of Suicidal Acts in New Anticonvulsant or Antidepressant Drug Users with Chronic Pain Conditions [958]**  
Elisabetta Paterno, Sonia Hernández-Díaz, Robert J Glynn, Jerry Avorn, Helen Mogun, Sebastian Schneeweiss. (United States)

**175 A Case-Control Study of Clinical Management Factors and Phenotypic Characteristics Increasing the Risk of Myocarditis with Clozapine [959]**  
Kathlyn J Ronaldson, Paul B Fitzgerald, Andrew J Taylor, Duncan J Topliss, Rory Wolfe, John J McNeil. (Australia)

**176 The Association between Antipsychotic Use and Tardive Dyskinesia, Parkinsonism and Akathisia in People with Mild Intellectual Disability [960]**  
Arlette Scheifes, Marjolein K van Nijndenberg, Joost Jan Stolker, Henk LI Nijman, Antoine CG Egberts, Eibert R Heerkink. (Netherlands)

**177 Methodologic Issues Related to an Evaluation of Opioid Abuse Deterrence in the Community [961]**  
David A Brown, Carl L Roland. (United States)

**178 Hepatotoxicity Related to New Antidepressants. A Case Non-Case Approach with Information from the Portuguese, French, Spanish and Italian Pharmacovigilance Systems [962]**  
François Montastruc, Haleh Bagheri, Stefania Scotto, Inês Ribeiro Vaz, Antonio Escudero, María Sáinz, María Teresa Herdeiro, Mauro Venegoni, Jean-Louis Montastruc, Alfonso Carvajal. (Spain)

**179 Design of a Post-Marketing Study Program To Assess the Effects of a Reformulated Extended-Release Oxycodone Tablet on Its Abuse [963]**  
Paul M Coplan, Howard D Chilcoat, Todd Baumgartner, Craig J Landau. (United States)

**180 Relative Risk of Myeloid Neoplasms in Patients Taking Benzodiazepines [964]**  
Amanda B Wilson, Marianne N Prout, Tuhina Neogi, Susan Jick. (United States)

**181 Abuse of Extended-Release (ER) and Immediate-Release Oxycodone in Kentucky Following Introduction of Reformulated ER Oxycodone [965]**  
A DeVeaugh-Geiss, C Leukefeld, J Havens, P Coplan, H Chilcoat. (United States)

**182 Risk-Benefit Analysis of Therapy in Multiple Sclerosis [966]**  
Nawab Qizilbash, Ignacio Méndez, Rainel Sánchez de la Rosa. (United Kingdom)

**183 Intensive Monitoring of Duloxetine, Results from a Web-Based Intensive Monitoring Study [967]**  
Linda Harmark, Eugene van Puijenbroek, Kees van Grootheest. (Netherlands)

- 184 Nested Case-Control Study in Psychiatric In-Patients: AMSP+ [968]**  
Eveline Jaquenoud Sirot, Patrik Stephan, Chin B Eap, Jan-Willem van der Velden, Pierre Baumann. (Switzerland)
- 185 Risk of Mortality (Including Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database [969]**  
Tarita Murray-Thomas, Deven Patel, Meghan Jones, Elizabeth Brunner, Chetan Shatapathy, Stephen Motsko, Tjeerd P van Staa. (United States)
- 186 Risk of Cardiac Mortality (Including Sudden Cardiac Death) in Olanzapine Users: A Study with the General Practice Research Database [970]**  
Meghan Jones, Deven Patel, Elizabeth Brunner, Chetan Shatapathy, Stephen Motsko, Giedra Campbell, Tarita Murray-Thomas, Tjeerd P van Staa. (United States)
- 187 Detection and Magnitude of Methylphenidate Abuse and Misuse Using Vigibase and Correlation with Level of Use in Europe [971]**  
Joelle Micallef, Kristina Star, Aurore Palmaro, Maryse Lapeyre-Mestre. (France)
- 188 Changes in Diversion Rates Following the Introduction of a Reformulated Extended Release Oxycodone Product [972]**  
J Davis, S G Severtson, B B Bartelson, A Munoz, M F Schneider, H Surratt, H D Chilcoat, P M Coplan, J L Green, R C Dart. (United States)
- 189 Risk Factors of Medication Non-Adherence in Depression and Anxiety, Preliminary Results [973]**  
Pierre M Bet, Stag D Van Laer, Jacqueline G Hugtenburg, Brenda WJH Penninx, Witte JG Hoogendijk. (Netherlands)
- 190 Antiepileptic Drugs and the Risk of Acute Hypothyroidism [974]**  
Edward Chia-Cheng Lai, Cheng-Yang Hsieh, Yea-Huei Kao Yang. (Taiwan)
- 191 Emergency Department Visits and Inpatient Admissions for Opioid Abuse-Related Events: National Estimates for the United States (2006-08) [975]**  
Hitesh S Chandwani, Scott A Strassels, Karen L Rascati, Kenneth Lawson, James P Wilson. (United States)
- 192 Cannabis Disorders Reported to the French Monitoring System of Abuse and Dependence: Increasing Reporting of Serious Cardiovascular Disorders [976]**  
Emilie Jouanjus, Maryse Lapeyre-Mestre, Joelle Micallef, l'Association Française des Centres d'Évaluation et d'Information sur la Pharmacodépendance – Addictovigilance (AFCEIP-A). (France)
- 193 The Association between Class and Dose Level of Antidepressant Medication with Suicidal Behaviors [977]**  
Sonja A Swanson, Til Stürmer, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)
- 194 Prevalence of Migraine in United States (U.S.) Emergency Departments (EDs) and the Association between Weekend ED Admissions and Opiate Use [978]**  
Vinay Mehta, Robert J LoCasale, Marcelo E Bigal. (United States)
- 195 Predictors of Severe Pain in a Cohort of 9,185 Individuals with Self-Reported Neuropathic Pain [979]**  
Bahman Farahmand, Stephen H Butler, Christina Branting-Ekenback, Cecilia Wadell, Bror Jonzon. (Sweden)
- 196 Descriptive Characteristics of 12,771 Potential Subjects for a Phase IIa Clinical Study in Neuropathic Pain [980]**  
Bahman Farahmand, Stephen H Butler, Christina Branting-Ekenback, Cecilia Wadell, Bror Jonzon. (Sweden)
- 197 Risk of Developing Alzheimer's Disease in Association with Influenza Infections [981]**  
Patrick Imfeld, Stephen Toovey, Susan S Jick, Christoph R Meier. (Switzerland)
- 198 The Prevalence of Diagnosed Depression and Depression Risk Factors in US Managed Care HIV Patients Compared to the General Population without HIV [982]**  
Woodie M Zachry, III, Bruce JO Wong, Kao-Tai Tsai, Jennifer M Griffith. (United States)
- 199 Use of Second Generation Antipsychotic Drugs during 1990 to 2009 [983]**  
Macarena C Cáceres, Humberto Fariñas, Eva M Peñas-LLedó, Adrián Llerena. (Spain)
- 200 Characteristics Associated with Delays in Diagnosis of Pompe Disease among Patients Enrolled in the Pompe Registry [986]**  
Amanda B Wilson, Hernán M Amartino, Christopher Lindberg, Timothy M Miller, Joan Keutzer, Priya S Kishnani. (United States)
- 201 Methods of Diagnosis of Patients with Pompe Disease: Data from the Pompe Registry [987]**  
Amanda B Wilson, Hernán M Amartino, Christopher Lindberg, Timothy M Miller, Joan Keutzer, Priya S Kishnani. (United States)
- 202 Comparison of the Use of Endocrine Therapy for Women with Breast Cancer in Australia and Several European Countries [988]**  
Agnes I Vitry, Eleanor Kelly, Christine Y Lu. (Australia)
- 203 Development of a Distributed Research Network in Japan: A Pilot Study on Antiemetics Use for Chemotherapy-Induced Nausea and Vomiting [989]**  
Katsuhito Hori, Norihiro Kobayashi, Tomomi Kimura, Hitoshi Atsumi, Akira Nagayama, Masako Kondoh, Ichiro Noge, Midori Kimura, Hiroaki Utsugi, Tsuyoshi Iwasaki, Masaki Nakamura, Michio Kimura, Junichi Kawakami. (Japan)
- 204 Use of Cetuximab (CTX) in 1st-Line Therapy of Metastatic Colorectal Cancer (mCRC): Patient Characteristics, Safety and Effectiveness in the EREBUS Cohort [990]**  
Annie Fourrier-Réglat, Denis Smith, Magali Rouyer, Eric François, Emmanuel Mitry, Alain Monnerneau, Antonio Sa-Cunha, Emmanuelle Bignon, Alise Le Monies, Régis Lassalle, Pernelle Noize, Nicholas Moore. (France)
- 205 The Impact of Depression on Interferon-Containing Therapy Initiation and Discontinuation among HCV Patients in a US Managed Care Population [991]**  
Bruce JO Wong, Gregory B Kruse, Stephanie Kirbach, Katherine Gooch. (United States)
- 206 Use of Hospital Discharge Data To Monitor Trends in Chemotherapy Use among Individuals Diagnosed with Stage III Colon Cancer in Denmark, 2004-2009 [992]**  
Jennifer L Lund, Rune Erichsen, Trine Frøslev, Til Stürmer, Henrik Toft Sørensen. (United States)
- 207 Patterns of 6-Mercaptopurine and Azathioprine Maintenance Therapy among Commercially Insured Individuals Diagnosed with Crohn's Disease in the US [993]**  
Jennifer L Lund, Suzanne F Cook, Jeffery K Allen, Michael D Kappelman. (United States)
- 208 Adherence with Oral Anticancer Agents [994]**  
Lonneke Timmers, Femke Kropff, Christel CLM Boons, Peter van de Ven, Eleonora L Swart, Epie Boven, Jacqueline Hugtenburg. (Netherlands)
- 209 Adherence, Exposure and Patient-Reported Side Effects of Erlotinib Used in Daily Practice [995]**  
Lonneke Timmers, Josee Moes-ten Hove, Christel CML Boons, Peter van de Ven, Eleonora L Swart, Egbert F Smit, Epie Boven, Jacqueline G Hugtenburg, A van Wijk. (Netherlands)
- 210 Cytostatic Drug Prescribing: Analysis of a South African Claims Database [996]**  
Ilse Truter. (South Africa)
- 211 Drug Use Study of Doxorubicin Using Japanese Claim Data of Inpatients [998]**  
Maki Noguchi, Chieko Ishiguro, Ayumi Endo, Kazuhiro Matsui, Mie Ikeda. (Japan)
- 212 Gadolinium Prescribing Trends – The Effect of Regulatory Action [999]**  
Jenny Wong. (United Kingdom)

### DUR Oncology & Immunology

- 202 Comparison of the Use of Endocrine Therapy for Women with Breast Cancer in Australia and Several European Countries [988]**  
Agnes I Vitry, Eleanor Kelly, Christine Y Lu. (Australia)

- 213 The Pattern of Use Human Immunoglobulins in the Clinical Centre University of Sarajevo (CCUS) [1000]**  
Begler Begovic, Tarik Catic, Lejla Begovic, Amra Cabaravdic. (Bosnia and Herzegovina)
- 214 Evaluation of the Process of Immunosuppressive Drug Dispensation for Renal Transplant Patients by Minas Gerais State Health Secretary at 2008 [1001]**  
Daniel ES Almeida, Maria GB Ceccato, Augusto A Guerra, Jr., Francisco A Acurcio. (Brazil)
- 215 Perception and Clinical Care of Depression in Breast Cancer Patients: A Survey of Oncology Practice in Japan [1002]**  
Izumi Sato, Haruhiko Makino, Kojiro Shimozuma, Yasuo Ohashi. (Japan)

### Oncology & Immunology

- 216 Linking a Voluntary Patient Registry with US State Cancer Registries for Signal Detection [1003]**  
Alicia W Gilseman, Nicole A Kellier, David H Harris, Elizabeth B Andrews, Daniel N Masica. (United States)
- 217 Second Malignancies (SM) among Multiple Myeloma (MM) Patients Exposed to Bortezomib (Btz) and Other Treatments: An Analysis of the US SEER-Medicare Linked Database [1004]**  
Dina Gifkins, Megan McAuliffe, Amy Matcho, Jane Porter, Scott Chavers, Patrick Ryan, Yola Moride, Maria Ponsillo, Jay King, Avinash Desai, Andrew Cakana, Dixie-Lee Esseltine. (United States)
- 218 Health Care Utilization (HCU) by Breast Cancer (BC) and Non-Hodgkin Lymphoma (NHL) Patients (pts) with Chemotherapy (CT) Induced Febrile Neutropenia (FN) in the Netherlands [1005]**  
Hans Gelderblom, Pieternella J Lugtenburg, Hans WR Nortier, Myrthe P Van Herk-Sukel, Djamila E Issa, Agnes Jager, Margarita De La Orden, Mirte E Van der Werf-Langenberg, Leanne MA Houweling, Floris A De Jong. (Netherlands)
- 219 Detection of Cerebral Infarction Associated with Oral 5-Fluorouracil S-1 and Other Fluoropyrimidines Using a Hospital Database [1006]**  
Katsuhito Hori, Michio Kimura, Junichi Kawakami. (Japan)
- 220 Immunosuppressants Associated with Progressive Multifocal Leukoencephalopathy within the US Adverse Event Reporting System [1007]**  
Niklas Schmedt, Frank Andersohn, Edeltraut Garbe. (Germany)
- 221 Relative Risk of Myeloid Neoplasms in Patients with Autoimmune Disease [1008]**  
Amanda B Wilson, Marianne N Prout, Tuhina Neogi, Susan Jick. (United States)

- 222 Chronic Comorbidities and Chemotherapy-Induced Febrile Neutropenia (FN) in Breast Cancer Patients [1009]**  
Victoria M Chia, John H Page, Roberto Rodriguez, Su-Jau Yang, Julie Huyhn, Michelle McGuire, Chun Chao. (United States)
- 223 Liver Enzyme Elevations in Patients with Solid Tumors [1010]**  
Sumitra Shantakumar, Beth Nordstrom, Kathy Fraeman, Weixu Luo, Sarah Landis. (United States)
- 224 Incidence of New-Onset Hypertension in Cancer Patients [1011]**  
Sumitra Shantakumar, Kathy Fraeman, Sarah Landis, Weixu Luo, Beth Nordstrom. (United States)
- 225 The Changing Pattern of Aflatoxins Exposure and Its Risk of HCC in Egypt [1012]**  
Mohamed A Hamzawy. (Egypt)
- 226 Preliminary Results from the Pilot Phase of a Chinese Hospital-Based Epidemiologic Study of Stomach Cancer (CHES): Tumor Characteristics, Treatment Patterns and Clinical Outcomes [1013]**  
Fei Yan, Naiqing Zhao, Yongzhe Piao, Lisa Wang, Yang Cao, Qun Wang, Laura Chu, Wei Dong, Zhenbin Shen. (United States)
- 227 Epidemiology of Metastatic Pancreatic Cancer in the United States and Selected European Countries [1014]**  
Victor M Gastanaga, Christine Bui, Lia Gutierrez, Alike Taylor, Michael A Kelsh. (United States)
- 228 Renal Impairment after Chemotherapy in Lung (LC), Colorectal (CRC), and Breast Cancer (BC) Patients (pts) from the Henry Ford Health System (HFHS) Tumor Registry [1015]**  
Marianne Ulcickas Yood, Laura Chu, Mahmoud Loghman-Adham, Karen Wells, Deborah Casso, Wei Dong, Susan A Oliveria. (United States)
- 229 Epidemiology of Cardiovascular Diseases in the General and Cancer Populations [1016]**  
Yuer Yan, Frank Delisle, Rohit Noghan, Christopher G Killian, Sreenivas Pandit, Shahab Hasnain. (United States)
- 230 Comorbidity Burden and Concomitant Medication Use for Patients with Brain, Colorectal, Breast, or Ovarian Cancer in an Employer Group Database [1017]**  
QuynhChau D Doan, Annette Beiderbeck, Patrick Reilly. (United States)

### Respiratory

- 231 Perfil Epidemiológico, Clínico y Terapéutico Del asma en Rabat (Marruecos): Estudio Multicéntrico [1018]**  
Imane Ghanname, Samir Ahid, Serge Arnaul Ebongue, Hicham Janah, Mouna Soualhi, Asmaa Wahid, Leila Herrak, Yahia Cherrah. (Morocco)

- 232 Clinical and Therapeutic Aspects in Asthma: A Multicenter Study [1019]**  
Imane Ghanname, Samir Ahid, Serge Arnaul Ebongue, Hicham Janah, Mouna Soualhi, Leila Herrak, Yahia Cherrah. (Morocco)
- 233 Pharmacists' Management in Early Symptoms of Influenza or ENT Disorders [1022]**  
Karine Danno, Brigitte Cognet-Demethon, Geneviève Thévenard, Gérard Duru, François-André Allaert, Marie-France Bordet. (France)
- 234 Persistence and Appropriateness of COPD Drug Treatment in a Real-world Setting: The OUTPUL Study [1023]**  
Mirko Di Martino, Lisa Bauleo, Nera Agabiti, Ursula Kirchmayer, Luigi Pinnarelli, Riccardo Pistelli, Danilo Fusco, Marina Davoli. (Italy)
- 235 Targets for Interventions To Optimize Pharmacotherapy in Asthma & COPD Patients [1025]**  
Job FM van Boven, Ada GG Stuurman-Bieze, Eric G Hiddink, Sipke T Visser, Maarten J Postma, Stefan Vegter. (Netherlands)
- 236 Astro-Lab Project: Assessment of the Safety of Long-Acting Beta Agonists (LABAS) in Asthma by Combining Health-Care Databases and Direct Patient Follow-Up): Focus on Detailed Pattern of Use of Therapy [1026]**  
Eric H Van Ganse, on behalf of ASTRO-LAB group. (France)
- 237 Drug Utilization Patterns for Routine Therapies in Patients with Cystic Fibrosis [1027]**  
Efe Eworuke, Almut G Winterstein. (United States)
- 238 Dosing Frequency and Adherence to Inhaled Corticosteroids in Patients with Asthma [1028]**  
Karen E Wells, Edward L Peterson, Brian K Ahmedani, L Keoki Williams. (United States)
- 239 Prediction of Non-Invasive Ventilation, Mechanical Ventilation and Mortality among Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Danish Population-Based Cohort Study [1029]**  
Martin B Johansen, Morten S Olsen, Sigrún A Jóhannesdóttir, Xiao Xu, Timothy L Lash, Joseph Parker, Nestor Molfino, Christian F Christiansen. (Denmark)
- 240 The Risk of Developing Depression in Association with Previously Diagnosed Influenza Infection [1030]**  
Delia Bornand, Stephen Toovey, Susan S Jick, Christoph R Meier. (Switzerland)
- 241 Use of Long-Acting  $\beta$ -Agonists in Asthma in Spain [1031]**  
Ana Afonso, Consuelo Huerta, Miguel Gil, Belen Oliva, Veronica Bryant, Dolores Montero. (Spain)

**242 Increased Risk of Mortality in COPD Patients Using Tiotropium Respimat vs. Tiotropium Handihaler [1032]**

Katia MC Verhamme, Ana S Afonso, Silvana Romio, Bruno BCh Stricker, Guy GO Brusselle, Miriam CJM Sturkenboom. (Netherlands)

**243 Endothelin Receptor Antagonists and Hepatotoxicity: Systematic Review and Meta-Analysis of Randomized Controlled Trials [1033]**

Diego Macias Saint-Gerons, César De la Fuente Honrubia, Ferrán Catalá-López, Dolores Montero Corominas. (Spain)

**Genito-Urinary-Hormones**

**244 Acute Renal Failure Following Oral Sodium Phosphate Bowel Preparation: A Population Based Case-Crossover Study [1034]**

Nam-Kyong Choi, Joongyub Lee, Ye-Jee Kim, Sun-Young Jung, Yoosoo Chang, Ju-Young Kim, Jin-Ho Lee, Byung-Joo Park. (Republic of Korea)

**245 DH Vigilance Programme Against Virility Products [1035]**

Christy Law, Joanna So, Clive Chan, Linda Woo, Heston Kwong. (Hong Kong)

**246 Androgenic Events Reported during Treatment with Intrinsa® (Testosterone Patch) Therapy: Results from an Observational Cohort Study in England [1036]**

Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

**247 5-alpha Reductase Inhibitors and Prostate Cancer Incidence and Mortality among Men with Benign Prostatic Hyperplasia [1037]**

Krishnan Bhaskaran, Ian Douglas, Liam Smeeth. (United Kingdom)

**248 Hormone Replacement Therapy and the Risk of Developing Gout [1038]**

Saskia G Bruderer, Susan S Jick, Christoph R Meier. (Switzerland)

**249 HRT Use amongst Women in India and Adverse Events Associated with It: A 4 Month Study from a Large Indian Hospital [1039]**

Priya Sindhvani, Pipasha Biswas. (India)

**250 Drug Use and Risk of Nephrotic Syndrome: A Danish Population-Based Case-Control Study [1040]**

Claus Sværke, Henrik T Sørensen, Christian F Christiansen. (Denmark)

**251 Effect of the Listing of Cinacalcet in the Quebec Drug Formulary on Parathyroidectomy Rates [1041]**

Jean-Philippe Lafrance, Jacques LeLorier. (Canada)

**Poster Walk - Medicines in Pregnancy SIG**

**252 Patterns of Antidepressant and Antipsychotic Use during Pregnancy [800]**

Andrea V Margulis, Elizabeth M Kang, Tarek A Hammad. (United States)

**253 Antipsychotic, Anticonvulsant and Lithium Use during Pregnancy [803]**

Richard A Epstein, William V Bobo, Richard C Shelton, Patrick G Arbogast, James A Morrow, William O Cooper. (United States)

**254 Neonatal Outcomes Following Late Gestation SSRI Exposure [804]**

Luke E Grzeskowiak, Andrew L Gilbert, Janna L Morrison. (Australia)

**255 Antidepressant Use during Pregnancy and Risk for Preeclampsia in the US Medicaid Population [806]**

Kristin Palmsten, Krista Huybrechts, Soko Setoguchi, Sonia Hernández-Díaz. (United States)

**256 Use of Selective Serotonin-Reuptake Inhibitors during Pregnancy and the Risk of Clubfoot [810]**

Mahsa M Yazdy, Allen M Mitchell, Carol Louik, Martha M Werler. (United States)

**257 The Association between Sertraline, Fluoxetine, and Paroxetine and Major Birth Defects, Data from the National Birth Defects Prevention Study, 1997-2007 [811]**

Jennita Reefhuis, Jan M Friedman, Carol Louik, Tiffany J Colarusso, Owen J Devine, Margaret A Honein. (United States)

**258 The 2009 Influenza Pandemic, Vaccination during Pregnancy and Fetal Death: A National Registry-Based Study in Norway [825]**

Siri E Håberg, Lill Trogstad, Nina Gunnes, Håkon K Gjessing, Sven Ove Samuelsen, Inger Cappelen, Anders Engeland, Preben Aavitsland, Steinar Madsen, Ingebjørg Buajordet, Kari Furu, Per Nafstad, Stein Emil Vollset, Berit Feiring, Hanne Nøkleby, Per Magnus, Camilla Stoltenberg. (Norway)

**259 Influenza A(H1N1)pdm09 Vaccination in Pregnancy and Risk of Fetal Death [827]**

Björn Pasternak, Henrik Svanström, Ditte Mølgaard-Nielsen, Tyra G Krause, Hanne-Dorthe Emborg, Mads Melbye, Anders Hviid. (Denmark)

**END SESSION C**



Image: Torre Agbar  
Author: Espai D'Imatge  
Credit: Turisme de Barcelona



# ANOLINX™

## REAL-WORLD HEALTHCARE RESEARCH

A specialized clinical research organization (CRO) focused on advanced analysis of health-care data in support of clinical research, drug development and clinical trials.

- ▶ pharmacoepidemiology
- ▶ outcomes research
- ▶ real-world evidence
- ▶ multi-site studies
- ▶ validation studies
- ▶ advanced analytics technologies
- ▶ natural language processing (NLP)
- ▶ comparative effectiveness research (CER)

Contact us for a tailored solution to meet your research needs

### ICPE 2012 Presentations

#### August 24th

1. **10:30-Noon - Oral:** Prevalence of Known Complications of Diabetes: A Comparison between Large EHR and Claims Databases in the U.S.
2. **Noon-1:30p - Abstract # 247:** Development of a Web-Based Interactive Tool To Display Cohort Characteristics from a Variety of Patient Populations and Data Sources.
3. **Noon-1:30p - Abstract # 250:** Using Natural Language Processing of Electronic Health Records To Identify Patients with ANCA-Associated Vasculitides in the Veterans Affairs.

#### August 25th

4. **Noon-1:30p - Abstract # 647:** Feasibility & Value of Longitudinal Patient Records from Transcribed Clinical Notes
5. **Noon-1:30p - Abstract # 661:** Using Advanced Healthcare Data Analytics To Identify and Characterize Central Venous Catheterization Episodes Via Electronic Health Records in the Veterans Affairs.

*info@anolinx.com ~ www.anolinx.com ~ +1.888.968.5469*

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>FRIDAY, AUGUST 24</b>				
<b>How Sweet it Isn't</b>				
1		10:30am	117	Oral
2		10:45am	117	Oral
3		11:00am	117	Oral
4		11:15am	117	Oral
5		11:30am	117	Oral
6		11:45am	117	Oral
<b>Inappropriate Use of Drugs</b>				
7		10:30am	115	Oral
8		10:45am	115	Oral
9		11:00am	115	Oral
10		11:15am	115	Oral
12		11:30am	115	Oral
11		11:45am	115	Oral
<b>Life of the Cancer Patient</b>				
13		10:30am	113	Oral
14		10:45am	113	Oral
740		11:00am	113	Oral
16		11:15am	113	Oral
17		11:30am	113	Oral
18		11:45am	113	Oral
<b>Methods Tapas</b>				
19		10:30am	111-112	Oral
20		10:45am	111-112	Oral
21		11:00am	111-112	Oral
22		11:15am	111-112	Oral
23		11:30am	111-112	Oral
24		11:45am	111-112	Oral
<b>Pregnancy: Macedonia</b>				
25		10:30am	114	Oral
26		10:45am	114	Oral
27		11:00am	114	Oral
28		11:15am	114	Oral
29		11:30am	114	Oral
30		11:45am	114	Oral
<b>Put Your Money Where Your Heart Is</b>				
31		10:30am	116	Oral
32		10:45am	116	Oral
33		11:00am	116	Oral
34		11:15am	116	Oral
35		11:30am	116	Oral
36		11:45am	116	Oral
<b>Breathless in Barcelona</b>				
37		1:30pm	114	Oral
38		1:45pm	114	Oral
39		2:00pm	114	Oral
40		2:15pm	114	Oral
41		2:30pm	114	Oral
42		2:45pm	114	Oral

Abstract #	Poster #	Presentation Time	Room	Format
<b>Broken Hearts or Bleeding Bodies</b>				
43		1:30pm	113	Oral
44		1:45pm	113	Oral
45		2:00pm	113	Oral
46		2:15pm	113	Oral
47		2:30pm	113	Oral
48		2:45pm	113	Oral
<b>Diabetic Treatment Outcomes Around the World</b>				
49		1:30pm	111-112	Oral
50		1:45pm	111-112	Oral
51		2:00pm	111-112	Oral
52		2:15pm	111-112	Oral
53		2:30pm	111-112	Oral
54		2:45pm	111-112	Oral
<b>Drug Utilization in Cardiovascular Disease</b>				
55		1:30pm	116	Oral
56		1:45pm	116	Oral
57		2:00pm	116	Oral
58		2:15pm	116	Oral
59		2:30pm	116	Oral
60		2:45pm	116	Oral
<b>Pregnancy, Brains and Pains</b>				
61		1:30pm	115	Oral
62		1:45pm	115	Oral
63		2:00pm	115	Oral
64		2:15pm	115	Oral
65		2:30pm	115	Oral
66		2:45pm	115	Oral
<b>Propensity Scores Estan de Moda</b>				
67		1:30pm	117	Oral
68		1:45pm	117	Oral
69		2:00pm	117	Oral
70		2:15pm	117	Oral
71		2:30pm	117	Oral
72		2:45pm	117	Oral
<b>Advanced Methods and Measures for Studying Complex Drug Utilization Patterns with Patient-Level Databases</b>				
73		5:00-6:30pm	111-112	Sympos.
<b>Biases To Consider When Studying the Risk of Medication Use in Pregnancy</b>				
74		5:00-6:30pm	117	Sympos.
<b>Databases, Therapeutics, and Biomarkers: The Challenges and Rewards of Incorporating Biological Specimens in Pharmacoepidemiologic Research</b>				
75		5:00-6:30pm	113	Sympos.
<b>How To Conduct Collaborative Studies in the EU? Lessons and Results from the Completed Safety of NSAIDs (SOS) Project</b>				
76		5:00-6:30pm	114	Sympos.
<b>Improving the Science of Regulatory Decision-Making Advances in 2011/2012</b>				
77		5:00-6:30pm	115	Sympos.

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>FRIDAY, AUGUST 24 CONTINUED</b>				
<b>Medicare Part D Data: Will the US Population-Based Data Be Advancing Pharmacoepidemiology and Public Health?</b>				
78		5:00-6:30pm	116	Sympos.
<b>Unique Device Identification System (UDIS): Implications for Postmarketing Safety and Effectiveness Assessment in the United States and Europe</b>				
79		5:00-6:30pm	132	Sympos.
<b>POSTER SESSION A</b>				
<b>Biologics</b>				
80	1	8:00am - 6:00pm		Poster
81	2	8:00am - 6:00pm		Poster
82	3	8:00am - 6:00pm		Poster
86	4	8:00am - 6:00pm		Poster
91	5	8:00am - 6:00pm		Poster
<b>Drug Utilization / Health Services Research</b>				
93	6	8:00am - 6:00pm		Poster
94	7	8:00am - 6:00pm		Poster
95	8	8:00am - 6:00pm		Poster
96	9	8:00am - 6:00pm		Poster
97	10	8:00am - 6:00pm		Poster
98	11	8:00am - 6:00pm		Poster
99	12	8:00am - 6:00pm		Poster
101	13	8:00am - 6:00pm		Poster
102	14	8:00am - 6:00pm		Poster
103	15	8:00am - 6:00pm		Poster
104	16	8:00am - 6:00pm		Poster
105	17	8:00am - 6:00pm		Poster
106	18	8:00am - 6:00pm		Poster
107	19	8:00am - 6:00pm		Poster
108	20	8:00am - 6:00pm		Poster
109	21	8:00am - 6:00pm		Poster
110	22	8:00am - 6:00pm		Poster
111	23	8:00am - 6:00pm		Poster
112	24	8:00am - 6:00pm		Poster
113	25	8:00am - 6:00pm		Poster
114	26	8:00am - 6:00pm		Poster
115	27	8:00am - 6:00pm		Poster
116	28	8:00am - 6:00pm		Poster
117	29	8:00am - 6:00pm		Poster
119	31	8:00am - 6:00pm		Poster
120	32	8:00am - 6:00pm		Poster
121	33	8:00am - 6:00pm		Poster
122	34	8:00am - 6:00pm		Poster
123	35	8:00am - 6:00pm		Poster
124	36	8:00am - 6:00pm		Poster
125	37	8:00am - 6:00pm		Poster
127	38	8:00am - 6:00pm		Poster
128	39	8:00am - 6:00pm		Poster
129	40	8:00am - 6:00pm		Poster
130	41	8:00am - 6:00pm		Poster
131	42	8:00am - 6:00pm		Poster
133	43	8:00am - 6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
134	44	8:00am - 6:00pm		Poster
135	45	8:00am - 6:00pm		Poster
136	46	8:00am - 6:00pm		Poster
137	47	8:00am - 6:00pm		Poster
<b>DUR in the Elderly</b>				
138	48	8:00am - 6:00pm		Poster
139	49	8:00am - 6:00pm		Poster
140	50	8:00am - 6:00pm		Poster
141	51	8:00am - 6:00pm		Poster
142	52	8:00am - 6:00pm		Poster
143	53	8:00am - 6:00pm		Poster
144	54	8:00am - 6:00pm		Poster
145	55	8:00am - 6:00pm		Poster
146	56	8:00am - 6:00pm		Poster
147	57	8:00am - 6:00pm		Poster
148	58	8:00am - 6:00pm		Poster
149	59	8:00am - 6:00pm		Poster
150	60	8:00am - 6:00pm		Poster
151	61	8:00am - 6:00pm		Poster
152	62	8:00am - 6:00pm		Poster
153	63	8:00am - 6:00pm		Poster
154	64	8:00am - 6:00pm		Poster
155	65	8:00am - 6:00pm		Poster
156	66	8:00am - 6:00pm		Poster
157	67	8:00am - 6:00pm		Poster
158	68	8:00am - 6:00pm		Poster
159	69	8:00am - 6:00pm		Poster
160	70	8:00am - 6:00pm		Poster
161	71	8:00am - 6:00pm		Poster
162	72	8:00am - 6:00pm		Poster
163	73	8:00am - 6:00pm		Poster
164	74	8:00am - 6:00pm		Poster
165	75	8:00am - 6:00pm		Poster
166	76	8:00am - 6:00pm		Poster
167	77	8:00am - 6:00pm		Poster
168	78	8:00am - 6:00pm		Poster
169	79	8:00am - 6:00pm		Poster
170	80	8:00am - 6:00pm		Poster
171	81	8:00am - 6:00pm		Poster
173	82	8:00am - 6:00pm		Poster
<b>Studies in the Elderly</b>				
175	83	8:00am - 6:00pm		Poster
177	84	8:00am - 6:00pm		Poster
178	85	8:00am - 6:00pm		Poster
179	86	8:00am - 6:00pm		Poster
180	87	8:00am - 6:00pm		Poster
181	88	8:00am - 6:00pm		Poster
182	89	8:00am - 6:00pm		Poster
183	90	8:00am - 6:00pm		Poster
184	91	8:00am - 6:00pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>FRIDAY, AUGUST 24 CONTINUED</b>				
<b>Patient with Infections and Their Treatments</b>				
185	92	8:00am - 6:00pm		Poster
186	93	8:00am - 6:00pm		Poster
187	94	8:00am - 6:00pm		Poster
188	95	8:00am - 6:00pm		Poster
189	96	8:00am - 6:00pm		Poster
190	97	8:00am - 6:00pm		Poster
192	98	8:00am - 6:00pm		Poster
193	99	8:00am - 6:00pm		Poster
194	100	8:00am - 6:00pm		Poster
195	101	8:00am - 6:00pm		Poster
197	102	8:00am - 6:00pm		Poster
198	103	8:00am - 6:00pm		Poster
199	104	8:00am - 6:00pm		Poster
200	105	8:00am - 6:00pm		Poster
201	106	8:00am - 6:00pm		Poster
202	107	8:00am - 6:00pm		Poster
203	108	8:00am - 6:00pm		Poster
204	109	8:00am - 6:00pm		Poster
205	110	8:00am - 6:00pm		Poster
206	111	8:00am - 6:00pm		Poster
207	112	8:00am - 6:00pm		Poster
208	113	8:00am - 6:00pm		Poster
209	114	8:00am - 6:00pm		Poster
210	115	8:00am - 6:00pm		Poster
211	116	8:00am - 6:00pm		Poster
212	117	8:00am - 6:00pm		Poster
213	118	8:00am - 6:00pm		Poster
214	119	8:00am - 6:00pm		Poster
215	120	8:00am - 6:00pm		Poster
216	121	8:00am - 6:00pm		Poster
217	122	8:00am - 6:00pm		Poster
218	123	8:00am - 6:00pm		Poster
219	124	8:00am - 6:00pm		Poster
220	125	8:00am - 6:00pm		Poster
221	126	8:00am - 6:00pm		Poster
222	127	8:00am - 6:00pm		Poster
223	128	8:00am - 6:00pm		Poster
224	129	8:00am - 6:00pm		Poster
225	130	8:00am - 6:00pm		Poster
<b>Hematology</b>				
226	131	8:00am - 6:00pm		Poster
227	132	8:00am - 6:00pm		Poster
228	133	8:00am - 6:00pm		Poster
229	134	8:00am - 6:00pm		Poster
230	135	8:00am - 6:00pm		Poster
231	136	8:00am - 6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
232	137	8:00am - 6:00pm		Poster
233	138	8:00am - 6:00pm		Poster
234	139	8:00am - 6:00pm		Poster
235	140	8:00am - 6:00pm		Poster
236	141	8:00am - 6:00pm		Poster
237	142	8:00am - 6:00pm		Poster
238	143	8:00am - 6:00pm		Poster
239	144	8:00am - 6:00pm		Poster
240	145	8:00am - 6:00pm		Poster
<b>Methods</b>				
242	147	8:00am - 6:00pm		Poster
243	148	8:00am - 6:00pm		Poster
244	149	8:00am - 6:00pm		Poster
245	150	8:00am - 6:00pm		Poster
246	151	8:00am - 6:00pm		Poster
247	152	8:00am - 6:00pm		Poster
248	153	8:00am - 6:00pm		Poster
249	154	8:00am - 6:00pm		Poster
250	155	8:00am - 6:00pm		Poster
251	156	8:00am - 6:00pm		Poster
252	157	8:00am - 6:00pm		Poster
253	158	8:00am - 6:00pm		Poster
254	159	8:00am - 6:00pm		Poster
255	160	8:00am - 6:00pm		Poster
256	161	8:00am - 6:00pm		Poster
257	162	8:00am - 6:00pm		Poster
258	163	8:00am - 6:00pm		Poster
259	164	8:00am - 6:00pm		Poster
260	165	8:00am - 6:00pm		Poster
261	166	8:00am - 6:00pm		Poster
262	167	8:00am - 6:00pm		Poster
263	168	8:00am - 6:00pm		Poster
264	169	8:00am - 6:00pm		Poster
265	170	8:00am - 6:00pm		Poster
266	171	8:00am - 6:00pm		Poster
267		8:00am - 6:00pm		<i>Abstract Withdrawn by Author</i>
268	172	8:00am - 6:00pm		Poster
269		8:00am - 6:00pm		<i>Abstract Withdrawn by Author</i>
270	173	8:00am - 6:00pm		Poster
271		8:00am - 6:00pm		<i>Abstract Withdrawn by Author</i>
272	174	8:00am - 6:00pm		Poster
273	175	8:00am - 6:00pm		Poster
274	176	8:00am - 6:00pm		Poster
<b>Pediatrics</b>				
275	177	8:00am - 6:00pm		Poster
276	178	8:00am - 6:00pm		Poster
279	179	8:00am - 6:00pm		Poster
281	180	8:00am - 6:00pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>FRIDAY, AUGUST 24 CONTINUED</b>				
282	181	8:00am - 6:00pm		Poster
283	182	8:00am - 6:00pm		Poster
286	183	8:00am - 6:00pm		Poster
287	184	8:00am - 6:00pm		Poster
289	185	8:00am - 6:00pm		Poster
290	186	8:00am - 6:00pm		Poster
291	187	8:00am - 6:00pm		Poster
292		8:00am - 6:00pm	<i>Abstract Withdrawn by Author</i>	
293	188	8:00am - 6:00pm		Poster
294	189	8:00am - 6:00pm		Poster
295	190	8:00am - 6:00pm		Poster
296	191	8:00am - 6:00pm		Poster
297	192	8:00am - 6:00pm		Poster
299	193	8:00am - 6:00pm		Poster
300	194	8:00am - 6:00pm		Poster
301	195	8:00am - 6:00pm		Poster
302	196	8:00am - 6:00pm		Poster
304	197	8:00am - 6:00pm		Poster
305	198	8:00am - 6:00pm		Poster
306	199	8:00am - 6:00pm		Poster
308	200	8:00am - 6:00pm		Poster
310	201	8:00am - 6:00pm		Poster
311	202	8:00am - 6:00pm		Poster
312	203	8:00am - 6:00pm		Poster
313	204	8:00am - 6:00pm		Poster
314	205	8:00am - 6:00pm		Poster
315	206	8:00am - 6:00pm		Poster
316	207	8:00am - 6:00pm		Poster
317	208	8:00am - 6:00pm		Poster
318	209	8:00am - 6:00pm		Poster
319	210	8:00am - 6:00pm		Poster
320	211	8:00am - 6:00pm		Poster
321	212	8:00am - 6:00pm		Poster
323	213	8:00am - 6:00pm		Poster
324	214	8:00am - 6:00pm		Poster
325	215	8:00am - 6:00pm		Poster
326	216	8:00am - 6:00pm		Poster
327	217	8:00am - 6:00pm		Poster
328	218	8:00am - 6:00pm		Poster
329	219	8:00am - 6:00pm		Poster
330	220	8:00am - 6:00pm		Poster
<b>Dermatology</b>				
331	221	8:00am - 6:00pm		Poster
333	222	8:00am - 6:00pm		Poster
334	223	8:00am - 6:00pm		Poster
335	224	8:00am - 6:00pm		Poster
<b>Poster Walk – Biologics SIG</b>				
83	225	8:00am - 6:00pm		P. Walk

Abstract #	Poster #	Presentation Time	Room	Format
84	226	8:00am - 6:00pm		P. Walk
85	227	8:00am - 6:00pm		P. Walk
87	228	8:00am - 6:00pm		P. Walk
88	229	8:00am - 6:00pm		P. Walk
89	230	8:00am - 6:00pm		P. Walk
90	231	8:00am - 6:00pm		P. Walk
92	232	8:00am - 6:00pm		P. Walk
92	232	8:00am - 6:00pm		P. Walk
<b>Poster Walk – Pediatrics SIG</b>				
277	233	8:00am - 6:00pm		P. Walk
278	234	8:00am - 6:00pm		P. Walk
284	235	8:00am - 6:00pm		P. Walk
285	236	8:00am - 6:00pm		P. Walk
288	237	8:00am - 6:00pm		P. Walk
303	238	8:00am - 6:00pm		P. Walk
307	239	8:00am - 6:00pm		P. Walk
309	240	8:00am - 6:00pm		P. Walk
322	241	8:00am - 6:00pm		P. Walk
332	242	8:00am - 6:00pm		P. Walk
<b>SATURDAY, AUGUST 25</b>				
<b>"A Joint Session" on Aches and Pains</b>				
336		8:30am	111-112	Oral
337		8:45am	111-112	Oral
338		9:00am	111-112	Oral
339		9:15am	111-112	Oral
340		9:30am	111-112	Oral
341		9:45am	111-112	Oral
<b>CV Meds: What Would You Do?</b>				
342		8:30am	117	Oral
343		8:45am	117	Oral
344		9:00am	117	Oral
345		9:15am	117	Oral
346		9:30am	117	Oral
347		9:45am	117	Oral
<b>Diabetes: A Little Bit of This and That</b>				
348		8:30am	113	Oral
349		8:45am	113	Oral
350		9:00am	113	Oral
351		9:15am	113	Oral
352		9:30am	113	Oral
353		9:45am	113	Oral
<b>Do You Trust Your Data?</b>				
354		8:30am	114	Oral
355		8:45am	114	Oral
356		9:00am	114	Oral
357		9:15am	114	Oral
358		9:30am	114	Oral
359		9:45am	114	Oral

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SATURDAY, AUGUST 25 CONTINUED</b>				
<b>Hormones: Can't Live with Them, Can't Live without Them</b>				
360		8:30am	115	Oral
361		8:45am	115	Oral
362		9:00am	115	Oral
363		9:15am	115	Oral
364		9:30am	115	Oral
365		9:45am	115	Oral
<b>Treating Pain</b>				
366		8:30am	116	Oral
367		8:45am	116	Oral
368		9:00am	116	Oral
369		9:15am	116	Oral
370		9:30am	116	Oral
371		9:45am	116	Oral
<b>Drug Utilization Research Methods</b>				
372		10:30am	111-112	Oral
373		10:45am	111-112	Oral
374		11:00am	111-112	Oral
375		11:15am	111-112	Oral
376		11:30am	111-112	Oral
377		11:45am	111-112	Oral
<b>NSAIDs - Measuring Drug Safety</b>				
378		10:30am	117	Oral
379		10:45am	117	Oral
380		11:00am	117	Oral
382		11:15am	117	Oral
383		11:30am	117	Oral
381		11:45am	117	Oral
<b>Pediatric Tapas</b>				
384		10:30am	113	Oral
385		10:45am	113	Oral
386		11:00am	113	Oral
387		11:15am	113	Oral
388		11:30am	113	Oral
389		11:45am	113	Oral
<b>Personalized Medicine Tapas</b>				
390		10:30am	114	Oral
391		10:45am	114	Oral
392		11:00am	114	Oral
393		11:15am	114	Oral
394		11:30am	114	Oral
395		11:45am	114	Oral
<b>Psychotropic Drug Utilization Research</b>				
396		10:30am	115	Oral
397		10:45am	115	Oral
398		11:00am	115	Oral

Abstract #	Poster #	Presentation Time	Room	Format
399		11:15am	115	Oral
400		11:30am	115	Oral
401		11:45am	115	Oral
<b>Tapas: Junk Drawer (Cajon de Sastre)</b>				
402		10:30am	116	Oral
403		10:45am	116	Oral
404		11:00am	116	Oral
405		11:15am	116	Oral
406		11:30am	116	Oral
407		11:45am	116	Oral
<b>FarmacoEpiEnRed, a Network for Pharmacoepidemiology in Spain</b>				
408		Noon - 1:30pm	129-130	Sympos.
<b>Safe and Effective Care for Elderly</b>				
409		1:30 - 2:30pm	111-112	Plenary
<b>The Stanley A. Edlavitch Award</b>				
410		2:30 - 3:30pm	111-112	Oral
<b>Cross-National or Multi-Database Research Networks: A New Initiative in Asia-Pacific Region and Ongoing Initiatives in Europe and US</b>				
411		4:30 - 5:00pm	111-112	Sympos.
<b>Electronic Healthcare Databases for Pregnancy Research: Panacea or Trojan Horse?</b>				
412		4:30 - 5:00pm	117	Sympos.
<b>Evaluating the Effectiveness of Risk Minimisation Measures in the Context of the New Pharmacovigilance Legislation in the EU</b>				
413		4:30 - 5:00pm	113	Sympos.
<b>Global Collaborations in Vaccine Safety, Present and Future</b>				
414		4:30 - 5:00pm	114	Sympos.
<b>Integrating Methods for Semi-Automated Drug Safety Monitoring of Newly Marketed Medications Using Databases: Illustrations with a Prototype</b>				
415		4:30 - 5:00pm	115	Sympos.
<b>Transparent, Reproducible and Reusable Research in Pharmacoepidemiology</b>				
416		4:30 - 5:00pm	116	Sympos.
<b>Validate in One Data Source and Apply Results to Another - What Could Possibly Go Wrong? Assumptions behind Addressing Outcome Misclassification in Distributed Data Models</b>				
417		4:30 - 5:00pm	132	Sympos.
<b>POSTER SESSION B</b>				
<b>Molecular Epidemiology</b>				
418	1	8:00am - 6:00pm		Poster
420	2	8:00am - 6:00pm		Poster
421	3	8:00am - 6:00pm		Poster
422	4	8:00am - 6:00pm		Poster
424	5	8:00am - 6:00pm		Poster
426	6	8:00am - 6:00pm		Poster
427	7	8:00am - 6:00pm		Poster
429	8	8:00am - 6:00pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SATURDAY, AUGUST 25 CONTINUED</b>				
<b>Risk Management &amp; Communication</b>				
432	9	8:00am - 6:00pm		Poster
433	10	8:00am - 6:00pm		Poster
434	11	8:00am - 6:00pm		Poster
435	12	8:00am - 6:00pm		Poster
436	13	8:00am - 6:00pm		Poster
437	14	8:00am - 6:00pm		Poster
438	15	8:00am - 6:00pm		Poster
439	16	8:00am - 6:00pm		Poster
440	17	8:00am - 6:00pm		Poster
441	18	8:00am - 6:00pm		Poster
442	19	8:00am - 6:00pm		Poster
443	20	8:00am - 6:00pm		Poster
444	21	8:00am - 6:00pm		Poster
445	22	8:00am - 6:00pm		Poster
446	23	8:00am - 6:00pm		Poster
447	24	8:00am - 6:00pm		Poster
448	25	8:00am - 6:00pm		Poster
449	26	8:00am - 6:00pm		Poster
450	27	8:00am - 6:00pm		Poster
451	28	8:00am - 6:00pm		Poster
452	29	8:00am - 6:00pm		Poster
453	30	8:00am - 6:00pm		Poster
454	31	8:00am - 6:00pm		Poster
455	32	8:00am - 6:00pm		Poster
456	33	8:00am - 6:00pm		Poster
457	34	8:00am - 6:00pm		Poster
458	35	8:00am - 6:00pm		Poster
459	36	8:00am - 6:00pm		Poster
460	37	8:00am - 6:00pm		Poster
461	38	8:00am - 6:00pm		Poster
462	39	8:00am - 6:00pm		Poster
463	40	8:00am - 6:00pm		Poster
464	41	8:00am - 6:00pm		Poster
466	42	8:00am - 6:00pm		Poster
<b>Pharmacovigilance</b>				
467	43	8:00am - 6:00pm		Poster
469	44	8:00am - 6:00pm		Poster
470	45	8:00am - 6:00pm		Poster
471	46	8:00am - 6:00pm		Poster
472	47	8:00am - 6:00pm		Poster
473	48	8:00am - 6:00pm		Poster
474	49	8:00am - 6:00pm		Poster
475	50	8:00am - 6:00pm		Poster
476	51	8:00am - 6:00pm		Poster
477	52	8:00am - 6:00pm		Poster
478	53	8:00am - 6:00pm		Poster
479	54	8:00am - 6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
480	55	8:00am - 6:00pm		Poster
481	56	8:00am - 6:00pm		Poster
482	57	8:00am - 6:00pm		Poster
483	58	8:00am - 6:00pm		Poster
484	59	8:00am - 6:00pm		Poster
485	60	8:00am - 6:00pm		Poster
488	61	8:00am - 6:00pm		Poster
<b>Pharmacovigilance Methods</b>				
489	62	8:00am - 6:00pm		Poster
490	63	8:00am - 6:00pm		Poster
491	64	8:00am - 6:00pm		Poster
492	65	8:00am - 6:00pm		Poster
493	66	8:00am - 6:00pm		Poster
494	67	8:00am - 6:00pm		Poster
495	68	8:00am - 6:00pm		Poster
496	69	8:00am - 6:00pm		Poster
<b>CER Methods</b>				
497	70	8:00am - 6:00pm		Poster
500	71	8:00am - 6:00pm		Poster
501	72	8:00am - 6:00pm		Poster
503	73	8:00am - 6:00pm		Poster
504	74	8:00am - 6:00pm		Poster
505	75	8:00am - 6:00pm		Poster
506	76	8:00am - 6:00pm		Poster
507	77	8:00am - 6:00pm		Poster
508	78	8:00am - 6:00pm		Poster
511	79	8:00am - 6:00pm		Poster
512	80	8:00am - 6:00pm		Poster
513	81	8:00am - 6:00pm		Poster
515	82	8:00am - 6:00pm		Poster
516	83	8:00am - 6:00pm		Poster
517	84	8:00am - 6:00pm		Poster
519	85	8:00am - 6:00pm		Poster
521	86	8:00am - 6:00pm		Poster
522	87	8:00am - 6:00pm		Poster
523	88	8:00am - 6:00pm		Poster
526	89	8:00am - 6:00pm		Poster
527	90	8:00am - 6:00pm		Poster
528	91	8:00am - 6:00pm		Poster
529	92	8:00am - 6:00pm		Poster
530	93	8:00am - 6:00pm		Poster
<b>Comparative Effectiveness Research (CER)</b>				
531		8:00am - 6:00pm	<i>Abstract Withdrawn by Author</i>	
532	94	8:00am - 6:00pm		Poster
533	95	8:00am - 6:00pm		Poster
534	96	8:00am - 6:00pm		Poster
535	97	8:00am - 6:00pm		Poster
536	98	8:00am - 6:00pm		Poster
537	99	8:00am - 6:00pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SATURDAY, AUGUST 25 CONTINUED</b>				
538	100	8:00am - 6:00pm		Poster
539	101	8:00am - 6:00pm		Poster
540	102	8:00am - 6:00pm		Poster
<b>Cardiovascular</b>				
541	103	8:00am - 6:00pm		Poster
542	104	8:00am - 6:00pm		Poster
543	105	8:00am - 6:00pm		Poster
544	106	8:00am - 6:00pm		Poster
545	107	8:00am - 6:00pm		Poster
546	108	8:00am - 6:00pm		Poster
547	109	8:00am - 6:00pm		Poster
548	110	8:00am - 6:00pm		Poster
549	111	8:00am - 6:00pm		Poster
550	112	8:00am - 6:00pm		Poster
551	113	8:00am - 6:00pm		Poster
552	114	8:00am - 6:00pm		Poster
553	115	8:00am - 6:00pm		Poster
554	116	8:00am - 6:00pm		Poster
555	117	8:00am - 6:00pm		Poster
556	118	8:00am - 6:00pm		Poster
557	119	8:00am - 6:00pm		Poster
558	120	8:00am - 6:00pm		Poster
559	121	8:00am - 6:00pm		Poster
560	122	8:00am - 6:00pm		Poster
561	123	8:00am - 6:00pm		Poster
562	124	8:00am - 6:00pm		Poster
563	125	8:00am - 6:00pm		Poster
564	126	8:00am - 6:00pm		Poster
565	127	8:00am - 6:00pm		Poster
566	128	8:00am - 6:00pm		Poster
567	129	8:00am - 6:00pm		Poster
568	130	8:00am - 6:00pm		Poster
569	131	8:00am - 6:00pm		Poster
570	132	8:00am - 6:00pm		Poster
571	133	8:00am - 6:00pm		Poster
572	134	8:00am - 6:00pm		Poster
573	135	8:00am - 6:00pm		Poster
574	136	8:00am - 6:00pm		Poster
575	137	8:00am - 6:00pm		Poster
576	138	8:00am - 6:00pm		Poster
<b>Diabetes &amp; Other Endocrine</b>				
577	139	8:00am - 6:00pm		Poster
578	140	8:00am - 6:00pm		Poster
579	141	8:00am - 6:00pm		Poster
580	142	8:00am - 6:00pm		Poster
581	143	8:00am - 6:00pm		Poster
582	144	8:00am - 6:00pm		Poster
583	145	8:00am - 6:00pm		Poster
584	146	8:00am - 6:00pm		Poster
585	147	8:00am - 6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
586	148	8:00am - 6:00pm		Poster
587	149	8:00am - 6:00pm		Poster
588	150	8:00am - 6:00pm		Poster
589	151	8:00am - 6:00pm		Poster
590	152	8:00am - 6:00pm		Poster
591	153	8:00am - 6:00pm		Poster
592	154	8:00am - 6:00pm		Poster
593	155	8:00am - 6:00pm		Poster
594	156	8:00am - 6:00pm		Poster
595	157	8:00am - 6:00pm		Poster
<b>CV, DM &amp; Endocrine DUR</b>				
596	158	8:00am - 6:00pm		Poster
597	159	8:00am - 6:00pm		Poster
598	160	8:00am - 6:00pm		Poster
599	161	8:00am - 6:00pm		Poster
601	162	8:00am - 6:00pm		Poster
602	163	8:00am - 6:00pm		Poster
603	164	8:00am - 6:00pm		Poster
604	165	8:00am - 6:00pm		Poster
605	166	8:00am - 6:00pm		Poster
606	167	8:00am - 6:00pm		Poster
607	168	8:00am - 6:00pm		Poster
608	169	8:00am - 6:00pm		Poster
609	170	8:00am - 6:00pm		Poster
610	171	8:00am - 6:00pm		Poster
611	172	8:00am - 6:00pm		Poster
612	173	8:00am - 6:00pm		Poster
613	174	8:00am - 6:00pm		Poster
616	175	8:00am - 6:00pm		Poster
617	176	8:00am - 6:00pm		Poster
618	177	8:00am - 6:00pm		Poster
619	178	8:00am - 6:00pm		Poster
620	179	8:00am - 6:00pm		Poster
621	180	8:00am - 6:00pm		Poster
622	181	8:00am - 6:00pm		Poster
623	182	8:00am - 6:00pm		Poster
624	183	8:00am - 6:00pm		Poster
625	184	8:00am - 6:00pm		Poster
628	185	8:00am - 6:00pm		Poster
629	186	8:00am - 6:00pm		Poster
630	187	8:00am - 6:00pm		Poster
631	188	8:00am - 6:00pm		Poster
632	189	8:00am - 6:00pm		Poster
633	190	8:00am - 6:00pm		Poster
634	191	8:00am - 6:00pm		Poster
635	192	8:00am - 6:00pm		Poster
636	193	8:00am - 6:00pm		Poster
637	194	8:00am - 6:00pm		Poster
638	195	8:00am - 6:00pm		Poster
639	196	8:00am - 6:00pm		Poster
640	197	8:00am - 6:00pm		Poster
641	198	8:00am - 6:00pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SATURDAY, AUGUST 25 CONTINUED</b>				
642	199	8:00am - 6:00pm		Poster
643	200	8:00am - 6:00pm		Poster
644	201	8:00am - 6:00pm		Poster
1042	256	8:00am - 6:00pm		Poster
<b>Methods in Databases</b>				
647	202	8:00am - 6:00pm		Poster
649	203	8:00am - 6:00pm		Poster
650	204	8:00am - 6:00pm		Poster
651	205	8:00am - 6:00pm		Poster
652	206	8:00am - 6:00pm		Poster
654	207	8:00am - 6:00pm		Poster
655	208	8:00am - 6:00pm		Poster
656	209	8:00am - 6:00pm		Poster
658	210	8:00am - 6:00pm		Poster
659	211	8:00am - 6:00pm		Poster
660	212	8:00am - 6:00pm		Poster
661	213	8:00am - 6:00pm		Poster
662	214	8:00am - 6:00pm		Poster
663	215	8:00am - 6:00pm		Poster
665	216	8:00am - 6:00pm		Poster
<b>Devices</b>				
668	217	8:00am - 6:00pm		Poster
669	218	8:00am - 6:00pm		Poster
676	219	8:00am - 6:00pm		Poster
<b>Pharmacoeconomics &amp; Outcomes Research</b>				
679	220	8:00am - 6:00pm		Poster
680	221	8:00am - 6:00pm		Poster
681	222	8:00am - 6:00pm		Poster
682	223	8:00am - 6:00pm		Poster
683	224	8:00am - 6:00pm		Poster
684	225	8:00am - 6:00pm		Poster
685	226	8:00am - 6:00pm		Poster
686	227	8:00am - 6:00pm		Poster
688	228	8:00am - 6:00pm		Poster
<b>Poster Walk – Molecular Epidemiology-Biomarkers-Pharmacogenetics SIG</b>				
419	229	8:00am - 6:00pm		P. Walk
423	230	8:00am - 6:00pm		P. Walk
425	231	8:00am - 6:00pm		P. Walk
428	232	8:00am - 6:00pm		P. Walk
431	233	8:00am - 6:00pm		P. Walk
<b>Poster Walk –CER (Comparative Effectiveness Research) SIG</b>				
499	234	8:00am - 6:00pm		P. Walk
502	235	8:00am - 6:00pm		P. Walkk
509	236	8:00am - 6:00pm		P. Walk
510	237	8:00am - 6:00pm		P. Walk
514	238	8:00am - 6:00pm		P. Walk
518	239	8:00am - 6:00pm		P. Walk
520	240	8:00am - 6:00pm		P. Walk
525	241	8:00am - 6:00pm		P. Walk

Abstract #	Poster #	Presentation Time	Room	Format
<b>Poster Walk –Databases SIG</b>				
645	242	8:00am - 6:00pm		P. Walk
646	243	8:00am - 6:00pm		P. Walk
648	244	8:00am - 6:00pm		P. Walk
653	245	8:00am - 6:00pm		P. Walk
657	246	8:00am - 6:00pm		P. Walk
664	247	8:00am - 6:00pm		P. Walk
666	248	8:00am - 6:00pm		P. Walk
667	249	8:00am - 6:00pm		P. Walk
<b>Poster Walk – Medical Devices SIG</b>				
671	250	8:00am - 6:00pm		P. Walk
672	251	8:00am - 6:00pm		P. Walk
675	252	8:00am - 6:00pm		P. Walk
677	253	8:00am - 6:00pm		P. Walk
678	254	8:00am - 6:00pm		P. Walk
<b>SUNDAY, AUGUST 26</b>				
<b>AEDs in Pregnancy and Beyond</b>				
689		8:30am	111-112	Oral
690		8:45am	111-112	Oral
691		9:00am	111-112	Oral
692		9:15am	111-112	Oral
693		9:30am	111-112	Oral
694		9:45am	111-112	Oral
<b>Disease-based Strategies for Active Surveillance</b>				
695		8:30am	117	Oral
696		8:45am	117	Oral
697		9:00am	117	Oral
698		9:15am	117	Oral
699		9:30am	117	Oral
700		9:45am	117	Oral
<b>Drug Utilization Research: Adherence and Persistence</b>				
701		8:30am	113	Oral
702		8:45am	113	Oral
703		9:00am	113	Oral
704		9:15am	113	Oral
705		9:30am	113	Oral
706		9:45am	113	Oral
<b>Keeping Your Eyes Open</b>				
707		8:30am	114	Oral
708		8:45am	114	Oral
709		9:00am	114	Oral
710		9:15am	114	Oral
711		9:30am	114	Oral
712		9:45am	114	Oral
<b>Safety of Psychotropic Medications in Adult Populations</b>				
713		8:30am	115	Oral
714		8:45am	115	Oral

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SUNDAY, AUGUST 26 CONTINUED</b>				
715		9:00am	115	Oral
716		9:15am	115	Oral
717		9:30am	115	Oral
718		9:45am	115	Oral
<b>Tapas: Classification Challenges</b>				
719		8:30am	116	Oral
720		8:45am	116	Oral
721		9:00am	116	Oral
722		9:15am	116	Oral
723		9:30am	116	Oral
724		9:45am	116	Oral
<b>Electronic and Personal Health Records: Utility and Challenges for Comparative Effectiveness Research (CER)</b>				
725		10:30 - Noon	111-112	Sympos.
<b>European Initiatives To Study Adverse Events of Treatments for Diabetes Mellitus</b>				
726		10:30 - Noon	117	Sympos.
<b>Globalisation of Utilisation Research: Current Challenges and Triumphs</b>				
727		10:30 - Noon	113	Sympos.
<b>Introduction to the Canadian Network for Observational Drug Effect Studies (CNODES)</b>				
728		10:30 - Noon	114	Sympos.
<b>New Pharmacovigilance Legislation: A Call to Arms to the Pharmacoepidemiology Community</b>				
729		10:30 - Noon	115	Sympos.
<b>Small Patients, Big Challenges – Current Topics in Pediatric Pharmacoepidemiology</b>				
730		10:30 - Noon	116	Sympos.
<b>The Real Potential of Routine Electronic Health Records for Clinical Trials: Putting Them to the Test</b>				
731		10:30 - Noon	132	Sympos.
<b>ADRS in Europe (with one exception)</b>				
732		1:30pm	111-112	Oral
733		1:45pm	111-112	Oral
734		2:00pm	111-112	Oral
735		2:15pm	111-112	Oral
736		2:30pm	111-112	Oral
737		2:45pm	111-112	Oral
<b>Cancer Pharmacoepidemiology</b>				
738		1:30pm	117	Oral
739		1:45pm	117	Oral
15		2:00pm	117	Oral
741		2:15pm	117	Oral
742		2:30pm	117	Oral
743		2:45pm	117	Oral
<b>Identifying Risks in Special Populations</b>				
744		1:30pm	113	Oral

Abstract #	Poster #	Presentation Time	Room	Format
745		1:45pm	113	Oral
746		2:00pm	113	Oral
747		2:15pm	113	Oral
748		2:30pm	113	Oral
749		2:45pm	113	Oral
<b>Measuring Impact of Risk Minimization</b>				
750		1:30pm	114	Oral
751		1:45pm	114	Oral
752		2:00pm	114	Oral
753		2:15pm	114	Oral
754		2:30pm	114	Oral
755		2:45pm	114	Oral
<b>Methods: The Real Deal</b>				
761		1:30pm	115	Oral
757		1:45pm	115	Oral
758		2:00pm	115	Oral
759		2:15pm	115	Oral
760		2:30pm	115	Oral
756		2:45pm	115	Oral
<b>Un Viaje por Vacunas: Vaccine Studies</b>				
762		1:30pm	116	Oral
763		1:45pm	116	Oral
764		2:00pm	116	Oral
765		2:15pm	116	Oral
766		2:30pm	116	Oral
767		2:45pm	116	Oral
<b>POSTER SESSION C</b>				
<b>Vaccines</b>				
768	1	8:00am - 1:45pm		Poster
772	2	8:00am - 1:45pm		Poster
773	3	8:00am - 1:45pm		Poster
774	4	8:00am - 1:45pm		Poster
775	5	8:00am - 1:45pm		Poster
776	6	8:00am - 1:45pm		Poster
777	7	8:00am - 1:45pm		Poster
778	8	8:00am - 1:45pm		Poster
779	9	8:00am - 1:45pm		Poster
780	10	8:00am - 1:45pm		Poster
781	11	8:00am - 1:45pm		Poster
782	12	8:00am - 1:45pm		Poster
783	13	8:00am - 1:45pm		Poster
785	14	8:00am - 1:45pm		Poster
786	15	8:00am - 1:45pm		Poster
787	16	8:00am - 1:45pm		Poster
<b>Pregnancy</b>				
788	17	8:00am - 1:45pm		Poster
789	18	8:00am - 1:45pm		Poster
790	19	8:00am - 1:45pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SUNDAY, AUGUST 26 CONTINUED</b>				
791	20	8:00am - 1:45pm		Poster
792	21	8:00am - 1:45pm		Poster
793	22	8:00am - 1:45pm		Poster
795	23	8:00am - 1:45pm		Poster
796	24	8:00am - 1:45pm		Poster
797	25	8:00am - 1:45pm		Poster
798	26	8:00am - 1:45pm		Poster
799	27	8:00am - 1:45pm		Poster
801	28	8:00am - 1:45pm		Poster
802	29	8:00am - 1:45pm		Poster
805	30	8:00am - 1:45pm		Poster
807	31	8:00am - 1:45pm		Poster
808	32	8:00am - 1:45pm		Poster
809	33	8:00am - 1:45pm		Poster
812	34	8:00am - 1:45pm		Poster
813	35	8:00am - 1:45pm		Poster
814	36	8:00am - 1:45pm		Poster
815	37	8:00am - 1:45pm		Poster
816	38	8:00am - 1:45pm		Poster
817	39	8:00am - 1:45pm		Poster
818	40	8:00am - 1:45pm		Poster
820	41	8:00am - 1:45pm		Poster
821	42	8:00am - 1:45pm		Poster
822	43	8:00am - 1:45pm		Poster
823	44	8:00am - 1:45pm		Poster
824	45	8:00am - 1:45pm		Poster
826	46	8:00am - 1:45pm		Poster
828	47	8:00am - 1:45pm		Poster
829	48	8:00am - 1:45pm		Poster
830	49	8:00am - 1:45pm		Poster
831	50	8:00am - 1:45pm		Poster
832	51	8:00am - 1:45pm		Poster
834	52	8:00am - 1:45pm		Poster
835	53	8:00am - 1:45pm		Poster
836	54	8:00am - 1:45pm		Poster
837	55	8:00am - 1:45pm		Poster
838	56	8:00am - 1:45pm		Poster
839	57	8:00am - 1:45pm		Poster
840	58	8:00am - 1:45pm		Poster
841	59	8:00am - 1:45pm		Poster
842	60	8:00am - 1:45pm		Poster
843	61	8:00am - 1:45pm		Poster
844	62	8:00am - 1:45pm		Poster
845	63	8:00am - 1:45pm		Poster
846	64	8:00am - 1:45pm		Poster
<b>Validity in Databases</b>				
847	65	8:00am - 1:45pm		Poster
848	66	8:00am - 1:45pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
849	67	8:00am - 1:45pm		Poster
850	68	8:00am - 1:45pm		Poster
852	69	8:00am - 1:45pm		Poster
853	70	8:00am - 1:45pm		Poster
854	71	8:00am - 1:45pm		Poster
855	72	8:00am - 1:45pm		Poster
856	73	8:00am - 1:45pm		Poster
857	74	8:00am - 1:45pm		Poster
858	75	8:00am - 1:45pm		Poster
859	76	8:00am - 1:45pm		Poster
860	77	8:00am - 1:45pm		Poster
861	78	8:00am - 1:45pm		Poster
862	79	8:00am - 1:45pm		Poster
863	80	8:00am - 1:45pm		Poster
864	81	8:00am - 1:45pm		Poster
<b>Musculoskeletal DUR</b>				
865	82	8:00am - 1:45pm		Poster
866	83	8:00am - 1:45pm		Poster
867	84	8:00am - 1:45pm		Poster
868	85	8:00am - 1:45pm		Poster
869	86	8:00am - 1:45pm		Poster
870	87	8:00am - 1:45pm		Poster
871	88	8:00am - 1:45pm		Poster
872	89	8:00am - 1:45pm		Poster
873	90	8:00am - 1:45pm		Poster
874	91	8:00am - 1:45pm		Poster
875	92	8:00am - 1:45pm		Poster
876	93	8:00am - 1:45pm		Poster
877	94	8:00am - 1:45pm		Poster
<b>Musculoskeletal</b>				
878	95	8:00am - 1:45pm		Poster
879	96	8:00am - 1:45pm		Poster
880	97	8:00am - 1:45pm		Poster
881	98	8:00am - 1:45pm		Poster
882	99	8:00am - 1:45pm		Poster
883	100	8:00am - 1:45pm		Poster
884	101	8:00am - 1:45pm		Poster
885	102	8:00am - 1:45pm		Poster
886	103	8:00am - 1:45pm		Poster
887	104	8:00am - 1:45pm		<i>Abstract Withdrawn by Author</i>
888	105	8:00am - 1:45pm		<i>Abstract Withdrawn by Author</i>
889	106	8:00am - 1:45pm		Poster
890	107	8:00am - 1:45pm		Poster
891	108	8:00am - 1:45pm		Poster
892	109	8:00am - 1:45pm		Poster
894	110	8:00am - 1:45pm		Poster
895	111	8:00am - 1:45pm		Poster
896	112	8:00am - 1:45pm		Poster
897	113	8:00am - 1:45pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SUNDAY, AUGUST 26 CONTINUED</b>				
898	114	8:00am - 1:45pm		Poster
899	115	8:00am - 1:45pm		Poster
900	116	8:00am - 1:45pm		Poster
901	117	8:00am - 1:45pm		Poster
902	118	8:00am - 1:45pm		Poster
903	119	8:00am - 1:45pm	<i>Abstract Withdrawn by Author</i>	
904	120	8:00am - 1:45pm	<i>Abstract Withdrawn by Author</i>	
905	121	8:00am - 1:45pm		Poster
906	122	8:00am - 1:45pm		Poster
907	123	8:00am - 1:45pm		Poster
908	124	8:00am - 1:45pm		Poster
909	125	8:00am - 1:45pm		Poster
910	126	8:00am - 1:45pm		Poster
<b>DUR Nervous System</b>				
911	127	8:00am - 1:45pm		Poster
912	128	8:00am - 1:45pm		Poster
913	129	8:00am - 1:45pm		Poster
914	130	8:00am - 1:45pm		Poster
915	131	8:00am - 1:45pm		Poster
916	132	8:00am - 1:45pm		Poster
917	133	8:00am - 1:45pm		Poster
918	134	8:00am - 1:45pm		Poster
919	135	8:00am - 1:45pm		Poster
920	136	8:00am - 1:45pm		Poster
921	137	8:00am - 1:45pm		Poster
922	138	8:00am - 1:45pm		Poster
923	139	8:00am - 1:45pm		Poster
924	140	8:00am - 1:45pm		Poster
925	141	8:00am - 1:45pm		Poster
926	142	8:00am - 1:45pm		Poster
927	143	8:00am - 1:45pm		Poster
928	144	8:00am - 1:45pm		Poster
929	145	8:00am - 1:45pm		Poster
930	146	8:00am - 1:45pm		Poster
931	147	8:00am - 1:45pm		Poster
932	148	8:00am - 1:45pm		Poster
933	149	8:00am - 1:45pm		Poster
934	150	8:00am - 1:45pm		Poster
935	151	8:00am - 1:45pm		Poster
936	152	8:00am - 1:45pm		Poster
937	153	8:00am - 1:45pm		Poster
938	154	8:00am - 1:45pm		Poster
939	155	8:00am - 1:45pm		Poster
940	156	8:00am - 1:45pm		Poster
941	157	8:00am - 1:45pm		Poster
942	158	8:00am - 1:45pm		Poster
943	159	8:00am - 1:45pm		Poster
944	160	8:00am - 1:45pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<b>Nervous System</b>				
945	161	8:00am - 1:45pm		Poster
946	162	8:00am - 1:45pm		Poster
947	163	8:00am - 1:45pm		Poster
948	164	8:00am - 1:45pm		Poster
949	165	8:00am - 1:45pm		Poster
950	166	8:00am - 1:45pm		Poster
951	167	8:00am - 1:45pm		Poster
952	168	8:00am - 1:45pm		Poster
953	169	8:00am - 1:45pm		Poster
954	170	8:00am - 1:45pm		Poster
955	171	8:00am - 1:45pm		Poster
956	172	8:00am - 1:45pm		Poster
957	173	8:00am - 1:45pm		Poster
958	174	8:00am - 1:45pm		Poster
959	175	8:00am - 1:45pm		Poster
960	176	8:00am - 1:45pm		Poster
961	177	8:00am - 1:45pm		Poster
962	178	8:00am - 1:45pm		Poster
963	179	8:00am - 1:45pm		Poster
964	180	8:00am - 1:45pm		Poster
965	181	8:00am - 1:45pm		Poster
966	182	8:00am - 1:45pm		Poster
967	183	8:00am - 1:45pm		Poster
968	184	8:00am - 1:45pm		Poster
969	185	8:00am - 1:45pm		Poster
970	186	8:00am - 1:45pm		Poster
971	187	8:00am - 1:45pm		Poster
972	188	8:00am - 1:45pm		Poster
973	189	8:00am - 1:45pm		Poster
974	190	8:00am - 1:45pm		Poster
975	191	8:00am - 1:45pm		Poster
976	192	8:00am - 1:45pm		Poster
977	193	8:00am - 1:45pm		Poster
978	194	8:00am - 1:45pm		Poster
979	195	8:00am - 1:45pm		Poster
980	196	8:00am - 1:45pm		Poster
981	197	8:00am - 1:45pm		Poster
982	198	8:00am - 1:45pm		Poster
983	199	8:00am - 1:45pm		Poster
986	200	8:00am - 1:45pm		Poster
987	201	8:00am - 1:45pm		Poster
<b>DUR Oncology &amp; Immunology</b>				
988	202	8:00am - 1:45pm		Poster
989	203	8:00am - 1:45pm		Poster
990	204	8:00am - 1:45pm		Poster
991	205	8:00am - 1:45pm		Poster
992	206	8:00am - 1:45pm		Poster
993	207	8:00am - 1:45pm		Poster

# ABSTRACT INDEX—FINAL PROGRAM

Abstract #	Poster #	Presentation Time	Room	Format
<b>SUNDAY, AUGUST 26 CONTINUED</b>				
994	208	8:00am - 1:45pm		Poster
995	209	8:00am - 1:45pm		Poster
996	210	8:00am - 1:45pm		Poster
998	211	8:00am - 1:45pm		Poster
999	212	8:00am - 1:45pm		Poster
1000	213	8:00am - 1:45pm		Poster
1001	214	8:00am - 1:45pm		Poster
1002	215	8:00am - 1:45pm		Poster

## Oncology & Immunology

1003	216	8:00am - 1:45pm		Poster
1004	217	8:00am - 1:45pm		Poster
1005	218	8:00am - 1:45pm		Poster
1006	219	8:00am - 1:45pm		Poster
1007	220	8:00am - 1:45pm		Poster
1008	221	8:00am - 1:45pm		Poster
1009	222	8:00am - 1:45pm		Poster
1010	223	8:00am - 1:45pm		Poster
1011	224	8:00am - 1:45pm		Poster
1012	225	8:00am - 1:45pm		Poster
1013	226	8:00am - 1:45pm		Poster
1014	227	8:00am - 1:45pm		Poster
1015	228	8:00am - 1:45pm		Poster
1016	229	8:00am - 1:45pm		Poster
1017	230	8:00am - 1:45pm		Poster

## Respiratory

1018	231	8:00am - 1:45pm		Poster
1019	232	8:00am - 1:45pm		Poster
1022	233	8:00am - 1:45pm		Poster
1023	234	8:00am - 1:45pm		Poster
1025	235	8:00am - 1:45pm		Poster
1026	236	8:00am - 1:45pm		Poster
1027	237	8:00am - 1:45pm		Poster
1028	238	8:00am - 1:45pm		Poster
1029	239	8:00am - 1:45pm		Poster
1030	240	8:00am - 1:45pm		Poster
1031	241	8:00am - 1:45pm		Poster
1032	242	8:00am - 1:45pm		Poster
1033	243	8:00am - 1:45pm		Poster

## Genito-Urinary-Hormones

1034	244	8:00am - 1:45pm		Poster
1035	245	8:00am - 1:45pm		Poster
1036	246	8:00am - 1:45pm		Poster
1037	247	8:00am - 1:45pm		Poster
1038	248	8:00am - 1:45pm		Poster
1039	249	8:00am - 1:45pm		Poster
1040	250	8:00am - 1:45pm		Poster
1041	251	8:00am - 1:45pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<b>Poster Walk – Medicines in Pregnancy SIG</b>				
800	252	8:00am - 1:45pm		P. Walk
803	253	8:00am - 1:45pm		P. Walk
804	254	8:00am - 1:45pm		P. Walk
806	255	8:00am - 1:45pm		P. Walk
810	256	8:00am - 1:45pm		P. Walk
811	257	8:00am - 1:45pm		P. Walk
825	258	8:00am - 1:45pm		P. Walk
827	259	8:00am - 1:45pm		P. Walk

*28th International Conference on*  
**PHARMACOEPIDEMOLOGY AND  
 THERAPEUTIC RISK MANAGEMENT**

## ADVERTISERS INDEX

■ Anolinx.....	77
■ Bayer HealthCare.....	29
■ Boehringer Ingelheim, GmbH.....	23
■ Celgene.....	9
■ CPRD, Clinical Practice Research Datalink .....	13
■ Eli Lilly & Company .....	26
■ F.Hoffmann-La Roche Ltd .....	10
■ HealthCore, Inc. ....	47
■ IMS Health .....	19
■ LA-SER Research .....	41
■ MAPI .....	21
■ Merck & Co. ....	42
■ Optum.....	18
■ ParagonRX.....	45
■ Pfizer .....	12
■ Quintiles Outcome .....	39
■ RTI Health Solutions.....	32
■ The Degge Group, LTD .....	49
■ United BioSource Corporation .....	34
■ Wiley-Blackwell .....	IBC



# PDS Pharmacoepidemiology & Drug Safety

Official Journal of the International Society for Pharmacoepidemiology

**Editor-in-Chief: Professor Brian L. Strom**

*Pharmacoepidemiology & Drug Safety* provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

\* Free online access for ISPE members via the society website

## Congratulations to The Ronald D. Mann Best Article of 2011 Award Winners



**Best paper:**

Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis by *John Paul Leombruno, Geoffrey C. Nguyen, Paul Grootendorst, David Juurlink, Tom Einarson*  
Vol 20, Issue 8, Pages 838–848

**Honorable mention:**

Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada by *Daren Lin, Jamie A. Seabrook, Doreen M. Matsui, Susan M. King, Michael J. Rieder, Yaron Finkelstein*  
Vol 20, Issue 12, Pages 1246–1252

**Honorable mention:**

Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy by *Robert L. Davis, David Eastman, Heather McPhillips, Marsha A. Raebel, Susan E. Andrade, David Smith, Marianne Ulcickas Yood, Sascha Dublin and Richard Platt*  
Vol 20, Issue 2, Pages 138–145

**Honorable mention:**

Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study by *Henriette Thisted Horsdal, Flemming Søndergaard, Søren Paaske Johnsen, Jørgen Rungby*  
Vol 20, Issue 4, Pages 331–337

For more information on these top papers and other journal features, please visit


[www.pdsjournal.org](http://www.pdsjournal.org)

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2012 Volume: 21 • Frequency: Monthly

 **WILEY-BLACKWELL**


# CONVENTION CENTRE

LEVEL 2




- FOYER 3171 M<sup>2</sup>
- BANQUET HALL 1711 M<sup>2</sup>
- MEETING ROOM 1350 M<sup>2</sup>
- TERRACE 602 M<sup>2</sup>

LEVEL M2



- M211 80 M<sup>2</sup>
- M212 34 M<sup>2</sup>
- M213 85 M<sup>2</sup>
- M214 37 M<sup>2</sup>
- M215 58 M<sup>2</sup>
- M216 55 M<sup>2</sup>
- M217 34 M<sup>2</sup>
- M218 - M221 4 x 54 M<sup>2</sup>

LEVEL 1




- MEETING ROOM 111 467 M<sup>2</sup>
- MEETING ROOM 112 337 M<sup>2</sup>
- MEETING ROOM 113 403 M<sup>2</sup>
- MEETING ROOM 114 403 M<sup>2</sup>
- MEETING ROOM 115 473 M<sup>2</sup>
- MEETING ROOM 116 485 M<sup>2</sup>
- MEETING ROOM 117 579 M<sup>2</sup>
- MEETING ROOMS 118-124 16 x 81 M<sup>2</sup>
- FOYER 1 1.336 M<sup>2</sup>
- FOYER 2 1.024 M<sup>2</sup>
- KITCHEN 418 M<sup>2</sup>
- KITCHEN 2 1.184 M<sup>2</sup>
- TERRACE 1207 M<sup>2</sup>

LEVEL M1



- VIP ROOM 396 M<sup>2</sup>

LEVEL 0



- EXHIBITION AREA TOTAL 11.815 M<sup>2</sup>
- AREA 1 3.901 M<sup>2</sup>
- AREA 2 1.132 M<sup>2</sup>
- AREA 3 2.174 M<sup>2</sup>
- AREA 4 1.157 M<sup>2</sup>
- AREA 5 1.140 M<sup>2</sup>
- AREA 6 396 M<sup>2</sup>
- AREA 7 1.140 M<sup>2</sup>
- AREA 8 588 M<sup>2</sup>
- ENTRANCE HALL 2.618 M<sup>2</sup>
- FOYER 1.387 M<sup>2</sup>
- LABORATORIES/HALLWAY